

## STATISTICAL ANALYSIS PLAN

### A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

#### Protocol PR-30-5020-C

Protocol Number: PR-30-5020-C

Protocol Version and Date: Version 8.0: 21 December 2017 (Amendment 5)  
Version 7.0: 07 April 2017 (Amendment 4)  
Version 6.0: 14 September 2016 (Amendment 3.2)  
Version 5.0: 07 September 2016 (Amendment 3.1)  
Version 4.0: 29 July 2016 (Amendment 3)  
Version 3.0: 24 May 2016 (Amendment 2)  
Version 2.0: 30 October 2015 (Amendment 1)  
Version 1.0: 17 December 2014 (Original)

Name of Test Drug: Niraparib ([3S]-3-[4-{7-(aminocarbonyl)-2H-indazol-2-yl}phenyl] piperidine [tosylate monohydrate salt])

Phase: Phase 2

Methodology: Open-Label, Single-Arm

Sponsor: TESARO, Inc.  
1000 Winter Street  
Waltham MA 02451  
Tel: PPD

Sponsor Representative: PPD MD  
Senior Medical Director

Analysis Plan Date: 19 January 2018

Addendum Date: 11 December 2018

Analysis Plan Version: Version 3.0

#### Confidentiality Statement

The information contained herein is confidential and the proprietary property of TESARO, Inc., and any unauthorized use or disclosure of such information without the prior written authorization of TESARO, Inc., is expressly prohibited.

### APPROVAL SIGNATURE PAGE

Protocol Title: A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Protocol Number: PR-30-5020-C

Sponsor: TESARO, Inc.  
1000 Winter Street  
Waltham MA 02451

Author: Veristat, LLC  
118 Turnpike Road  
Southborough, MA 01772

Author Signatory: \_\_\_\_\_  
PPD  
Signature: \_\_\_\_\_  
Principal Biostatistician  
Date: 22 January 2018

Sponsor Approval:  
By signing this document, I acknowledge that I have read the document and approve of the planned statistical analyses described herein. I agree that the planned statistical analyses are appropriate for this study, are in accordance with the study objectives, and are consistent with the statistical methodology described in the protocol, clinical development plan, and all applicable regulatory guidances and guidelines.  
I have discussed any questions I have regarding the contents of this document with the biostatistical author.  
I also understand that any subsequent changes to the planned statistical analyses, as described herein, may have a regulatory impact and/or result in timeline adjustments. All changes to the planned analyses will be \_\_\_\_\_  
PPD

Sponsor Signatory: \_\_\_\_\_  
Romnee Clark, MD  
Senior Medical Director  
Signature: \_\_\_\_\_  
Date: 01/19/2018

Yong Li, PhD  
Director, Biostatistics  
Signature: \_\_\_\_\_  
Date: 01/19/2018

## TABLE OF CONTENTS

1.	INFORMATION FROM THE STUDY PROTOCOL .....	10
1.1.	Introduction and Objectives .....	10
1.1.1.	Introduction.....	10
1.1.2.	Study Objectives .....	10
1.2.	Study Design.....	12
1.2.1.	Synopsis of Study Design .....	12
1.2.2.	Randomization Methodology .....	13
1.2.3.	Stopping Rules and Unblinding.....	13
1.2.4.	Study Procedures .....	13
1.2.5.	Efficacy, Pharmacokinetic, and Safety Parameters .....	17
1.2.5.1.	Efficacy Parameters .....	17
1.2.5.2.	Pharmacokinetic Parameters.....	17
1.2.5.3.	Safety Parameters.....	17
2.	PATIENT POPULATION.....	19
2.1.	Population Definitions .....	19
2.2.	Protocol Deviations.....	19
3.	GENERAL STATISTICAL METHODS .....	20
3.1.	Sample Size Justification .....	20
3.2.	General Methods.....	20
3.3.	Computing Environment.....	21
3.4.	Baseline Definitions.....	22
3.5.	Methods of Pooling Data .....	22
3.6.	Adjustments for Covariates.....	22
3.7.	Multiple Comparisons/Multiplicity .....	22
3.8.	Subpopulations.....	22
3.8.1.	Prior Lines of Chemotherapy.....	22
3.8.2.	Response to the Last Platinum-Based Therapy .....	22
3.8.3.	Prior PARP Treatment.....	23
3.8.4.	Biomarker Subpopulations .....	23
3.8.4.1.	Biomarker Definitions .....	23
3.8.4.2.	Study-Specific Biomarker Populations.....	24

3.9.	Withdrawals, Dropouts, Loss to Follow-up .....	24
3.10.	Missing Data .....	24
3.11.	Visit Windows .....	25
3.12.	Administrative Interim Analyses .....	26
4.	STUDY ANALYSES .....	27
4.1.	Patient Disposition .....	27
4.2.	Demographics, Baseline Characteristics, and Medical History .....	27
4.3.	Efficacy Evaluation.....	28
4.3.1.	Efficacy Variables for Primary and Key Secondary Analyses.....	28
4.3.2.	Secondary Efficacy Variables.....	32
4.3.2.1.	Duration of Response.....	32
4.3.2.2.	Disease Control Rate.....	33
4.3.2.3.	Progression-Free Survival.....	33
4.3.2.4.	Time to First Subsequent Therapy .....	34
4.3.2.5.	Overall Survival .....	34
4.3.2.6.	Pharmacokinetic Evaluations.....	34
4.4.	Safety Analyses.....	34
4.4.1.	Study Treatment Exposure.....	34
4.4.2.	Study Treatment Compliance .....	35
4.4.3.	Adverse Events .....	36
4.4.3.1.	Overview.....	36
4.4.3.2.	Adverse Events of Special Interest .....	38
4.4.3.3.	Other Adverse Events of Interest.....	39
4.4.3.4.	Examination of Adverse Events Controlling for Duration of Drug Exposure.....	40
4.4.3.5.	Examination of Duration of Adverse Events .....	41
4.4.4.	Laboratory Data .....	41
4.4.5.	Vital Signs and Physical Examination.....	42
4.4.6.	Electrocardiogram.....	42
4.4.7.	Concomitant Medications .....	43
5.	CHANGES TO PLANNED ANALYSES.....	45
6.	REFERENCES .....	46

7.	APPENDIX.....	47
7.1.	MedDRA Preferred Terms for Adverse Events of Special Groups.....	47
7.2.	SMQ Terms for Malignant Tumors .....	51
7.3.	SMQ Terms for Pregnancy and Neonatal Topics.....	101
7.4.	SMQ Terms for Hypertension .....	172
7.5.	List of Per-Protocol Chemotherapy Regimens in Preferred Term.....	175
8.	STATISTICAL OUTPUT SHELLS.....	177
9.	REVISION HISTORY.....	178

**TABLES INCLUDED IN THE TEXT**

Table 1-1	Schedule of Assessments.....	14
Table 3-1	Evaluation Intervals.....	25
Table 4-1	Overall Response for Patients with Measurable Disease at Study Entry .....	29
Table 4-2:	Best Overall Response when Confirmation of CR and PR Required.....	30
Table 4-3:	Censoring Rules used in Duration of Response Analysis .....	32
Table 4-4:	Censoring Rules used in Progression-Free Survival Analysis .....	33
Table 4-5:	Adverse Events of Special Interest and Other Grouped Events .....	40

## LIST OF ABBREVIATIONS AND DEFINITION OF TERMS

Abbreviation	Definition
AE	Adverse event
AESI	Adverse event(s) of special interest
ALT	Alanine aminotransferase
AML	Acute myeloid leukemia
AST	Aspartate aminotransferase
ATC	Anatomical Therapeutic Chemical
BER	Base excision repair
BMI	Body mass index
BRCA	Breast cancer gene
CA-125	Cancer antigen 125
CBC	Complete blood count
CI	Confidence interval
CR	Complete response
CSR	Clinical study report
CT	Computed tomography
CTCAE	Common Terminology Criteria for Adverse Events
DCR	Disease control rate
DNA	Deoxyribonucleic acid
DOR	Duration of response
ECG	Electrocardiogram
ECOG	Eastern Cooperative Oncology Group
eCRF	Electronic case report form
EOT	End of treatment
FDA	(United States) Food and Drug Administration
FIGO	International Federation of Gynecology and Obstetrics
FISH	Fluorescence in situ hybridization
gBRCA <sup>mut</sup>	Germline breast cancer gene mutation
GCIG	Gynecologic Cancer Intergroup
GCP	Good Clinical Practice
GGT	Gamma glutamyl transferase
H <sub>0</sub>	Null hypothesis
H <sub>1</sub>	Alternative hypothesis
HEENT	Head, Eyes, Ears, Neck, and Throat
HRD	Homologous recombination deficiency
ICF	Informed consent form
ICH	International Conference on Harmonisation
IEC	Independent Ethics Committee

<b>Abbreviation</b>	<b>Definition</b>
IRB	Institutional Review Board
ITT	Intent-to-treat
KM	Kaplan-Meier
LLN	Lower limit of normal
MDS	Myelodysplastic syndrome
MedDRA	Medical Dictionary for Regulatory Activities
MRI	Magnetic resonance imaging
NCI	National Cancer Institute
ORR	Objective response rate
OS	Overall survival
PARP	Poly(ADP-ribose) polymerase
PD	Progressive disease (in the context of disease evaluation) or protocol deviation
PEY	Patient-exposure year
PFI	Platinum-free interval
PFS	Progression-free survival
PK	Pharmacokinetic
PP	Per-protocol
PR	Partial response
PT	Preferred Term (MedDRA)
Q <sub>1</sub>	First quartile
Q <sub>3</sub>	Third quartile
QD	Once daily
QTc	QT interval corrected for heart rate
QTcB	QT interval corrected for heart rate using Bazett's formula
QTcF	QT interval corrected for heart rate using Fridericia's formula
RECIST	Response Evaluation Criteria in Solid Tumors
SAE	Serious adverse event
SAF	Safety
SAP	Statistical analysis plan
sBRCA <sup>mut</sup>	Somatic breast cancer gene mutation
SD	Stable disease (in the context of disease evaluation) or standard deviation (in the context of statistics)
SOC	System Organ Class (MedDRA)
tBRCA <sup>mut</sup>	Tumor breast cancer gene mutation
tBRCA <sup>wt</sup>	Tumor breast cancer gene wild-type
TEAE	Treatment-emergent adverse event
TFST	Time to first subsequent therapy
ULN	Upper limit of normal



<b>Abbreviation</b>	<b>Definition</b>
WHO	World Health Organization
WHODD	World Health Organization Drug Dictionary

## 1. INFORMATION FROM THE STUDY PROTOCOL

### 1.1. Introduction and Objectives

#### 1.1.1. Introduction

Niraparib is a potent, orally active poly(ADP-ribose) polymerases (PARP)-1 and -2 inhibitor being developed as an agent for tumors with defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.

PARP-1 and -2 are zinc-finger DNA-binding enzymes that play a crucial role in DNA repair. Upon formation of DNA breaks, PARP binds at the end of broken DNA strands, a process that activates its enzymatic activity. Activated PARP catalyzes addition of long polymers of ADP-ribose onto PARP and several other proteins associated with chromatin, including histones and various DNA repair proteins. This results in chromatin relaxation, fast recruitment of DNA repair proteins, and efficient repair of DNA breaks. In this manner, PARP plays a key role in sensing DNA damage and converting it into intracellular signals that activate the base excision repair (BER) and single-strand break repair pathways.

Clinical studies have shown that PARP inhibitors are active for recurrent ovarian cancer.[1, 2, 3, 4, 5, 6, 7] Clinical anti-cancer activity has been observed in patients with and without germline breast cancer gene (BRCA) mutation (gBRCA<sup>mut</sup>) and in patients who are platinum-sensitive and platinum-resistant. PARP inhibition appears to be most active in patients with gBRCA<sup>mut</sup> platinum-sensitive disease.[1, 3, 5] Additionally, maintenance therapy in patients with relapsed, platinum-sensitive ovarian cancer appears promising.[6] Of patients with a BRCA mutation, median progression-free survival (PFS) was significantly longer in the PARP inhibitor group than in the placebo group (11.2 months vs 4.3 months; hazard ratio: 0.18;  $p < 0.0001$ ). Similar findings were noted for patients with wild-type BRCA, although the difference between groups was smaller (7.4 months vs 5.5 months; hazard ratio: 0.54;  $p = 0.007$ ). Patient-reported outcomes, including Functional Assessment of Cancer Therapy – Ovarian Symptom Index, did not show a significant difference between the placebo and treatment groups, suggesting that maintenance treatment did not decrease functioning or quality of life in these patients. Patient-reported outcome data beyond progression was not captured, and therefore quality of life effects related to subsequent chemotherapy treatments (likely to occur sooner in the placebo group) could not be used to assess the benefit of extending PFS on patient-reported outcomes for patients treated with a PARP inhibitor vs placebo.

#### 1.1.2. Study Objectives

In this document, “ovarian cancer” refers to high-grade serous epithelial cancers of the ovary, fallopian tube, or primary peritoneal cancer. As detailed in [Section 3.8](#), “sensitivity to platinum-based therapy” is defined by platinum-free interval (PFI) following the first platinum-based therapy (required for eligibility) or the last platinum-based therapy (defines patient population for primary and key secondary objectives). Homologous recombination deficiency (HRD) status is based upon the Myriad MyChoice HRD test and/or a centralized gBRCA test.

The primary objective of the study is to evaluate the Objective Response Rate (ORR) of niraparib in HRD-positive patients with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received 3 or 4 prior lines of

anti-cancer therapy and are platinum-sensitive to the last platinum-based therapy (excluding patients with prior PARP treatment).

The key secondary objectives of the study are as follows:

- To evaluate the ORR of niraparib in all patients with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received 3 or 4 prior lines of anti-cancer therapy and are platinum-sensitive to the last platinum-based therapy (excluding patients with prior PARP treatment).
- To evaluate the ORR of niraparib in all patients with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received 3 or 4 prior lines of anti-cancer therapy and are platinum-sensitive or platinum-resistant to the last platinum-based therapy (excluding patients with prior PARP treatment).
- To evaluate the ORR of niraparib in all patients with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Other secondary objectives of the study are as follows:

- To evaluate the efficacy (duration of response [DOR], disease control rate [DCR], PFS, time to first subsequent therapy [TFST] and overall survival [OS]) of niraparib in patients who have received 3 or 4 prior lines of anti-cancer therapy.
- To evaluate the efficacy (DOR, DCR, PFS, TFST and OS) of niraparib in all patients regardless of prior lines of anti-cancer therapy.
- To evaluate the safety and tolerability of niraparib.

The exploratory objectives of the study are as follows:

- To evaluate the efficacy and safety of niraparib in all patients who are platinum-refractory to the last platinum-based therapy.
- To evaluate the efficacy and safety of niraparib in all patients with prior PARP treatment.
- To evaluate QT interval corrected for heart rate (QTc) in a subset of niraparib-treated ovarian cancer patients.
- To assess population pharmacokinetics (PK) and estimate PK parameters for niraparib and its major metabolite.
- To explore potential biomarkers related to ovarian cancer and poly(ADP-ribose) polymerase (PARP) inhibition (eg, DNA repair pathways).

This statistical analysis plan (SAP) is designed to outline the methods to be used in the analyses of study data in order to answer the study objectives. Patient populations to be used for analyses, data handling rules, statistical methods, and formats for data presentation are identified and provided. The statistical analyses and summary tabulations described in this SAP will provide the basis for the results sections of the clinical study report (CSR) for this trial.

This SAP will also outline any differences in the currently planned analytical objectives relative to those planned in the study protocol.

The SAP is based upon the following study documents:

- Study Protocol v8.0 dated 21 December 2017
- Electronic Case Report Form (eCRF) v.1.184 dated 23 October 2017
- Analyses of PK data are described in a separate SAP, but all data will be displayed in the listings associated with this SAP.

## 1.2. Study Design

### 1.2.1. Synopsis of Study Design

This study is a multicenter, open-label, single-arm, Phase 2 study evaluating the safety and efficacy of niraparib in patients with recurrent ovarian cancer who experienced a response lasting at least 6 months to first-line platinum-based therapy and who previously treated with 3 or 4 lines of anti-cancer therapy (including, but not limited to, gemcitabine, doxorubicin, topotecan, carboplatin, oxaliplatin, cisplatin, bevacizumab, or PARP inhibitors as single agents or in combination per standard of care). Study objectives are discussed in [Section 1.1.2](#).

In order to determine eligibility, a tumor sample will be sent to a centralized laboratory for immediate HRD testing. Archival or fresh tissue is required in order to enroll in the study. The sample may be sent in advance of the protocol-defined screening period in order to facilitate the screening and enrollment process. Patients must wait for the results from the on-study centralized HRD testing prior to enrollment, unless they have previously detected gBRCA mutation. Blood samples also will be collected for all patients during screening for determination of gBRCAmut status. If HRD status is known, then it is not necessary to wait for HRD testing results for enrollment into the study, however confirmatory HRD testing still needs to be performed.

In order to evaluate tumor markers, an optional fresh biopsy may be done at screening and at the end of treatment (EOT) visit.

Niraparib 300 mg will be administered orally QD continuously beginning on Day 1 and every cycle (28 days) thereafter until the patient discontinues study treatment. Three capsules of 100 mg strength will be taken at each dose administration. Dose interruption (no longer than 28 days) and dose reductions to 2 capsules daily (200 mg), and subsequently to 1 capsule daily (100 mg), will be allowed (no further dose reductions will be allowed). Dose interruption and/or reduction may be implemented at any time for any grade toxicity considered intolerable by the patient. The timing of efficacy or safety evaluations should not be affected by dose interruptions or reductions. Patients will continue on study medication until disease progression as long as in the Investigator's opinion they are benefiting from treatment and do not meet any other discontinuation criteria.

Blood samples for measurements of plasma levels of niraparib and its major metabolite will be obtained on Cycle 1/Day 1 predose and 2 hours postdose, Cycle 2/Day 1 predose and 2 hours postdose, Cycle 4/ Day 1 predose, and Cycle 8/ Day 1 predose. At selected sites, a subset of approximately 12 patients will undergo intensive, triplicate ECG monitoring to coincide with PK evaluation on Cycle 1/Day 1. Triplicate ECGs should be performed between 2 and 5 minutes apart and should be performed prior to blood draws for PK. These patients will have triplicate ECGs and PK samples taken predose and at 1, 2, 4, 6, and 8 hours postdose. Patients will be supine and rested for approximately 2 minutes before ECGs are recorded. The average of the triplicate measures will be used for analysis. This subset of patients will undergo all other

assessments in the study. As of 09 February 2016, the PK QTc sub-study had reached the enrollment target of 12 patients and is now closed to enrollment.

Blood samples will be collected for all patients at screening for the exploratory evaluation of circulating biomarkers.

Clinic visits will be weekly during Cycle 1 and then every 4 weeks ( $\pm 3$  days) for subsequent cycles. Response Evaluation Criteria in Solid Tumors (RECIST; v.1.1) tumor assessment via CT or MRI of the abdomen/pelvis and clinically indicated areas is required every 8 weeks ( $\pm 7$  days) from Cycle 1/Day 1 for 6 months and then every 12 weeks until progression. Copies of scans will be collected for future central evaluation if needed. Cycle timing will not be delayed for treatment interruptions, and tumor assessment should occur according to this schedule regardless of whether study treatment is interrupted. All AEs and serious adverse events (SAEs) will be collected and recorded for each patient from the day of signing the screening informed consent form (ICF) until the EOT visit. New SAEs (including deaths) will be collected for 30 days after the last dose of study treatment. All AEs and SAEs experienced by a patient, irrespective of the suspected causality, will be monitored until the AE or SAE has resolved, any abnormal laboratory values have returned to baseline or normalized, until there is a satisfactory explanation for the changes observed, until the patient is lost to follow-up, or until the patient has died. The Adverse Events of Special Interest (AESIs) for this study are myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and secondary cancers (new malignancies other than MDS/AML, pneumonitis, and embryo-fetal toxicity. AESIs must be reported to the Sponsor as soon as the Investigator becomes aware of them (per Section 6.2.5.3 of the protocol).

Approximately 500 patients will be enrolled in the study at approximately 60 sites. The study will be conducted in conformance with Good Clinical Practice (GCP).

#### 1.2.2. Randomization Methodology

Not applicable as this is a single-arm study.

#### 1.2.3. Stopping Rules and Unblinding

There are no pre-specified stopping rules for the study. Unblinding is not applicable as this is a single-arm, open-label study.

#### 1.2.4. Study Procedures

The schedule of assessments, as outlined in the study protocol, is provided in [Table 1-1](#).

**Table 1-1 Schedule of Assessments**

Cycle <sup>a</sup>	Screening <sup>b</sup>	1				Subsequent Cycles <sup>a</sup>	EOT (within 7 days of last dose)	Post-Treatment Assessments
		1	8	15	22			
Informed consent <sup>b, c</sup>	X							
Demographics	X							
Medical, surgical, cancer, and medication history	X							
Sample collection (tumor) for centralized <i>tBRCA<sup>mut</sup></i> /HRD testing <sup>c</sup>	X <sup>c</sup>							
Sample collection (whole blood) for <i>gBRCA<sup>mut</sup></i> testing	X							
Tumor sample ( <i>optional</i> ) <sup>d</sup>	X						X	
Blood sample for exploratory biomarker analysis <sup>e</sup>	X							
Blood sample for PK <sup>f</sup>		X				X		
Tumor assessment (RECIST) <sup>g</sup>	X					X <sup>g</sup>	X	X <sup>g</sup>
Chest CT/MRI <sup>h</sup>	X							
Pregnancy test <sup>i</sup>	X					X		
Serum chemistry	X	X <sup>j</sup>		X		X	X	
CBC <sup>k</sup>	X	X <sup>j</sup>	X <sup>l</sup>	X	X <sup>l</sup>	X	X	
Serum CA-125 <sup>j</sup>	X	X <sup>g</sup>				X <sup>g</sup>	X	X
ECG <sup>m</sup>	X <sup>m</sup>							
Physical examination	X							
Symptom-directed physical examination		X		X		X <sup>n</sup>	X	
Vital signs, height, weight <sup>o</sup>	X	X		X		X	X	

Cycle <sup>a</sup>	Screening <sup>b</sup>	1				Subsequent Cycles <sup>a</sup>	EOT (within 7 days of last dose)	Post-Treatment Assessments
Day	-28 to -1	1	8	15	22	Cycle <i>n</i> , Day 1		
ECOG performance status	X					X <sup>n</sup>	X	
Bone marrow aspirate and biopsy <sup>p</sup>		X <sup>p</sup>						
Concomitant medication	X	X		X		X	X	
Adverse event monitoring	X	X		X		X	X <sup>q</sup>	X
Study treatment dispensed/collected		X				X	X	
Survival assessment <sup>f</sup>								X

Abbreviations: AE = adverse event; AML = acute myloid leukemia; BP = blood pressure; CA-125 = cancer antigen 125; CBC = complete blood count; CT = computed tomography; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; EOT = end of treatment; *gBRCA<sup>mut</sup>* = germline breast cancer gene mutation; HRD = homologous recombination deficiency; ICF = informed consent form; MDS = myelodysplastic syndrome; MRI = magnetic resonance imaging; PK = pharmacokinetics; RECIST = Response Evaluation Criteria in Solid Tumors; SAE = serious adverse event; *tBRCA<sup>mut</sup>* = tumor breast cancer gene mutation.

- <sup>a</sup> Treatment cycles are 28 days long, with visits on Day 1 of each cycle unless otherwise specified. Visits (other than Cycle 1) continue every 28 days until study treatment discontinuation. All visits have a window of ±3 days (calculated in reference to Cycle 1/Day 1).
- <sup>b</sup> Screening tests that could be considered standard of care (ie, CT/MRI, physical examination, vital signs, height, weight, and assessment of serum chemistry, CBC, pregnancy testing, and serum CA-125) that were performed within the protocol-required timelines (ie, within the 28-day screening window; within 72 hours prior to first dose [ie, Cycle 1/Day 1] where required) but prior to informed consent being obtained may be used as part of the patient's screening assessment.
- <sup>c</sup> For patients who do not have archival tissue, tissue from a fresh biopsy must be obtained prior to study treatment initiation. Centralized HRD testing of tumor sample must be completed with results reported prior to enrollment. The sample may be sent in advance of the protocol-defined screening period in order to facilitate the screening and enrollment process. A separate ICF may be signed prior to the screening period for HRD testing in order to facilitate early testing. Depending on local site requirements, patients may sign a screening study ICF prior to the screening period to facilitate early HRD testing only. All other study tests and procedures must be done in the screening window (Day -28 to Day -1). For patients who do not have archival tissue, tissue from a fresh biopsy must be obtained.
- <sup>d</sup> Formalin-fixed, paraffin-embedded tumor sample consisting of a total of 100-micron thickness of sections (≥80-micron minimum) or unsectioned paraffin block.
- <sup>e</sup> Blood samples will be collected for all patients during screening for the exploratory evaluation of circulating markers of efficacy. The sponsor may discontinue the blood collection when samples have been collected from an adequate number of patients.
- <sup>f</sup> Blood samples for PK may be collected on Cycle 1/Day 1 predose (within 30 minutes) and 2 hours (± 15 minutes) postdose, on Cycle 2/ Day 1 predose (within 30 minutes) and 2 hours (± 15 minutes) postdose, on Cycle 4/Day 1 predose (within 30 minutes), and on Cycle 8/Day 1 predose (within 30 minutes). At selected sites, a subset of patients (approximately 12) will undergo triplicate ECG monitoring to coincide with PK evaluation on Cycle 1/Day 1 predose and at 1, 2, 4, 6, and 8 hours postdose. Note: The exact time of the PK blood draw will be recorded, and ECG monitoring is to be completed prior to the PK blood draw or other laboratory evaluations.

- <sup>g</sup> RECIST tumor assessment via CT or MRI of abdomen/pelvis and clinically indicated areas required at screening, every 8 weeks ( $\pm 7$  days) from Cycle 1/Day 1 (ie, Cycle 3, Cycle 5, Cycle 7) for 6 months, and then every 12 weeks (ie, Cycle 10, Cycle 13, Cycle 16, etc) until progression. Positron emission tomography/CT may be used according to RECIST guidelines. Cycle timing will not be delayed for treatment interruptions, and tumor assessment should occur according to this schedule regardless of whether study treatment is interrupted. If a patient discontinues treatment for a reason other than disease progression as defined in the protocol or death, withdrawal of consent, or loss to follow-up, then scans and CA-125 testing should continue at the specified intervals (until the start of subsequent anticancer treatment). If a patient had a CT/MRI of the abdomen/pelvis and clinically indicated areas within the 28-day screening window before Cycle 1/Day 1 but prior to signing the main ICF, the patient is not required to complete an additional CT/MRI scan for study screening. CT/MRI scans completed during screening prior to signing the main ICF must have been performed and be able to be submitted per the image acquisition guidelines.
- <sup>h</sup> Chest CT/MRI if not done as part of RECIST tumor assessment at screening. If the chest CT/MRI is clear at screening, repeat chest imaging is not required in the absence of lesions to be followed or in the absence of clinical indication requiring follow-up.
- <sup>i</sup> Negative serum pregnancy test required within 72 hours from first dose of study treatment (ie, Cycle 1/Day 1) for females of childbearing potential; repeated every 3 months for duration of study (ie, Cycle 4, Cycle 7, etc).
- <sup>j</sup> If screening laboratory testing (serum chemistry, CBC, CA-125) performed within 72 hours of Day 1, repeat testing is not required.
- <sup>k</sup> If dose interruption or modification is required at any point on study because of hematologic toxicity, weekly blood draws for CBC will be monitored until the AE resolves, and to ensure safety of the new dose, weekly blood draws for CBC will be also required for an additional 4 weeks after the AE has been resolved to the specified levels, after which monitoring every 4 weeks may resume.
- <sup>l</sup> Collection of blood for the Cycle 1/Day 8 and Day 22 CBC may be done at the study center's local laboratory or at a laboratory local to the patient, if approved by the Principal Investigator as an adequate laboratory. The laboratory must have the capability to provide results to the Principal Investigator electronically or by fax within 24 hours of blood collection.
- <sup>m</sup> Patients will undergo a single ECG monitoring assessment at screening, prior to laboratory evaluations. At selected sites, a subset of patients (approximately 12) will undergo triplicate ECG monitoring to coincide with PK evaluation on Cycle 1/Day 1 predose and at 1, 2, 4, 6, and 8 hours postdose. Triplicate ECGs should be performed between 2 and 5 minutes apart and should be performed prior to blood draws for PK or other laboratory evaluations.
- <sup>n</sup> Symptom-directed physical examination is to be conducted at every visit and ECOG assessed every 12 weeks ( $\pm 7$  days) until EOT.
- <sup>o</sup> Vital signs include BP, pulse, and temperature. Height obtained at screening only.
- <sup>p</sup> For any suspected MDS/AML case reported while a patient is receiving treatment or being followed for post-treatment assessments, bone marrow aspirate and biopsy testing must be completed by a local hematologist. A whole blood sample will also be collected for cytogenetic analysis (mutations of select myeloid-associated genes). Testing completed as part of standard of care is sufficient as long as the methods are acceptable to the Sponsor's Medical Monitor. The study site must receive a copy of the hematologist's report of aspirate/biopsy findings (which must include a classification according to World Health Organization criteria) and other sample testing results related to MDS/AML.
- <sup>q</sup> New SAEs recorded up to 30 days after last dose of study treatment administration.
- <sup>r</sup> Every 90 ( $\pm 7$ ) days after treatment discontinuation. In addition to survival, this assessment also includes outcomes for subsequent anticancer therapies including any new malignancy information.



### 1.2.5. Efficacy, Pharmacokinetic, and Safety Parameters

#### 1.2.5.1. Efficacy Parameters

Protocol-specified efficacy parameters include:

- ORR, which is defined as the proportion of patients achieving confirmed complete response (CR) or partial response (PR) as assessed by the Investigator per RECIST (v1.1).
- DOR, which is defined as the time from first documentation of CR or PR until the earlier date of first documentation of progressive disease (PD) or death by any cause in the absence of progression as assessed by the Investigator per RECIST (v1.1).
- DCR, which is defined as the proportion of patients achieving best overall response of CR, PR, or stable disease (SD) as assessed by the Investigator per RECIST (v1.1).
- PFS, which is defined as the time from the date of first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression as assessed by the Investigator per RECIST (v1.1).
- OS, which is defined as the time from the date of first dose to the date of death for any cause.
- TFST, which is defined as the time from the date of first dose of study treatment to the date of first dose of first subsequent therapy or death, whichever occurs first.

#### 1.2.5.2. Pharmacokinetic Parameters

A separate analysis plan will describe PK parameters and analyses.

#### 1.2.5.3. Safety Parameters

Safety parameters evaluated during the conduct of the study include: treatment-emergent AEs (TEAEs), clinical laboratory (hematology, chemistry, coagulation, and urinalysis), vital signs, ECG, physical examination, Eastern Cooperative Oncology Group (ECOG) performance status, and use of concomitant medications. The safety endpoints are:

- TEAEs
- Clinical laboratory:
  - Complete blood count (CBC): hemoglobin, platelets, mean platelet volume (optional), mean corpuscular volume, white blood cell count, differential white cell count (absolute lymphocyte count, percent lymphocytes, absolute neutrophil count, and percent neutrophils)
  - Serum chemistry assessments for safety include: sodium, potassium, calcium, magnesium, chloride, glucose, creatinine, total bilirubin, gamma glutamyltransferase (GGT), alkaline phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea or blood urea nitrogen, total protein, albumin, lactate dehydrogenase, amylase
  - Serum CA-125
  - Serum pregnancy testing

- Physical examination, which includes assessments of the following body systems:
  - General Appearance
  - Dermatologic
  - Head, Eyes, Ears, Nose, and Throat (HEENT)
  - Thyroid
  - Lymph Nodes
  - Respiratory
  - Cardiovascular
  - Gastrointestinal
  - Extremities
  - Musculoskeletal
  - Psychiatric
- Vital signs:
  - Height (at screening only)
  - Weight
  - Blood pressure
  - Pulse
  - Temperature
- ECOG performance status
- ECG (all patients at screening, PK QTc sub-study patients at all time points)
- Concomitant medications

Additional safety parameters include study treatment exposure and compliance.

## **2. PATIENT POPULATION**

### **2.1. Population Definitions**

The following patient populations will be evaluated and used for presentation and analysis of the data:

- Safety (SAF) population is defined as all patients who receive at least 1 dose of study drug.
- Intent-to-Treat (ITT) population is defined as all dosed patients with measurable disease at baseline. Measurable disease at baseline is determined by the existence of at least 1 target lesion at baseline tumor scan.
- Response-Evaluable (RE) population is defined as all ITT patients with at least 1 evaluable post-baseline tumor scan.

Given the single arm study design, the SAF population will be used to summarize the patient disposition and baseline characteristics in this study. The ITT population is the primary population for the analysis of efficacy endpoints. The SAF population is the primary population for the analysis of safety endpoints. The RE population will be used in supportive analyses when applicable.

### **2.2. Protocol Deviations**

Protocol Deviations (PD) will be assessed as important or significant per Sponsor's SOP.

- A PD is classified as important if there is the potential to impact the completeness, accuracy, and/or reliability of the study data, or affect a patient's rights, safety, or well-being.
- An important PD is classified as significant if it is confirmed to adversely impact the completeness, accuracy, and/or reliability of the study data, or affect a patient's rights, safety, or well-being.

All PDs will be identified and finalized prior to database lock.

The following protocol deviation summaries will be provided:

- Number and percentage of patients with a significant protocol deviation by type of deviation.
- Number and percentage of patients with an important protocol deviation by type of deviation.
- A listing of all protocol deviations.

Per-protocol analysis that excludes patients with significant protocol deviations will not be performed.

### 3. GENERAL STATISTICAL METHODS

#### 3.1. Sample Size Justification

The study protocol initially allowed enrollment of all patients with at least 3 prior lines of anti-cancer therapy. In the subsequent protocol amendments, the study enrollment was adjusted to allow only HRD-positive patients with 3 or 4 prior lines of anti-cancer therapy. This adjustment was made in consideration of the evolving role of PARP inhibitors in ovarian cancer treatment based on external data. Overall, approximately 500 patients are expected in the study. The study enrollment is also expected to include a minimum number of tBRCAmut patients ( $\geq 50$ ) and HRD-positive patients ( $\geq 150$ ).

For the primary efficacy endpoint of ORR in HRD-positive patients who have received 3 or 4 prior lines of anti-cancer therapy and are platinum-sensitive to the last platinum-based therapy, an alternative hypothesis of ORR  $\geq 30\%$  is considered against a null hypothesis of ORR  $\leq 10\%$ .

For the key secondary efficacy endpoints of ORR tested in broader subgroups to include platinum-resistant patients and/or HRD-negative/unknown patients, an alternative hypothesis of ORR  $\geq 25\%$  is considered against a null hypothesis of ORR  $\leq 10\%$ .

It is estimated that 45 patients would provide 90% power for testing the primary efficacy analyses. Statistical power for various sample sizes are presented below to provide guidance for the key secondary hypotheses when tested individually (regardless of sequential testing) using 1-sided alpha 0.025. The power is calculated by assuming the exact binomial distribution using East® software Version 6.4.

n	Statistical Power*
45	72%
60	85%
75	92%
90	96%

\* Ho: ORR  $\leq 10\%$  vs Ha: ORR  $\geq 25\%$

As of August 2017, approximately 450 patients were dosed in the study. Approximately 320 patients had 3 or 4 prior lines of anti-cancer therapy (~150 HRD positive). Based on a preliminary calculation of the platinum-sensitivity to the last platinum-based therapy, the number of enrolled patients for the primary endpoint and the key secondary efficacy endpoints are considered adequate to ensure sufficient power for the planned analysis.

#### 3.2. General Methods

All safety data listings that contain an evaluation date will also contain a relative study day. Pre-treatment and on-treatment study days are numbered relative to the day of the first dose of study drug which is designated as Day 1. The preceding day is Day -1, the day before that is Day -2, etc. The last day of study drug is designated with an “L” (eg, Day 14L). Post-treatment study days are numbered relative to the last dose and are designated as Day +1, Day +2, etc. In addition to relative day, cycle and day of treatment within cycle will be calculated and presented.

All output will be incorporated into Microsoft Word or Excel files or Adobe Acrobat PDF files, sorted and labeled according to the International Conference on Harmonisation (ICH) recommendations[8], and formatted to the appropriate page size(s).

Tabulations will be produced for appropriate demographic, baseline, efficacy, and safety parameters. Unless otherwise stated, all tabulations will be summarized for patients with 3 or 4 previous chemotherapy regimens,  $\geq 5$  previous chemotherapy regimens, and overall (all lines of previous chemotherapy regimens including  $\leq 2$  lines).

For categorical variables, summary tabulations of the number and percentage of patients within each category of the parameter will be presented. Percentages will be based on the patients with a non-missing parameter. Percentages will be reported to 1 decimal place. Percentages will not be presented for zero counts.

For continuous variables, the number of patients, mean, standard deviation (SD), median, first quartile (Q<sub>1</sub>), third quartile (Q<sub>3</sub>), minimum, and maximum values will be presented. Mean, median, Q<sub>1</sub>, and Q<sub>3</sub> will be reported to 1 more decimal place than the raw data, while the SD will be reported to 2 more decimal places than the raw data.

Time-to-event data will be summarized using Kaplan-Meier (KM) methodology using 25<sup>th</sup>, 50<sup>th</sup> (median), and 75<sup>th</sup> percentiles with associated 2-sided 95% confidence intervals (CIs), as well as percentage of censored observations.

Formal statistical hypothesis testing will be performed on the primary efficacy endpoint as described in the sections below.

In addition:

- P-values greater than or equal to 0.001, in general, will be presented to 3 decimal places; p-values less than 0.001 will be presented as “<0.001”
- CIs will be presented to 1 more decimal place than the raw data
- Weeks will be calculated as Number of days divided by 7
- Months will be calculated as Number of days divided by 30.4375
- Years will be calculated as Number of days divided by 365.25
- Day 1 will be considered as the first day of treatment
- End of Study is defined as the last available study assessment
- All tables, figures, and listings will include footers at the bottom of the page reflecting the path and date of the datasets, datasets used to generate the tables, figures, and listings, and date and time of the generation of the output

### **3.3. Computing Environment**

All statistical analyses will be performed using SAS statistical software v9.4 or later, unless otherwise noted. Medical history and AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) v20.0 or later. Laboratory parameter changes will be described using shift tables, relative to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Concomitant medications will be coded using the latest version of the World Health Organization’s (WHO) Anatomical Therapeutic Chemical (ATC) classification.

### **3.4. Baseline Definitions**

For all analyses except ECG, baseline is defined as the most recent measurement prior to the first administration of study drug. For ECG analyses, baseline will be defined as the average of the closest triplicate (if triplicates were collected) readings prior to dosing on the first day that study drug is administered.

### **3.5. Methods of Pooling Data**

Data will be pooled across study sites.

### **3.6. Adjustments for Covariates**

No formal statistical analyses that adjust for possible covariate effects are planned for the efficacy or safety endpoints. Formal analyses adjusting for possible covariate effects for the PK endpoints are contained in a separate SAP.

### **3.7. Multiple Comparisons/Multiplicity**

Multiplicity is controlled by conducting a hierarchical testing of the primary endpoint and the key secondary endpoints.

### **3.8. Subpopulations**

#### **3.8.1. Prior Lines of Chemotherapy**

The reported cancer therapy regimens from eCRF page (Ovarian Cancer Treatment) will be checked with the per-protocol list of chemotherapy regimens to determine patients with 3 or 4 previous chemotherapy regimens consistent with the protocol inclusion criteria #5:

- Patients must have completed 3 or 4 previous chemotherapy regimens (eg, gemcitabine, doxorubicin, topotecan, carboplatin, oxaliplatin, cisplatin, bevacizumab, or PARP inhibitors as single agents or in combination per standard of care).

A list of the per-protocol chemotherapy regimens is provided in the Appendix ([Section 7.5](#)). Patients will be classified by  $\leq 2$ , 3-4, and  $\geq 5$  previous chemotherapy regimens based on the per-protocol chemotherapy regimens, and summarized by:

- Number and percentage by the number of prior chemotherapy regimens
- Duration (in months) between the end date of the last chemotherapy regimen and the date of first dose of study treatment

#### **3.8.2. Response to the Last Platinum-Based Therapy**

Platinum-free interval (PFI) to the last platinum-based therapy will be determined between the reported stop date of the last platinum-based therapy and the reported date of disease progression following the last platinum-based therapy.

- Platinum-sensitive: PFI  $\geq 6$  months (180 days) after the end date of last platinum-based therapy
- Platinum-resistant: PFI  $> 4$  weeks (28 days) and  $< 6$  months (180 days) after the end date of last platinum-based therapy

- Platinum-refractory: PFI  $\leq$  4 weeks (28 days) after the end date of last platinum-based therapy
- Response-unknown: PFI is missing. PFI is missing if both dates are completely missing. Partial dates will be handled according to [Section 3.10](#)

The per-protocol platinum-based therapies are determined using the list in the Appendix ([Section 7.5](#)).

Patients will be summarized by:

- Number and percentage by the number of prior platinum-based therapies
- Duration (in months) between the end date of the last platinum-based therapy and the date of first dose of study treatment

### 3.8.3. Prior PARP Treatment

Patients with any PARP treatment prior to the first dose of study treatment will be identified and analyzed for exploratory purpose.

The list of prior PARP treatment includes: niraparib, olaparib, rucaparib, and veliparib.

### 3.8.4. Biomarker Subpopulations

#### 3.8.4.1. Biomarker Definitions

**BRCA mutation (BRCA-mut):** A deleterious or suspected deleterious BRCA1 or BRCA2 mutation found in a tumor and/or in blood. In this document, BRCA-mut refers to patients with either germline or somatic mutation.

- **Germline BRCA mutation (gBRCA-mut):** A germline BRCA mutation is an inherited deleterious or suspected deleterious mutation in either a BRCA1 or BRCA2 tumor suppressor gene found in blood.
- **Somatic BRCA mutation (sBRCA-mut):** A somatic BRCA mutation is a deleterious or suspected deleterious alteration in the BRCA1 or BRCA2 genes that is acquired after conception (not hereditary). sBRCA-mut can be determined by the presence of tumor BRCA mutation (tBRCA-mut) but the absence of gBRCA-mut in blood.

**BRCA wild type (BRCA-wt):** A tumor and/or blood does not possess either a deleterious or suspected deleterious germline or a somatic BRCA mutation. In this document, BRCA-wt refers to patients without gBRCA-mut and sBRCA-mut.

**Homologous recombination deficiency (HRD) –** Dysregulation in the homologous recombination pathway (due to genetic mutations or alterations) leading to cellular genomic instability and an inability to efficiently repair damaged DNA.

**HRD positive (HRD-pos):** HRD positive status may be determined by the myChoice HRD test. Any tumor that scores  $\geq$ 42 or has a deleterious or suspected deleterious BRCA mutation would be considered HRD positive.

**HRD negative (HRD-neg):** HRD negative status may be determined by the myChoice HRD test. Any tumor that scores  $<$ 42 and does not possess a deleterious or suspected deleterious BRCA mutation would be considered HRD negative.

#### 3.8.4.2. Study-Specific Biomarker Populations

In this study, tumor BRCA and HRD status are determined by tumor samples at screening via the myChoice HRD test. The gBRCA status is determined by a central test of blood samples at screening and recorded in the eCRF BRCA form.

All patients will be classified by BRCA mutation status as follows:

- BRCA-mut:
  - gBRCA-mut: patients with any variant or large rearrangement found in BRCA1/2 that is either positive for a deleterious mutation or genetic variant for suspected deleterious
  - sBRCA-mut: patients with tBRCA-mut but without gBRCA-mut
- BRCA-wt: patients without gBRCA-mut and sBRCA-mut
- BRCA unknown (BRCA-unk): None of tBRCA and gBRCA test results available (eg, test canceled, incomplete/inconclusive, or data missing for a patient).

All patients will be summarized by HRD status in the following subgroups:

- HRD-pos:
  - BRCA-mut
  - (BRCA-wt or BRCA-unk) and HRD test score  $\geq 42$
- HRD-neg: (BRCA-wt or BRCA-unk) and HRD test score  $< 42$
- HRD unknown (HRD-unk): HRD test result not available (eg, test canceled, incomplete/inconclusive, or data missing for a patient)

In addition, the tBRCA-mut patients will also be summarized based on the reported BRCA variants found in tumor:

- BRCA1 variant
- BRCA2 variant

The gBRCAmut patients will also be summarized based on the reported BRCA variants found in blood and recorded in the eCRF BRCA form:

- BRCA1 variant
- BRCA2 variant
- Large rearrangement in BRCA1/2

If applicable, other exploratory biomarker subpopulations may be further defined and analyzed.

### 3.9. Withdrawals, Dropouts, Loss to Follow-up

Patients who are withdrawn or discontinued from the study will not be replaced.

### 3.10. Missing Data

In general, there will be no substitutions made to accommodate missing data points. All data recorded on the eCRF will be included in data listings that will accompany the CSR.



When calculating PFI to the last platinum-based therapy, partial dates of the last platinum-based therapy and the disease progression following the last platinum-based therapy will be handled as follows. If the day of the month is missing, the day will be set to the first day of the month. If the day and month are both missing, the day and month will be assumed to be January 1. If the imputed date of the disease progression following the last platinum-based therapy is earlier than the end date of the last platinum-based therapy, the imputed date of the disease progression will be set equal to the end date of the last platinum-based therapy. Imputation of partial dates is used only to estimate PFI; data listings will present the partial date as recorded in the eCRF.

When tabulating AE data, partial dates will be handled as follows. If the day of the month is missing, the onset day will be set to the first day of the month unless it is the same month and year as study treatment. In this case, in order to conservatively report the event as treatment-emergent, the onset date will be assumed to be the date of treatment. If the onset day and month are both missing, the day and month will be assumed to be January 1, unless the event occurred in the same year as the study treatment. In this case, the event onset will be coded to the day of treatment in order to conservatively report the event as treatment-emergent. A missing onset date will be coded as the day of treatment. If the resulting onset date is after a reported date of resolution, the onset date will be set equal to the date of resolution. Imputation of partial dates is used only to determine whether an event is treatment-emergent; data listings will present the partial date as recorded in the eCRF.

### 3.11. Visit Windows

**Table 3-1 Evaluation Intervals**

Evaluation	Protocol-Specified Interval	Interval for Analysis
Screening	Day -28 to Day -1	Day -28 to Day -1
Cycle 1, Day 1	Day 1	Day 1
Cycle 1, Day 8	Day 5 to Day 11	Day 5 to Day 11
Cycle 1, Day 15	Day 12 to Day 18	Day 12 to Day 18
Cycle 1, Day 22	Day 19 to Day 25	Day 19 to Day 25
Cycle <i>n</i> , Day 1	Day $28(n-1) - 3$ to Day $28(n-1) + 3^*$	Day $28(n-1) - 3$ to Day $28(n-1) + 3^*$
End of Treatment	Within 7 days of last dose, except for AEs which will be collected for up to 30 days after the date of the last dose	Within 7 days of last dose, except for AEs which will be collected for up to 30 days after the date of the last dose

Abbreviations: AE = adverse event; ECOG = Eastern Cooperative Oncology Group; RECIST = Response Evaluation Criteria in Solid Tumors.

\* Symptom-directed physical examination and ECOG performance status are required every 12 weeks ( $\pm 7$  days), serum pregnancy tests are required at 3-month intervals from screening (Cycles 4, 7, etc), and RECIST (v1.1) tumor assessments (as clinically indicated) are required every 8 weeks ( $\pm 7$  days) for 6 months and then every 12 weeks ( $\pm 7$  days) until progression. Therefore, the symptom-directed physical examinations and ECOG performance status are required at Cycle 4, Cycle 7, etc, with a protocol-specified interval and an interval for analysis of Day  $28(n-1) - 7$  to Day  $28(n-1) + 7$  (where *n* is the cycle number). RECIST tumor assessments are required at Cycles 3, 5, 7, 10, 13, etc, with a protocol-specified interval and an interval for analysis of Day  $28(n-1) - 7$  to Day  $28(n-1) + 7$  (where *n* is the cycle number).

Note: Day 25 is contained within both the Cycle 1 Day 22 and the Cycle 2 Day 1 visit windows. Visits occurring on Day 25 will be classified based on the purpose of the visit.

It is expected that all visits should occur according to the protocol schedule. By-visit summaries and analyses will be by nominal visit (all data will be tabulated per the evaluation visit as recorded on the eCRF even if the assessment is outside of the visit window for analysis). In data listings, the relative day of all dates will be presented.

### **3.12. Administrative Interim Analyses**

Safety data from this study collected through 20 May 2016 was analyzed to write an interim CSR and for inclusion as part of the integrated summaries of safety in the niraparib submission in the second half of 2016. Efficacy data from this study were not analyzed.

## 4. STUDY ANALYSES

### 4.1. Patient Disposition

Patient disposition will be tabulated and include the numbers of screened patients (who have signed informed consent) and the numbers of patients in each patient population for analysis, the numbers who discontinued treatment and discontinued study and reason(s) for withdrawal, and the number of patients who died.

Tables will be summarized by 3-4 prior lines,  $\geq 5$  prior lines, and Overall. A by-patient data listing of study completion information including the reasons for treatment discontinuation and/or study discontinuation will be presented.

### 4.2. Demographics, Baseline Characteristics, and Medical History

Demographics, baseline characteristics, and medical history information will be summarized using descriptive statistics. Tables will be summarized by 3-4 prior lines,  $\geq 5$  prior lines, and Overall. No formal statistical comparisons will be performed.

Demographic and baseline data for each patient will be provided in data listings.

The demographic and baseline characteristics tables will include the following variables:

- Region (US, Canada)
- Age at time of screening (years) calculated as date of screening minus date of birth / 365.25, unless local regulations prevent the collection of date of birth, in which case age, as reported on the eCRF, will be used
- Age categories (18 to <65, 65 to <75,  $\geq 75$ ; and  $\geq 65$ )
- Reproductive status (childbearing/non-childbearing potential)
- Race (White, Black, Asian, American Indian/Alaska native, native Hawaiian or other Pacific Islander, other, unknown, and not reported)
- Ethnicity (Hispanic, non-Hispanic, unknown, and not reported)
- Time from first diagnosis to first dose (years)
- Primary tumor site (ovarian, primary peritoneal, or fallopian tube)
- International Federation of Gynecology and Obstetrics (FIGO) stage at time of initial diagnosis
- Baseline weight (in kilograms, last value prior to first dose; if weight is reported in pounds, convert to kilograms by dividing by 2.2)
- Baseline height (in centimeters, last value prior to first dose; if height is reported in inches, convert to centimeters by multiplying by 2.54)
- Baseline body mass index (BMI) ( $\text{kg}/\text{m}^2$ ), calculated using the patient's height and weight at Baseline [ $\text{BMI} (\text{kg}/\text{m}^2) = \text{weight} (\text{kg}) / \text{height} (\text{m})^2$ ]
- ECOG performance status at baseline
- History of myelosuppression (thrombocytopenia, leukopenia, anemia, or neutropenia) within the past year

- History of blood transfusion
- History of thrombocytopenia with grade 3 or 4 (repeated for leukopenia, anemia, and neutropenia)
- Prior ovarian cancer treatment, including number of prior lines of chemotherapy, number of prior platinum courses, any surgeries/procedures related to the study indication, number of surgeries, any radiotherapy prior to enrollment, response to last platinum-based therapy, PFI (months) after the last platinum-based therapy
- Histology and grade of disease at diagnosis and most recent biopsy, if additional biopsy performed
- BRCA and HRD status including:
  - gBRCA-mut variant [BRCA1, BRCA2, Large rearrangement in BRCA1/2]
  - tBRCA-mut variant [BRCA1, BRCA2]
  - BRCA status [BRCA-mut, gBRCA-mut and sBRCA-mut status within BRCA-mut; BRCA-wt; BRCA-unk]
  - HRD status [HRD-pos, BRCA-mut and (BRCA-wt/BRCA-unk and HRD  $\geq$ 42) within HRD-pos; HRD-neg; HRD-unk]
- Prior PARP treatment (yes, no)

Medical history will be coded using MedDRA v20.0 or later, and the number and percentage of patients experiencing at least 1 such diagnosis by MedDRA System Organ Class (SOC) and preferred term (PT) will be reported.

In addition, the following baseline subgroups will be presented for all patients, patients without prior PARP treatment and with prior PARP, respectively.

- BRCA status [BRCA-mut, BRCA-wt, BRCA-unk] by the response to the last platinum-based therapy
- HRD status [HRD-pos, HRD-neg, HRD-unk] by the response to the last platinum-based therapy

### **4.3. Efficacy Evaluation**

#### **4.3.1. Efficacy Variables for Primary and Key Secondary Analyses**

The primary and key secondary efficacy analyses will be based on the investigator-assessed confirmed ORR per RECIST v1.1.

At each evaluation, the criteria in [Table 4-1](#) were used to define each patient's overall response at that evaluation.

**Table 4-1 Overall Response for Patients with Measureable Disease at Study Entry**

Target Lesions	Non-Target Lesions	New Lesions	Overall Response
CR	CR	No	CR
CR	Non-CR/Non-PD	No	PR
CR	Not evaluated	No	PR
PR	Non-CR/Non-PD/Not evaluated	No	PR
SD	Non-CR/Non-PD/Not evaluated	No	SD
PD	Any	Yes or No	PD
Any	PD	Yes or No	PD
Any	Any	Yes	PD

Abbreviations: CR = complete response; PD = progressive disease; PR = partial response; SD = stable disease.

As confirmed CR/PR is required, the best overall response (BOR) will be determined as shown in [Table 4-2](#).

Given protocol scheduled tumor assessment interval is every 8 weeks ( $\pm 7$  days) from Cycle 1/Day 1 for 6 months and then every 12 weeks ( $\pm 7$  days) until progression. The minimum criteria for SD duration are at least 7 weeks from the date of first dose of study treatment.

**Table 4-2: Best Overall Response when Confirmation of CR and PR Required**

Overall Response First Time Point	Overall Response Subsequent Time Point (at least 4 weeks)	Best Overall Response
CR	CR	CR
CR	PR	SD provided minimum criteria for SD duration met, otherwise, PD
CR	SD	SD provided minimum criteria for SD duration met, otherwise, PD
CR	PD	SD provided minimum criteria for SD duration met, otherwise, PD
CR	NE	SD provided minimum criteria for SD duration met, otherwise, NE
PR	CR	PR
PR	PR	PR
PR	SD	SD provided minimum criteria for SD duration met, otherwise, NE
PR	PD	SD provided minimum criteria for SD duration met, otherwise, PD
PR	NE	SD provided minimum criteria for SD duration met, otherwise, NE
SD	SD	SD provided minimum criteria for SD duration met, otherwise, NE
SD	PD	SD provided minimum criteria for SD duration met, otherwise, PD
SD	NE	SD provided minimum criteria for SD duration met, otherwise, NE
NE	NE	NE

Abbreviations: CR = complete response; NE = not evaluable; PD = progressive disease; PR = partial response; SD = stable disease.

For each patient, BOR will be determined based on the overall responses at all time points between the date of first dose and the date of first documented radiological disease progression, or the date of subsequent anti-cancer therapy, or the date of study discontinuation, whichever occurs first. Specifically:

- Day 1 can be determined from the “dose administration date” field on the “first dose” form.
- The date of radiological disease progression can be determined by selecting the earliest date from the “date of the radiological scan or assessment on which the response evaluation was based” field on the “evaluation of response (RECIST)” form where “overall response” = PD.
- Subsequent anti-cancer therapy can be determined by checking for any entries made on the “follow up anti-cancer therapy” form.

- The date of premature study discontinuation can be determined by using the “date of premature study discontinuation” field on the “premature study discontinuation” form. This date should be compared to the date on the “discontinuation of treatment” form where the primary reason for discontinuation is listed as “lost to follow up,” “death,” “sponsor decision to terminate study,” or “patient withdrew consent.” If these dates differ, select the earlier date.
- For each patient, select all “evaluation of response (RECIST)” forms meeting the following criteria:
  - The “date of the radiological scan or assessment on which the response evaluation was based” is after Day 1.
  - The “date of the radiological scan or assessment on which the response evaluation was based” is on or before the date of radiological disease progression, date that anti-cancer therapy first began, and the date of study discontinuation. If the patient did not experience radiological disease progression, begin anti-cancer therapy, or discontinue the study prematurely, select all forms after Day 1.

Patients with a BOR of either confirmed CR or PR are considered to have responded to treatment (“responders”) for the primary efficacy variable (ORR). All other patients are considered to have not responded to treatment (“non-responders”) for the primary efficacy variable.

The primary efficacy analysis will be testing the alternative hypothesis of  $ORR \geq 30\%$  will be tested against a null hypothesis of  $ORR \leq 10\%$  in the HRD-positive patients who have received 3 or 4 prior lines of anti-cancer therapy and are platinum-sensitive to the last platinum-based therapy. Patients with prior PARP inhibitor treatment are excluded.

The key secondary efficacy analyses will be sequentially testing the alternative hypothesis of  $ORR \geq 25\%$  against a null hypothesis of  $ORR \leq 10\%$  in:

- All patients who have received 3 or 4 prior lines of anti-cancer therapy and are platinum-sensitive to the last platinum-based therapy, regardless of HRD status (excluding patients with prior PARP treatment)
- All patients who have received 3 or 4 prior lines of anti-cancer therapy and are platinum-sensitive or platinum-resistant to the last platinum-based therapy, regardless of HRD status (excluding patients with prior PARP treatment)
- All patients treated in the study

The ORR and 2-sided 95% confidence interval along with a 1-sided p-value for testing the null hypothesis (one-sided alpha 0.025) based on the binomial distribution will be provided. The exact (Clopper-Pearson) method will be used to calculate 2-sided 95% CI. This can be programmed in SAS by appending the “/ BINOMIAL(EXACT)” option to the end of the appropriate “TABLE” statement.

The following subgroup analyses on ORR will be performed for the largest patient population achieving statistical significance among the sequential testing of primary and key secondary endpoints, and for all treated patients unless already available:

- Age categories [ $<65, \geq 65$ ]
- Primary tumor site [ovarian, primary peritoneal, fallopian tube]
- Response to last platinum-based therapy [platinum-sensitive, platinum-resistant, platinum-refractory, response-unknown]
- BRCA status [BRCA-mut, BRCA-wt, BRCA-unk]
- HRD status [HRD-pos, HRD-neg, HRD-unk]
- HRD-pos [BRCA-mut, (BRCA-wt/BRCA-unk and HRD score  $\geq 42$ )]
- BRCA-mut [gBRCA-mut, sBRCA-mut]
- tBRCA-mut variant [BRCA1, BRCA2]
- gBRCA-mut variant [BRCA1, BRCA2, large rearrangement in BRCA1/2]
- Prior PARP treatment [yes, no]

#### 4.3.2. Secondary Efficacy Variables

##### 4.3.2.1. Duration of Response

For patients who responded to treatment, DOR (in months) is defined as the earliest date of initial response date of confirmed CR or PR to the earliest date of radiological PD or death, calculated as:

$$\frac{[\text{Earliest date of radiological PD or death} - \text{Earliest of (Date of confirmed CR or PR) + 1}]}{30.4375}$$

Table 4-3 provides a summary of the censoring rules used in DOR analysis.

**Table 4-3: Censoring Rules used in Duration of Response Analysis**

Situation	Date of Event or Censoring	Outcome
Start of subsequent anti-cancer therapy prior to a documented radiological progression or death	Date of last radiological tumor assessment prior to or on the date of initiation of the subsequent anti-cancer therapy	Censored
Free of radiological progression and no subsequent anti-cancer therapy started and no death	Date of last radiological tumor assessment	Censored
Documented radiological progression or death after 2 or more consecutive missing radiological assessments	Date of last radiological tumor assessment prior to the missed radiological assessment	Censored
Documented radiological progression or death	Earliest date of documented radiological progression or death	Event

Details about defining CR, PR, PD, and end of study can be found in [Section 4.3.1](#).



For each of the patient populations in the primary and key secondary endpoints, a time-to-event analysis of DOR will be performed respectively using KM methods including quartile estimates and 2-sided 95% CIs. A figure will be produced.

The same subgroup analyses performed for ORR will be performed for DOR.

#### 4.3.2.2. Disease Control Rate

Patients who achieved a best overall response rate of CR, PR, or SD (SD must have met the 7-week criteria described in [Section 4.3.1](#)) will be considered “responders” for this endpoint. All other patients will be considered “non-responders” for this endpoint. Details about defining best overall response rate can be found in [Section 4.3.1](#).

For each of the patient populations in the primary and key secondary endpoints, the DCR and 2-sided 95% CI will be provided respectively. The exact (Clopper-Pearson) method will be used to calculate 95% CI. This can be programmed in SAS by appending the “/ BINOMIAL(EXACT)” option to the end of the appropriate “TABLE” statement.

#### 4.3.2.3. Progression-Free Survival

Progressive disease (PD) will be determined based on RECIST criteria as defined in [Section 4.3.1](#).

PFS (in months) is defined as the time from the date of first dose to the earlier date of radiological PD or death from any cause, calculated as:

$$[\text{Earlier of (Date of radiological PD or death)} - \text{First dose date} + 1] / 30.4375$$

[Table 4-4](#) provides a summary of the censoring rules used in PFS analysis.

**Table 4-4: Censoring Rules used in Progression-Free Survival Analysis**

Situation	Date of Event or Censoring	Outcome
No baseline tumor assessments	First dose date	Censored
No post-baseline tumor assessments and no death	First dose date	Censored
Start of subsequent anti-cancer therapy without a prior documented radiological progression or death	Date of last post-baseline radiological tumor assessment prior to or on the date of initiation of the subsequent anti-cancer therapy	Censored
Free of radiological progression and no subsequent anti-cancer therapy started and no death	Date of last post-baseline radiological tumor assessment	Censored
Documented radiological progression or death after 2 or more consecutive missing radiological assessments	Date of last post-baseline radiological tumor assessment prior to the missed radiological assessment	Censored
Documented radiological progression or death	Earliest date of radiological PD or death	Event

For each of the patient populations in the primary and key secondary endpoints, a time-to-event analysis of PFS will be performed respectively using KM methods including quartile estimates and 2-sided 95% CIs. A figure will be produced.

#### 4.3.2.4. Time to First Subsequent Therapy

TFST (in months) is defined as the date of first dose of study treatment in the current study to the earlier date of first dose of first subsequent therapy or death, calculated as:

$$[\text{Earlier of (First dose of first subsequent therapy or death) - First dose date} + 1] / 30.4375$$

Patients who are alive without a subsequent therapy will be censored on the last contact date.

For each of the patient populations in the primary and key secondary endpoints, a time-to-event analysis of TFST will be performed respectively using KM methods including quartile estimates and 2-sided 95% CIs. A figure will be produced.

#### 4.3.2.5. Overall Survival

Overall survival (in months) is defined as the time from the date of the first dose to the date of death for any cause, calculated as:

$$[\text{Date of Death} - \text{First dose date} + 1] / 30.4375$$

Patients who are known to be alive will be censored at the last contact date.

For each of the patient populations in the primary and key secondary endpoints, a time-to-event analysis of OS will be performed respectively using KM methods including quartile estimates and 2-sided 95% CIs. A figure will be produced.

#### 4.3.2.6. Pharmacokinetic Evaluations

Details of the population PK and intensive PK analyses, including combined analyses of the ECG variables and PK parameters, will be contained in a separate analysis plan.

### 4.4. Safety Analyses

Safety analyses will be conducted using the Safety population.

#### 4.4.1. Study Treatment Exposure

Extent of treatment will be summarized as follows:

- Number and percent of patients beginning 1, 2, 3, ..., 12, and >12 cycles.
- Number of cycles started summarized as a continuous variable.
- Overall treatment exposure (months), defined as the  $[\text{last dose date} - \text{first dose date} + 1] / 30.4375$ , will be summarized and graphed both as a continuous and time-to-event variable.
- Time on study (months), defined as the  $[\text{last visit date or date of death} - \text{first dose date} + 1] / 30.4375$ , will be summarized and graphed both as a continuous and time-to-event variable.

Intensity of study treatment:

- The total number of capsules consumed is the sum of the number of capsules dispensed less the sum of the number of capsules returned by the patient during the study. The sum of the daily doses consumed (mg) is the total number of capsules consumed multiplying by 100 mg. Unused capsules not returned will be assumed to have been consumed.

- Dose intensity (mg/day), defined as sum of the daily doses actually consumed divided by overall treatment exposure (converted to days), will be summarized as a continuous variable.
- Relative dose intensity (%), defined as dose intensity (mg/day) divided by intended dose intensity (mg/day), where intended dose intensity is 300 mg/day, will be summarized as a continuous variable.

Dose reductions and dose interruptions by cycle:

- Number and percentage of patients with a dose reduction, defined as the dose consumed is less than the dose prescribed, for any reason and due to an AE.
- Number and percentage of patients with a dose interruption, defined as the dose consumed is 0 mg, for any reason and due to an AE.

Dosing information for each patient will be presented in a data listing.

#### 4.4.2. Study Treatment Compliance

Patient compliance with the study drug will be assessed via pill counts during the study.

For each cycle, study drug compliance (%) will be defined on the patient level by the dosing compliance ratio: the number of capsules consumed (the number of capsules dispensed less the number of capsules returned by the patient) divided by the number of capsules prescribed per protocol for a patient in a cycle.

- Number of capsules dispensed per cycle is 93 capsules in a bottle throughout the trial. If the prescribed dose level at a cycle is unknown, assume both number of capsules prescribed and number of capsules dispensed at this cycle is 0. Otherwise:
  - Number of capsules prescribed for 300 mg/day per cycle is calculated by 3 capsules per day multiplied by the actual treatment duration (day) in the cycle
  - Number of capsules prescribed for 200 mg/day per cycle is calculated by 2 capsules per day multiplied by the actual treatment duration (day) in the cycle
  - Number of capsules prescribed for 100 mg/day per cycle is calculated by 1 capsule per day multiplied by the actual treatment duration (day) in the cycle
  - The calculated number of capsules prescribed for a cycle will be capped at the maximum number of 93 capsules
- The treatment duration in a cycle  $n$  is calculated by the start date of dose prescribed at next cycle  $n+1$  minus the start date of dose prescribed at cycle  $n$ . If a patient discontinued study treatment during the cycle  $n$ , the treatment duration is calculated by the date of the last study dose minus the start date of dose prescribed at cycle  $n$ . The relevant data are in the eCRF pages: First Dose, Study Medication, and Discontinuation of Treatment.
  - If the treatment duration for a cycle can not be derived due to missing date, assume 28 days
  - If the number of returned capsules is missing in a cycle, assume the number of capsules consumed to be the prescribed number of capsules/day (eg, 3/2/1 capsules per day) multiplied by the treatment duration in that cycle

- Any dose reduction in the middle of a cycle will not impact the compliance calculation in the current cycle. It will be taken into account for the compliance calculation at the next cycle as the reduced dose level will become the prescribed dose for that patient at the start of the next cycle.
- For any patients still ongoing with treatment at the time of analysis, compliance will be calculated up to and including the most recently completed cycle.

The overall study drug compliance (%) on the patient level is the total number of capsules consumed by a patient in all cycles divided by the total number of capsules prescribed per protocol for a patient in all cycles during the study.

A patient is evaluated as compliant if the patient has taken 80% to 120% of the prescribed capsules during the study. Study drug compliance rate (%) and the proportions of patients (<80%, 80%-120%, >120%) will be summarized.

#### 4.4.3. Adverse Events

##### 4.4.3.1. Overview

All AEs will be classified using MedDRA v20.0 or later. The severity of the toxicities will be graded according to the NCI CTCAE v4.03. Any AEs leading to death or discontinuation of study treatment, events classified as NCI CTCAE v4.03 Grade 3 or higher, study treatment-related events, and SAEs will be presented.

Any TEAEs will be defined as:

- Any new AE (one that was not seen prior to the start of treatment) that occurs for the first time after at least 1 dose of study treatment has been administered; or,
- A preexisting condition (one that was seen prior to the start of treatment) that worsens in severity (according to the CTCAE grade) after at least 1 dose of study treatment has been administered.
- Note: If the start date is missing for an AE and the actual start date cannot be determined from a partial date, the AE will be considered treatment-emergent.

All AEs will be collected from the time of signing the main ICF through the EOT visit. New SAEs (including deaths) will be collected for 30 days after the EOT visit. Any AEs recorded in the database that occur from the time of informed consent to first dose will be listed only and not included in safety analyses. Pre-existing conditions will be recorded in the eCRF on the Medical History or appropriate page.

Related TEAEs are defined as TEAEs considered likely related or related to treatment as judged by the Investigator. Any AEs for which the relationship to study drug is missing will be considered as related to study treatment.

The number and percentage of patients reporting a TEAE will be summarized by SOC, PT, toxicity grade, and relationship to study drug.

The toxicity grade of AEs as assessed by the investigator will be graded using NCI CTCAE v4.03. Within the same MedDRA PT, only the most severe AE for each patient will be counted in tabulations by severity. Within a MedDRA SOC, patients with more than 1 MedDRA PT will be counted only once for the most severe AE reported.

The relationship of each AE to the study drug will be summarized as assessed by the Investigator. All AEs for which the relationship to study drug is missing will be considered as related. Within the same MedDRA PT, only the AE with the highest ranked relationship to treatment for each patient will be counted in tabulations by relationship to treatment. Within a MedDRA SOC, patients with more than 1 MedDRA PT will be counted only once for the AE that is most related to treatment. The imputation for a missing relationship will take place prior to determining the most related AE within a SOC or PT for a given patient.

A high-level overview of AEs will be presented in a summary table. This table will include the number and percentage of patients for the following categories: any TEAE, any related TEAE, any grade  $\geq 3$  TEAE, any treatment-related grade  $\geq 3$  TEAE, any treatment-emergent serious adverse events (SAEs), any treatment-related serious TEAE, any AE leading to study drug interruption, any AE leading to study drug reduction, any AE leading to study drug withdrawal, any TEAE leading to death, and any pregnancies.

All AE tables will be summarized on the SAF population by 3-4 prior lines,  $\geq 5$  prior lines, and Overall. Subgroup analyses of TEAEs will be conducted in the following subgroups on the SAF respectively by 3-4 prior lines,  $\geq 5$  prior lines, and Overall:

- Age (<65 vs  $\geq 65$  years)
- Primary tumor site (ovarian, peritoneal, fallopian tube)
- Response to last platinum-based therapy (platinum-sensitive, platinum-resistant, platinum-refractory, response-unknown)
- Patients with prior PARP treatment

The following lists the AE tables to be displayed; those designated with an ‘\*’ will be produced for the subgroups described above.

- Overview of AEs\*
- TEAE by SOC and PT\*
- TEAE by PT (sorted by frequency)\*
- Related TEAE by SOC and PT
- Treatment-emergent SAEs by SOC and PT\*
- Related treatment-emergent SAEs by SOC and PT
- TEAE by SOC, PT, and maximum grade
- Related TEAE by SOC, PT, and maximum grade
- Grade  $\geq 3$  TEAEs by SOC and PT\*
- Grade  $\geq 3$  TEAEs by PT (sorted by frequency)\*
- Related Grade  $\geq 3$  TEAEs by SOC and PT
- TEAEs resulting in death by SOC and PT
- TEAEs resulting in study drug dose interruption by SOC and PT
- TEAEs resulting in study drug dose reduction by SOC and PT
- TEAEs resulting in study drug withdrawal by SOC and PT\*

- TEAEs of special interest (AESI) and other grouped events in [Section 4.4.3.2](#), by the grouped event and PT within each group
  - All TEAEs\*
  - Grade  $\geq 3$  TEAE\*
  - SAEs
  - TEAE resulting in dose interruption
  - TEAE resulting in dose reduction
  - TEAE resulting in study drug withdrawal
  - Grade  $\geq 3$  TEAE resulting in study drug withdrawal
- Non-serious TEAEs  $\geq 5\%$  by SOC and PT (required by ClinicalTrials.gov)

Tables structured as listings will be provided for the following:

- Deaths
- SAEs
- TEAEs resulting in study drug interruption
- TEAEs resulting in study drug dose reduction
- TEAEs resulting in study drug withdrawn
- AESI and other grouped events
- Mapping of AE reported term to PT
- Patients developing MDS/AML; this listing will include the following:
  - Age and weight of patients with documented MDS/AML
  - Number of previous chemotherapy regimens
  - Types of previous chemotherapies
  - Time from last platinum therapy to start of study drug
  - Prior history of myelosuppression
  - Myelosuppression AESIs on study
  - Fluorescence in situ hybridization (FISH) result if available

Adverse event summaries will be ordered in terms of decreasing frequency for SOC (alphabetically for SOCs with the same number of AEs reported), and decreasing frequency for PT within SOC (alphabetically for PTs with the same number of AEs reported within a SOC).

#### 4.4.3.2. Adverse Events of Special Interest

In the latest protocol amendment v8.0, the Adverse Events of Special Interest (AESIs) for this study are MDS, AML, secondary cancers (new malignancies other than MDS/AML), pneumonitis, and embryo-fetal toxicity.

#### 4.4.3.3. Other Adverse Events of Interest

In addition to AESIs, other AEs such as myelosuppression and hypertension are also grouped for analysis. [Table 4-5](#) outlines all the grouped events including AESIs with the criteria of mapping MedDRA PTs for each group using Standardized MedDRA Queries (SMQs), High Level Terms (HLTs), and/or PTs. A complete list of grouped events is provided in the Appendix ([Section 7.1](#)).

For TEAEs of special interest and other grouped events, the following analyses will be performed:

- Tabulations of all TEAEs, Grade  $\geq 3$  TEAEs, SAEs, TEAEs leading to dose interruption, dose reduction and withdrawal of study drug will be presented.
- A summary of all myelosuppression events and myelosuppression events  $\geq$  Grade 3 in severity will be produced to display the incidence of these events amongst patients with and without a prior history of myelosuppression.
- Tabulations of the thrombocytopenia event will be summarized by baseline platelet cutoffs.
- Tabulations of the anemia event will be summarized by baseline hemoglobin level.
- Tabulations of the thrombocytopenia, anemia, leukopenia, and neutropenia event will be summarized based on prior history of thrombocytopenia, anemia, leukopenia, and neutropenia event, respectively.
- Tabulations of all the AESI and other grouped events and  $\geq$  Grade 3 events for the subgroups described in the analysis of all TEAEs.
- A summary tabulation for patients who experienced thrombocytopenia event and who did and did not receive platelet transfusion (World Health Organization [WHO] drug preferred terms of platelets or platelets concentrated).
- A summary tabulation for patients who experienced anemia event and who did and did not receive red blood cell transfusion (WHO drug preferred terms of blood cells, packed human; red blood cells; red blood cells concentration; blood transfusion, auxiliary products) or who did and did not receive erythropoietin.
- A summary tabulation for patients who experienced neutropenia event and who did and did not receive colony stimulating factors (WHO drug preferred terms of filgrastim or granulocyte colony stimulating factor).
- A summary tabulation and a figure of time to first onset for each grouped event.

**Table 4-5: Adverse Events of Special Interest and Other Grouped Events**

Group Term	MedDRA V18.1 Criteria for Selection of Preferred Terms <sup>1</sup>
Thrombocytopenia events	Haematopoietic thrombocytopenia SMQ (Broad)
Anemia events	Haematopoietic erythropenia SMQ (Broad)
Leukopenia events	Haematopoietic leukopenia SMQ (Broad)
Neutropenia events	Selected PTs related to neutropenia in the Haematopoietic leukopenia SMQ (Broad)
Pancytopenia events	Haematopoietic cytopenias SMQ (Broad)
AESI (MDS/AML events)	MedDRA PTs associated with MDS/AML
AESI (new malignancies other than MDS/AML)	Malignant tumor SMQ (other than MDS/AML)
AESI (pneumonitis)	Lower respiratory tract inflammatory and immunologic conditions (HLT)
AESI (embryo-fetal toxicity)	Pregnancy and neonatal topics SMQ
Hypertension events	Hypertension SMQ

Abbreviations: AESI = adverse event of special interest; AML = acute myelogenous leukemia; HLT = high-level term; MDS = myelodysplastic syndrome; MedDRA = medical dictionary for regulatory activities; PT = preferred term; SMQ = Standardized MedDRA Query.

<sup>1</sup> The list of preferred terms for each group is provided in the Appendix (Section 7.1).

#### 4.4.3.4. Examination of Adverse Events Controlling for Duration of Drug Exposure

Since patients' duration of exposure to study drug will vary, AEs will also be presented as rates normalized for cumulative exposure. Total duration of exposure will be calculated as the last treatment date – first treatment date + 1.

In these tables, incidence rates per patient-exposure year (PEY) will be calculated as the number of patients experiencing an event in the numerator, and the total exposure time in PEY in the denominator. PEY is defined as follows: for each patient with the AE, the exposure-years will be the time of exposure to the drug in years at the time of first occurrence of the AE; for patients without the AE, the exposure-years will be defined as their total exposure in years on the study. For recurring events, the first occurrence of an AE (by MedDRA preferred term) will be reported.

The US Food and Drug Administration (FDA) guidance recommends examining AE incidence by cumulative exposure time (as discussed above), but notes that it is necessary to assume a constant risk of AEs across time for such analyses. If there is not a constant risk for a given AE, the incidence per PEY analysis would be biased. Therefore, a second method will be used to summarize AEs occurring by duration of exposure to study treatment within specific reporting intervals as defined by cycles of therapy. The number of patients on study—that is patients who have not withdrawn from the study, at the start of the reporting interval (number at risk)—will be used as the denominator for incidence and prevalence calculations.

**Reporting of Incidence by Cycle:** For incidence rates by cycle, the specific AE will be assigned to the relevant time period if the start date of the AE occurs within the period. For recurrent events during a reporting interval, the first event occurrence is reported. For events that recur in more than 1 reporting interval (event start date is in different reporting intervals), the event will be reported in the first applicable reporting interval. In addition, incidence adjusted for exposure on a per-interval basis will be performed. This analysis will calculate the cumulative exposure in



patient-months up to the beginning of each interval, and divide the total number of patients with first incidence of the specific event in the interval by this cumulative exposure. Incidence of AESIs and the potentially bothersome gastrointestinal events of nausea and vomiting will be analyzed using these methods, for any severity event as well as for  $\geq$ Grade 3 events.

Reporting of Prevalence by Cycle: For prevalence rates by cycle, the specific AE will be assigned to the relevant time period if the AE occurs within the period, regardless of the interval in which the event started. For events that recur in more than 1 reporting interval (event occurs in different reporting intervals), the event will be reported in each applicable reporting interval. In addition, prevalence adjusted for exposure on a per-interval basis will be performed. This analysis will calculate the cumulative exposure in patient-months up to the beginning of each interval, and divide the total number of patients with any occurrence of the specific event in the interval by this cumulative exposure. Prevalence of AESIs and the gastrointestinal events of nausea and vomiting will be analyzed using these methods, for any severity event as well as for  $\geq$ Grade 3 events.

#### 4.4.3.5. Examination of Duration of Adverse Events

The duration of AESIs by category and the gastrointestinal events of nausea and vomiting will be calculated on a per-patient basis as the sum of the durations of each discrete episode of occurrence. The duration in days of overlapping occurrences will be calculated as the first start date to the last stop date + 1. The average duration over patients for these events of any severity and of  $\geq$ Grade 3 severity will be summarized with descriptive statistics. Ongoing events will be censored at the time of the analysis cut-off date.

As individual events of long duration may be clinically relevant, the incidence of anemia events of  $\geq 28$  days in duration for events of any severity and for events of  $\geq$ Grade 3 severity will be tabulated. In addition, events of  $\geq$ Grade 2 hematologic toxicities (defined as thrombocytopenia, leukopenia, neutropenia, or pancytopenia events)  $\geq 28$  days with any grade anemia  $\geq 28$  days will be summarized. Note that these durations are for specific instances of the event, and not based on cumulative time with the event. Incidence categories of 0, 1, 2, 3, and 4 or more will be summarized.

#### 4.4.4. Laboratory Data

Laboratory assessments will be performed locally at each center's laboratory by means of their established methods. All laboratory values will be converted to SI units and classified as normal, low, or high based on normal ranges supplied by the local laboratories. Laboratory assessments will be assigned to cycles based on the start date of the cycle based on exposure data.

Hematologic and chemistry laboratory results will be graded according to the cut points defined in the NCI CTCAE v4.03 severity grade. Laboratory results will be summarized by maximum CTCAE grade as available. For platelet count decrease, an additional category for CTCAE v4.03 will be included for values that are  $< 10,000/\mu\text{L}$ . Continuous results will be analyzed using change from baseline and shift values.

Change from baseline will be summarized and analyzed according to the largest increase, decrease, and at EOT, irrespective of scheduled or unscheduled visit. Graphical line mean changes over time may be provided, but due to the varying visits, no repeated measures analysis will be performed.

Shift from baseline to the smallest, largest, and EOT will be reported using number and percentage of patients. Baseline and post-baseline results will be categorized as low, normal, or high relative to the normal range, or by CTCAE grade as applicable.

A listing of potential Hy's Law cases (patients with AST or ALT  $>3 \times$  upper limit of normal [ULN] in combination with bilirubin  $>2 \times$ ULN and ALP within normal range or  $\leq 1.5 \times$ ULN) will be also presented. Additionally, a Hy's Law (DILI) plot will be produced which plots peak ALT and peak total bilirubin in 1 panel and peak AST and peak total bilirubin in a second panel.

A distribution boxplot of liver function test (albumin, ALT, AST, alkaline phosphatase, total bilirubin, direct bilirubin and GGT) and selected hematology and other chemistry laboratory test values over time will be presented. A side panel will be added to the plot to show the distribution of maximum values.

A by-patient listing of all laboratory data will be provided, with laboratory reference ranges and abnormal values highlighted, and including center, patient identifier, and visit.

#### 4.4.5. Vital Signs and Physical Examination

Summaries of vital signs parameters (systolic and diastolic blood pressures, pulse rate, and temperature) and weight will be presented by visit. Summary statistics will be produced for both observed and change from baseline values, for each parameter.

Change from baseline will be summarized and analyzed according to the largest increase, decrease, and at the end of treatment, irrespective of scheduled or unscheduled visit. Graphical line mean changes over time may be provided, but due to the varying visits no repeated measures analysis will be performed.

Vital sign measurements will be presented for each patient in a data listing.

The number and percentage of patients experiencing at least 1 abnormal result at the baseline physical examination will be summarized by body system. Subsequent symptom-targeted physical examination findings will be presented for each patient in a data listing.

All physical examination findings will be presented in a data listing.

#### 4.4.6. Electrocardiogram

All patients will undergo a single ECG assessment at the screening visit. A subset of approximately 12 patients will undergo intensive, triplicate ECG monitoring to coincide with PK evaluation on Cycle 1/Day 1 and all other assessments in the study. The average of each of the triplicate measures will be used for analysis.

Any ECG findings that were assessed as clinically significant and were reported as an AE or SAE will be summarized in the tables and listings.

Electrocardiogram results will be summarized descriptively. Baseline will be defined as the average of the closest triplicate (if triplicates were collected) readings prior to dosing on the first day that study drug is administered.

Electrocardiogram measurements including PR interval, QT interval, RR interval, and QRS complex will be collected.

QTc will be used for the data analysis and interpretation. Commonly used techniques including Bazett's (QTcB) and Fridericia's (QTcF) methods are applied. QTcF will be used for the

primary QT evaluation. A summary of the number and percentage of patients with QTc interval exceeding some predefined upper limit (eg, >450 ms, >480 ms, >500 ms) will be provided. A summary of the number and percentage of patients with change from baseline in QTc interval exceeding some predefined upper limit (eg, >30 ms, >60 ms) will be provided. A separate summary will be provided which summarizes the change from baseline to the most extreme high or low value at any time during treatment. Change from baseline will be summarized and analyzed according to the largest increase, decrease, and at EOT, irrespective of scheduled or unscheduled visit. Graphical line mean changes over time may be provided.

No values will be imputed for missing data except for averaging of triplicate measurements. If 1 or 2 of the triplicate measurements for an ECG parameter are missing, the average of the remaining 2 measurements or the single measurement will be used in analyses. If all triplicate measurements are missing at a time point for an ECG parameter, no values will be imputed for this time point and no analyses related to this time point will be performed. If the triplicate is not good because of an artifact, then if the triplicate is repeated within about  $\pm 15$  minutes, it can be used at that nominal time. Patients who have data on other days or unscheduled ECGs but not at the scheduled time points will be included in the categorical tables but not the statistical analyses.

All ECG data for each patient will be provided in a data listing.

#### 4.4.7. Concomitant Medications

All medications will be coded using the September 2017 or later version of the WHO Drug Dictionary (WHODD). Medication start and stop dates will be compared to the date of first dose of study drug to allow medications to be classified as either Prior only, both Prior and Concomitant, or Concomitant only. Medications starting after the treatment withdrawal date will be listed but will not be classified or summarized.

Medications that start and stop prior to the date of first dose of study drug will be classified as Prior only. If a medication starts before the date of first dose of study drug and stops on or after the date of first dose of study drug, then the medication will be classified as both Prior and Concomitant. Medications will be classified as Concomitant only if they have a start date on or after the date of first dose of study drug. Concomitant medication will be summarized by ATC level 3 and PT in frequency tables by treatment. Patients with more than 1 medication in a given ATC level and PT will be counted only once in that category.

If medication start and/or stop dates are missing or partial, the dates will be compared as far as possible with the date of first dose of study drug. Medications will be assumed to be Concomitant only, unless there is clear evidence (through comparison of partial dates) to suggest that the medication started prior to the first dose of study drug. If there is clear evidence to suggest that the medication started prior to the first dose of study drug, the medication will be assumed to be both Prior and Concomitant, unless there is clear evidence to suggest that the medication stopped prior to the first dose of study drug. If there is clear evidence to suggest that the medication stopped prior to the first dose of study drug, the medication will be assumed to be Prior only. The following lists the concomitant medication tables to be displayed:

- Number and percentage with at least 1 prior medication by ATC level 3 and PT
- Number and percentage with at least 1 concomitant medication by ATC level 3 and PT

- Number and percentage with at least 1 prior and concomitant medication by ATC level 3 and PT

The use of concomitant medications will be included in a by-patient data listing.

## **5. CHANGES TO PLANNED ANALYSES**

As of this date, there have been no changes between the protocol-defined statistical analyses and those presented in this SAP.

If any modifications in the experimental design, dosages, parameters, patient selection, or any other sections of the protocol are indicated or required, the Investigator will consult with the Sponsor before such changes are instituted. Modifications will be accomplished through formal amendments to this protocol by the Sponsor and approval from the appropriate Institutional Review Board (IRB) or Independent Ethics Committee (IEC).

## 6. REFERENCES

- <sup>1</sup> Fong, P.C., et al., Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med*, 2009. 361(2): p. 123-34.
- <sup>2</sup> Audeh, M.W., et al., Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet*, 2010. 376(9737): p. 245-51.
- <sup>3</sup> Gelmon, K.A., et al., Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol*, 2011. 12(9): p. 852-61.
- <sup>4</sup> Kummar, S., et al., A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. *Clin Cancer Res*, 2012. 18(6): p. 1726-34.
- <sup>5</sup> Ledermann, J., et al., Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. *N Engl J Med*, 2012. 366(15): p. 1382-92.
- <sup>6</sup> Ledermann, J., et al., Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. *Lancet Oncol*, 2014. 15(8): p. 852-61.
- <sup>7</sup> Sandhu, S.K., et al., The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. *Lancet Oncol*, 2013. 14(9): p. 882-92.
- <sup>8</sup> US Federal Register. International Conference on Harmonization; Guidance on Statistical Principles for Clinical Trials. Department of Health and Human Services: Food and Drug Administration [Docket No. 97D 0174]. Federal Register Volume 63, Number, pages 49583 49598. September 16, 1998.

**7. APPENDIX**

**7.1. MedDRA Preferred Terms for Adverse Events of Special Groups**

<b>AE Category MedDRA Level</b>	<b>Preferred Terms</b>	<b>SMQ Scope</b>
Thrombocytopenia Event Haematopoietic cytopenias affecting more than 1 type of blood cell (SMQ) [20000028]	Megakaryocytes decreased Platelet count decreased Platelet maturation arrest Platelet production decreased Platelet toxicity Thrombocytopenia Megakaryocytes abnormal Platelet count abnormal Platelet disorder Plateletcrit abnormal Plateletcrit decreased Thrombocytopenia neonatal	Narrow Narrow Narrow Narrow Narrow Narrow Broad Broad Broad Broad Broad Broad
Anemia Event: Haematopoietic erythropenia (SMQ) [20000029]	Anaemia macrocytic Aplasia pure red cell Aplastic anaemia Erythroblast count decreased Erythroid maturation arrest Erythropenia Hypoplastic anaemia Microcytic anaemia Proerythroblast count decreased Red blood cell count decreased Reticulocyte count decreased Reticulocytopenia Anaemia Anaemia neonatal Erythroblast count abnormal Erythropoiesis abnormal Haematocrit abnormal Haematocrit decreased Haemoglobin abnormal Haemoglobin decreased Leukoerythroblastic anaemia Normochromic normocytic anaemia Proerythroblast count abnormal Red blood cell count abnormal Reticulocyte count abnormal Reticulocyte percentage decreased	Narrow Narrow Narrow Narrow Narrow Narrow Narrow Narrow Narrow Narrow Narrow Narrow Broad Broad Broad Broad Broad Broad Broad Broad Broad Broad Broad Broad Broad Broad Broad Broad Broad Broad







AE Category MedDRA Level	Preferred Terms	SMQ Scope
	Primary myelofibrosis Scan bone marrow abnormal	Broad Broad
MDS/AML Event: MedDRA PTs as listed	Myelodysplastic syndrome Myelodysplastic syndrome transformation Myelodysplastic syndrome unclassifiable Acute myeloid leukaemia Acute myeloid leukaemia recurrent Blast crisis in myelogenous leukaemia Myeloid leukaemia	NA NA NA NA NA NA NA
New malignancies other than MDS/AML Malignant Tumours (SMQ) [20000194]	See <a href="#">Section 7.2</a>	
Pneumonitis Event: Lower respiratory tract inflammatory and immunologic conditions (HLT)	Pneumonitis Acute interstitial pneumonitis	NA NA
Embryo-fetal toxicity Pregnancy and neonatal topics (SMQ) [20000185]	See <a href="#">Section 7.3</a>	
Hypertension Event: Hypertension SMQ [20000147]	See <a href="#">Section 7.4</a>	

Abbreviations: AE = adverse event; AML = acute myelogenous leukemia; HLT = high-level term; MDS = myelodysplastic syndrome; MedDRA = medical dictionary for regulatory activities; PT = preferred term; SMQ = Standardized MedDRA Query.  
 \* Preferred terms are included in the Neutropenia Event.

## 7.2. SMQ Terms for Malignant Tumors

SMQ Export: 20.1 - English

1/8/2018 2:20:21 PM

Include Inactive PT: No

Term Attributes: Name, Code, Level, Scope, Category, Weight, Status, Addition Version, Last Modified Version

**Malignant tumours (SMQ) [20000194]**

**Haematological malignant tumours (SMQ) [20000227]**

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
5q minus syndrome	10068532	PT	Narrow	A	0	Active	11.1	20.0
Acute biphenotypic leukaemia	10067399	PT	Narrow	A	0	Active	10.1	20.0
Acute leukaemia	10000830	PT	Narrow	A	0	Active	10.0	20.0
Acute leukaemia in remission	10060930	PT	Narrow	A	0	Active	10.0	20.0
Acute lymphocytic leukaemia	10000846	PT	Narrow	A	0	Active	10.0	20.0
Acute lymphocytic leukaemia (in remission)	10000847	PT	Narrow	A	0	Active	10.0	20.0
Acute lymphocytic leukaemia recurrent	10063620	PT	Narrow	A	0	Active	10.0	20.0
Acute lymphocytic leukaemia refractory	10076866	PT	Narrow	A	0	Active	18.1	20.0
Acute megakaryocytic leukaemia	10000860	PT	Narrow	A	0	Active	10.0	20.0
Acute megakaryocytic leukaemia (in remission)	10057194	PT	Narrow	A	0	Active	10.0	20.0
Acute monocytic leukaemia	10000871	PT	Narrow	A	0	Active	10.0	20.0
Acute monocytic leukaemia (in remission)	10000872	PT	Narrow	A	0	Active	10.0	20.0
Acute myeloid leukaemia (in remission)	10000881	PT	Narrow	A	0	Active	10.0	20.0
Acute myelomonocytic leukaemia	10000890	PT	Narrow	A	0	Active	10.0	20.0
Acute promyelocytic leukaemia	10001019	PT	Narrow	A	0	Active	10.0	20.0
Acute undifferentiated leukaemia	10073479	PT	Narrow	A	0	Active	16.0	20.0
Adult T-cell lymphoma/leukaemia	10001413	PT	Narrow	A	0	Active	10.0	20.0
Adult T-cell lymphoma/leukaemia recurrent	10001416	PT	Narrow	A	0	Active	10.0	20.0
Adult T-cell lymphoma/leukaemia refractory	10001417	PT	Narrow	A	0	Active	10.0	20.0
Adult T-cell lymphoma/leukaemia stage I	10001418	PT	Narrow	A	0	Active	10.0	20.0
Adult T-cell lymphoma/leukaemia stage II	10001419	PT	Narrow	A	0	Active	10.0	20.0
Adult T-cell lymphoma/leukaemia stage III	10001420	PT	Narrow	A	0	Active	10.0	20.0
Adult T-cell lymphoma/leukaemia stage IV	10001421	PT	Narrow	A	0	Active	10.0	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Aleukaemic leukaemia	10001660	PT	Narrow	A	0	Active	10.0	20.0
Anaplastic large cell lymphoma T- and null-cell types	10002227	PT	Narrow	A	0	Active	10.0	20.0
Anaplastic large cell lymphoma T- and null-cell types recurrent	10002229	PT	Narrow	A	0	Active	10.0	20.0
Anaplastic large cell lymphoma T- and null-cell types refractory	10002230	PT	Narrow	A	0	Active	10.0	20.0
Anaplastic large cell lymphoma T- and null-cell types stage I	10002231	PT	Narrow	A	0	Active	10.0	20.0
Anaplastic large cell lymphoma T- and null-cell types stage II	10002232	PT	Narrow	A	0	Active	10.0	20.0
Anaplastic large cell lymphoma T- and null-cell types stage III	10002233	PT	Narrow	A	0	Active	10.0	20.0
Anaplastic large cell lymphoma T- and null-cell types stage IV	10002234	PT	Narrow	A	0	Active	10.0	20.0
Anaplastic large-cell lymphoma	10073478	PT	Narrow	A	0	Active	16.0	20.0
Angiocentric lymphoma	10002411	PT	Narrow	A	0	Active	10.0	20.0
Angiocentric lymphoma recurrent	10002414	PT	Narrow	A	0	Active	10.0	20.0
Angiocentric lymphoma refractory	10002415	PT	Narrow	A	0	Active	10.0	20.0
Angiocentric lymphoma stage I	10002416	PT	Narrow	A	0	Active	10.0	20.0
Angiocentric lymphoma stage II	10002417	PT	Narrow	A	0	Active	10.0	20.0
Angiocentric lymphoma stage III	10002418	PT	Narrow	A	0	Active	10.0	20.0
Angiocentric lymphoma stage IV	10002419	PT	Narrow	A	0	Active	10.0	20.0
Angioimmunoblastic T-cell lymphoma	10002449	PT	Narrow	A	0	Active	10.0	20.0
Angioimmunoblastic T-cell lymphoma recurrent	10002452	PT	Narrow	A	0	Active	10.0	20.0
Angioimmunoblastic T-cell lymphoma refractory	10002453	PT	Narrow	A	0	Active	10.0	20.0
Angioimmunoblastic T-cell lymphoma stage I	10002454	PT	Narrow	A	0	Active	10.0	20.0
Angioimmunoblastic T-cell lymphoma stage II	10002455	PT	Narrow	A	0	Active	10.0	20.0
Angioimmunoblastic T-cell lymphoma stage III	10002456	PT	Narrow	A	0	Active	10.0	20.0
Angioimmunoblastic T-cell lymphoma stage IV	10002457	PT	Narrow	A	0	Active	10.0	20.0
B precursor type acute leukaemia	10003890	PT	Narrow	A	0	Active	10.0	20.0
B-cell lymphoma	10003899	PT	Narrow	A	0	Active	10.0	20.0
B-cell lymphoma recurrent	10003902	PT	Narrow	A	0	Active	10.0	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
B-cell lymphoma refractory	10003903	PT	Narrow	A	0	Active	10.0	20.0
B-cell lymphoma stage I	10003904	PT	Narrow	A	0	Active	10.0	20.0
B-cell lymphoma stage II	10003905	PT	Narrow	A	0	Active	10.0	20.0
B-cell lymphoma stage III	10003906	PT	Narrow	A	0	Active	10.0	20.0
B-cell lymphoma stage IV	10003907	PT	Narrow	A	0	Active	10.0	20.0
B-cell prolymphocytic leukaemia	10073480	PT	Narrow	A	0	Active	16.0	20.0
B-cell small lymphocytic lymphoma	10003908	PT	Narrow	A	0	Active	10.0	20.0
B-cell small lymphocytic lymphoma recurrent	10003911	PT	Narrow	A	0	Active	10.0	20.0
B-cell small lymphocytic lymphoma refractory	10003912	PT	Narrow	A	0	Active	10.0	20.0
B-cell small lymphocytic lymphoma stage I	10003913	PT	Narrow	A	0	Active	10.0	20.0
B-cell small lymphocytic lymphoma stage II	10003914	PT	Narrow	A	0	Active	10.0	20.0
B-cell small lymphocytic lymphoma stage III	10003915	PT	Narrow	A	0	Active	10.0	20.0
B-cell small lymphocytic lymphoma stage IV	10003916	PT	Narrow	A	0	Active	10.0	20.0
B-cell type acute leukaemia	10003917	PT	Narrow	A	0	Active	10.0	20.0
B-cell unclassifiable lymphoma high grade	10003922	PT	Narrow	A	0	Active	10.0	20.0
B-cell unclassifiable lymphoma low grade	10003923	PT	Narrow	A	0	Active	10.0	20.0
Blast crisis in myelogenous leukaemia	10050282	PT	Narrow	A	0	Active	10.0	20.0
Blastic plasmacytoid dendritic cell neoplasia	10075460	PT	Narrow	A	0	Active	17.1	20.0
Bone marrow leukaemic cell infiltration	10049557	PT	Narrow	A	0	Active	10.0	20.0
Bone marrow tumour cell infiltration	10049556	PT	Narrow	A	0	Active	10.0	20.0
Burkitt's leukaemia	10067184	PT	Narrow	A	0	Active	10.0	20.0
Burkitt's lymphoma	10006595	PT	Narrow	A	0	Active	10.0	20.0
Burkitt's lymphoma recurrent	10006598	PT	Narrow	A	0	Active	10.0	20.0
Burkitt's lymphoma refractory	10006599	PT	Narrow	A	0	Active	10.0	20.0
Burkitt's lymphoma stage I	10006600	PT	Narrow	A	0	Active	10.0	20.0
Burkitt's lymphoma stage II	10006601	PT	Narrow	A	0	Active	10.0	20.0
Burkitt's lymphoma stage III	10006602	PT	Narrow	A	0	Active	10.0	20.0
Burkitt's lymphoma stage IV	10006603	PT	Narrow	A	0	Active	10.0	20.0
Central nervous system leukaemia	10066231	PT	Narrow	A	0	Active	10.0	20.0
Central nervous system lymphoma	10007953	PT	Narrow	A	0	Active	10.0	20.0
Chloroma	10008583	PT	Narrow	A	0	Active	10.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Chloroma (in remission)	10008584	PT	Narrow	A	0	Active	10.0	20.0
Chronic eosinophilic leukaemia	10065854	PT	Narrow	A	0	Active	10.0	20.0
Chronic leukaemia	10008943	PT	Narrow	A	0	Active	10.0	20.0
Chronic leukaemia in remission	10061042	PT	Narrow	A	0	Active	10.0	20.0
Chronic lymphocytic leukaemia	10008958	PT	Narrow	A	0	Active	10.0	20.0
Chronic lymphocytic leukaemia (in remission)	10008959	PT	Narrow	A	0	Active	10.0	20.0
Chronic lymphocytic leukaemia recurrent	10008961	PT	Narrow	A	0	Active	10.0	20.0
Chronic lymphocytic leukaemia refractory	10008962	PT	Narrow	A	0	Active	10.0	20.0
Chronic lymphocytic leukaemia stage 0	10008963	PT	Narrow	A	0	Active	10.0	20.0
Chronic lymphocytic leukaemia stage 1	10008964	PT	Narrow	A	0	Active	10.0	20.0
Chronic lymphocytic leukaemia stage 2	10008965	PT	Narrow	A	0	Active	10.0	20.0
Chronic lymphocytic leukaemia stage 3	10008966	PT	Narrow	A	0	Active	10.0	20.0
Chronic lymphocytic leukaemia stage 4	10008967	PT	Narrow	A	0	Active	10.0	20.0
Chronic lymphocytic leukaemia transformation	10058717	PT	Narrow	A	0	Active	10.0	20.0
Chronic myeloid leukaemia	10009013	PT	Narrow	A	0	Active	10.0	20.0
Chronic myeloid leukaemia (in remission)	10009014	PT	Narrow	A	0	Active	10.0	20.0
Chronic myeloid leukaemia recurrent	10075081	PT	Narrow	A	0	Active	17.1	20.0
Chronic myeloid leukaemia transformation	10068232	PT	Narrow	A	0	Active	11.0	20.0
Chronic myelomonocytic leukaemia	10009018	PT	Narrow	A	0	Active	10.0	20.0
Chronic myelomonocytic leukaemia (in remission)	10009019	PT	Narrow	A	0	Active	10.0	20.0
Composite lymphoma	10073957	PT	Narrow	A	0	Active	16.1	20.0
Cutaneous lymphoma	10079945	PT	Narrow	A	0	Active	20.1	20.1
Diffuse large B-cell lymphoma	10012818	PT	Narrow	A	0	Active	10.0	20.0
Diffuse large B-cell lymphoma recurrent	10012821	PT	Narrow	A	0	Active	10.0	20.0
Diffuse large B-cell lymphoma refractory	10012822	PT	Narrow	A	0	Active	10.0	20.0
Diffuse large B-cell lymphoma stage I	10012823	PT	Narrow	A	0	Active	10.0	20.0
Diffuse large B-cell lymphoma stage II	10012824	PT	Narrow	A	0	Active	10.0	20.0
Diffuse large B-cell lymphoma stage III	10012825	PT	Narrow	A	0	Active	10.0	20.0
Diffuse large B-cell lymphoma stage IV	10012826	PT	Narrow	A	0	Active	10.0	20.0
Disseminated large cell lymphoma	10054951	PT	Narrow	A	0	Active	10.0	20.0
Double hit lymphoma	10080202	PT	Narrow	A	0	Active	20.1	20.1

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Enteropathy-associated T-cell lymphoma	10073481	PT	Narrow	A	0	Active	16.0	20.0
Eosinophilic leukaemia	10014958	PT	Narrow	A	0	Active	10.0	20.0
Epstein-Barr virus associated lymphoma	10071441	PT	Narrow	A	0	Active	14.1	20.0
Erythraemic myelosis (in remission)	10015246	PT	Narrow	A	0	Active	10.0	20.0
Erythroleukaemia	10015281	PT	Narrow	A	0	Active	10.0	20.0
Extranodal marginal zone B-cell lymphoma (MALT type)	10061850	PT	Narrow	A	0	Active	10.0	20.0
Extranodal marginal zone B-cell lymphoma (MALT type) recurrent	10015823	PT	Narrow	A	0	Active	10.0	20.0
Extranodal marginal zone B-cell lymphoma (MALT type) refractory	10015824	PT	Narrow	A	0	Active	10.0	20.0
Extranodal marginal zone B-cell lymphoma (MALT type) stage I	10015825	PT	Narrow	A	0	Active	10.0	20.0
Extranodal marginal zone B-cell lymphoma (MALT type) stage II	10015826	PT	Narrow	A	0	Active	10.0	20.0
Extranodal marginal zone B-cell lymphoma (MALT type) stage III	10015827	PT	Narrow	A	0	Active	10.0	20.0
Extranodal marginal zone B-cell lymphoma (MALT type) stage IV	10015828	PT	Narrow	A	0	Active	10.0	20.0
Follicle centre lymphoma diffuse small cell lymphoma	10061957	PT	Narrow	A	0	Active	10.0	20.0
Follicle centre lymphoma diffuse small cell lymphoma recurrent	10016897	PT	Narrow	A	0	Active	10.0	20.0
Follicle centre lymphoma diffuse small cell lymphoma refractory	10016898	PT	Narrow	A	0	Active	10.0	20.0
Follicle centre lymphoma diffuse small cell lymphoma stage I	10016899	PT	Narrow	A	0	Active	10.0	20.0
Follicle centre lymphoma diffuse small cell lymphoma stage II	10016900	PT	Narrow	A	0	Active	10.0	20.0
Follicle centre lymphoma diffuse small cell lymphoma stage III	10016901	PT	Narrow	A	0	Active	10.0	20.0
Follicle centre lymphoma diffuse small cell lymphoma stage IV	10016902	PT	Narrow	A	0	Active	10.0	20.0
Follicle centre lymphoma, follicular grade I, II, III	10061170	PT	Narrow	A	0	Active	10.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Follicle centre lymphoma, follicular grade I, II, III recurrent	10016905	PT	Narrow	A	0	Active	10.0	20.0
Follicle centre lymphoma, follicular grade I, II, III refractory	10016906	PT	Narrow	A	0	Active	10.0	20.0
Follicle centre lymphoma, follicular grade I, II, III stage I	10016907	PT	Narrow	A	0	Active	10.0	20.0
Follicle centre lymphoma, follicular grade I, II, III stage II	10016908	PT	Narrow	A	0	Active	10.0	20.0
Follicle centre lymphoma, follicular grade I, II, III stage III	10016909	PT	Narrow	A	0	Active	10.0	20.0
Follicle centre lymphoma, follicular grade I, II, III stage IV	10016910	PT	Narrow	A	0	Active	10.0	20.0
Follicular dendritic cell sarcoma	10075332	PT	Narrow	A	0	Active	17.1	20.0
Gastrointestinal lymphoma	10017973	PT	Narrow	A	0	Active	10.0	20.1
Haematological malignancy	10066476	PT	Narrow	A	0	Active	10.0	20.0
Hairy cell leukaemia	10019053	PT	Narrow	A	0	Active	10.0	20.0
Hairy cell leukaemia recurrent	10077403	PT	Narrow	A	0	Active	19.0	20.0
Hepatosplenic T-cell lymphoma	10066957	PT	Narrow	A	0	Active	10.0	20.0
High grade B-cell lymphoma Burkitt-like lymphoma	10020067	PT	Narrow	A	0	Active	10.0	20.0
High grade B-cell lymphoma Burkitt-like lymphoma recurrent	10020070	PT	Narrow	A	0	Active	10.0	20.0
High grade B-cell lymphoma Burkitt-like lymphoma refractory	10020071	PT	Narrow	A	0	Active	10.0	20.0
High grade B-cell lymphoma Burkitt-like lymphoma stage I	10020072	PT	Narrow	A	0	Active	10.0	20.0
High grade B-cell lymphoma Burkitt-like lymphoma stage II	10020073	PT	Narrow	A	0	Active	10.0	20.0
High grade B-cell lymphoma Burkitt-like lymphoma stage III	10020074	PT	Narrow	A	0	Active	10.0	20.0
High grade B-cell lymphoma Burkitt-like lymphoma stage IV	10020075	PT	Narrow	A	0	Active	10.0	20.0
High-grade B-cell lymphoma	10080215	PT	Narrow	A	0	Active	20.1	20.1
Histiocytic medullary reticulosis	10068785	PT	Narrow	A	0	Active	12.0	20.0



Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Histiocytic sarcoma	10076876	PT	Narrow	A	0	Active	18.1	20.0
Hodgkin's disease	10020206	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte depletion stage I site unspecified	10020208	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte depletion stage I subdiaphragm	10020209	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte depletion stage I supradiaphragm	10020210	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte depletion stage II site unspecified	10020211	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte depletion stage II subdiaphragm	10020212	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte depletion stage II supradiaphragm	10020213	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte depletion type recurrent	10020215	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte depletion type refractory	10020216	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte depletion type stage III	10020217	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte depletion type stage IV	10020218	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte depletion type stage unspecified	10020219	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte predominance stage I site unspec	10020220	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte predominance stage I subdiaphragm	10020221	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte predominance stage I supradiaphragm	10020222	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte predominance stage II site unspec	10020223	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte predominance stage II subdiaphragm	10020224	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte predominance stage II supradiaphragm	10020225	PT	Narrow	A	0	Active	10.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Hodgkin's disease lymphocyte predominance type recurrent	10020227	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte predominance type refractory	10020228	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte predominance type stage III	10020229	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte predominance type stage IV	10020230	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease lymphocyte predominance type stage unspecified	10020231	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease mixed cellularity recurrent	10020233	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease mixed cellularity refractory	10020234	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease mixed cellularity stage I site unspecified	10020235	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease mixed cellularity stage I subdiaphragmatic	10020236	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease mixed cellularity stage I supradiaphragmatic	10020237	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease mixed cellularity stage II subdiaphragmatic	10020238	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease mixed cellularity stage II supradiaphragmatic	10020239	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease mixed cellularity stage III	10020240	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease mixed cellularity stage IV	10020241	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease mixed cellularity stage unspecified	10020242	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease nodular sclerosis	10020244	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease nodular sclerosis recurrent	10020245	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease nodular sclerosis refractory	10020246	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease nodular sclerosis stage I	10073535	PT	Narrow	A	0	Active	16.0	20.0
Hodgkin's disease nodular sclerosis stage II	10073534	PT	Narrow	A	0	Active	16.0	20.0
Hodgkin's disease nodular sclerosis stage III	10020252	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease nodular sclerosis stage IV	10020253	PT	Narrow	A	0	Active	10.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Hodgkin's disease recurrent	10020266	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease refractory	10020267	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease stage I	10020268	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease stage II	10020269	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease stage III	10020270	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease stage IV	10061597	PT	Narrow	A	0	Active	10.0	20.0
Hodgkin's disease unclassifiable	10020271	PT	Narrow	A	0	Active	10.0	20.0
Immunoblastic lymphoma	10053574	PT	Narrow	A	0	Active	10.0	20.0
Intestinal T-cell lymphoma recurrent	10022706	PT	Narrow	A	0	Active	10.0	20.0
Intestinal T-cell lymphoma refractory	10022707	PT	Narrow	A	0	Active	10.0	20.0
Intestinal T-cell lymphoma stage I	10022708	PT	Narrow	A	0	Active	10.0	20.0
Intestinal T-cell lymphoma stage II	10022709	PT	Narrow	A	0	Active	10.0	20.0
Intestinal T-cell lymphoma stage III	10022710	PT	Narrow	A	0	Active	10.0	20.0
Intestinal T-cell lymphoma stage IV	10022711	PT	Narrow	A	0	Active	10.0	20.0
Juvenile chronic myelomonocytic leukaemia	10023249	PT	Narrow	A	0	Active	10.0	20.0
Leptomeningeal myelomatosis	10078282	PT	Narrow	A	0	Active	19.1	20.0
Leukaemia	10024288	PT	Narrow	A	0	Active	10.0	20.0
Leukaemia basophilic	10024293	PT	Narrow	A	0	Active	10.0	20.0
Leukaemia cutis	10053180	PT	Narrow	A	0	Active	10.0	20.0
Leukaemia granulocytic	10024299	PT	Narrow	A	0	Active	10.0	20.0
Leukaemia in remission	10061220	PT	Narrow	A	0	Active	10.0	20.0
Leukaemia monocytic	10024305	PT	Narrow	A	0	Active	10.0	20.0
Leukaemia recurrent	10062489	PT	Narrow	A	0	Active	10.0	20.0
Leukaemic cardiac infiltration	10077563	PT	Narrow	A	0	Active	19.0	20.0
Leukaemic infiltration	10069360	PT	Narrow	A	0	Active	12.1	20.0
Leukaemic infiltration extramedullary	10067117	PT	Narrow	A	0	Active	10.0	20.0
Leukaemic infiltration gingiva	10067431	PT	Narrow	A	0	Active	10.1	20.0
Leukaemic infiltration hepatic	10058671	PT	Narrow	A	0	Active	10.0	20.0
Leukaemic infiltration ovary	10075853	PT	Narrow	A	0	Active	18.0	20.0
Leukaemic infiltration pulmonary	10052368	PT	Narrow	A	0	Active	10.0	20.0
Leukaemic infiltration renal	10069359	PT	Narrow	A	0	Active	12.1	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Leukaemic lymphoma	10024325	PT	Narrow	A	0	Active	10.0	20.0
Leukaemic retinopathy	10059239	PT	Narrow	A	0	Active	10.0	20.0
Lymphangiosarcoma	10025223	PT	Narrow	A	0	Active	10.0	20.0
Lymphangiosis carcinomatosa	10053132	PT	Narrow	A	0	Active	10.0	20.0
Lymphocytic leukaemia	10025270	PT	Narrow	A	0	Active	10.0	20.0
Lymphocytic lymphoma	10052178	PT	Narrow	A	0	Active	10.0	20.0
Lymphoid leukaemia (in remission)	10025300	PT	Narrow	A	0	Active	10.0	20.0
Lymphoma	10025310	PT	Narrow	A	0	Active	10.0	20.0
Lymphoma AIDS related	10025312	PT	Narrow	A	0	Active	10.0	20.0
Lymphoma cutis	10051708	PT	Narrow	A	0	Active	10.0	20.0
Lymphoma transformation	10064344	PT	Narrow	A	0	Active	10.0	20.0
Lymphoplasmacytoid lymphoma/immunocytoma	10025342	PT	Narrow	A	0	Active	10.0	20.0
Lymphoplasmacytoid lymphoma/immunocytoma recurrent	10025345	PT	Narrow	A	0	Active	10.0	20.0
Lymphoplasmacytoid lymphoma/immunocytoma refractory	10025346	PT	Narrow	A	0	Active	10.0	20.0
Lymphoplasmacytoid lymphoma/immunocytoma stage I	10025347	PT	Narrow	A	0	Active	10.0	20.0
Lymphoplasmacytoid lymphoma/immunocytoma stage II	10025348	PT	Narrow	A	0	Active	10.0	20.0
Lymphoplasmacytoid lymphoma/immunocytoma stage III	10025349	PT	Narrow	A	0	Active	10.0	20.0
Lymphoplasmacytoid lymphoma/immunocytoma stage IV	10025350	PT	Narrow	A	0	Active	10.0	20.0
Malignant histiocytosis	10025581	PT	Narrow	A	0	Active	10.0	20.0
Malignant lymphoid neoplasm	10061240	PT	Narrow	A	0	Active	10.0	20.0
Malignant lymphoma unclassifiable high grade	10025635	PT	Narrow	A	0	Active	10.0	20.0
Malignant lymphoma unclassifiable low grade	10025636	PT	Narrow	A	0	Active	10.0	20.0
Malignant mast cell neoplasm	10025638	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of thymus	10026533	PT	Narrow	A	0	Active	10.0	20.0
Malignant splenic neoplasm	10026702	PT	Narrow	A	0	Active	10.0	20.0
Mantle cell lymphoma	10061275	PT	Narrow	A	0	Active	10.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Mantle cell lymphoma recurrent	10026800	PT	Narrow	A	0	Active	10.0	20.0
Mantle cell lymphoma refractory	10026801	PT	Narrow	A	0	Active	10.0	20.0
Mantle cell lymphoma stage I	10026802	PT	Narrow	A	0	Active	10.0	20.0
Mantle cell lymphoma stage II	10026803	PT	Narrow	A	0	Active	10.0	20.0
Mantle cell lymphoma stage III	10026804	PT	Narrow	A	0	Active	10.0	20.0
Mantle cell lymphoma stage IV	10026805	PT	Narrow	A	0	Active	10.0	20.0
Marginal zone lymphoma	10076596	PT	Narrow	A	0	Active	18.1	20.0
Marginal zone lymphoma recurrent	10077533	PT	Narrow	A	0	Active	19.0	20.0
Marginal zone lymphoma refractory	10077534	PT	Narrow	A	0	Active	19.0	20.0
Marginal zone lymphoma stage I	10077529	PT	Narrow	A	0	Active	19.0	20.0
Marginal zone lymphoma stage II	10077530	PT	Narrow	A	0	Active	19.0	20.0
Marginal zone lymphoma stage III	10077531	PT	Narrow	A	0	Active	19.0	20.0
Marginal zone lymphoma stage IV	10077532	PT	Narrow	A	0	Active	19.0	20.0
Mastocytic leukaemia	10056450	PT	Narrow	A	0	Active	10.0	20.0
Mature B-cell type acute leukaemia	10026945	PT	Narrow	A	0	Active	10.0	20.0
Metastases to bone marrow	10051662	PT	Narrow	A	0	Active	10.0	20.0
Metastases to lymph nodes	10027459	PT	Narrow	A	0	Active	10.0	20.0
Metastases to spleen	10051682	PT	Narrow	A	0	Active	10.0	20.0
Metastatic lymphoma	10071541	PT	Narrow	A	0	Active	14.1	20.0
Minimal residual disease	10079987	PT	Narrow	A	0	Active	20.1	20.1
Monocytic leukaemia in remission	10061295	PT	Narrow	A	0	Active	10.0	20.0
Mycosis fungoides	10028483	PT	Narrow	A	0	Active	10.0	20.0
Mycosis fungoides recurrent	10028501	PT	Narrow	A	0	Active	10.0	20.0
Mycosis fungoides refractory	10028502	PT	Narrow	A	0	Active	10.0	20.0
Mycosis fungoides stage I	10028503	PT	Narrow	A	0	Active	10.0	20.0
Mycosis fungoides stage II	10028504	PT	Narrow	A	0	Active	10.0	20.0
Mycosis fungoides stage III	10028505	PT	Narrow	A	0	Active	10.0	20.0
Mycosis fungoides stage IV	10028506	PT	Narrow	A	0	Active	10.0	20.0
Myeloblastoma	10051141	PT	Narrow	A	0	Active	10.0	20.0
Myeloid leukaemia in remission	10061301	PT	Narrow	A	0	Active	10.0	20.0
Natural killer-cell leukaemia	10028811	PT	Narrow	A	0	Active	10.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Natural killer-cell lymphoblastic lymphoma	10058975	PT	Narrow	A	0	Active	10.0	20.0
Neonatal leukaemia	10028958	PT	Narrow	A	0	Active	10.0	20.0
Nodal marginal zone B-cell lymphoma	10029460	PT	Narrow	A	0	Active	10.0	20.0
Nodal marginal zone B-cell lymphoma recurrent	10029463	PT	Narrow	A	0	Active	10.0	20.0
Nodal marginal zone B-cell lymphoma refractory	10029464	PT	Narrow	A	0	Active	10.0	20.0
Nodal marginal zone B-cell lymphoma stage I	10029465	PT	Narrow	A	0	Active	10.0	20.0
Nodal marginal zone B-cell lymphoma stage II	10029466	PT	Narrow	A	0	Active	10.0	20.0
Nodal marginal zone B-cell lymphoma stage III	10029467	PT	Narrow	A	0	Active	10.0	20.0
Nodal marginal zone B-cell lymphoma stage IV	10029468	PT	Narrow	A	0	Active	10.0	20.0
Nodular lymphocyte predominant Hodgkin lymphoma	10080201	PT	Narrow	A	0	Active	20.1	20.1
Non-Hodgkin's lymphoma	10029547	PT	Narrow	A	0	Active	10.0	20.0
Non-Hodgkin's lymphoma metastatic	10071535	PT	Narrow	A	0	Active	14.1	20.0
Non-Hodgkin's lymphoma recurrent	10029600	PT	Narrow	A	0	Active	10.0	20.0
Non-Hodgkin's lymphoma refractory	10029601	PT	Narrow	A	0	Active	10.0	20.0
Non-Hodgkin's lymphoma stage I	10029602	PT	Narrow	A	0	Active	10.0	20.0
Non-Hodgkin's lymphoma stage II	10029603	PT	Narrow	A	0	Active	10.0	20.0
Non-Hodgkin's lymphoma stage III	10029604	PT	Narrow	A	0	Active	10.0	20.0
Non-Hodgkin's lymphoma stage IV	10029605	PT	Narrow	A	0	Active	10.0	20.0
Non-Hodgkin's lymphoma transformed recurrent	10061871	PT	Narrow	A	0	Active	10.0	20.0
Non-Hodgkin's lymphoma unspecified histology aggressive	10063908	PT	Narrow	A	0	Active	10.0	20.0
Non-Hodgkin's lymphoma unspecified histology aggressive recurrent	10029609	PT	Narrow	A	0	Active	10.0	20.0
Non-Hodgkin's lymphoma unspecified histology aggressive refractory	10029610	PT	Narrow	A	0	Active	10.0	20.0
Non-Hodgkin's lymphoma unspecified histology aggressive stage I	10029611	PT	Narrow	A	0	Active	10.0	20.0
Non-Hodgkin's lymphoma unspecified histology aggressive stage II	10029612	PT	Narrow	A	0	Active	10.0	20.0
Non-Hodgkin's lymphoma unspecified histology aggressive stage III	10029613	PT	Narrow	A	0	Active	10.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Non-Hodgkin's lymphoma unspecified histology aggressive stage IV	10029614	PT	Narrow	A	0	Active	10.0	20.0
Non-Hodgkin's lymphoma unspecified histology indolent	10065856	PT	Narrow	A	0	Active	10.0	20.0
Non-Hodgkin's lymphoma unspecified histology indolent stage I	10029622	PT	Narrow	A	0	Active	10.0	20.0
Non-Hodgkin's lymphoma unspecified histology indolent stage II	10029623	PT	Narrow	A	0	Active	10.0	20.0
Non-Hodgkin's lymphoma unspecified histology indolent stage III	10029624	PT	Narrow	A	0	Active	10.0	20.0
Non-Hodgkin's lymphoma unspecified histology indolent stage IV	10029625	PT	Narrow	A	0	Active	10.0	20.0
Ocular lymphoma	10075324	PT	Narrow	A	0	Active	17.1	20.0
Peripheral T-cell lymphoma unspecified	10034623	PT	Narrow	A	0	Active	10.0	20.0
Peripheral T-cell lymphoma unspecified recurrent	10034625	PT	Narrow	A	0	Active	10.0	20.0
Peripheral T-cell lymphoma unspecified refractory	10034626	PT	Narrow	A	0	Active	10.0	20.0
Peripheral T-cell lymphoma unspecified stage I	10034627	PT	Narrow	A	0	Active	10.0	20.0
Peripheral T-cell lymphoma unspecified stage II	10034628	PT	Narrow	A	0	Active	10.0	20.0
Peripheral T-cell lymphoma unspecified stage III	10034629	PT	Narrow	A	0	Active	10.0	20.0
Peripheral T-cell lymphoma unspecified stage IV	10034630	PT	Narrow	A	0	Active	10.0	20.0
Plasma cell leukaemia	10035222	PT	Narrow	A	0	Active	10.0	20.0
Plasma cell leukaemia in remission	10060406	PT	Narrow	A	0	Active	10.0	20.0
Plasma cell myeloma	10035226	PT	Narrow	A	0	Active	10.0	20.0
Plasma cell myeloma in remission	10073132	PT	Narrow	A	0	Active	16.0	20.0
Plasma cell myeloma recurrent	10073133	PT	Narrow	A	0	Active	16.0	20.0
Plasmablastic lymphoma	10065039	PT	Narrow	A	0	Active	10.0	20.0
Plasmacytoma	10035484	PT	Narrow	A	0	Active	10.0	20.0
Precursor B-lymphoblastic lymphoma	10036523	PT	Narrow	A	0	Active	10.0	20.0
Precursor B-lymphoblastic lymphoma recurrent	10060910	PT	Narrow	A	0	Active	10.0	20.0
Precursor B-lymphoblastic lymphoma refractory	10060911	PT	Narrow	A	0	Active	10.0	20.0
Precursor B-lymphoblastic lymphoma stage I	10036532	PT	Narrow	A	0	Active	10.0	20.0
Precursor B-lymphoblastic lymphoma stage II	10036533	PT	Narrow	A	0	Active	10.0	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Precursor B-lymphoblastic lymphoma stage III	10036534	PT	Narrow	A	0	Active	10.0	20.0
Precursor B-lymphoblastic lymphoma stage IV	10036535	PT	Narrow	A	0	Active	10.0	20.0
Precursor T-lymphoblastic lymphoma/leukaemia	10036543	PT	Narrow	A	0	Active	10.0	20.0
Precursor T-lymphoblastic lymphoma/leukaemia recurrent	10036546	PT	Narrow	A	0	Active	10.0	20.0
Precursor T-lymphoblastic lymphoma/leukaemia refractory	10036547	PT	Narrow	A	0	Active	10.0	20.0
Precursor T-lymphoblastic lymphoma/leukaemia stage I	10036548	PT	Narrow	A	0	Active	10.0	20.0
Precursor T-lymphoblastic lymphoma/leukaemia stage II	10036549	PT	Narrow	A	0	Active	10.0	20.0
Precursor T-lymphoblastic lymphoma/leukaemia stage III	10036550	PT	Narrow	A	0	Active	10.0	20.0
Precursor T-lymphoblastic lymphoma/leukaemia stage IV	10036551	PT	Narrow	A	0	Active	10.0	20.0
Primary cardiac lymphoma	10075993	PT	Narrow	A	0	Active	18.0	20.0
Primary effusion lymphoma	10065857	PT	Narrow	A	0	Active	10.0	20.0
Primary gastrointestinal follicular lymphoma	10078972	PT	Narrow	A	0	Active	20.0	20.0
Primary mediastinal large B-cell lymphoma	10036710	PT	Narrow	A	0	Active	10.0	20.0
Primary mediastinal large B-cell lymphoma recurrent	10036713	PT	Narrow	A	0	Active	10.0	20.0
Primary mediastinal large B-cell lymphoma refractory	10036714	PT	Narrow	A	0	Active	10.0	20.0
Primary mediastinal large B-cell lymphoma stage I	10036715	PT	Narrow	A	0	Active	10.0	20.0
Primary mediastinal large B-cell lymphoma stage II	10036716	PT	Narrow	A	0	Active	10.0	20.0
Primary mediastinal large B-cell lymphoma stage III	10036717	PT	Narrow	A	0	Active	10.0	20.0
Primary mediastinal large B-cell lymphoma stage IV	10036718	PT	Narrow	A	0	Active	10.0	20.0
Prolymphocytic leukaemia	10036888	PT	Narrow	A	0	Active	10.0	20.0
Richter's syndrome	10058728	PT	Narrow	A	0	Active	10.0	20.0
Splenic marginal zone lymphoma	10062113	PT	Narrow	A	0	Active	10.0	20.0
Splenic marginal zone lymphoma recurrent	10041652	PT	Narrow	A	0	Active	10.0	20.0
Splenic marginal zone lymphoma refractory	10041653	PT	Narrow	A	0	Active	10.0	20.0
Splenic marginal zone lymphoma stage I	10041654	PT	Narrow	A	0	Active	10.0	20.0
Splenic marginal zone lymphoma stage II	10041655	PT	Narrow	A	0	Active	10.0	20.0
Splenic marginal zone lymphoma stage III	10041656	PT	Narrow	A	0	Active	10.0	20.0



Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Splenic marginal zone lymphoma stage IV	10041657	PT	Narrow	A	0	Active	10.0	20.0
T-cell chronic lymphocytic leukaemia	10042970	PT	Narrow	A	0	Active	10.0	20.0
T-cell lymphoma	10042971	PT	Narrow	A	0	Active	10.0	20.0
T-cell lymphoma recurrent	10042979	PT	Narrow	A	0	Active	10.0	20.0
T-cell lymphoma refractory	10042980	PT	Narrow	A	0	Active	10.0	20.0
T-cell lymphoma stage I	10042981	PT	Narrow	A	0	Active	10.0	20.0
T-cell lymphoma stage II	10042982	PT	Narrow	A	0	Active	10.0	20.0
T-cell lymphoma stage III	10042983	PT	Narrow	A	0	Active	10.0	20.0
T-cell lymphoma stage IV	10042984	PT	Narrow	A	0	Active	10.0	20.0
T-cell prolymphocytic leukaemia	10042985	PT	Narrow	A	0	Active	10.0	20.0
T-cell type acute leukaemia	10042987	PT	Narrow	A	0	Active	10.0	20.0
T-cell unclassifiable lymphoma high grade	10042989	PT	Narrow	A	0	Active	10.0	20.0
T-cell unclassifiable lymphoma low grade	10042990	PT	Narrow	A	0	Active	10.0	20.0
Thymic cancer metastatic	10055108	PT	Narrow	A	0	Active	10.0	20.0
Thymoma malignant	10061031	PT	Narrow	A	0	Active	10.0	20.0
Thymoma malignant recurrent	10043674	PT	Narrow	A	0	Active	10.0	20.0
Thyroid B-cell lymphoma	10072613	PT	Narrow	A	0	Active	15.1	20.0
Transformation to acute myeloid leukaemia	10079107	PT	Narrow	A	0	Active	20.0	20.0
Triple hit lymphoma	10080200	PT	Narrow	A	0	Active	20.1	20.1
Waldenstrom's macroglobulinaemia	10047801	PT	Narrow	A	0	Active	10.0	20.0
Waldenstrom's macroglobulinaemia recurrent	10047804	PT	Narrow	A	0	Active	10.0	20.0
Waldenstrom's macroglobulinaemia refractory	10047805	PT	Narrow	A	0	Active	10.0	20.0
Waldenstrom's macroglobulinaemia stage I	10047806	PT	Narrow	A	0	Active	10.0	20.0
Waldenstrom's macroglobulinaemia stage II	10047807	PT	Narrow	A	0	Active	10.0	20.0
Waldenstrom's macroglobulinaemia stage III	10047808	PT	Narrow	A	0	Active	10.0	20.0
Waldenstrom's macroglobulinaemia stage IV	10047809	PT	Narrow	A	0	Active	10.0	20.0

**Non-haematological malignant tumours (SMQ) [20000228]**

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Abdominal wall neoplasm malignant	10071023	PT	Narrow	A	0	Active	14.0	20.0
Acinar cell carcinoma of pancreas	10073363	PT	Narrow	A	0	Active	16.0	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Acinic cell carcinoma of salivary gland	10073369	PT	Narrow	A	0	Active	16.0	20.0
Acral lentiginous melanoma	10000583	PT	Narrow	A	0	Active	10.0	20.0
Acral lentiginous melanoma stage I	10000585	PT	Narrow	A	0	Active	10.0	20.0
Acral lentiginous melanoma stage II	10000586	PT	Narrow	A	0	Active	10.0	20.0
Acral lentiginous melanoma stage III	10000587	PT	Narrow	A	0	Active	10.0	20.0
Acral lentiginous melanoma stage IV	10000588	PT	Narrow	A	0	Active	10.0	20.0
Adenocarcinoma	10001141	PT	Narrow	A	0	Active	10.0	20.0
Adenocarcinoma gastric	10001150	PT	Narrow	A	0	Active	10.0	20.0
Adenocarcinoma of appendix	10073359	PT	Narrow	A	0	Active	16.0	20.0
Adenocarcinoma of colon	10001167	PT	Narrow	A	0	Active	10.0	20.0
Adenocarcinoma of salivary gland	10068068	PT	Narrow	A	0	Active	11.0	20.0
Adenocarcinoma of the cervix	10001197	PT	Narrow	A	0	Active	10.0	20.0
Adenocarcinoma pancreas	10052747	PT	Narrow	A	0	Active	10.0	20.0
Adenoid cystic carcinoma	10053231	PT	Narrow	A	0	Active	10.0	20.0
Adenoid cystic carcinoma of external auditory canal	10078057	PT	Narrow	A	0	Active	19.0	20.0
Adenoid cystic carcinoma of salivary gland	10073370	PT	Narrow	A	0	Active	16.0	20.0
Adenosquamous carcinoma of the cervix	10001244	PT	Narrow	A	0	Active	10.0	20.0
Adenosquamous carcinoma of vagina	10073978	PT	Narrow	A	0	Active	16.1	20.0
Adenosquamous cell carcinoma	10068873	PT	Narrow	A	0	Active	12.0	20.0
Adenosquamous cell lung cancer	10001245	PT	Narrow	A	0	Active	10.0	20.0
Adenosquamous cell lung cancer recurrent	10001247	PT	Narrow	A	0	Active	10.0	20.0
Adenosquamous cell lung cancer stage 0	10001248	PT	Narrow	A	0	Active	10.0	20.0
Adenosquamous cell lung cancer stage I	10001249	PT	Narrow	A	0	Active	10.0	20.0
Adenosquamous cell lung cancer stage II	10001250	PT	Narrow	A	0	Active	10.0	20.0
Adenosquamous cell lung cancer stage III	10001251	PT	Narrow	A	0	Active	10.0	20.0
Adenosquamous cell lung cancer stage IV	10001254	PT	Narrow	A	0	Active	10.0	20.0
Adrenal gland cancer	10073152	PT	Narrow	A	0	Active	16.0	20.0
Adrenal gland cancer metastatic	10055095	PT	Narrow	A	0	Active	10.0	20.0
Adrenocortical carcinoma	10001388	PT	Narrow	A	0	Active	10.0	20.0
Aesthesioneuroblastoma	10001433	PT	Narrow	A	0	Active	10.0	20.0
Alveolar rhabdomyosarcoma	10065867	PT	Narrow	A	0	Active	10.0	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Alveolar soft part sarcoma	10001882	PT	Narrow	A	0	Active	10.0	20.0
Alveolar soft part sarcoma metastatic	10001884	PT	Narrow	A	0	Active	10.0	20.0
Alveolar soft part sarcoma recurrent	10001887	PT	Narrow	A	0	Active	10.0	20.0
Anal cancer	10061424	PT	Narrow	A	0	Active	10.0	20.0
Anal cancer metastatic	10055096	PT	Narrow	A	0	Active	10.0	20.0
Anal cancer recurrent	10002133	PT	Narrow	A	0	Active	10.0	20.0
Anal cancer stage 0	10002134	PT	Narrow	A	0	Active	10.0	20.0
Anal cancer stage I	10002135	PT	Narrow	A	0	Active	10.0	20.0
Anal cancer stage II	10002136	PT	Narrow	A	0	Active	10.0	20.0
Anal cancer stage III	10002137	PT	Narrow	A	0	Active	10.0	20.0
Anal cancer stage IV	10002138	PT	Narrow	A	0	Active	10.0	20.0
Anal squamous cell carcinoma	10073358	PT	Narrow	A	0	Active	16.0	20.0
Anaplastic astrocytoma	10002224	PT	Narrow	A	0	Active	10.0	20.0
Anaplastic meningioma	10073127	PT	Narrow	A	0	Active	16.0	20.0
Anaplastic oligodendroglioma	10073128	PT	Narrow	A	0	Active	16.0	20.0
Anaplastic thyroid cancer	10002240	PT	Narrow	A	0	Active	10.0	20.0
Angiocentric glioma	10073129	PT	Narrow	A	0	Active	16.0	20.0
Angiosarcoma	10002476	PT	Narrow	A	0	Active	10.0	20.0
Angiosarcoma metastatic	10002477	PT	Narrow	A	0	Active	10.0	20.0
Angiosarcoma non-metastatic	10057700	PT	Narrow	A	0	Active	10.0	20.0
Angiosarcoma recurrent	10002480	PT	Narrow	A	0	Active	10.0	20.0
Apocrine breast carcinoma	10066206	PT	Narrow	A	0	Active	10.0	20.0
Appendix cancer	10073360	PT	Narrow	A	0	Active	16.0	20.0
Astrocytoma	10003571	PT	Narrow	A	0	Active	10.0	20.0
Astrocytoma malignant	10060971	PT	Narrow	A	0	Active	10.0	20.0
Atypical teratoid/rhabdoid tumour of CNS	10065907	PT	Narrow	A	0	Active	10.0	20.0
Basal cell carcinoma	10004146	PT	Narrow	A	0	Active	10.0	20.0
Basosquamous carcinoma	10004178	PT	Narrow	A	0	Active	10.0	20.0
Basosquamous carcinoma of skin	10004179	PT	Narrow	A	0	Active	10.0	20.0
Bile duct adenocarcinoma	10004585	PT	Narrow	A	0	Active	10.0	20.0
Bile duct adenosquamous carcinoma	10004589	PT	Narrow	A	0	Active	10.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Bile duct cancer	10004593	PT	Narrow	A	0	Active	10.0	20.0
Bile duct cancer recurrent	10004596	PT	Narrow	A	0	Active	10.0	20.0
Bile duct cancer stage 0	10059384	PT	Narrow	A	0	Active	10.0	20.0
Bile duct cancer stage I	10059373	PT	Narrow	A	0	Active	10.0	20.0
Bile duct cancer stage II	10059374	PT	Narrow	A	0	Active	10.0	20.0
Bile duct cancer stage III	10059375	PT	Narrow	A	0	Active	10.0	20.0
Bile duct cancer stage IV	10059376	PT	Narrow	A	0	Active	10.0	20.0
Bile duct squamous cell carcinoma	10004633	PT	Narrow	A	0	Active	10.0	20.0
Biliary cancer metastatic	10055111	PT	Narrow	A	0	Active	10.0	20.0
Biphasic mesothelioma	10073062	PT	Narrow	A	0	Active	16.0	20.0
Bladder adenocarcinoma recurrent	10004986	PT	Narrow	A	0	Active	10.0	20.0
Bladder adenocarcinoma stage 0	10004987	PT	Narrow	A	0	Active	10.0	20.0
Bladder adenocarcinoma stage I	10004988	PT	Narrow	A	0	Active	10.0	20.0
Bladder adenocarcinoma stage II	10004989	PT	Narrow	A	0	Active	10.0	20.0
Bladder adenocarcinoma stage III	10004990	PT	Narrow	A	0	Active	10.0	20.0
Bladder adenocarcinoma stage IV	10004991	PT	Narrow	A	0	Active	10.0	20.0
Bladder adenocarcinoma stage unspecified	10004992	PT	Narrow	A	0	Active	10.0	20.0
Bladder cancer	10005003	PT	Narrow	A	0	Active	10.0	20.0
Bladder cancer recurrent	10005005	PT	Narrow	A	0	Active	10.0	20.0
Bladder cancer stage 0, with cancer in situ	10005006	PT	Narrow	A	0	Active	10.0	20.0
Bladder cancer stage 0, without cancer in situ	10005007	PT	Narrow	A	0	Active	10.0	20.0
Bladder cancer stage I, with cancer in situ	10005008	PT	Narrow	A	0	Active	10.0	20.0
Bladder cancer stage I, without cancer in situ	10005009	PT	Narrow	A	0	Active	10.0	20.0
Bladder cancer stage II	10005010	PT	Narrow	A	0	Active	10.0	20.0
Bladder cancer stage III	10005011	PT	Narrow	A	0	Active	10.0	20.0
Bladder cancer stage IV	10005012	PT	Narrow	A	0	Active	10.0	20.0
Bladder squamous cell carcinoma recurrent	10005075	PT	Narrow	A	0	Active	10.0	20.0
Bladder squamous cell carcinoma stage 0	10005076	PT	Narrow	A	0	Active	10.0	20.0
Bladder squamous cell carcinoma stage I	10005077	PT	Narrow	A	0	Active	10.0	20.0
Bladder squamous cell carcinoma stage II	10005078	PT	Narrow	A	0	Active	10.0	20.0
Bladder squamous cell carcinoma stage III	10005079	PT	Narrow	A	0	Active	10.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Bladder squamous cell carcinoma stage IV	10005080	PT	Narrow	A	0	Active	10.0	20.0
Bladder squamous cell carcinoma stage unspecified	10005081	PT	Narrow	A	0	Active	10.0	20.0
Bladder transitional cell carcinoma	10005084	PT	Narrow	A	0	Active	10.0	20.0
Bladder transitional cell carcinoma metastatic	10071664	PT	Narrow	A	0	Active	14.1	20.0
Bladder transitional cell carcinoma recurrent	10066750	PT	Narrow	A	0	Active	10.0	20.0
Bladder transitional cell carcinoma stage 0	10066749	PT	Narrow	A	0	Active	10.0	20.0
Bladder transitional cell carcinoma stage I	10066751	PT	Narrow	A	0	Active	10.0	20.0
Bladder transitional cell carcinoma stage II	10066753	PT	Narrow	A	0	Active	10.0	20.0
Bladder transitional cell carcinoma stage III	10066754	PT	Narrow	A	0	Active	10.0	20.0
Bladder transitional cell carcinoma stage IV	10066752	PT	Narrow	A	0	Active	10.0	20.0
Bone cancer	10005949	PT	Narrow	A	0	Active	10.0	20.0
Bone cancer metastatic	10055101	PT	Narrow	A	0	Active	10.0	20.0
Bone giant cell tumour malignant	10073106	PT	Narrow	A	0	Active	16.0	20.0
Bone sarcoma	10006007	PT	Narrow	A	0	Active	10.0	20.0
Bowen's disease	10006059	PT	Narrow	A	0	Active	10.0	20.0
Brain cancer metastatic	10055093	PT	Narrow	A	0	Active	10.0	20.0
Brain neoplasm malignant	10006131	PT	Narrow	A	0	Active	10.0	20.0
Brain sarcoma	10073857	PT	Narrow	A	0	Active	16.1	20.0
Brain stem glioma	10006143	PT	Narrow	A	0	Active	10.0	20.0
Breast angiosarcoma	10072813	PT	Narrow	A	0	Active	15.1	20.0
Breast angiosarcoma metastatic	10072814	PT	Narrow	A	0	Active	15.1	20.0
Breast cancer	10006187	PT	Narrow	A	0	Active	10.0	20.0
Breast cancer female	10057654	PT	Narrow	A	0	Active	10.0	20.0
Breast cancer in situ	10006189	PT	Narrow	A	0	Active	10.0	20.0
Breast cancer male	10061020	PT	Narrow	A	0	Active	10.0	20.0
Breast cancer metastatic	10055113	PT	Narrow	A	0	Active	10.0	20.0
Breast cancer recurrent	10006198	PT	Narrow	A	0	Active	10.0	20.0
Breast cancer stage I	10006199	PT	Narrow	A	0	Active	10.0	20.0
Breast cancer stage II	10006200	PT	Narrow	A	0	Active	10.0	20.0
Breast cancer stage III	10006201	PT	Narrow	A	0	Active	10.0	20.0
Breast cancer stage IV	10006202	PT	Narrow	A	0	Active	10.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Breast sarcoma	10068582	PT	Narrow	A	0	Active	11.1	20.0
Breast sarcoma metastatic	10068583	PT	Narrow	A	0	Active	11.1	20.0
Breast sarcoma recurrent	10068584	PT	Narrow	A	0	Active	11.1	20.0
Bronchial carcinoma	10006417	PT	Narrow	A	0	Active	10.0	20.0
Bronchioloalveolar carcinoma	10058354	PT	Narrow	A	0	Active	10.0	20.0
Buschke-Lowenstein's tumour	10059427	PT	Narrow	A	0	Active	10.0	20.0
Cancer in remission	10065305	PT	Narrow	A	0	Active	10.0	20.0
Carcinoid tumour	10007275	PT	Narrow	A	0	Active	10.0	20.0
Carcinoid tumour of the appendix	10007277	PT	Narrow	A	0	Active	10.0	20.0
Carcinoid tumour of the caecum	10007278	PT	Narrow	A	0	Active	10.0	20.0
Carcinoid tumour of the duodenum	10050110	PT	Narrow	A	0	Active	10.0	20.0
Carcinoid tumour of the gastrointestinal tract	10007279	PT	Narrow	A	0	Active	10.0	20.0
Carcinoid tumour of the pancreas	10055007	PT	Narrow	A	0	Active	10.0	20.0
Carcinoid tumour of the prostate	10007280	PT	Narrow	A	0	Active	10.0	20.0
Carcinoid tumour of the small bowel	10052819	PT	Narrow	A	0	Active	10.0	20.0
Carcinoid tumour of the stomach	10007281	PT	Narrow	A	0	Active	10.0	20.0
Carcinoid tumour pulmonary	10007282	PT	Narrow	A	0	Active	10.0	20.0
Carcinoma ex-pleomorphic adenoma	10077435	PT	Narrow	A	0	Active	19.0	20.0
Carcinoma in situ	10061450	PT	Narrow	A	0	Active	10.0	20.0
Carcinoma in situ of eye	10007368	PT	Narrow	A	0	Active	10.0	20.0
Carcinoma in situ of penis	10007384	PT	Narrow	A	0	Active	10.0	20.0
Carcinoma in situ of skin	10007390	PT	Narrow	A	0	Active	10.0	20.0
Carcinoma in situ of trachea	10007401	PT	Narrow	A	0	Active	10.0	20.0
Cardiac neoplasm malignant	10061025	PT	Narrow	A	0	Active	10.0	20.0
Central nervous system melanoma	10077160	PT	Narrow	A	0	Active	18.1	20.0
Central nervous system neuroblastoma	10073130	PT	Narrow	A	0	Active	16.0	20.0
Cervix cancer metastatic	10055094	PT	Narrow	A	0	Active	10.0	20.0
Cervix carcinoma	10008342	PT	Narrow	A	0	Active	10.0	20.0
Cervix carcinoma recurrent	10008344	PT	Narrow	A	0	Active	10.0	20.0
Cervix carcinoma stage 0	10061809	PT	Narrow	A	0	Active	10.0	20.0
Cervix carcinoma stage I	10008345	PT	Narrow	A	0	Active	10.0	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Cervix carcinoma stage II	10008346	PT	Narrow	A	0	Active	10.0	20.0
Cervix carcinoma stage III	10008347	PT	Narrow	A	0	Active	10.0	20.0
Cervix carcinoma stage IV	10008348	PT	Narrow	A	0	Active	10.0	20.0
Cholangiocarcinoma	10008593	PT	Narrow	A	0	Active	10.0	20.0
Cholangiosarcoma	10077861	PT	Narrow	A	0	Active	19.0	20.0
Chondrosarcoma	10008734	PT	Narrow	A	0	Active	10.0	20.0
Chondrosarcoma metastatic	10008736	PT	Narrow	A	0	Active	10.0	20.0
Chondrosarcoma recurrent	10008738	PT	Narrow	A	0	Active	10.0	20.0
Chordoma	10008747	PT	Narrow	A	0	Active	10.0	20.0
Choriocarcinoma	10008757	PT	Narrow	A	0	Active	10.0	20.0
Choroid melanoma	10008773	PT	Narrow	A	0	Active	10.0	20.0
Choroid plexus carcinoma	10067478	PT	Narrow	A	0	Active	10.1	20.0
Clear cell carcinoma of cervix	10074909	PT	Narrow	A	0	Active	17.1	20.0
Clear cell endometrial carcinoma	10009252	PT	Narrow	A	0	Active	10.0	20.0
Clear cell renal cell carcinoma	10073251	PT	Narrow	A	0	Active	16.0	20.0
Clear cell sarcoma of soft tissue	10073140	PT	Narrow	A	0	Active	16.0	20.0
Clear cell sarcoma of the kidney	10009253	PT	Narrow	A	0	Active	10.0	20.0
CNS germinoma	10065852	PT	Narrow	A	0	Active	10.0	20.0
Colon cancer	10009944	PT	Narrow	A	0	Active	10.0	20.0
Colon cancer metastatic	10055114	PT	Narrow	A	0	Active	10.0	20.0
Colon cancer recurrent	10009952	PT	Narrow	A	0	Active	10.0	20.0
Colon cancer stage 0	10063523	PT	Narrow	A	0	Active	10.0	20.0
Colon cancer stage I	10009953	PT	Narrow	A	0	Active	10.0	20.0
Colon cancer stage II	10009954	PT	Narrow	A	0	Active	10.0	20.0
Colon cancer stage III	10009955	PT	Narrow	A	0	Active	10.0	20.0
Colon cancer stage IV	10009956	PT	Narrow	A	0	Active	10.0	20.0
Colorectal adenocarcinoma	10052360	PT	Narrow	A	0	Active	10.0	20.0
Colorectal cancer	10061451	PT	Narrow	A	0	Active	10.0	20.0
Colorectal cancer metastatic	10052358	PT	Narrow	A	0	Active	10.0	20.0
Colorectal cancer recurrent	10010030	PT	Narrow	A	0	Active	10.0	20.0
Colorectal cancer stage I	10010032	PT	Narrow	A	0	Active	10.0	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Colorectal cancer stage II	10010033	PT	Narrow	A	0	Active	10.0	20.0
Colorectal cancer stage III	10010034	PT	Narrow	A	0	Active	10.0	20.0
Colorectal cancer stage IV	10010035	PT	Narrow	A	0	Active	10.0	20.0
Colorectal carcinoma stage 0	10010038	PT	Narrow	A	0	Active	10.0	20.0
Congenital fibrosarcoma	10065859	PT	Narrow	A	0	Active	10.0	20.0
Congenital malignant neoplasm	10073492	PT	Narrow	A	0	Active	16.0	20.0
Congenital retinoblastoma	10073470	PT	Narrow	A	0	Active	16.0	20.0
Conjunctival melanoma	10066384	PT	Narrow	A	0	Active	10.0	20.0
Cystadenocarcinoma ovary	10054912	PT	Narrow	A	0	Active	10.0	20.0
Dedifferentiated liposarcoma	10073135	PT	Narrow	A	0	Active	16.0	20.0
Dermatofibrosarcoma protuberans	10057070	PT	Narrow	A	0	Active	10.0	20.0
Dermatofibrosarcoma protuberans metastatic	10073574	PT	Narrow	A	0	Active	16.1	20.0
Desmoplastic melanoma	10072449	PT	Narrow	A	0	Active	15.1	20.0
Desmoplastic mesothelioma	10073063	PT	Narrow	A	0	Active	16.0	20.0
Desmoplastic small round cell tumour	10064581	PT	Narrow	A	0	Active	10.0	20.0
Ductal adenocarcinoma of pancreas	10073364	PT	Narrow	A	0	Active	16.0	20.0
Ear neoplasm malignant	10055017	PT	Narrow	A	0	Active	10.0	20.0
Eccrine carcinoma	10069680	PT	Narrow	A	0	Active	12.1	20.0
Embryonal rhabdomyosarcoma	10065868	PT	Narrow	A	0	Active	10.0	20.0
Endocrine neoplasm malignant	10061122	PT	Narrow	A	0	Active	10.0	20.0
Endometrial adenocarcinoma	10014720	PT	Narrow	A	0	Active	10.0	20.0
Endometrial cancer	10014733	PT	Narrow	A	0	Active	10.0	20.0
Endometrial cancer metastatic	10014734	PT	Narrow	A	0	Active	10.0	20.0
Endometrial cancer recurrent	10014736	PT	Narrow	A	0	Active	10.0	20.0
Endometrial cancer stage 0	10014737	PT	Narrow	A	0	Active	10.0	20.0
Endometrial cancer stage I	10014738	PT	Narrow	A	0	Active	10.0	20.0
Endometrial cancer stage II	10014739	PT	Narrow	A	0	Active	10.0	20.0
Endometrial cancer stage III	10014740	PT	Narrow	A	0	Active	10.0	20.0
Endometrial cancer stage IV	10014741	PT	Narrow	A	0	Active	10.0	20.0
Endometrial sarcoma	10057649	PT	Narrow	A	0	Active	10.0	20.0
Endometrial sarcoma metastatic	10067065	PT	Narrow	A	0	Active	10.0	20.0



<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Endometrial sarcoma recurrent	10067064	PT	Narrow	A	0	Active	10.0	20.0
Endometrial stromal sarcoma	10048397	PT	Narrow	A	0	Active	10.0	20.0
Endotheliomatosis	10076868	PT	Narrow	A	0	Active	18.1	20.0
Ependymoma malignant	10014968	PT	Narrow	A	0	Active	10.0	20.0
Epididymal cancer	10073115	PT	Narrow	A	0	Active	16.0	20.0
Epiglottic carcinoma	10057438	PT	Narrow	A	0	Active	10.0	20.0
Epithelioid mesothelioma	10073064	PT	Narrow	A	0	Active	16.0	20.0
Epithelioid sarcoma	10015099	PT	Narrow	A	0	Active	10.0	20.0
Epithelioid sarcoma metastatic	10015101	PT	Narrow	A	0	Active	10.0	20.0
Epithelioid sarcoma recurrent	10015104	PT	Narrow	A	0	Active	10.0	20.0
Ewing's sarcoma	10015560	PT	Narrow	A	0	Active	10.0	20.0
Ewing's sarcoma metastatic	10015562	PT	Narrow	A	0	Active	10.0	20.0
Ewing's sarcoma recurrent	10015564	PT	Narrow	A	0	Active	10.0	20.0
Extragenadal primary embryonal carcinoma	10015789	PT	Narrow	A	0	Active	10.0	20.0
Extragenadal primary germ cell tumour	10073055	PT	Narrow	A	0	Active	16.0	20.0
Extragenadal primary germ cell tumour mixed	10073056	PT	Narrow	A	0	Active	16.0	20.0
Extragenadal primary germ cell tumour mixed stage I	10015800	PT	Narrow	A	0	Active	10.0	20.0
Extragenadal primary germ cell tumour mixed stage II	10015801	PT	Narrow	A	0	Active	10.0	20.0
Extragenadal primary germ cell tumour mixed stage III	10015802	PT	Narrow	A	0	Active	10.0	20.0
Extragenadal primary malignant teratoma	10061848	PT	Narrow	A	0	Active	10.0	20.0
Extragenadal primary non-seminoma	10061849	PT	Narrow	A	0	Active	10.0	20.0
Extragenadal primary non-seminoma stage I	10015805	PT	Narrow	A	0	Active	10.0	20.0
Extragenadal primary non-seminoma stage II	10015806	PT	Narrow	A	0	Active	10.0	20.0
Extragenadal primary non-seminoma stage III	10015809	PT	Narrow	A	0	Active	10.0	20.0
Extragenadal primary non-seminoma stage IV	10015810	PT	Narrow	A	0	Active	10.0	20.0
Extragenadal primary seminoma (pure)	10073057	PT	Narrow	A	0	Active	16.0	20.0
Extragenadal primary seminoma (pure) stage I	10015811	PT	Narrow	A	0	Active	10.0	20.0
Extragenadal primary seminoma (pure) stage II	10015812	PT	Narrow	A	0	Active	10.0	20.0
Extragenadal primary seminoma (pure) stage III	10015815	PT	Narrow	A	0	Active	10.0	20.0
Extragenadal primary seminoma (pure) stage IV	10015816	PT	Narrow	A	0	Active	10.0	20.0
Extramammary Paget's disease	10068223	PT	Narrow	A	0	Active	11.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Extraocular retinoblastoma	10015831	PT	Narrow	A	0	Active	10.0	20.0
Extra-osseous Ewing's sarcoma	10015759	PT	Narrow	A	0	Active	10.0	20.0
Extra-osseous Ewing's sarcoma metastatic	10015761	PT	Narrow	A	0	Active	10.0	20.0
Extra-osseous Ewing's sarcoma recurrent	10015764	PT	Narrow	A	0	Active	10.0	20.0
Extraskelatal chondrosarcoma metastatic	10015840	PT	Narrow	A	0	Active	10.0	20.0
Extraskelatal chondrosarcoma recurrent	10015843	PT	Narrow	A	0	Active	10.0	20.0
Extraskelatal myxoid chondrosarcoma	10073134	PT	Narrow	A	0	Active	16.0	20.0
Extraskelatal osteosarcoma	10015847	PT	Narrow	A	0	Active	10.0	20.0
Extraskelatal osteosarcoma metastatic	10015849	PT	Narrow	A	0	Active	10.0	20.0
Extraskelatal osteosarcoma recurrent	10015852	PT	Narrow	A	0	Active	10.0	20.0
Fallopian tube cancer	10016180	PT	Narrow	A	0	Active	10.0	20.0
Fallopian tube cancer metastatic	10016182	PT	Narrow	A	0	Active	10.0	20.0
Fallopian tube cancer stage I	10016184	PT	Narrow	A	0	Active	10.0	20.0
Fallopian tube cancer stage II	10016185	PT	Narrow	A	0	Active	10.0	20.0
Fallopian tube cancer stage III	10016186	PT	Narrow	A	0	Active	10.0	20.0
Fallopian tube cancer stage IV	10016187	PT	Narrow	A	0	Active	10.0	20.0
Familial medullary thyroid cancer	10073153	PT	Narrow	A	0	Active	16.0	20.0
Female reproductive tract carcinoma in situ	10061154	PT	Narrow	A	0	Active	10.0	20.0
Fibrosarcoma	10016632	PT	Narrow	A	0	Active	10.0	20.0
Fibrosarcoma metastatic	10016635	PT	Narrow	A	0	Active	10.0	20.0
Follicular thyroid cancer	10016935	PT	Narrow	A	0	Active	10.0	20.0
Gallbladder adenocarcinoma	10058286	PT	Narrow	A	0	Active	10.0	20.0
Gallbladder adenosquamous carcinoma	10073067	PT	Narrow	A	0	Active	16.0	20.0
Gallbladder cancer	10017614	PT	Narrow	A	0	Active	10.0	20.0
Gallbladder cancer metastatic	10066879	PT	Narrow	A	0	Active	10.0	20.0
Gallbladder cancer recurrent	10017619	PT	Narrow	A	0	Active	10.0	20.0
Gallbladder cancer stage 0	10059316	PT	Narrow	A	0	Active	10.0	20.0
Gallbladder cancer stage I	10059317	PT	Narrow	A	0	Active	10.0	20.0
Gallbladder cancer stage II	10058281	PT	Narrow	A	0	Active	10.0	20.0
Gallbladder cancer stage III	10058282	PT	Narrow	A	0	Active	10.0	20.0
Gallbladder cancer stage IV	10058283	PT	Narrow	A	0	Active	10.0	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Gallbladder squamous cell carcinoma	10073068	PT	Narrow	A	0	Active	16.0	20.0
Ganglioglioma	10017701	PT	Narrow	A	0	Active	10.0	20.0
Ganglioneuroblastoma	10017708	PT	Narrow	A	0	Active	10.0	20.0
Gastric cancer	10017758	PT	Narrow	A	0	Active	10.0	20.0
Gastric cancer recurrent	10017761	PT	Narrow	A	0	Active	10.0	20.0
Gastric cancer stage 0	10017762	PT	Narrow	A	0	Active	10.0	20.0
Gastric cancer stage I	10017763	PT	Narrow	A	0	Active	10.0	20.0
Gastric cancer stage II	10017764	PT	Narrow	A	0	Active	10.0	20.0
Gastric cancer stage III	10017765	PT	Narrow	A	0	Active	10.0	20.0
Gastric cancer stage IV	10061967	PT	Narrow	A	0	Active	10.0	20.0
Gastric sarcoma	10055008	PT	Narrow	A	0	Active	10.0	20.0
Gastrinoma malignant	10051709	PT	Narrow	A	0	Active	10.0	20.0
Gastroenteropancreatic neuroendocrine tumour disease	10077559	PT	Narrow	A	0	Active	19.0	20.0
Gastrointestinal cancer metastatic	10053548	PT	Narrow	A	0	Active	10.0	20.0
Gastrointestinal carcinoma	10017940	PT	Narrow	A	0	Active	10.0	20.0
Gastrointestinal carcinoma in situ	10061168	PT	Narrow	A	0	Active	10.0	20.0
Gastrointestinal melanoma	10077167	PT	Narrow	A	0	Active	18.1	20.0
Gastrointestinal stromal cancer	10071653	PT	Narrow	A	0	Active	14.1	20.0
Gastroesophageal cancer	10062878	PT	Narrow	A	0	Active	10.0	20.0
Genital cancer male	10073116	PT	Narrow	A	0	Active	16.0	20.0
Genital cancer male in situ	10073124	PT	Narrow	A	0	Active	16.0	20.0
Genital neoplasm malignant female	10018160	PT	Narrow	A	0	Active	10.0	20.0
Genitourinary melanoma	10077166	PT	Narrow	A	0	Active	18.1	20.0
Germ cell cancer	10061184	PT	Narrow	A	0	Active	10.0	20.0
Germ cell cancer metastatic	10068971	PT	Narrow	A	0	Active	12.0	20.0
Gestational trophoblastic tumour	10061988	PT	Narrow	A	0	Active	10.0	20.0
Gingival cancer	10067807	PT	Narrow	A	0	Active	11.0	20.0
Glioblastoma	10018336	PT	Narrow	A	0	Active	10.0	20.0
Glioblastoma multiforme	10018337	PT	Narrow	A	0	Active	10.0	20.0
Glioma	10018338	PT	Narrow	A	0	Active	10.0	20.0
Gliomatosis cerebri	10066254	PT	Narrow	A	0	Active	10.0	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Glioneuronal tumour	10068601	PT	Narrow	A	0	Active	11.1	20.0
Gliosarcoma	10018340	PT	Narrow	A	0	Active	10.0	20.0
Glottis carcinoma	10018395	PT	Narrow	A	0	Active	10.0	20.0
Glucagonoma	10018404	PT	Narrow	A	0	Active	10.0	20.0
Haemangiopericytoma	10018825	PT	Narrow	A	0	Active	10.0	20.0
Haemangiopericytoma of meninges	10018826	PT	Narrow	A	0	Active	10.0	20.0
Head and neck cancer	10067821	PT	Narrow	A	0	Active	11.0	20.0
Head and neck cancer metastatic	10071540	PT	Narrow	A	0	Active	14.1	20.0
Head and neck cancer stage I	10071539	PT	Narrow	A	0	Active	14.1	20.0
Head and neck cancer stage II	10071538	PT	Narrow	A	0	Active	14.1	20.0
Head and neck cancer stage III	10071537	PT	Narrow	A	0	Active	14.1	20.0
Head and neck cancer stage IV	10071536	PT	Narrow	A	0	Active	14.1	20.0
Hepatic angiosarcoma	10067388	PT	Narrow	A	0	Active	10.1	20.0
Hepatic cancer	10073069	PT	Narrow	A	0	Active	16.0	20.0
Hepatic cancer metastatic	10055110	PT	Narrow	A	0	Active	10.0	20.0
Hepatic cancer recurrent	10073070	PT	Narrow	A	0	Active	16.0	20.0
Hepatic cancer stage I	10059318	PT	Narrow	A	0	Active	10.0	20.0
Hepatic cancer stage II	10059319	PT	Narrow	A	0	Active	10.0	20.0
Hepatic cancer stage III	10059324	PT	Narrow	A	0	Active	10.0	20.0
Hepatic cancer stage IV	10059325	PT	Narrow	A	0	Active	10.0	20.0
Hepatobiliary cancer	10073073	PT	Narrow	A	0	Active	16.0	20.0
Hepatobiliary cancer in situ	10073074	PT	Narrow	A	0	Active	16.0	20.0
Hepatoblastoma	10062001	PT	Narrow	A	0	Active	10.0	20.0
Hepatoblastoma recurrent	10019823	PT	Narrow	A	0	Active	10.0	20.0
Hepatocellular carcinoma	10073071	PT	Narrow	A	0	Active	16.0	20.0
HER-2 positive breast cancer	10065430	PT	Narrow	A	0	Active	10.0	20.0
HER-2 positive gastric cancer	10066896	PT	Narrow	A	0	Active	10.0	20.0
Hereditary leiomyomatosis renal cell carcinoma	10067944	PT	Narrow	A	0	Active	11.0	20.0
Hereditary papillary renal carcinoma	10067943	PT	Narrow	A	0	Active	11.0	20.0
Hidradenocarcinoma	10073088	PT	Narrow	A	0	Active	16.0	20.0
Hormone refractory breast cancer	10076935	PT	Narrow	A	0	Active	18.1	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Hormone-dependent prostate cancer	10071119	PT	Narrow	A	0	Active	14.0	20.0
Hormone-refractory prostate cancer	10062904	PT	Narrow	A	0	Active	10.0	20.0
Huerthle cell carcinoma	10066136	PT	Narrow	A	0	Active	10.0	20.0
Hypopharyngeal cancer	10021042	PT	Narrow	A	0	Active	10.0	20.0
Hypopharyngeal cancer recurrent	10021044	PT	Narrow	A	0	Active	10.0	20.0
Hypopharyngeal cancer stage 0	10021045	PT	Narrow	A	0	Active	10.0	20.0
Hypopharyngeal cancer stage I	10021046	PT	Narrow	A	0	Active	10.0	20.0
Hypopharyngeal cancer stage II	10021047	PT	Narrow	A	0	Active	10.0	20.0
Hypopharyngeal cancer stage III	10021048	PT	Narrow	A	0	Active	10.0	20.0
Hypopharyngeal cancer stage IV	10021049	PT	Narrow	A	0	Active	10.0	20.0
Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma	10072796	PT	Narrow	A	0	Active	15.1	20.0
Inflammatory carcinoma of breast recurrent	10021977	PT	Narrow	A	0	Active	10.0	20.0
Inflammatory carcinoma of breast stage III	10021978	PT	Narrow	A	0	Active	10.0	20.0
Inflammatory carcinoma of breast stage IV	10021979	PT	Narrow	A	0	Active	10.0	20.0
Inflammatory carcinoma of the breast	10021980	PT	Narrow	A	0	Active	10.0	20.0
Inflammatory malignant fibrous histiocytoma	10073142	PT	Narrow	A	0	Active	16.0	20.0
Inflammatory myofibroblastic tumour	10067917	PT	Narrow	A	0	Active	11.0	20.0
Intestinal adenocarcinoma	10051925	PT	Narrow	A	0	Active	10.0	20.0
Intestinal metastasis	10080311	PT	Narrow	A	0	Active	20.1	20.1
Intracranial germ cell tumour	10073751	PT	Narrow	A	0	Active	16.1	20.0
Intracranial meningioma malignant	10022770	PT	Narrow	A	0	Active	10.0	20.0
Intraductal papillary breast neoplasm	10073540	PT	Narrow	A	0	Active	16.0	20.0
Intraductal papillary-mucinous carcinoma of pancreas	10073365	PT	Narrow	A	0	Active	16.0	20.0
Intraductal proliferative breast lesion	10073094	PT	Narrow	A	0	Active	16.0	20.0
Intraocular melanoma	10061252	PT	Narrow	A	0	Active	10.0	20.0
Invasive breast carcinoma	10075713	PT	Narrow	A	0	Active	18.0	20.0
Invasive ductal breast carcinoma	10073095	PT	Narrow	A	0	Active	16.0	20.0
Invasive lobular breast carcinoma	10073096	PT	Narrow	A	0	Active	16.0	20.0
Invasive papillary breast carcinoma	10073098	PT	Narrow	A	0	Active	16.0	20.0
Iris melanoma	10073086	PT	Narrow	A	0	Active	16.0	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Kaposi's sarcoma	10023284	PT	Narrow	A	0	Active	10.0	20.0
Kaposi's sarcoma AIDS related	10023286	PT	Narrow	A	0	Active	10.0	20.0
Kaposi's sarcoma classical type	10023288	PT	Narrow	A	0	Active	10.0	20.0
Keratinising squamous cell carcinoma of nasopharynx	10073324	PT	Narrow	A	0	Active	16.0	20.0
Keratoacanthoma	10023347	PT	Narrow	A	0	Active	13.1	20.0
Langerhans cell sarcoma	10078782	PT	Narrow	A	0	Active	20.0	20.0
Large cell lung cancer	10023774	PT	Narrow	A	0	Active	10.0	20.0
Large cell lung cancer metastatic	10069730	PT	Narrow	A	0	Active	13.0	20.0
Large cell lung cancer recurrent	10023775	PT	Narrow	A	0	Active	10.0	20.0
Large cell lung cancer stage 0	10023776	PT	Narrow	A	0	Active	10.0	20.0
Large cell lung cancer stage I	10023777	PT	Narrow	A	0	Active	10.0	20.0
Large cell lung cancer stage II	10023778	PT	Narrow	A	0	Active	10.0	20.0
Large cell lung cancer stage III	10023779	PT	Narrow	A	0	Active	10.0	20.0
Large cell lung cancer stage IV	10023780	PT	Narrow	A	0	Active	10.0	20.0
Laryngeal cancer	10023825	PT	Narrow	A	0	Active	10.0	20.0
Laryngeal cancer metastatic	10070902	PT	Narrow	A	0	Active	14.0	20.0
Laryngeal cancer recurrent	10023828	PT	Narrow	A	0	Active	10.0	20.0
Laryngeal cancer stage 0	10023829	PT	Narrow	A	0	Active	10.0	20.0
Laryngeal cancer stage I	10023830	PT	Narrow	A	0	Active	10.0	20.0
Laryngeal cancer stage II	10023831	PT	Narrow	A	0	Active	10.0	20.0
Laryngeal cancer stage III	10023832	PT	Narrow	A	0	Active	10.0	20.0
Laryngeal cancer stage IV	10023833	PT	Narrow	A	0	Active	10.0	20.0
Laryngeal squamous cell carcinoma	10023856	PT	Narrow	A	0	Active	10.0	20.0
Leiomyosarcoma	10024189	PT	Narrow	A	0	Active	10.0	20.0
Leiomyosarcoma metastatic	10024191	PT	Narrow	A	0	Active	10.0	20.0
Leiomyosarcoma recurrent	10024194	PT	Narrow	A	0	Active	10.0	20.0
Lentigo maligna	10024218	PT	Narrow	A	0	Active	10.0	20.0
Lentigo maligna recurrent	10024220	PT	Narrow	A	0	Active	10.0	20.0
Lentigo maligna stage I	10024221	PT	Narrow	A	0	Active	10.0	20.0
Lentigo maligna stage II	10024222	PT	Narrow	A	0	Active	10.0	20.0
Lentigo maligna stage III	10024223	PT	Narrow	A	0	Active	10.0	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Lentigo maligna stage IV	10024224	PT	Narrow	A	0	Active	10.0	20.0
Leydig cell tumour of the testis	10024407	PT	Narrow	A	0	Active	10.0	20.0
Linitis plastica	10024520	PT	Narrow	A	0	Active	10.0	20.0
Lip and/or oral cavity cancer	10061523	PT	Narrow	A	0	Active	10.0	20.0
Lip and/or oral cavity cancer recurrent	10024535	PT	Narrow	A	0	Active	10.0	20.0
Lip and/or oral cavity cancer stage 0	10024536	PT	Narrow	A	0	Active	10.0	20.0
Lip and/or oral cavity cancer stage I	10024537	PT	Narrow	A	0	Active	10.0	20.0
Lip and/or oral cavity cancer stage II	10024538	PT	Narrow	A	0	Active	10.0	20.0
Lip and/or oral cavity cancer stage III	10024539	PT	Narrow	A	0	Active	10.0	20.0
Lip and/or oral cavity cancer stage IV	10024540	PT	Narrow	A	0	Active	10.0	20.0
Lip neoplasm malignant stage unspecified	10024557	PT	Narrow	A	0	Active	10.0	20.0
Lip squamous cell carcinoma	10064055	PT	Narrow	A	0	Active	10.0	20.0
Liposarcoma	10024627	PT	Narrow	A	0	Active	10.0	20.0
Liposarcoma metastatic	10024629	PT	Narrow	A	0	Active	10.0	20.0
Liposarcoma recurrent	10024632	PT	Narrow	A	0	Active	10.0	20.0
Lobular breast carcinoma in situ	10073099	PT	Narrow	A	0	Active	16.0	20.0
Lung adenocarcinoma	10025031	PT	Narrow	A	0	Active	10.0	20.0
Lung adenocarcinoma recurrent	10025033	PT	Narrow	A	0	Active	10.0	20.0
Lung adenocarcinoma stage 0	10025034	PT	Narrow	A	0	Active	10.0	20.0
Lung adenocarcinoma stage I	10025035	PT	Narrow	A	0	Active	10.0	20.0
Lung adenocarcinoma stage II	10025036	PT	Narrow	A	0	Active	10.0	20.0
Lung adenocarcinoma stage III	10025037	PT	Narrow	A	0	Active	10.0	20.0
Lung adenocarcinoma stage IV	10025038	PT	Narrow	A	0	Active	10.0	20.0
Lung cancer metastatic	10050017	PT	Narrow	A	0	Active	10.0	20.0
Lung carcinoma cell type unspecified recurrent	10025065	PT	Narrow	A	0	Active	10.0	20.0
Lung carcinoma cell type unspecified stage 0	10025066	PT	Narrow	A	0	Active	10.0	20.0
Lung carcinoma cell type unspecified stage I	10025067	PT	Narrow	A	0	Active	10.0	20.0
Lung carcinoma cell type unspecified stage II	10025068	PT	Narrow	A	0	Active	10.0	20.0
Lung carcinoma cell type unspecified stage III	10025069	PT	Narrow	A	0	Active	10.0	20.0
Lung carcinoma cell type unspecified stage IV	10025070	PT	Narrow	A	0	Active	10.0	20.0
Lung infiltration malignant	10062041	PT	Narrow	A	0	Active	10.0	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Lung neoplasm malignant	10058467	PT	Narrow	A	0	Active	10.0	20.0
Lung squamous cell carcinoma metastatic	10071533	PT	Narrow	A	0	Active	14.1	20.0
Lung squamous cell carcinoma recurrent	10025120	PT	Narrow	A	0	Active	10.0	20.0
Lung squamous cell carcinoma stage 0	10025121	PT	Narrow	A	0	Active	10.0	20.0
Lung squamous cell carcinoma stage I	10025122	PT	Narrow	A	0	Active	10.0	20.0
Lung squamous cell carcinoma stage II	10025123	PT	Narrow	A	0	Active	10.0	20.0
Lung squamous cell carcinoma stage III	10025124	PT	Narrow	A	0	Active	10.0	20.0
Lung squamous cell carcinoma stage IV	10025125	PT	Narrow	A	0	Active	10.0	20.0
Malignant anorectal neoplasm	10061237	PT	Narrow	A	0	Active	10.0	20.0
Malignant blue naevus	10072448	PT	Narrow	A	0	Active	15.1	20.0
Malignant connective tissue neoplasm	10074340	PT	Narrow	A	0	Active	17.0	20.0
Malignant cranial nerve neoplasm	10061238	PT	Narrow	A	0	Active	10.0	20.0
Malignant fibrous histiocytoma	10025552	PT	Narrow	A	0	Active	10.0	20.0
Malignant fibrous histiocytoma metastatic	10025554	PT	Narrow	A	0	Active	10.0	20.0
Malignant fibrous histiocytoma of bone	10025557	PT	Narrow	A	0	Active	10.0	20.0
Malignant fibrous histiocytoma recurrent	10025561	PT	Narrow	A	0	Active	10.0	20.0
Malignant genitourinary tract neoplasm	10074419	PT	Narrow	A	0	Active	17.0	20.0
Malignant giant cell fibrous histiocytoma	10073141	PT	Narrow	A	0	Active	16.0	20.0
Malignant glioma	10065443	PT	Narrow	A	0	Active	10.0	20.0
Malignant haemangiopericytoma	10025566	PT	Narrow	A	0	Active	10.0	20.0
Malignant haemangiopericytoma metastatic	10025567	PT	Narrow	A	0	Active	10.0	20.0
Malignant haemangiopericytoma recurrent	10025570	PT	Narrow	A	0	Active	10.0	20.0
Malignant hydatidiform mole	10025598	PT	Narrow	A	0	Active	10.0	20.0
Malignant joint neoplasm	10078145	PT	Narrow	A	0	Active	19.1	20.0
Malignant mediastinal neoplasm	10061241	PT	Narrow	A	0	Active	10.0	20.0
Malignant melanoma	10025650	PT	Narrow	A	0	Active	10.0	20.0
Malignant melanoma in situ	10025652	PT	Narrow	A	0	Active	10.0	20.0
Malignant melanoma of eyelid	10063706	PT	Narrow	A	0	Active	10.0	20.0
Malignant melanoma of sites other than skin	10025654	PT	Narrow	A	0	Active	10.0	20.0
Malignant melanoma stage I	10025668	PT	Narrow	A	0	Active	10.0	20.0
Malignant melanoma stage II	10025669	PT	Narrow	A	0	Active	10.0	20.0



<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Malignant melanoma stage III	10025670	PT	Narrow	A	0	Active	10.0	20.0
Malignant melanoma stage IV	10025671	PT	Narrow	A	0	Active	10.0	20.0
Malignant meningioma metastatic	10077758	PT	Narrow	A	0	Active	19.0	20.0
Malignant mesenchymoma	10061526	PT	Narrow	A	0	Active	10.0	20.0
Malignant mesenchymoma metastatic	10025674	PT	Narrow	A	0	Active	10.0	20.0
Malignant mesenchymoma recurrent	10025677	PT	Narrow	A	0	Active	10.0	20.0
Malignant mesenteric neoplasm	10067369	PT	Narrow	A	0	Active	10.1	20.0
Malignant middle ear neoplasm	10061267	PT	Narrow	A	0	Active	10.0	20.0
Malignant muscle neoplasm	10062050	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of ampulla of Vater	10025697	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of auricular cartilage	10057272	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of choroid	10025839	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of conjunctiva	10025861	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of cornea	10025871	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of eye	10025910	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of eyelid	10063693	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of islets of Langerhans	10025997	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of lacrimal duct	10026030	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of lacrimal gland	10026031	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of orbit	10026183	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of paraurethral glands	10026326	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of placenta	10026350	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of pleura	10026351	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of pleura metastatic	10072432	PT	Narrow	A	0	Active	15.1	20.0
Malignant neoplasm of renal pelvis	10026426	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of retina	10026432	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of seminal vesicle	10068124	PT	Narrow	A	0	Active	11.0	20.0
Malignant neoplasm of spermatic cord	10026470	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of spinal cord	10026472	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of thorax	10026532	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm of unknown primary site	10073059	PT	Narrow	A	0	Active	16.0	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Malignant neoplasm of uterine adnexa	10026616	PT	Narrow	A	0	Active	10.0	20.0
Malignant neoplasm papilla of Vater	10077303	PT	Narrow	A	0	Active	19.0	20.0
Malignant neoplasm progression	10051398	PT	Narrow	A	0	Active	10.0	20.0
Malignant nervous system neoplasm	10061268	PT	Narrow	A	0	Active	10.0	20.0
Malignant nipple neoplasm	10062051	PT	Narrow	A	0	Active	10.0	20.0
Malignant nipple neoplasm female	10053129	PT	Narrow	A	0	Active	10.0	20.0
Malignant nipple neoplasm male	10053128	PT	Narrow	A	0	Active	10.0	20.0
Malignant oligodendroglioma	10026659	PT	Narrow	A	0	Active	10.0	20.0
Malignant ovarian cyst	10026662	PT	Narrow	A	0	Active	10.0	20.0
Malignant palate neoplasm	10026663	PT	Narrow	A	0	Active	10.0	20.0
Malignant pericardial neoplasm	10054946	PT	Narrow	A	0	Active	10.0	20.0
Malignant peritoneal neoplasm	10061269	PT	Narrow	A	0	Active	10.0	20.0
Malignant pituitary tumour	10026672	PT	Narrow	A	0	Active	10.0	20.0
Malignant polyp	10078695	PT	Narrow	A	0	Active	19.1	20.0
Malignant respiratory tract neoplasm	10061270	PT	Narrow	A	0	Active	10.0	20.0
Malignant sweat gland neoplasm	10073087	PT	Narrow	A	0	Active	16.0	20.0
Malignant transformation	10064912	PT	Narrow	A	0	Active	10.0	20.0
Malignant urinary tract neoplasm	10061272	PT	Narrow	A	0	Active	10.0	20.0
Marjolin's ulcer	10076248	PT	Narrow	A	0	Active	18.0	20.0
Maternal cancer in pregnancy	10079877	PT	Narrow	A	0	Active	20.1	20.1
Medullary carcinoma of breast	10027095	PT	Narrow	A	0	Active	10.0	20.0
Medullary thyroid cancer	10027105	PT	Narrow	A	0	Active	10.0	20.0
Medulloblastoma	10027107	PT	Narrow	A	0	Active	10.0	20.0
Medulloblastoma recurrent	10066594	PT	Narrow	A	0	Active	10.0	20.0
Melanoma recurrent	10066600	PT	Narrow	A	0	Active	10.0	20.0
Meningioma malignant	10027193	PT	Narrow	A	0	Active	10.0	20.0
Mesothelioma malignant	10027407	PT	Narrow	A	0	Active	10.0	20.0
Mesothelioma malignant recurrent	10027411	PT	Narrow	A	0	Active	10.0	20.0
Metaplastic breast carcinoma	10073100	PT	Narrow	A	0	Active	16.0	20.0
Metastases to abdominal cavity	10027450	PT	Narrow	A	0	Active	10.0	20.0
Metastases to abdominal wall	10051664	PT	Narrow	A	0	Active	10.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Metastases to adrenals	10027451	PT	Narrow	A	0	Active	10.0	20.0
Metastases to biliary tract	10062195	PT	Narrow	A	0	Active	10.0	20.0
Metastases to bladder	10049722	PT	Narrow	A	0	Active	10.0	20.0
Metastases to bone	10027452	PT	Narrow	A	0	Active	10.0	20.0
Metastases to breast	10027454	PT	Narrow	A	0	Active	10.0	20.0
Metastases to central nervous system	10059282	PT	Narrow	A	0	Active	10.0	20.0
Metastases to chest wall	10051663	PT	Narrow	A	0	Active	10.0	20.0
Metastases to diaphragm	10051665	PT	Narrow	A	0	Active	10.0	20.0
Metastases to Eustachian tube	10051666	PT	Narrow	A	0	Active	10.0	20.0
Metastases to eye	10049724	PT	Narrow	A	0	Active	10.0	20.0
Metastases to fallopian tube	10049727	PT	Narrow	A	0	Active	10.0	20.0
Metastases to gallbladder	10051667	PT	Narrow	A	0	Active	10.0	20.0
Metastases to gastrointestinal tract	10062196	PT	Narrow	A	0	Active	10.0	20.0
Metastases to heart	10049717	PT	Narrow	A	0	Active	10.0	20.0
Metastases to kidney	10027455	PT	Narrow	A	0	Active	10.0	20.0
Metastases to larynx	10051668	PT	Narrow	A	0	Active	10.0	20.0
Metastases to liver	10027457	PT	Narrow	A	0	Active	10.0	20.0
Metastases to lung	10027458	PT	Narrow	A	0	Active	10.0	20.0
Metastases to meninges	10051696	PT	Narrow	A	0	Active	10.0	20.0
Metastases to mouth	10051669	PT	Narrow	A	0	Active	10.0	20.0
Metastases to muscle	10049730	PT	Narrow	A	0	Active	10.0	20.0
Metastases to nasal sinuses	10051670	PT	Narrow	A	0	Active	10.0	20.0
Metastases to neck	10027460	PT	Narrow	A	0	Active	10.0	20.0
Metastases to nervous system	10061287	PT	Narrow	A	0	Active	10.0	20.0
Metastases to oesophagus	10051671	PT	Narrow	A	0	Active	10.0	20.0
Metastases to ovary	10027462	PT	Narrow	A	0	Active	10.0	20.0
Metastases to pancreas	10049721	PT	Narrow	A	0	Active	10.0	20.0
Metastases to pelvis	10070913	PT	Narrow	A	0	Active	14.0	20.0
Metastases to penis	10051672	PT	Narrow	A	0	Active	10.0	20.0
Metastases to perineum	10051673	PT	Narrow	A	0	Active	10.0	20.0
Metastases to peripheral nervous system	10051674	PT	Narrow	A	0	Active	10.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Metastases to peripheral vascular system	10058307	PT	Narrow	A	0	Active	10.0	20.0
Metastases to peritoneum	10051676	PT	Narrow	A	0	Active	10.0	20.0
Metastases to pharynx	10051677	PT	Narrow	A	0	Active	10.0	20.0
Metastases to pituitary gland	10049728	PT	Narrow	A	0	Active	10.0	20.0
Metastases to placenta	10049725	PT	Narrow	A	0	Active	10.0	20.0
Metastases to pleura	10027463	PT	Narrow	A	0	Active	10.0	20.0
Metastases to prostate	10051678	PT	Narrow	A	0	Active	10.0	20.0
Metastases to rectum	10051679	PT	Narrow	A	0	Active	10.0	20.0
Metastases to reproductive organ	10061288	PT	Narrow	A	0	Active	10.0	20.0
Metastases to retroperitoneum	10051680	PT	Narrow	A	0	Active	10.0	20.0
Metastases to salivary gland	10051681	PT	Narrow	A	0	Active	10.0	20.0
Metastases to skin	10027465	PT	Narrow	A	0	Active	10.0	20.0
Metastases to soft tissue	10062197	PT	Narrow	A	0	Active	10.0	20.0
Metastases to spinal cord	10078267	PT	Narrow	A	0	Active	19.1	20.0
Metastases to spine	10027468	PT	Narrow	A	0	Active	10.0	20.0
Metastases to stomach	10049718	PT	Narrow	A	0	Active	10.0	20.0
Metastases to testicle	10051683	PT	Narrow	A	0	Active	10.0	20.0
Metastases to the mediastinum	10027469	PT	Narrow	A	0	Active	10.0	20.0
Metastases to the respiratory system	10061600	PT	Narrow	A	0	Active	10.0	20.0
Metastases to thorax	10051684	PT	Narrow	A	0	Active	10.0	20.0
Metastases to thyroid	10049723	PT	Narrow	A	0	Active	10.0	20.0
Metastases to tonsils	10077476	PT	Narrow	A	0	Active	19.0	20.0
Metastases to trachea	10051685	PT	Narrow	A	0	Active	10.0	20.0
Metastases to urinary tract	10056251	PT	Narrow	A	0	Active	10.0	20.0
Metastases to uterus	10049726	PT	Narrow	A	0	Active	10.0	20.0
Metastases to vagina	10075555	PT	Narrow	A	0	Active	18.0	20.0
Metastasis	10062194	PT	Narrow	A	0	Active	10.0	20.0
Metastatic bronchial carcinoma	10058306	PT	Narrow	A	0	Active	10.0	20.0
Metastatic carcinoid tumour	10068115	PT	Narrow	A	0	Active	11.0	20.0
Metastatic carcinoma of the bladder	10057352	PT	Narrow	A	0	Active	10.0	20.0
Metastatic choriocarcinoma	10071532	PT	Narrow	A	0	Active	14.1	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Metastatic gastric cancer	10063916	PT	Narrow	A	0	Active	10.0	20.0
Metastatic glioma	10063157	PT	Narrow	A	0	Active	10.0	20.0
Metastatic glucagonoma	10075245	PT	Narrow	A	0	Active	17.1	20.0
Metastatic malignant melanoma	10027480	PT	Narrow	A	0	Active	10.0	20.0
Metastatic neoplasm	10061289	PT	Narrow	A	0	Active	10.0	20.0
Metastatic nervous system neoplasm	10077703	PT	Narrow	A	0	Active	19.0	20.0
Metastatic ocular melanoma	10068117	PT	Narrow	A	0	Active	11.0	20.0
Metastatic renal cell carcinoma	10050513	PT	Narrow	A	0	Active	10.0	20.0
Metastatic salivary gland cancer	10066882	PT	Narrow	A	0	Active	10.0	20.0
Metastatic squamous cell carcinoma	10063569	PT	Narrow	A	0	Active	10.0	20.0
Metastatic uterine cancer	10068116	PT	Narrow	A	0	Active	11.0	20.0
Microsatellite instability cancer	10079618	PT	Narrow	A	0	Active	20.1	20.1
Mismatch repair cancer syndrome	10077888	PT	Narrow	A	0	Active	19.0	20.0
Mixed adenoneuroendocrine carcinoma	10076748	PT	Narrow	A	0	Active	18.1	20.0
Mixed hepatocellular cholangiocarcinoma	10027761	PT	Narrow	A	0	Active	10.0	20.0
Mixed-type liposarcoma	10073136	PT	Narrow	A	0	Active	16.0	20.0
Mucinous adenocarcinoma of appendix	10073361	PT	Narrow	A	0	Active	16.0	20.0
Mucinous breast carcinoma	10073101	PT	Narrow	A	0	Active	16.0	20.0
Mucinous cystadenocarcinoma of pancreas	10073366	PT	Narrow	A	0	Active	16.0	20.0
Mucinous cystadenocarcinoma ovary	10054914	PT	Narrow	A	0	Active	10.0	20.0
Mucinous endometrial carcinoma	10028076	PT	Narrow	A	0	Active	10.0	20.0
Mucoepidermoid carcinoma	10057269	PT	Narrow	A	0	Active	10.0	20.0
Mucoepidermoid carcinoma of salivary gland	10073371	PT	Narrow	A	0	Active	16.0	20.0
Musculoskeletal cancer	10077675	PT	Narrow	A	0	Active	19.0	20.0
Myxofibrosarcoma	10066948	PT	Narrow	A	0	Active	10.0	20.0
Myxoid liposarcoma	10073137	PT	Narrow	A	0	Active	16.0	20.0
Naevoid melanoma	10079054	PT	Narrow	A	0	Active	20.0	20.0
Nasal cavity cancer	10028729	PT	Narrow	A	0	Active	10.0	20.0
Nasal sinus cancer	10028767	PT	Narrow	A	0	Active	10.0	20.0
Nasopharyngeal cancer	10061306	PT	Narrow	A	0	Active	10.0	20.0
Nasopharyngeal cancer metastatic	10079104	PT	Narrow	A	0	Active	20.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Nasopharyngeal cancer recurrent	10028787	PT	Narrow	A	0	Active	10.0	20.0
Nasopharyngeal cancer stage 0	10028788	PT	Narrow	A	0	Active	10.0	20.0
Nasopharyngeal cancer stage I	10028789	PT	Narrow	A	0	Active	10.0	20.0
Nasopharyngeal cancer stage II	10028790	PT	Narrow	A	0	Active	10.0	20.0
Nasopharyngeal cancer stage III	10028791	PT	Narrow	A	0	Active	10.0	20.0
Nasopharyngeal cancer stage IV	10028792	PT	Narrow	A	0	Active	10.0	20.0
Neonatal neuroblastoma	10049793	PT	Narrow	A	0	Active	10.0	20.0
Neoplasm malignant	10028997	PT	Narrow	A	0	Active	10.0	20.0
Nephroblastoma	10029145	PT	Narrow	A	0	Active	10.0	20.0
Neuroblastoma	10029260	PT	Narrow	A	0	Active	10.0	20.0
Neuroblastoma recurrent	10066595	PT	Narrow	A	0	Active	10.0	20.0
Neuroendocrine breast tumour	10073103	PT	Narrow	A	0	Active	16.0	20.0
Neuroendocrine carcinoma	10057270	PT	Narrow	A	0	Active	10.0	20.0
Neuroendocrine carcinoma metastatic	10071542	PT	Narrow	A	0	Active	14.1	20.0
Neuroendocrine carcinoma of the bladder	10078341	PT	Narrow	A	0	Active	19.1	20.0
Neuroendocrine carcinoma of the skin	10029266	PT	Narrow	A	0	Active	10.0	20.0
Neuroendocrine tumour	10052399	PT	Narrow	A	0	Active	10.0	20.0
Neuroendocrine tumour of the lung	10078174	PT	Narrow	A	0	Active	19.1	20.0
Neuroendocrine tumour of the lung metastatic	10078175	PT	Narrow	A	0	Active	19.1	20.0
Neurofibrosarcoma	10061527	PT	Narrow	A	0	Active	10.0	20.0
Neurofibrosarcoma metastatic	10029274	PT	Narrow	A	0	Active	10.0	20.0
Neurofibrosarcoma recurrent	10029277	PT	Narrow	A	0	Active	10.0	20.0
Nodular melanoma	10029488	PT	Narrow	A	0	Active	10.0	20.0
Nongerminomatous germ cell tumour of the CNS	10065871	PT	Narrow	A	0	Active	10.0	20.0
Nonkeratinising carcinoma of nasopharynx	10073325	PT	Narrow	A	0	Active	16.0	20.0
Non-renal cell carcinoma of kidney	10061872	PT	Narrow	A	0	Active	10.0	20.0
Non-small cell lung cancer	10061873	PT	Narrow	A	0	Active	10.0	20.0
Non-small cell lung cancer metastatic	10059515	PT	Narrow	A	0	Active	10.0	20.0
Non-small cell lung cancer recurrent	10029515	PT	Narrow	A	0	Active	10.0	20.0
Non-small cell lung cancer stage 0	10029516	PT	Narrow	A	0	Active	10.0	20.0
Non-small cell lung cancer stage I	10029517	PT	Narrow	A	0	Active	10.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Non-small cell lung cancer stage II	10029518	PT	Narrow	A	0	Active	10.0	20.0
Non-small cell lung cancer stage III	10029519	PT	Narrow	A	0	Active	10.0	20.0
Non-small cell lung cancer stage IIIA	10029520	PT	Narrow	A	0	Active	10.0	20.0
Non-small cell lung cancer stage IIIB	10029521	PT	Narrow	A	0	Active	10.0	20.0
Non-small cell lung cancer stage IV	10029522	PT	Narrow	A	0	Active	10.0	20.0
NUT midline carcinoma	10078295	PT	Narrow	A	0	Active	19.1	20.0
Ocular cancer metastatic	10055099	PT	Narrow	A	0	Active	10.0	20.0
Ocular haemangiopericytoma	10057416	PT	Narrow	A	0	Active	10.0	20.0
Oesophageal adenocarcinoma	10030137	PT	Narrow	A	0	Active	10.0	20.0
Oesophageal adenocarcinoma recurrent	10030140	PT	Narrow	A	0	Active	10.0	20.0
Oesophageal adenocarcinoma stage 0	10030141	PT	Narrow	A	0	Active	10.0	20.0
Oesophageal adenocarcinoma stage I	10030142	PT	Narrow	A	0	Active	10.0	20.0
Oesophageal adenocarcinoma stage II	10030143	PT	Narrow	A	0	Active	10.0	20.0
Oesophageal adenocarcinoma stage III	10030144	PT	Narrow	A	0	Active	10.0	20.0
Oesophageal adenocarcinoma stage IV	10030145	PT	Narrow	A	0	Active	10.0	20.0
Oesophageal cancer metastatic	10055102	PT	Narrow	A	0	Active	10.0	20.0
Oesophageal carcinoma	10030155	PT	Narrow	A	0	Active	10.0	20.0
Oesophageal carcinoma recurrent	10030159	PT	Narrow	A	0	Active	10.0	20.0
Oesophageal carcinoma stage 0	10030162	PT	Narrow	A	0	Active	10.0	20.0
Oesophageal squamous cell carcinoma	10061534	PT	Narrow	A	0	Active	10.0	20.0
Oesophageal squamous cell carcinoma metastatic	10058527	PT	Narrow	A	0	Active	10.0	20.0
Oesophageal squamous cell carcinoma recurrent	10030187	PT	Narrow	A	0	Active	10.0	20.0
Oesophageal squamous cell carcinoma stage 0	10030188	PT	Narrow	A	0	Active	10.0	20.0
Oesophageal squamous cell carcinoma stage I	10030189	PT	Narrow	A	0	Active	10.0	20.0
Oesophageal squamous cell carcinoma stage II	10030190	PT	Narrow	A	0	Active	10.0	20.0
Oesophageal squamous cell carcinoma stage III	10030191	PT	Narrow	A	0	Active	10.0	20.0
Oesophageal squamous cell carcinoma stage IV	10030192	PT	Narrow	A	0	Active	10.0	20.0
Oestrogen receptor positive breast cancer	10070577	PT	Narrow	A	0	Active	13.1	20.0
Oligoastrocytoma	10073131	PT	Narrow	A	0	Active	16.0	20.0
Oligodendroglioma	10030286	PT	Narrow	A	0	Active	10.0	20.0
Optic glioma	10073338	PT	Narrow	A	0	Active	16.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Oral cavity cancer metastatic	10055098	PT	Narrow	A	0	Active	10.0	20.0
Oropharyngeal cancer	10031096	PT	Narrow	A	0	Active	10.0	20.0
Oropharyngeal cancer recurrent	10031098	PT	Narrow	A	0	Active	10.0	20.0
Oropharyngeal cancer stage 0	10031099	PT	Narrow	A	0	Active	10.0	20.0
Oropharyngeal cancer stage I	10031100	PT	Narrow	A	0	Active	10.0	20.0
Oropharyngeal cancer stage II	10031101	PT	Narrow	A	0	Active	10.0	20.0
Oropharyngeal cancer stage III	10031102	PT	Narrow	A	0	Active	10.0	20.0
Oropharyngeal cancer stage IV	10064099	PT	Narrow	A	0	Active	10.0	20.0
Oropharyngeal lymphoepithelioma	10031104	PT	Narrow	A	0	Active	10.0	20.0
Oropharyngeal squamous cell carcinoma	10031112	PT	Narrow	A	0	Active	10.0	20.0
Osteosarcoma	10031291	PT	Narrow	A	0	Active	10.0	20.0
Osteosarcoma metastatic	10031294	PT	Narrow	A	0	Active	10.0	20.0
Osteosarcoma recurrent	10031296	PT	Narrow	A	0	Active	10.0	20.0
Otic cancer metastatic	10055100	PT	Narrow	A	0	Active	10.0	20.0
Ovarian cancer	10033128	PT	Narrow	A	0	Active	10.0	20.0
Ovarian cancer metastatic	10057529	PT	Narrow	A	0	Active	10.0	20.0
Ovarian cancer recurrent	10066697	PT	Narrow	A	0	Active	10.0	20.0
Ovarian cancer stage I	10070905	PT	Narrow	A	0	Active	14.0	20.0
Ovarian cancer stage II	10070906	PT	Narrow	A	0	Active	14.0	20.0
Ovarian cancer stage III	10070907	PT	Narrow	A	0	Active	14.0	20.0
Ovarian cancer stage IV	10070908	PT	Narrow	A	0	Active	14.0	20.0
Ovarian clear cell carcinoma	10073268	PT	Narrow	A	0	Active	16.0	20.0
Ovarian dysgerminoma stage I	10033144	PT	Narrow	A	0	Active	10.0	20.0
Ovarian dysgerminoma stage II	10033148	PT	Narrow	A	0	Active	10.0	20.0
Ovarian dysgerminoma stage III	10033152	PT	Narrow	A	0	Active	10.0	20.0
Ovarian dysgerminoma stage IV	10033156	PT	Narrow	A	0	Active	10.0	20.0
Ovarian dysgerminoma stage unspecified	10052759	PT	Narrow	A	0	Active	10.0	20.0
Ovarian embryonal carcinoma	10056266	PT	Narrow	A	0	Active	10.0	20.0
Ovarian endometrioid carcinoma	10073269	PT	Narrow	A	0	Active	16.0	20.0
Ovarian epithelial cancer	10061328	PT	Narrow	A	0	Active	10.0	20.0
Ovarian epithelial cancer metastatic	10033158	PT	Narrow	A	0	Active	10.0	20.0



<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Ovarian epithelial cancer recurrent	10033160	PT	Narrow	A	0	Active	10.0	20.0
Ovarian epithelial cancer stage I	10033161	PT	Narrow	A	0	Active	10.0	20.0
Ovarian epithelial cancer stage II	10033162	PT	Narrow	A	0	Active	10.0	20.0
Ovarian epithelial cancer stage III	10033163	PT	Narrow	A	0	Active	10.0	20.0
Ovarian epithelial cancer stage IV	10033164	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell cancer	10061893	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell cancer stage I	10061894	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell cancer stage II	10061895	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell cancer stage III	10061896	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell cancer stage IV	10061897	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell choriocarcinoma	10073262	PT	Narrow	A	0	Active	16.0	20.0
Ovarian germ cell choriocarcinoma stage I	10033183	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell choriocarcinoma stage II	10033187	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell choriocarcinoma stage III	10033191	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell choriocarcinoma stage IV	10033195	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell embryonal carcinoma stage I	10033196	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell embryonal carcinoma stage II	10033200	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell embryonal carcinoma stage III	10033204	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell embryonal carcinoma stage IV	10033208	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell endodermal sinus tumour	10073263	PT	Narrow	A	0	Active	16.0	20.0
Ovarian germ cell endodermal sinus tumour stage I	10033218	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell endodermal sinus tumour stage II	10033219	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell endodermal sinus tumour stage III	10033220	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell endodermal sinus tumour stage IV	10033221	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell polyembryoma	10073264	PT	Narrow	A	0	Active	16.0	20.0
Ovarian germ cell polyembryoma stage I	10033223	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell polyembryoma stage II	10033227	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell polyembryoma stage III	10033231	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell polyembryoma stage IV	10033235	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell teratoma	10073265	PT	Narrow	A	0	Active	16.0	20.0
Ovarian germ cell teratoma stage I	10033237	PT	Narrow	A	0	Active	10.0	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Ovarian germ cell teratoma stage II	10033241	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell teratoma stage III	10033245	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell teratoma stage IV	10033249	PT	Narrow	A	0	Active	10.0	20.0
Ovarian germ cell tumour mixed	10073259	PT	Narrow	A	0	Active	16.0	20.0
Ovarian granulosa-theca cell tumour	10057376	PT	Narrow	A	0	Active	10.0	20.0
Ovarian low malignant potential tumour	10033268	PT	Narrow	A	0	Active	10.0	20.0
Ovarian stromal cancer	10065858	PT	Narrow	A	0	Active	10.0	20.0
Paget's disease of nipple	10033364	PT	Narrow	A	0	Active	10.0	20.0
Paget's disease of penis	10033365	PT	Narrow	A	0	Active	10.0	20.0
Paget's disease of the vulva	10033369	PT	Narrow	A	0	Active	10.0	20.0
Pancoast's tumour	10033572	PT	Narrow	A	0	Active	10.0	20.0
Pancreatic carcinoma	10033609	PT	Narrow	A	0	Active	10.0	20.0
Pancreatic carcinoma metastatic	10033610	PT	Narrow	A	0	Active	10.0	20.0
Pancreatic carcinoma recurrent	10033613	PT	Narrow	A	0	Active	10.0	20.0
Pancreatic carcinoma stage 0	10059320	PT	Narrow	A	0	Active	10.0	20.0
Pancreatic carcinoma stage I	10059321	PT	Narrow	A	0	Active	10.0	20.0
Pancreatic carcinoma stage II	10059322	PT	Narrow	A	0	Active	10.0	20.0
Pancreatic carcinoma stage III	10059323	PT	Narrow	A	0	Active	10.0	20.0
Pancreatic carcinoma stage IV	10059326	PT	Narrow	A	0	Active	10.0	20.0
Pancreatic neuroendocrine tumour	10067517	PT	Narrow	A	0	Active	10.1	20.0
Pancreatic neuroendocrine tumour metastatic	10068909	PT	Narrow	A	0	Active	12.0	20.0
Pancreatic sarcoma	10055006	PT	Narrow	A	0	Active	10.0	20.0
Pancreatoblastoma	10073367	PT	Narrow	A	0	Active	16.0	20.0
Papillary renal cell carcinoma	10078493	PT	Narrow	A	0	Active	19.1	20.0
Papillary serous endometrial carcinoma	10033700	PT	Narrow	A	0	Active	10.0	20.0
Papillary thyroid cancer	10033701	PT	Narrow	A	0	Active	10.0	20.0
Paraganglion neoplasm malignant	10033791	PT	Narrow	A	0	Active	10.0	20.0
Paranasal sinus and nasal cavity malignant neoplasm	10061909	PT	Narrow	A	0	Active	10.0	20.0
Paranasal sinus and nasal cavity malignant neoplasm recurrent	10033855	PT	Narrow	A	0	Active	10.0	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Paranasal sinus and nasal cavity malignant neoplasm stage 0	10033856	PT	Narrow	A	0	Active	10.0	20.0
Paranasal sinus and nasal cavity malignant neoplasm stage I	10033857	PT	Narrow	A	0	Active	10.0	20.0
Paranasal sinus and nasal cavity malignant neoplasm stage II	10033858	PT	Narrow	A	0	Active	10.0	20.0
Paranasal sinus and nasal cavity malignant neoplasm stage III	10033859	PT	Narrow	A	0	Active	10.0	20.0
Paranasal sinus and nasal cavity malignant neoplasm stage IV	10033860	PT	Narrow	A	0	Active	10.0	20.0
Parathyroid tumour malignant	10033965	PT	Narrow	A	0	Active	10.0	20.0
Penile cancer	10034299	PT	Narrow	A	0	Active	10.0	20.0
Penile squamous cell carcinoma	10059631	PT	Narrow	A	0	Active	10.0	20.0
Penis carcinoma metastatic	10034329	PT	Narrow	A	0	Active	10.0	20.0
Penis carcinoma recurrent	10034331	PT	Narrow	A	0	Active	10.0	20.0
Penis carcinoma stage I	10034332	PT	Narrow	A	0	Active	10.0	20.0
Penis carcinoma stage II	10034333	PT	Narrow	A	0	Active	10.0	20.0
Penis carcinoma stage III	10034334	PT	Narrow	A	0	Active	10.0	20.0
Penis carcinoma stage IV	10034335	PT	Narrow	A	0	Active	10.0	20.0
Pericardial mesothelioma malignant	10073066	PT	Narrow	A	0	Active	16.0	20.0
Pericardial mesothelioma malignant recurrent	10034480	PT	Narrow	A	0	Active	10.0	20.0
Peripheral nerve sheath tumour malignant	10034590	PT	Narrow	A	0	Active	10.0	20.0
Peripheral neuroepithelioma of bone	10061342	PT	Narrow	A	0	Active	10.0	20.0
Peripheral neuroepithelioma of bone metastatic	10034603	PT	Narrow	A	0	Active	10.0	20.0
Peripheral neuroepithelioma of bone recurrent	10034605	PT	Narrow	A	0	Active	10.0	20.0
Peripheral neuroepithelioma of soft tissue	10057646	PT	Narrow	A	0	Active	10.0	20.0
Peripheral primitive neuroectodermal bone tumour	10073107	PT	Narrow	A	0	Active	16.0	20.0
Peripheral primitive neuroectodermal tumour of soft tissue	10073144	PT	Narrow	A	0	Active	16.0	20.0
Peritoneal carcinoma metastatic	10068974	PT	Narrow	A	0	Active	12.0	20.0
Peritoneal mesothelioma malignant	10056558	PT	Narrow	A	0	Active	10.0	20.0
Peritoneal mesothelioma malignant recurrent	10034671	PT	Narrow	A	0	Active	10.0	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Peritoneal sarcoma	10051949	PT	Narrow	A	0	Active	10.0	20.0
Phaeochromocytoma malignant	10051710	PT	Narrow	A	0	Active	10.0	20.0
Pharyngeal cancer	10034811	PT	Narrow	A	0	Active	10.0	20.0
Pharyngeal cancer metastatic	10055104	PT	Narrow	A	0	Active	10.0	20.0
Pharyngeal cancer recurrent	10034813	PT	Narrow	A	0	Active	10.0	20.0
Pharyngeal cancer stage 0	10034814	PT	Narrow	A	0	Active	10.0	20.0
Pharyngeal cancer stage I	10034815	PT	Narrow	A	0	Active	10.0	20.0
Pharyngeal cancer stage II	10034816	PT	Narrow	A	0	Active	10.0	20.0
Pharyngeal cancer stage III	10034817	PT	Narrow	A	0	Active	10.0	20.0
Pharyngeal cancer stage IV	10034818	PT	Narrow	A	0	Active	10.0	20.0
Pilomatrix carcinoma	10075614	PT	Narrow	A	0	Active	18.0	20.0
Pineal germinoma	10035052	PT	Narrow	A	0	Active	10.0	20.0
Pineal parenchymal neoplasm malignant	10061537	PT	Narrow	A	0	Active	10.0	20.0
Pinealoblastoma	10050487	PT	Narrow	A	0	Active	10.0	20.0
Pituitary cancer metastatic	10055106	PT	Narrow	A	0	Active	10.0	20.0
Pituitary neoplasm malignant recurrent	10057838	PT	Narrow	A	0	Active	10.0	20.0
Pleomorphic liposarcoma	10073138	PT	Narrow	A	0	Active	16.0	20.0
Pleomorphic malignant fibrous histiocytoma	10073143	PT	Narrow	A	0	Active	16.0	20.0
Pleural mesothelioma	10035603	PT	Narrow	A	0	Active	10.0	20.0
Pleural mesothelioma malignant	10059518	PT	Narrow	A	0	Active	10.0	20.0
Pleural mesothelioma malignant recurrent	10035607	PT	Narrow	A	0	Active	10.0	20.0
Pleural sarcoma	10051950	PT	Narrow	A	0	Active	10.0	20.0
Poorly differentiated thyroid carcinoma	10076603	PT	Narrow	A	0	Active	18.1	20.0
Porocarcinoma	10063609	PT	Narrow	A	0	Active	10.0	20.0
Postericoid cancer	10036334	PT	Narrow	A	0	Active	10.0	20.0
Primitive neuroectodermal tumour	10057846	PT	Narrow	A	0	Active	10.0	20.0
Primitive neuroectodermal tumour metastatic	10068910	PT	Narrow	A	0	Active	12.0	20.0
Prostate cancer	10060862	PT	Narrow	A	0	Active	10.0	20.0
Prostate cancer metastatic	10036909	PT	Narrow	A	0	Active	10.0	20.0
Prostate cancer recurrent	10036911	PT	Narrow	A	0	Active	10.0	20.0
Prostate cancer stage 0	10036912	PT	Narrow	A	0	Active	10.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Prostate cancer stage I	10036917	PT	Narrow	A	0	Active	10.0	20.0
Prostate cancer stage II	10036918	PT	Narrow	A	0	Active	10.0	20.0
Prostate cancer stage III	10036919	PT	Narrow	A	0	Active	10.0	20.0
Prostate cancer stage IV	10036920	PT	Narrow	A	0	Active	10.0	20.0
Pseudosarcoma	10051807	PT	Narrow	A	0	Active	10.0	20.0
Queyrat erythroplasia	10037732	PT	Narrow	A	0	Active	17.0	20.0
Rectal adenocarcinoma	10038019	PT	Narrow	A	0	Active	10.0	20.0
Rectal cancer	10038038	PT	Narrow	A	0	Active	10.0	20.0
Rectal cancer metastatic	10055097	PT	Narrow	A	0	Active	10.0	20.0
Rectal cancer recurrent	10038046	PT	Narrow	A	0	Active	10.0	20.0
Rectal cancer stage 0	10038047	PT	Narrow	A	0	Active	10.0	20.0
Rectal cancer stage I	10038048	PT	Narrow	A	0	Active	10.0	20.0
Rectal cancer stage II	10038049	PT	Narrow	A	0	Active	10.0	20.0
Rectal cancer stage III	10038050	PT	Narrow	A	0	Active	10.0	20.0
Rectal cancer stage IV	10038051	PT	Narrow	A	0	Active	10.0	20.0
Rectosigmoid cancer	10038086	PT	Narrow	A	0	Active	10.0	20.0
Rectosigmoid cancer metastatic	10069728	PT	Narrow	A	0	Active	13.0	20.0
Rectosigmoid cancer recurrent	10038094	PT	Narrow	A	0	Active	10.0	20.0
Rectosigmoid cancer stage 0	10038095	PT	Narrow	A	0	Active	10.0	20.0
Rectosigmoid cancer stage I	10038096	PT	Narrow	A	0	Active	10.0	20.0
Rectosigmoid cancer stage II	10038097	PT	Narrow	A	0	Active	10.0	20.0
Rectosigmoid cancer stage III	10038098	PT	Narrow	A	0	Active	10.0	20.0
Rectosigmoid cancer stage IV	10038099	PT	Narrow	A	0	Active	10.0	20.0
Recurrent cancer	10038111	PT	Narrow	A	0	Active	10.0	20.0
Refractory cancer	10070308	PT	Narrow	A	0	Active	13.0	20.0
Renal cancer	10038389	PT	Narrow	A	0	Active	10.0	20.0
Renal cancer metastatic	10050018	PT	Narrow	A	0	Active	10.0	20.0
Renal cancer recurrent	10038390	PT	Narrow	A	0	Active	10.0	20.0
Renal cancer stage I	10038391	PT	Narrow	A	0	Active	10.0	20.0
Renal cancer stage II	10038392	PT	Narrow	A	0	Active	10.0	20.0
Renal cancer stage III	10038393	PT	Narrow	A	0	Active	10.0	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Renal cancer stage IV	10038394	PT	Narrow	A	0	Active	10.0	20.0
Renal cell carcinoma	10067946	PT	Narrow	A	0	Active	11.0	20.0
Renal cell carcinoma recurrent	10038410	PT	Narrow	A	0	Active	10.0	20.0
Renal cell carcinoma stage I	10038411	PT	Narrow	A	0	Active	10.0	20.0
Renal cell carcinoma stage II	10038412	PT	Narrow	A	0	Active	10.0	20.0
Renal cell carcinoma stage III	10038413	PT	Narrow	A	0	Active	10.0	20.0
Renal cell carcinoma stage IV	10038414	PT	Narrow	A	0	Active	10.0	20.0
Respiratory tract carcinoma in situ	10038724	PT	Narrow	A	0	Active	10.0	20.0
Retinal melanoma	10038878	PT	Narrow	A	0	Active	10.0	20.0
Retinoblastoma	10038916	PT	Narrow	A	0	Active	10.0	20.0
Retroperitoneal cancer	10038977	PT	Narrow	A	0	Active	10.0	20.0
Retroperitoneal neoplasm metastatic	10062485	PT	Narrow	A	0	Active	10.0	20.0
Rhabdoid tumour	10073334	PT	Narrow	A	0	Active	16.0	20.0
Rhabdoid tumour of the kidney	10039019	PT	Narrow	A	0	Active	10.0	20.0
Rhabdomyosarcoma	10039022	PT	Narrow	A	0	Active	10.0	20.0
Rhabdomyosarcoma recurrent	10039027	PT	Narrow	A	0	Active	10.0	20.0
Round cell liposarcoma	10073139	PT	Narrow	A	0	Active	16.0	20.0
Salivary gland cancer	10061934	PT	Narrow	A	0	Active	10.0	20.0
Salivary gland cancer recurrent	10039398	PT	Narrow	A	0	Active	10.0	20.0
Salivary gland cancer stage 0	10039399	PT	Narrow	A	0	Active	10.0	20.0
Salivary gland cancer stage I	10039400	PT	Narrow	A	0	Active	10.0	20.0
Salivary gland cancer stage II	10039401	PT	Narrow	A	0	Active	10.0	20.0
Salivary gland cancer stage III	10039402	PT	Narrow	A	0	Active	10.0	20.0
Salivary gland cancer stage IV	10039403	PT	Narrow	A	0	Active	10.0	20.0
Sarcoma	10039491	PT	Narrow	A	0	Active	10.0	20.0
Sarcoma metastatic	10068595	PT	Narrow	A	0	Active	11.1	20.0
Sarcoma of skin	10039495	PT	Narrow	A	0	Active	10.0	20.0
Sarcoma uterus	10039497	PT	Narrow	A	0	Active	10.0	20.0
Sarcomatoid mesothelioma	10073065	PT	Narrow	A	0	Active	16.0	20.0
Sarcomatosis	10039500	PT	Narrow	A	0	Active	10.0	20.0
Scrotal cancer	10039744	PT	Narrow	A	0	Active	10.0	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Sebaceous carcinoma	10068784	PT	Narrow	A	0	Active	12.0	20.0
Second primary malignancy	10039801	PT	Narrow	A	0	Active	10.0	20.0
Seminoma	10039956	PT	Narrow	A	0	Active	10.0	20.0
Serous cystadenocarcinoma of pancreas	10073368	PT	Narrow	A	0	Active	16.0	20.0
Serous cystadenocarcinoma ovary	10054913	PT	Narrow	A	0	Active	10.0	20.0
Signet-ring cell carcinoma	10057266	PT	Narrow	A	0	Active	10.0	20.0
Sinus cancer metastatic	10055105	PT	Narrow	A	0	Active	10.0	20.0
Skin angiosarcoma	10072891	PT	Narrow	A	0	Active	16.0	20.0
Skin cancer	10040808	PT	Narrow	A	0	Active	10.0	20.0
Skin cancer metastatic	10055115	PT	Narrow	A	0	Active	10.0	20.0
Skin squamous cell carcinoma metastatic	10077314	PT	Narrow	A	0	Active	19.0	20.0
Small cell carcinoma	10041056	PT	Narrow	A	0	Active	10.0	20.0
Small cell carcinoma of the cervix	10041057	PT	Narrow	A	0	Active	10.0	20.0
Small cell lung cancer	10041067	PT	Narrow	A	0	Active	10.0	20.0
Small cell lung cancer extensive stage	10041068	PT	Narrow	A	0	Active	10.0	20.0
Small cell lung cancer limited stage	10041069	PT	Narrow	A	0	Active	10.0	20.0
Small cell lung cancer metastatic	10059514	PT	Narrow	A	0	Active	10.0	20.0
Small cell lung cancer recurrent	10041070	PT	Narrow	A	0	Active	10.0	20.0
Small intestine adenocarcinoma	10073373	PT	Narrow	A	0	Active	16.0	20.0
Small intestine carcinoma	10054184	PT	Narrow	A	0	Active	10.0	20.0
Small intestine carcinoma metastatic	10041121	PT	Narrow	A	0	Active	10.0	20.0
Small intestine carcinoma recurrent	10041124	PT	Narrow	A	0	Active	10.0	20.0
Small intestine carcinoma stage 0	10059368	PT	Narrow	A	0	Active	10.0	20.0
Small intestine carcinoma stage I	10059369	PT	Narrow	A	0	Active	10.0	20.0
Small intestine carcinoma stage II	10059370	PT	Narrow	A	0	Active	10.0	20.0
Small intestine carcinoma stage III	10059371	PT	Narrow	A	0	Active	10.0	20.0
Small intestine carcinoma stage IV	10059372	PT	Narrow	A	0	Active	10.0	20.0
Small intestine leiomyosarcoma	10041127	PT	Narrow	A	0	Active	10.0	20.0
Soft tissue sarcoma	10075333	PT	Narrow	A	0	Active	17.1	20.0
Solid pseudopapillary tumour of the pancreas	10069345	PT	Narrow	A	0	Active	12.1	20.0
Spermatocytic seminoma	10073118	PT	Narrow	A	0	Active	16.0	20.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Spinal meningioma malignant	10041580	PT	Narrow	A	0	Active	10.0	20.0
Spindle cell sarcoma	10049067	PT	Narrow	A	0	Active	10.0	20.0
Squamous cell breast carcinoma	10079307	PT	Narrow	A	0	Active	20.0	20.0
Squamous cell carcinoma	10041823	PT	Narrow	A	0	Active	10.0	20.0
Squamous cell carcinoma of head and neck	10060121	PT	Narrow	A	0	Active	10.0	20.0
Squamous cell carcinoma of lung	10041826	PT	Narrow	A	0	Active	10.0	20.0
Squamous cell carcinoma of pharynx	10066471	PT	Narrow	A	0	Active	10.0	20.0
Squamous cell carcinoma of skin	10041834	PT	Narrow	A	0	Active	10.0	20.0
Squamous cell carcinoma of the cervix	10041848	PT	Narrow	A	0	Active	10.0	20.0
Squamous cell carcinoma of the hypopharynx	10041849	PT	Narrow	A	0	Active	10.0	20.0
Squamous cell carcinoma of the oral cavity	10041857	PT	Narrow	A	0	Active	10.0	20.0
Squamous cell carcinoma of the tongue	10041865	PT	Narrow	A	0	Active	10.0	20.0
Squamous cell carcinoma of the vagina	10041866	PT	Narrow	A	0	Active	10.0	20.0
Squamous cell carcinoma of the vulva	10041875	PT	Narrow	A	0	Active	10.0	20.0
Squamous endometrial carcinoma	10041883	PT	Narrow	A	0	Active	10.0	20.0
Stewart-Treves syndrome	10059498	PT	Narrow	A	0	Active	10.0	20.0
Superficial spreading melanoma stage I	10042549	PT	Narrow	A	0	Active	10.0	20.0
Superficial spreading melanoma stage II	10042550	PT	Narrow	A	0	Active	10.0	20.0
Superficial spreading melanoma stage III	10042551	PT	Narrow	A	0	Active	10.0	20.0
Superficial spreading melanoma stage IV	10042552	PT	Narrow	A	0	Active	10.0	20.0
Superficial spreading melanoma stage unspecified	10042553	PT	Narrow	A	0	Active	10.0	20.0
Synovial sarcoma	10042863	PT	Narrow	A	0	Active	10.0	20.0
Synovial sarcoma metastatic	10042864	PT	Narrow	A	0	Active	10.0	20.0
Synovial sarcoma recurrent	10042867	PT	Narrow	A	0	Active	10.0	20.0
Testicular cancer metastatic	10055103	PT	Narrow	A	0	Active	10.0	20.0
Testicular choriocarcinoma	10062122	PT	Narrow	A	0	Active	10.0	20.0
Testicular choriocarcinoma recurrent	10069812	PT	Narrow	A	0	Active	13.0	20.0
Testicular choriocarcinoma stage I	10043303	PT	Narrow	A	0	Active	10.0	20.0
Testicular choriocarcinoma stage II	10043304	PT	Narrow	A	0	Active	10.0	20.0
Testicular choriocarcinoma stage III	10043305	PT	Narrow	A	0	Active	10.0	20.0
Testicular embryonal carcinoma	10062123	PT	Narrow	A	0	Active	10.0	20.0



<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Testicular embryonal carcinoma stage I	10043309	PT	Narrow	A	0	Active	10.0	20.0
Testicular embryonal carcinoma stage II	10043310	PT	Narrow	A	0	Active	10.0	20.0
Testicular embryonal carcinoma stage III	10043311	PT	Narrow	A	0	Active	10.0	20.0
Testicular germ cell cancer	10061378	PT	Narrow	A	0	Active	10.0	20.0
Testicular germ cell cancer metastatic	10068694	PT	Narrow	A	0	Active	11.1	20.0
Testicular germ cell tumour mixed	10073119	PT	Narrow	A	0	Active	16.0	20.0
Testicular germ cell tumour mixed stage I	10043331	PT	Narrow	A	0	Active	10.0	20.0
Testicular germ cell tumour mixed stage II	10043332	PT	Narrow	A	0	Active	10.0	20.0
Testicular germ cell tumour mixed stage III	10043333	PT	Narrow	A	0	Active	10.0	20.0
Testicular leiomyosarcoma	10057340	PT	Narrow	A	0	Active	10.0	20.0
Testicular malignant teratoma	10073120	PT	Narrow	A	0	Active	16.0	20.0
Testicular malignant teratoma stage I	10043339	PT	Narrow	A	0	Active	10.0	20.0
Testicular malignant teratoma stage II	10043340	PT	Narrow	A	0	Active	10.0	20.0
Testicular malignant teratoma stage III	10043341	PT	Narrow	A	0	Active	10.0	20.0
Testicular seminoma (pure)	10062124	PT	Narrow	A	0	Active	10.0	20.0
Testicular seminoma (pure) stage I	10043350	PT	Narrow	A	0	Active	10.0	20.0
Testicular seminoma (pure) stage II	10043351	PT	Narrow	A	0	Active	10.0	20.0
Testicular seminoma (pure) stage III	10043352	PT	Narrow	A	0	Active	10.0	20.0
Testicular yolk sac tumour	10073121	PT	Narrow	A	0	Active	16.0	20.0
Testicular yolk sac tumour stage I	10043357	PT	Narrow	A	0	Active	10.0	20.0
Testicular yolk sac tumour stage II	10043358	PT	Narrow	A	0	Active	10.0	20.0
Testicular yolk sac tumour stage III	10043359	PT	Narrow	A	0	Active	10.0	20.0
Testis cancer	10057644	PT	Narrow	A	0	Active	10.0	20.0
Testis cancer recurrent	10069813	PT	Narrow	A	0	Active	13.0	20.0
Throat cancer	10043515	PT	Narrow	A	0	Active	10.0	20.0
Thyroid cancer	10066474	PT	Narrow	A	0	Active	10.0	20.0
Thyroid cancer metastatic	10055107	PT	Narrow	A	0	Active	10.0	20.0
Thyroid cancer recurrent	10072162	PT	Narrow	A	0	Active	15.0	20.0
Thyroid cancer stage 0	10070567	PT	Narrow	A	0	Active	13.1	20.0
Thyroid cancer stage I	10071027	PT	Narrow	A	0	Active	14.0	20.0
Thyroid cancer stage II	10071028	PT	Narrow	A	0	Active	14.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Thyroid cancer stage III	10071029	PT	Narrow	A	0	Active	14.0	20.0
Thyroid cancer stage IV	10071030	PT	Narrow	A	0	Active	14.0	20.0
Tongue cancer metastatic	10055109	PT	Narrow	A	0	Active	10.0	20.0
Tongue cancer recurrent	10071251	PT	Narrow	A	0	Active	14.1	20.0
Tongue carcinoma stage 0	10058429	PT	Narrow	A	0	Active	10.0	20.0
Tongue carcinoma stage I	10058430	PT	Narrow	A	0	Active	10.0	20.0
Tongue carcinoma stage II	10058431	PT	Narrow	A	0	Active	10.0	20.0
Tongue carcinoma stage III	10058432	PT	Narrow	A	0	Active	10.0	20.0
Tongue carcinoma stage IV	10058433	PT	Narrow	A	0	Active	10.0	20.0
Tongue neoplasm malignant stage unspecified	10043966	PT	Narrow	A	0	Active	10.0	20.0
Tonsil cancer	10044002	PT	Narrow	A	0	Active	10.0	20.0
Tonsil cancer metastatic	10072792	PT	Narrow	A	0	Active	15.1	20.0
Tracheal cancer	10044285	PT	Narrow	A	0	Active	10.0	20.0
Transitional cell cancer of renal pelvis and ureter metastatic	10044406	PT	Narrow	A	0	Active	10.0	20.0
Transitional cell cancer of the renal pelvis and ureter	10044407	PT	Narrow	A	0	Active	10.0	20.0
Transitional cell cancer of the renal pelvis and ureter localised	10044408	PT	Narrow	A	0	Active	10.0	20.0
Transitional cell cancer of the renal pelvis and ureter recurrent	10044410	PT	Narrow	A	0	Active	10.0	20.0
Transitional cell cancer of the renal pelvis and ureter regional	10044411	PT	Narrow	A	0	Active	10.0	20.0
Transitional cell carcinoma	10044412	PT	Narrow	A	0	Active	10.0	20.0
Transitional cell carcinoma metastatic	10071080	PT	Narrow	A	0	Active	14.0	20.0
Transitional cell carcinoma recurrent	10077051	PT	Narrow	A	0	Active	18.1	20.0
Transitional cell carcinoma urethra	10044426	PT	Narrow	A	0	Active	10.0	20.0
Triple negative breast cancer	10075566	PT	Narrow	A	0	Active	18.0	20.0
Tubular breast carcinoma	10073104	PT	Narrow	A	0	Active	16.0	20.0
Tumour budding	10076969	PT	Narrow	A	0	Active	18.1	20.0
Undifferentiated carcinoma of colon	10073362	PT	Narrow	A	0	Active	16.0	20.0
Undifferentiated nasopharyngeal carcinoma	10073328	PT	Narrow	A	0	Active	16.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Undifferentiated sarcoma	10045515	PT	Narrow	A	0	Active	10.0	20.0
Ureteric cancer	10046392	PT	Narrow	A	0	Active	10.0	20.0
Ureteric cancer local	10046393	PT	Narrow	A	0	Active	10.0	20.0
Ureteric cancer metastatic	10046394	PT	Narrow	A	0	Active	10.0	20.0
Ureteric cancer recurrent	10046396	PT	Narrow	A	0	Active	10.0	20.0
Ureteric cancer regional	10046397	PT	Narrow	A	0	Active	10.0	20.0
Urethral cancer	10046431	PT	Narrow	A	0	Active	10.0	20.0
Urethral cancer metastatic	10046433	PT	Narrow	A	0	Active	10.0	20.0
Urethral cancer recurrent	10046435	PT	Narrow	A	0	Active	10.0	20.0
Urethral melanoma metastatic	10072793	PT	Narrow	A	0	Active	15.1	20.0
Urinary bladder sarcoma	10051690	PT	Narrow	A	0	Active	10.0	20.0
Urinary tract carcinoma in situ	10061396	PT	Narrow	A	0	Active	10.0	20.0
Uterine cancer	10046766	PT	Narrow	A	0	Active	10.0	20.0
Uterine carcinoma in situ	10046770	PT	Narrow	A	0	Active	10.0	20.0
Uterine leiomyosarcoma	10046799	PT	Narrow	A	0	Active	10.0	20.0
Vaginal adenocarcinoma	10065349	PT	Narrow	A	0	Active	10.0	20.0
Vaginal cancer	10046885	PT	Narrow	A	0	Active	10.0	20.0
Vaginal cancer metastatic	10046887	PT	Narrow	A	0	Active	10.0	20.0
Vaginal cancer recurrent	10046889	PT	Narrow	A	0	Active	10.0	20.0
Vaginal cancer stage 0	10046890	PT	Narrow	A	0	Active	10.0	20.0
Vaginal cancer stage I	10046891	PT	Narrow	A	0	Active	10.0	20.0
Vaginal cancer stage II	10046892	PT	Narrow	A	0	Active	10.0	20.0
Vaginal cancer stage III	10046893	PT	Narrow	A	0	Active	10.0	20.0
Vaginal cancer stage IVA	10046894	PT	Narrow	A	0	Active	10.0	20.0
Vaginal cancer stage IVB	10046895	PT	Narrow	A	0	Active	10.0	20.0
Vulval cancer	10047741	PT	Narrow	A	0	Active	10.0	20.0
Vulval cancer metastatic	10047742	PT	Narrow	A	0	Active	10.0	20.0
Vulval cancer recurrent	10047744	PT	Narrow	A	0	Active	10.0	20.0
Vulval cancer stage 0	10047745	PT	Narrow	A	0	Active	10.0	20.0
Vulval cancer stage I	10047746	PT	Narrow	A	0	Active	10.0	20.0
Vulval cancer stage II	10047747	PT	Narrow	A	0	Active	10.0	20.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Vulval cancer stage III	10047748	PT	Narrow	A	0	Active	10.0	20.0
Vulval cancer stage IV	10047749	PT	Narrow	A	0	Active	10.0	20.0
Vulvar adenocarcinoma	10063536	PT	Narrow	A	0	Active	10.0	20.0

### 7.3. SMQ Terms for Pregnancy and Neonatal Topics

SMQ Export: 20.1 - English

1/8/2018 2:22:18 PM

Include Inactive PT: No

Term Attributes: Name, Code, Level, Scope, Category, Weight, Status, Addition Version, Last Modified Version

**Pregnancy and neonatal topics (SMQ) [20000185]**

**Congenital, familial and genetic disorders (SMQ) [20000077]**

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
11-beta-hydroxylase deficiency	10000002	PT	Narrow	A	0	Active	10.0	14.0
17,20-desmolase deficiency	10000013	PT	Narrow	A	0	Active	10.0	14.0
17-alpha-hydroxylase deficiency	10000014	PT	Narrow	A	0	Active	10.0	14.0
18q minus syndrome	10068533	PT	Narrow	A	0	Active	11.1	14.0
20,22-desmolase deficiency	10000020	PT	Narrow	A	0	Active	10.0	14.0
21-hydroxylase deficiency	10000021	PT	Narrow	A	0	Active	10.0	14.0
2-Hydroxyglutaric aciduria	10078971	PT	Narrow	A	0	Active	20.0	20.0
3-hydroxyacetyl-coenzyme A dehydrogenase deficiency	10072273	PT	Narrow	A	0	Active	15.0	15.0
5-alpha-reductase deficiency	10000029	PT	Narrow	A	0	Active	10.0	14.0
Aase syndrome	10063429	PT	Narrow	A	0	Active	10.0	14.0
Abdominal transposition	10000098	PT	Narrow	A	0	Active	10.0	14.0
Abdominal wall anomaly	10000101	PT	Narrow	A	0	Active	10.0	14.0
Abnormal palmar/plantar creases	10000162	PT	Narrow	A	0	Active	10.0	14.0
ABO haemolytic disease of newborn	10000205	PT	Narrow	A	0	Active	10.0	14.0
Acardia	10075721	PT	Narrow	A	0	Active	18.0	18.0
Accessory auricle	10000361	PT	Narrow	A	0	Active	10.0	14.0
Accessory breast	10049786	PT	Narrow	A	0	Active	10.0	14.0
Accessory carpal bone	10000362	PT	Narrow	A	0	Active	10.0	14.0
Accessory kidney	10048781	PT	Narrow	A	0	Active	10.0	14.0
Accessory liver lobe	10052752	PT	Narrow	A	0	Active	10.0	14.0
Accessory muscle	10000364	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Accessory navicular syndrome	10062626	PT	Narrow	A	0	Active	10.0	14.0
Accessory salivary gland	10000368	PT	Narrow	A	0	Active	10.0	14.0
Accessory spleen	10068059	PT	Narrow	A	0	Active	11.0	14.0
Acetylcholinesterase deficiency	10071435	PT	Narrow	A	0	Active	14.1	14.1
Achromotrichia congenital	10049864	PT	Narrow	A	0	Active	10.0	14.0
Acral peeling skin syndrome	10078538	PT	Narrow	A	0	Active	19.1	19.1
Acrodermatitis enteropathica	10000596	PT	Narrow	A	0	Active	10.0	14.0
Acrodysostosis	10079856	PT	Narrow	A	0	Active	20.1	20.1
Acrokeratosis verruciformis	10069445	PT	Narrow	A	0	Active	12.1	14.0
Activated PI3 kinase delta syndrome	10078281	PT	Narrow	A	0	Active	19.1	19.1
Adactyly	10049207	PT	Narrow	A	0	Active	10.0	14.0
Adams-Oliver syndrome	10079369	PT	Narrow	A	0	Active	20.0	20.0
Adenine phosphoribosyl transferase deficiency	10072609	PT	Narrow	A	0	Active	15.1	15.1
Adenomatous polyposis coli	10056981	PT	Narrow	A	0	Active	10.0	14.0
Adrenal insufficiency neonatal	10001368	PT	Narrow	A	0	Active	10.0	14.0
Adrenogenital syndrome	10061630	PT	Narrow	A	0	Active	10.0	14.0
Adrenoleukodystrophy	10051260	PT	Narrow	A	0	Active	10.0	14.0
Adult polyglucosan body disease	10077946	PT	Narrow	A	0	Active	19.0	19.0
Aglossia	10001501	PT	Narrow	A	0	Active	10.0	14.0
Aicardi's syndrome	10054935	PT	Narrow	A	0	Active	10.0	14.0
Alagille syndrome	10053870	PT	Narrow	A	0	Active	10.0	14.0
Albinism	10001557	PT	Narrow	A	0	Active	10.0	14.0
Albright's disease	10052032	PT	Narrow	A	0	Active	10.0	14.0
Alkaptonuria	10001689	PT	Narrow	A	0	Active	10.0	14.0
Allan-Herndon-Dudley syndrome	10078821	PT	Narrow	A	0	Active	20.0	20.0
Alpers' disease	10062943	PT	Narrow	A	0	Active	10.0	14.0
Alpha-1 anti-trypsin deficiency	10001806	PT	Narrow	A	0	Active	10.0	14.0
Alport's syndrome	10001843	PT	Narrow	A	0	Active	10.0	14.0
Alstroem syndrome	10068783	PT	Narrow	A	0	Active	12.0	14.0
Alternating hemiplegia of childhood	10077948	PT	Narrow	A	0	Active	19.0	19.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Alveolar capillary dysplasia	10077023	PT	Narrow	A	0	Active	18.1	18.1
Amblyopia congenital	10001908	PT	Narrow	A	0	Active	10.0	14.0
Amegakaryocytic thrombocytopenia	10076744	PT	Narrow	A	0	Active	18.1	18.1
Aminoaciduria	10001939	PT	Narrow	A	0	Active	10.0	14.0
Amniotic band syndrome	10064100	PT	Narrow	A	0	Active	10.0	14.0
Amyotrophic lateral sclerosis gene carrier	10052653	PT	Narrow	A	0	Active	10.0	14.0
Anal atresia	10002120	PT	Narrow	A	0	Active	10.0	14.0
Androgen insensitivity syndrome	10056292	PT	Narrow	A	0	Active	10.0	14.0
Anencephaly	10002320	PT	Narrow	A	0	Active	10.0	14.0
Angelman's syndrome	10049004	PT	Narrow	A	0	Active	10.0	14.0
Angiotensin converting enzyme inhibitor foetopathy	10051098	PT	Narrow	A	0	Active	10.0	14.0
Aniridia	10002532	PT	Narrow	A	0	Active	10.0	14.0
Ankyloglossia congenital	10049244	PT	Narrow	A	0	Active	10.0	14.0
Annular pancreas	10071757	PT	Narrow	A	0	Active	15.0	15.0
Anodontia	10002583	PT	Narrow	A	0	Active	10.0	14.0
Anomalous arrangement of pancreaticobiliary duct	10064902	PT	Narrow	A	0	Active	10.0	14.0
Anomalous pulmonary venous connection	10058079	PT	Narrow	A	0	Active	10.0	14.0
Anomaly of external ear congenital	10062339	PT	Narrow	A	0	Active	10.0	14.0
Anomaly of middle ear congenital	10060957	PT	Narrow	A	0	Active	10.0	14.0
Anomaly of orbit, congenital	10002633	PT	Narrow	A	0	Active	10.0	14.0
Anophthalmos	10002640	PT	Narrow	A	0	Active	10.0	14.0
Anorchism	10002641	PT	Narrow	A	0	Active	10.0	14.0
Anorectal agenesis	10056271	PT	Narrow	A	0	Active	10.0	14.0
Anotia	10002654	PT	Narrow	A	0	Active	10.0	14.0
Anterior chamber cleavage syndrome	10059199	PT	Narrow	A	0	Active	10.0	14.0
Anterior displaced anus	10071651	PT	Narrow	A	0	Active	14.1	14.1
Antithrombin III deficiency	10002832	PT	Narrow	A	0	Active	10.0	14.0
Aorta hypoplasia	10049209	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Aortic valve atresia	10066801	PT	Narrow	A	0	Active	10.0	14.0
Aorticopulmonary septal defect	10063732	PT	Narrow	A	0	Active	10.0	14.0
Apert's syndrome	10002943	PT	Narrow	A	0	Active	10.0	14.0
Aphakia congenital	10002947	PT	Narrow	A	0	Active	10.0	14.0
Aplasia	10002961	PT	Narrow	A	0	Active	10.1	14.0
Aplasia cutis congenita	10002963	PT	Narrow	A	0	Active	10.0	14.0
Apparent mineralocorticoid excess	10080229	PT	Narrow	A	0	Active	20.1	20.1
Arachnodactyly	10063847	PT	Narrow	A	0	Active	10.0	14.0
Arcuate foramen	10067850	PT	Narrow	A	0	Active	11.0	14.0
Arginase deficiency	10062695	PT	Narrow	A	0	Active	10.0	14.0
Argininosuccinate lyase deficiency	10058299	PT	Narrow	A	0	Active	10.0	14.0
Argininosuccinate synthetase deficiency	10058298	PT	Narrow	A	0	Active	10.0	14.0
Arnold-Chiari malformation	10003101	PT	Narrow	A	0	Active	10.0	14.0
Arrhythmogenic right ventricular dysplasia	10058093	PT	Narrow	A	0	Active	10.0	14.0
Arterial tortuosity syndrome	10080250	PT	Narrow	A	0	Active	20.1	20.1
Arteriovenous malformation	10003193	PT	Narrow	A	0	Active	10.0	14.0
Ash leaf macule	10076367	PT	Narrow	A	0	Active	18.0	18.0
Aspartate-glutamate-transporter deficiency	10079140	PT	Narrow	A	0	Active	20.0	20.0
Aspartylglucosaminuria	10068220	PT	Narrow	A	0	Active	11.0	14.0
Asphyxiating thoracic dystrophy	10057621	PT	Narrow	A	0	Active	10.0	14.0
Asplenia	10053622	PT	Narrow	A	0	Active	10.0	14.0
Asymptomatic gene carrier	10061662	PT	Narrow	A	0	Active	10.0	14.0
Ataxia telangiectasia	10003594	PT	Narrow	A	0	Active	10.0	14.0
Atrial septal defect	10003664	PT	Narrow	A	0	Active	10.0	14.0
Atrioventricular node dispersion	10077893	PT	Narrow	A	0	Active	19.0	19.0
Atrioventricular septal defect	10063836	PT	Narrow	A	0	Active	10.0	14.0
Auditory neuropathy spectrum disorder	10072198	PT	Narrow	A	0	Active	15.0	15.0
Autoimmune lymphoproliferative syndrome	10069521	PT	Narrow	A	0	Active	12.1	14.0
Autosomal chromosome anomaly	10060975	PT	Narrow	A	0	Active	10.0	14.0
Azygos lobe	10069490	PT	Narrow	A	0	Active	12.1	14.0



Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Baltic myoclonic epilepsy	10054895	PT	Narrow	A	0	Active	10.0	14.0
Bannayan-Riley-Ruvalcaba syndrome	10080314	PT	Narrow	A	0	Active	20.1	20.1
Baraitser Rodeck Garner syndrome	10076038	PT	Narrow	A	0	Active	18.0	18.0
Barakat syndrome	10075281	PT	Narrow	A	0	Active	17.1	17.1
Barth syndrome	10078537	PT	Narrow	A	0	Active	19.1	19.1
Bartter's syndrome	10050839	PT	Narrow	A	0	Active	10.0	14.0
Basal cell naevus syndrome	10062804	PT	Narrow	A	0	Active	10.0	14.0
Becker's muscular dystrophy	10059117	PT	Narrow	A	0	Active	10.0	14.0
Beckwith-Wiedemann syndrome	10050344	PT	Narrow	A	0	Active	10.0	14.0
Benign congenital hypotonia	10051900	PT	Narrow	A	0	Active	10.0	14.0
Benign familial haematuria	10060876	PT	Narrow	A	0	Active	10.0	14.0
Benign familial neonatal convulsions	10067866	PT	Narrow	A	0	Active	11.0	14.0
Benign familial pemphigus	10004265	PT	Narrow	A	0	Active	10.0	14.0
Berdon's syndrome	10064596	PT	Narrow	A	0	Active	10.0	14.0
Beta ketothiolase deficiency	10067728	PT	Narrow	A	0	Active	10.1	14.0
Bicuspid aortic valve	10004552	PT	Narrow	A	0	Active	10.0	14.0
Bicuspid pulmonary valve	10063730	PT	Narrow	A	0	Active	10.0	14.0
Biliary hamartoma	10074610	PT	Narrow	A	0	Active	17.0	17.0
Biotinidase deficiency	10071434	PT	Narrow	A	0	Active	14.1	14.1
Birth mark	10004950	PT	Narrow	A	0	Active	10.0	14.0
Birt-Hogg-Dube syndrome	10067736	PT	Narrow	A	0	Active	10.1	14.0
Bladder agenesis	10056655	PT	Narrow	A	0	Active	10.0	14.0
Blau syndrome	10071755	PT	Narrow	A	0	Active	15.0	15.0
Blepharophimosis congenital	10049241	PT	Narrow	A	0	Active	10.0	14.0
Blindness congenital	10005176	PT	Narrow	A	0	Active	10.0	14.0
Bloch-Sulzberger syndrome	10077624	PT	Narrow	A	0	Active	19.0	19.0
Blood incompatibility haemolytic anaemia of newborn	10056369	PT	Narrow	A	0	Active	10.0	14.0
Bloom syndrome	10073032	PT	Narrow	A	0	Active	16.0	16.0
Brachycephaly	10053682	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Brachydactyly	10072883	PT	Narrow	A	0	Active	16.0	16.0
Brain malformation	10048409	PT	Narrow	A	0	Active	10.0	14.0
Branchial cleft sinus	10006162	PT	Narrow	A	0	Active	10.0	14.0
Branchial cyst	10006164	PT	Narrow	A	0	Active	10.0	14.0
Branchiogenic syndrome	10058169	PT	Narrow	A	0	Active	10.0	14.0
Branchio-oto-renal syndrome	10071135	PT	Narrow	A	0	Active	14.0	14.0
Breast malformation	10006271	PT	Narrow	A	0	Active	10.0	14.0
Bronchogenic cyst	10064585	PT	Narrow	A	0	Active	10.0	14.0
Bruton's agammaglobulinaemia	10060360	PT	Narrow	A	0	Active	10.0	14.0
Bulbospinal muscular atrophy congenital	10068597	PT	Narrow	A	0	Active	11.1	14.0
Buried penis syndrome	10067131	PT	Narrow	A	0	Active	10.0	14.0
Camptodactyly congenital	10049028	PT	Narrow	A	0	Active	10.0	14.0
Camptomelia	10078297	PT	Narrow	A	0	Active	19.1	19.1
Canavan disease	10067608	PT	Narrow	A	0	Active	10.1	14.0
Cancer gene carrier	10052648	PT	Narrow	A	0	Active	10.0	14.0
CANDLE syndrome	10073960	PT	Narrow	A	0	Active	16.1	16.1
Carbamoyl phosphate synthetase deficiency	10058297	PT	Narrow	A	0	Active	10.0	14.0
Carbohydrate metabolism disorder	10061023	PT	Narrow	A	0	Active	10.0	14.0
Carcinogenic effect in offspring	10007268	PT	Narrow	A	0	Active	10.0	14.0
Cardiac lymphangioma	10055010	PT	Narrow	A	0	Active	10.0	14.0
Cardiac malposition	10007585	PT	Narrow	A	0	Active	10.0	14.0
Cardiac septal defect	10064021	PT	Narrow	A	0	Active	10.0	14.0
Carney complex	10076601	PT	Narrow	A	0	Active	18.1	18.1
Carnitine palmitoyltransferase deficiency	10050215	PT	Narrow	A	0	Active	10.0	14.0
Carnitine-acylcarnitine translocase deficiency	10078729	PT	Narrow	A	0	Active	19.1	19.1
Carpus curvus	10007700	PT	Narrow	A	0	Active	10.0	14.0
Cartilage-hair hypoplasia	10069596	PT	Narrow	A	0	Active	12.1	14.0
Cataract congenital	10007747	PT	Narrow	A	0	Active	10.0	14.0
Caudal regression syndrome	10059387	PT	Narrow	A	0	Active	10.0	14.0
Central core disease	10057620	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Central nervous system dermoid tumour	10007942	PT	Narrow	A	0	Active	10.0	14.0
Cerebellar dysplasia	10072942	PT	Narrow	A	0	Active	16.0	16.0
Cerebellar hypoplasia	10008033	PT	Narrow	A	0	Active	10.0	14.0
Cerebral arteriovenous malformation haemorrhagic	10008086	PT	Narrow	A	0	Active	10.0	14.0
Cerebral atrophy congenital	10052236	PT	Narrow	A	0	Active	10.0	14.0
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy	10065551	PT	Narrow	A	0	Active	10.0	14.0
Cerebral dysgenesis	10056467	PT	Narrow	A	0	Active	10.0	14.0
Cerebral palsy	10008129	PT	Narrow	A	0	Active	10.0	14.0
Cerebrohepatorenal syndrome	10053684	PT	Narrow	A	0	Active	10.0	14.0
Cerebrovascular arteriovenous malformation	10056371	PT	Narrow	A	0	Active	10.0	14.0
Cervical auricle	10008227	PT	Narrow	A	0	Active	10.0	14.0
Cervical rib	10008299	PT	Narrow	A	0	Active	10.0	14.0
CHARGE syndrome	10064063	PT	Narrow	A	0	Active	10.0	14.0
Chediak-Higashi syndrome	10008415	PT	Narrow	A	0	Active	10.0	14.0
Chiari network	10069393	PT	Narrow	A	0	Active	12.1	14.0
Chimerism	10068051	PT	Narrow	A	0	Active	11.0	14.0
Choanal atresia	10008587	PT	Narrow	A	0	Active	10.0	14.0
Choanal stenosis	10074053	PT	Narrow	A	0	Active	16.1	16.1
Cholangiectasis congenital	10053630	PT	Narrow	A	0	Active	10.0	14.0
Choledochal cyst	10008625	PT	Narrow	A	0	Active	11.0	14.0
Chondrodystrophy	10008723	PT	Narrow	A	0	Active	10.0	14.0
Chondroectodermal dysplasia	10008724	PT	Narrow	A	0	Active	10.0	14.0
Chordee	10008746	PT	Narrow	A	0	Active	15.0	15.0
Chorioretinal degeneration congenital	10008763	PT	Narrow	A	0	Active	10.0	14.0
Choroidal coloboma	10057402	PT	Narrow	A	0	Active	10.0	14.0
Chromosomal deletion	10061764	PT	Narrow	A	0	Active	10.0	14.0
Chromosomal mutation	10061765	PT	Narrow	A	0	Active	10.0	14.0
Chronic granulomatous disease	10008906	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Chronic infantile neurological cutaneous and articular syndrome	10064568	PT	Narrow	A	0	Active	10.0	14.0
Citrate transporter deficiency	10077947	PT	Narrow	A	0	Active	19.0	19.0
Cleft lip	10009259	PT	Narrow	A	0	Active	10.0	14.0
Cleft lip and palate	10009260	PT	Narrow	A	0	Active	10.0	14.0
Cleft palate	10009269	PT	Narrow	A	0	Active	10.0	14.0
Cleft uvula	10053507	PT	Narrow	A	0	Active	10.0	14.0
Cleidocranial dysostosis	10075994	PT	Narrow	A	0	Active	18.0	18.0
Clinodactyly	10058668	PT	Narrow	A	0	Active	10.0	14.0
Cloacal exstrophy	10067424	PT	Narrow	A	0	Active	10.1	14.0
Coagulation factor mutation	10065442	PT	Narrow	A	0	Active	10.0	14.0
Coarctation of the aorta	10009807	PT	Narrow	A	0	Active	10.0	14.0
Cobb syndrome	10068841	PT	Narrow	A	0	Active	12.0	14.0
Cockayne's syndrome	10009835	PT	Narrow	A	0	Active	10.0	14.0
Cohen syndrome	10049066	PT	Narrow	A	0	Active	10.0	14.0
Collodion baby	10009926	PT	Narrow	A	0	Active	10.0	16.1
Coloboma	10009934	PT	Narrow	A	0	Active	10.0	14.0
Colour blindness	10010050	PT	Narrow	A	0	Active	10.0	14.0
Combined immunodeficiency	10010099	PT	Narrow	A	0	Active	10.0	14.0
Complement deficiency disease	10075551	PT	Narrow	A	0	Active	18.0	18.0
Congenital abdominal hernia	10067183	PT	Narrow	A	0	Active	10.0	14.0
Congenital absence of bile ducts	10010317	PT	Narrow	A	0	Active	10.0	14.0
Congenital absence of cranial vault	10010318	PT	Narrow	A	0	Active	10.0	14.0
Congenital absence of vertebra	10010320	PT	Narrow	A	0	Active	10.0	14.0
Congenital acrochordon	10050730	PT	Narrow	A	0	Active	10.0	14.0
Congenital adrenal gland hypoplasia	10049057	PT	Narrow	A	0	Active	10.0	14.0
Congenital amputation	10079701	PT	Narrow	A	0	Active	20.1	20.1
Congenital anaemia	10010329	PT	Narrow	A	0	Active	10.0	14.0
Congenital androgen deficiency	10063469	PT	Narrow	A	0	Active	10.0	14.0
Congenital anomalies of ear ossicles	10010341	PT	Narrow	A	0	Active	10.0	14.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Congenital anomaly	10010356	PT	Narrow	A	0	Active	10.0	14.0
Congenital anomaly in offspring	10063726	PT	Narrow	A	0	Active	10.0	14.0
Congenital anomaly of adrenal gland	10062341	PT	Narrow	A	0	Active	10.0	14.0
Congenital anomaly of inner ear	10062340	PT	Narrow	A	0	Active	10.0	14.0
Congenital anosmia	10079876	PT	Narrow	A	0	Active	20.1	20.1
Congenital aortic anomaly	10061052	PT	Narrow	A	0	Active	10.0	14.0
Congenital aortic atresia	10010368	PT	Narrow	A	0	Active	10.0	14.0
Congenital aortic dilatation	10058150	PT	Narrow	A	0	Active	10.0	14.0
Congenital aortic stenosis	10010369	PT	Narrow	A	0	Active	10.0	14.0
Congenital aortic valve incompetence	10010370	PT	Narrow	A	0	Active	10.0	14.0
Congenital aortic valve stenosis	10010371	PT	Narrow	A	0	Active	10.0	14.0
Congenital aplastic anaemia	10053138	PT	Narrow	A	0	Active	10.0	14.0
Congenital aqueductal stenosis	10066084	PT	Narrow	A	0	Active	10.0	14.0
Congenital arterial malformation	10062325	PT	Narrow	A	0	Active	10.0	14.0
Congenital arteriovenous fistula	10010374	PT	Narrow	A	0	Active	10.0	14.0
Congenital astigmatism	10074992	PT	Narrow	A	0	Active	17.1	17.1
Congenital aural fistula	10054215	PT	Narrow	A	0	Active	10.0	14.0
Congenital benign neoplasm	10073493	PT	Narrow	A	0	Active	16.0	16.0
Congenital bladder anomaly	10061053	PT	Narrow	A	0	Active	10.0	14.0
Congenital bladder diverticulum	10010381	PT	Narrow	A	0	Active	10.0	14.0
Congenital bladder neck obstruction	10010382	PT	Narrow	A	0	Active	10.0	14.0
Congenital bowing of long bones	10054064	PT	Narrow	A	0	Active	10.0	14.0
Congenital brain damage	10010390	PT	Narrow	A	0	Active	10.0	14.0
Congenital bronchiectasis	10010391	PT	Narrow	A	0	Active	10.0	14.0
Congenital bronchomalacia	10010392	PT	Narrow	A	0	Active	10.0	14.0
Congenital calyceal diverticulum	10057510	PT	Narrow	A	0	Active	10.0	14.0
Congenital cardiovascular anomaly	10061054	PT	Narrow	A	0	Active	10.0	14.0
Congenital carnitine deficiency	10062698	PT	Narrow	A	0	Active	10.0	14.0
Congenital central diabetes insipidus	10073008	PT	Narrow	A	0	Active	16.0	16.0
Congenital central hypoventilation syndrome	10066131	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Congenital central nervous system anomaly	10010411	PT	Narrow	A	0	Active	10.0	14.0
Congenital cerebellar agenesis	10048784	PT	Narrow	A	0	Active	10.0	14.0
Congenital cerebral cyst	10054954	PT	Narrow	A	0	Active	10.0	14.0
Congenital cerebral haemangioma	10048924	PT	Narrow	A	0	Active	10.0	14.0
Congenital cerebrovascular anomaly	10062327	PT	Narrow	A	0	Active	10.0	14.0
Congenital choroid plexus cyst	10048785	PT	Narrow	A	0	Active	10.0	14.0
Congenital choroidal anomaly	10057886	PT	Narrow	A	0	Active	10.0	14.0
Congenital chylothorax	10078770	PT	Narrow	A	0	Active	20.0	20.0
Congenital clavicular agenesis	10010416	PT	Narrow	A	0	Active	10.0	14.0
Congenital claw toe	10010417	PT	Narrow	A	0	Active	10.0	14.0
Congenital coagulopathy	10063563	PT	Narrow	A	0	Active	10.0	14.0
Congenital condyloma	10066944	PT	Narrow	A	0	Active	10.0	14.0
Congenital corneal anomaly	10061059	PT	Narrow	A	0	Active	10.0	14.0
Congenital coronary artery malformation	10061060	PT	Narrow	A	0	Active	10.0	14.0
Congenital cranial nerve paralysis	10069774	PT	Narrow	A	0	Active	13.0	14.0
Congenital cutis laxa	10057042	PT	Narrow	A	0	Active	10.0	14.0
Congenital cyst	10062328	PT	Narrow	A	0	Active	10.0	14.0
Congenital cystic disease of liver	10010427	PT	Narrow	A	0	Active	10.0	14.0
Congenital cystic kidney disease	10010428	PT	Narrow	A	0	Active	10.0	14.0
Congenital cystic lung	10010429	PT	Narrow	A	0	Active	10.0	14.0
Congenital cytomegalovirus infection	10010430	PT	Narrow	A	0	Active	10.0	14.0
Congenital deformity of clavicle	10010434	PT	Narrow	A	0	Active	10.0	14.0
Congenital dermal sinus	10048728	PT	Narrow	A	0	Active	10.0	14.0
Congenital diaphragmatic anomaly	10061061	PT	Narrow	A	0	Active	10.0	14.0
Congenital diaphragmatic eventration	10010438	PT	Narrow	A	0	Active	10.0	14.0
Congenital diaphragmatic hernia	10010439	PT	Narrow	A	0	Active	10.0	14.0
Congenital disorder of glycosylation	10075892	PT	Narrow	A	0	Active	18.0	18.0
Congenital dysfibrinogenaemia	10051123	PT	Narrow	A	0	Active	10.0	14.0
Congenital dyskeratosis	10062759	PT	Narrow	A	0	Active	10.0	14.0
Congenital ectodermal dysplasia	10010452	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Congenital ectopic bladder	10010453	PT	Narrow	A	0	Active	10.0	14.0
Congenital ectopic pancreas	10056987	PT	Narrow	A	0	Active	10.0	14.0
Congenital elevation of scapula	10010455	PT	Narrow	A	0	Active	10.0	14.0
Congenital emphysema	10010456	PT	Narrow	A	0	Active	10.0	14.0
Congenital endocrine anomaly	10062329	PT	Narrow	A	0	Active	10.0	14.0
Congenital epiblepharon	10056531	PT	Narrow	A	0	Active	10.0	14.0
Congenital epiglottal anomaly	10062330	PT	Narrow	A	0	Active	10.0	14.0
Congenital Eustachian tube anomaly	10062331	PT	Narrow	A	0	Active	10.0	14.0
Congenital eye disorder	10059159	PT	Narrow	A	0	Active	10.0	14.0
Congenital eye naevus	10051050	PT	Narrow	A	0	Active	10.0	14.0
Congenital eyelid malformation	10061146	PT	Narrow	A	0	Active	10.0	14.0
Congenital facial nerve hypoplasia	10049449	PT	Narrow	A	0	Active	10.0	14.0
Congenital fallopian tube anomaly	10061062	PT	Narrow	A	0	Active	10.0	14.0
Congenital fibrosarcoma	10065859	PT	Narrow	A	0	Active	10.0	14.0
Congenital flaccid paralysis	10010474	PT	Narrow	A	0	Active	10.0	14.0
Congenital flat feet	10010475	PT	Narrow	A	0	Active	10.0	14.0
Congenital floppy infant	10053153	PT	Narrow	A	0	Active	10.0	14.0
Congenital foot malformation	10062332	PT	Narrow	A	0	Active	10.0	14.0
Congenital gastric anomaly	10061063	PT	Narrow	A	0	Active	10.0	14.0
Congenital gastrointestinal vessel anomaly	10062342	PT	Narrow	A	0	Active	10.0	14.0
Congenital generalised lipodystrophy	10053547	PT	Narrow	A	0	Active	10.0	14.0
Congenital genital malformation	10062333	PT	Narrow	A	0	Active	10.0	14.0
Congenital genital malformation female	10010481	PT	Narrow	A	0	Active	10.0	14.0
Congenital genital malformation male	10059492	PT	Narrow	A	0	Active	10.0	14.0
Congenital genitourinary abnormality	10062334	PT	Narrow	A	0	Active	10.0	14.0
Congenital great vessel anomaly	10061080	PT	Narrow	A	0	Active	10.0	14.0
Congenital haematological disorder	10072107	PT	Narrow	A	0	Active	15.0	15.0
Congenital hair disorder	10061064	PT	Narrow	A	0	Active	10.0	14.0
Congenital hand malformation	10062335	PT	Narrow	A	0	Active	10.0	14.0
Congenital hearing disorder	10010493	PT	Narrow	A	0	Active	10.0	14.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Congenital heart valve disorder	10064086	PT	Narrow	A	0	Active	10.0	14.0
Congenital heart valve incompetence	10077594	PT	Narrow	A	0	Active	19.0	19.0
Congenital hemiparesis	10071359	PT	Narrow	A	0	Active	14.1	14.1
Congenital hepatic fibrosis	10056533	PT	Narrow	A	0	Active	10.0	14.0
Congenital hepatitis B infection	10010496	PT	Narrow	A	0	Active	10.0	14.0
Congenital hepatobiliary anomaly	10061065	PT	Narrow	A	0	Active	10.0	14.0
Congenital hepatomegaly	10051130	PT	Narrow	A	0	Active	10.0	14.0
Congenital herpes simplex infection	10019949	PT	Narrow	A	0	Active	10.0	14.0
Congenital hiatus hernia	10010501	PT	Narrow	A	0	Active	10.0	14.0
Congenital high airway obstruction syndrome	10074187	PT	Narrow	A	0	Active	16.1	16.1
Congenital HIV infection	10010504	PT	Narrow	A	0	Active	10.0	14.0
Congenital Horner's syndrome	10074554	PT	Narrow	A	0	Active	17.0	17.0
Congenital hydrocele renalis	10051147	PT	Narrow	A	0	Active	10.0	14.0
Congenital hydrocephalus	10010506	PT	Narrow	A	0	Active	10.0	14.0
Congenital hydronephrosis	10050975	PT	Narrow	A	0	Active	10.0	14.0
Congenital hypercoagulation	10070954	PT	Narrow	A	0	Active	14.0	14.0
Congenital hyperextension of knee	10048954	PT	Narrow	A	0	Active	10.0	14.0
Congenital hyperextension of spine	10048953	PT	Narrow	A	0	Active	10.0	14.0
Congenital hyperthyroidism	10062264	PT	Narrow	A	0	Active	10.0	14.0
Congenital hypertrichosis	10010507	PT	Narrow	A	0	Active	10.0	14.0
Congenital hypogammaglobulinaemia	10060747	PT	Narrow	A	0	Active	10.0	14.0
Congenital hypoparathyroidism	10051315	PT	Narrow	A	0	Active	10.0	14.0
Congenital hypothyroidism	10010510	PT	Narrow	A	0	Active	10.0	14.0
Congenital infection	10062343	PT	Narrow	A	0	Active	10.0	14.0
Congenital inguinal hernia	10068321	PT	Narrow	A	0	Active	11.1	14.0
Congenital intestinal malformation	10061067	PT	Narrow	A	0	Active	10.0	14.0
Congenital intestinal obstruction	10073207	PT	Narrow	A	0	Active	16.0	16.0
Congenital intrinsic factor deficiency	10070440	PT	Narrow	A	0	Active	13.0	14.0
Congenital iris anomaly	10057411	PT	Narrow	A	0	Active	10.0	14.0
Congenital jaw malformation	10062336	PT	Narrow	A	0	Active	10.0	14.0



Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Congenital joint malformation	10062337	PT	Narrow	A	0	Active	10.0	14.0
Congenital knee deformity	10061068	PT	Narrow	A	0	Active	10.0	14.0
Congenital knee dislocation	10010520	PT	Narrow	A	0	Active	10.0	14.0
Congenital kyphoscoliosis	10048890	PT	Narrow	A	0	Active	10.0	14.0
Congenital labia pudendi adhesions	10050268	PT	Narrow	A	0	Active	10.0	14.0
Congenital lacrimal gland anomaly	10010523	PT	Narrow	A	0	Active	10.0	14.0
Congenital lacrimal passage anomaly	10062338	PT	Narrow	A	0	Active	10.0	14.0
Congenital large intestinal atresia	10010526	PT	Narrow	A	0	Active	10.0	14.0
Congenital laryngeal stridor	10010527	PT	Narrow	A	0	Active	10.0	14.0
Congenital lenticonus	10064660	PT	Narrow	A	0	Active	10.0	14.0
Congenital limb hyperextension	10049011	PT	Narrow	A	0	Active	10.0	14.0
Congenital lip fistula	10010532	PT	Narrow	A	0	Active	10.0	14.0
Congenital lymphoedema	10010535	PT	Narrow	A	0	Active	10.0	14.0
Congenital malaria	10010538	PT	Narrow	A	0	Active	10.0	14.0
Congenital malignant neoplasm	10073492	PT	Narrow	A	0	Active	16.0	16.0
Congenital megacolon	10010539	PT	Narrow	A	0	Active	10.0	14.0
Congenital megaureter	10010540	PT	Narrow	A	0	Active	10.0	14.0
Congenital melanocytic naevus	10072036	PT	Narrow	A	0	Active	15.0	15.0
Congenital melanosis	10010541	PT	Narrow	A	0	Active	10.0	14.0
Congenital methaemoglobinaemia	10010543	PT	Narrow	A	0	Active	10.0	14.0
Congenital midline defect	10079687	PT	Narrow	A	0	Active	20.1	20.1
Congenital mitochondrial cytopathy	10057954	PT	Narrow	A	0	Active	10.0	14.0
Congenital mitral valve incompetence	10010547	PT	Narrow	A	0	Active	10.0	14.0
Congenital mitral valve stenosis	10010548	PT	Narrow	A	0	Active	10.0	14.0
Congenital monorchidism	10069505	PT	Narrow	A	0	Active	12.1	14.0
Congenital multiplex arthrogryposis	10051643	PT	Narrow	A	0	Active	10.0	14.0
Congenital muscle absence	10010550	PT	Narrow	A	0	Active	10.0	14.0
Congenital musculoskeletal anomaly	10062344	PT	Narrow	A	0	Active	10.0	14.0
Congenital myopathy	10062547	PT	Narrow	A	0	Active	10.0	14.0
Congenital myopia	10069153	PT	Narrow	A	0	Active	12.0	14.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Congenital naevus	10067248	PT	Narrow	A	0	Active	10.0	14.0
Congenital nail disorder	10010557	PT	Narrow	A	0	Active	10.0	14.0
Congenital neoplasm	10078557	PT	Narrow	A	0	Active	19.1	19.1
Congenital nephrogenic diabetes insipidus	10068304	PT	Narrow	A	0	Active	11.1	14.0
Congenital nephrotic syndrome	10060737	PT	Narrow	A	0	Active	10.0	14.0
Congenital neurological degeneration	10010558	PT	Narrow	A	0	Active	10.0	14.0
Congenital neurological disorder	10062345	PT	Narrow	A	0	Active	10.0	14.0
Congenital neuropathy	10062346	PT	Narrow	A	0	Active	10.0	14.0
Congenital night blindness	10010559	PT	Narrow	A	0	Active	10.0	14.0
Congenital nose malformation	10062347	PT	Narrow	A	0	Active	10.0	14.0
Congenital nystagmus	10010562	PT	Narrow	A	0	Active	10.0	14.0
Congenital oculomotor apraxia	10053877	PT	Narrow	A	0	Active	10.0	14.0
Congenital oesophageal anomaly	10061069	PT	Narrow	A	0	Active	10.0	14.0
Congenital oesophageal stenosis	10010564	PT	Narrow	A	0	Active	10.0	14.0
Congenital oesophageal web	10010565	PT	Narrow	A	0	Active	10.0	14.0
Congenital optic nerve anomaly	10061528	PT	Narrow	A	0	Active	10.0	14.0
Congenital oral malformation	10061070	PT	Narrow	A	0	Active	10.0	14.0
Congenital osteodystrophy	10010582	PT	Narrow	A	0	Active	10.0	14.0
Congenital ovarian anomaly	10061071	PT	Narrow	A	0	Active	10.0	14.0
Congenital oxalosis	10068593	PT	Narrow	A	0	Active	11.1	14.0
Congenital pancreatic anomaly	10061072	PT	Narrow	A	0	Active	10.0	14.0
Congenital perforated nasal septum	10010588	PT	Narrow	A	0	Active	10.0	14.0
Congenital pharyngeal anomaly	10061073	PT	Narrow	A	0	Active	10.0	14.0
Congenital pigmentation disorder	10010593	PT	Narrow	A	0	Active	10.0	14.0
Congenital pneumonia	10010594	PT	Narrow	A	0	Active	10.0	14.0
Congenital poikiloderma	10052465	PT	Narrow	A	0	Active	10.0	14.0
Congenital pseudarthrosis	10061573	PT	Narrow	A	0	Active	10.0	14.0
Congenital pulmonary artery anomaly	10061074	PT	Narrow	A	0	Active	10.0	14.0
Congenital pulmonary hypertension	10050701	PT	Narrow	A	0	Active	10.0	14.0
Congenital pulmonary valve atresia	10052644	PT	Narrow	A	0	Active	10.0	14.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Congenital pulmonary valve disorder	10061075	PT	Narrow	A	0	Active	10.0	14.0
Congenital pyelocaliectasis	10049938	PT	Narrow	A	0	Active	10.0	14.0
Congenital renal cyst	10010607	PT	Narrow	A	0	Active	10.0	14.0
Congenital renal disorder	10066875	PT	Narrow	A	0	Active	10.0	14.0
Congenital retinoblastoma	10073470	PT	Narrow	A	0	Active	16.0	16.0
Congenital rubella infection	10010619	PT	Narrow	A	0	Active	10.0	14.0
Congenital salivary gland anomaly	10010620	PT	Narrow	A	0	Active	10.0	14.0
Congenital scleral disorder	10061530	PT	Narrow	A	0	Active	10.0	14.0
Congenital scoliosis	10050694	PT	Narrow	A	0	Active	10.0	14.0
Congenital scrotal hypertrophy	10048800	PT	Narrow	A	0	Active	10.0	14.0
Congenital skin dimples	10072978	PT	Narrow	A	0	Active	16.0	16.0
Congenital skin disorder	10067769	PT	Narrow	A	0	Active	11.0	14.0
Congenital small intestinal atresia	10010626	PT	Narrow	A	0	Active	10.0	14.0
Congenital spinal cord anomaly	10061076	PT	Narrow	A	0	Active	10.0	14.0
Congenital spinal fusion	10010629	PT	Narrow	A	0	Active	10.0	14.0
Congenital spinal stenosis	10077379	PT	Narrow	A	0	Active	19.0	19.0
Congenital spondylolisthesis	10010633	PT	Narrow	A	0	Active	10.0	14.0
Congenital spondylolysis	10010634	PT	Narrow	A	0	Active	10.0	14.0
Congenital syphilis	10010641	PT	Narrow	A	0	Active	10.0	14.0
Congenital syphilitic encephalitis	10010643	PT	Narrow	A	0	Active	10.0	14.0
Congenital syphilitic meningitis	10010644	PT	Narrow	A	0	Active	10.0	14.0
Congenital syphilitic osteochondritis	10054002	PT	Narrow	A	0	Active	10.0	14.0
Congenital teratoma	10052012	PT	Narrow	A	0	Active	10.0	14.0
Congenital thrombocyte disorder	10058896	PT	Narrow	A	0	Active	10.0	14.0
Congenital thrombocytopenia	10077833	PT	Narrow	A	0	Active	19.0	19.0
Congenital thymus absence	10048801	PT	Narrow	A	0	Active	10.0	14.0
Congenital thyroid disorder	10076602	PT	Narrow	A	0	Active	18.1	18.1
Congenital tongue anomaly	10061077	PT	Narrow	A	0	Active	10.0	14.0
Congenital torticollis	10010650	PT	Narrow	A	0	Active	10.0	14.0
Congenital toxoplasmosis	10010652	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Congenital tracheomalacia	10010654	PT	Narrow	A	0	Active	10.0	14.0
Congenital trichomegaly	10073654	PT	Narrow	A	0	Active	16.1	16.1
Congenital tricuspid valve atresia	10049767	PT	Narrow	A	0	Active	10.0	14.0
Congenital tricuspid valve incompetence	10067887	PT	Narrow	A	0	Active	11.0	14.0
Congenital tricuspid valve stenosis	10010656	PT	Narrow	A	0	Active	10.0	14.0
Congenital tuberculosis	10010657	PT	Narrow	A	0	Active	10.0	14.0
Congenital umbilical hernia	10010658	PT	Narrow	A	0	Active	10.0	15.1
Congenital ureteric anomaly	10061078	PT	Narrow	A	0	Active	10.0	14.0
Congenital ureterocele	10056434	PT	Narrow	A	0	Active	10.0	14.0
Congenital ureterovesical junction anomaly	10068133	PT	Narrow	A	0	Active	11.0	14.0
Congenital urethral anomaly	10062349	PT	Narrow	A	0	Active	10.0	14.0
Congenital urinary tract obstruction	10010663	PT	Narrow	A	0	Active	10.0	14.0
Congenital uterine anomaly	10061079	PT	Narrow	A	0	Active	10.0	14.0
Congenital vaginal cyst	10063457	PT	Narrow	A	0	Active	10.0	14.0
Congenital varicella infection	10010668	PT	Narrow	A	0	Active	10.0	14.0
Congenital varicocele	10074459	PT	Narrow	A	0	Active	17.0	17.0
Congenital vas deferens absence	10010670	PT	Narrow	A	0	Active	10.0	14.0
Congenital vesicoureteric reflux	10010672	PT	Narrow	A	0	Active	10.0	14.0
Congenital visual acuity reduced	10059157	PT	Narrow	A	0	Active	10.0	14.0
Congenital vitreous anomaly	10061085	PT	Narrow	A	0	Active	10.0	14.0
Congenital white blood cell disorder	10061086	PT	Narrow	A	0	Active	10.0	14.0
Conjoined twins	10010688	PT	Narrow	A	0	Active	10.0	14.0
Conjunctivitis gonococcal neonatal	10010749	PT	Narrow	A	0	Active	10.0	14.0
Constricted ear deformity	10071233	PT	Narrow	A	0	Active	14.1	14.1
Cor biloculare	10010967	PT	Narrow	A	0	Active	10.0	14.0
Cor triatriatum	10010972	PT	Narrow	A	0	Active	10.0	14.0
Corneal dystrophy	10011005	PT	Narrow	A	0	Active	10.0	14.0
Corneal opacity congenital	10011037	PT	Narrow	A	0	Active	10.0	14.0
Cornelia de Lange syndrome	10077707	PT	Narrow	A	0	Active	19.0	19.0
Corrected transposition of great vessels	10011120	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Cortical dysplasia	10070666	PT	Narrow	A	0	Active	13.1	14.0
Costello syndrome	10067380	PT	Narrow	A	0	Active	10.1	14.0
Cowden's disease	10051906	PT	Narrow	A	0	Active	10.0	14.0
Craniofacial deformity	10074180	PT	Narrow	A	0	Active	16.1	16.1
Craniofacial dysostosis	10066946	PT	Narrow	A	0	Active	10.0	14.0
Craniolacunia	10072116	PT	Narrow	A	0	Active	15.0	15.0
Craniorachischisis	10011321	PT	Narrow	A	0	Active	10.0	14.0
Craniosynostosis	10049889	PT	Narrow	A	0	Active	12.0	14.0
Craniotabes	10065419	PT	Narrow	A	0	Active	10.0	14.0
Cri du Chat syndrome	10011385	PT	Narrow	A	0	Active	10.0	14.0
Crigler-Najjar syndrome	10011386	PT	Narrow	A	0	Active	10.0	14.0
Cryopyrin associated periodic syndrome	10068850	PT	Narrow	A	0	Active	12.0	14.0
Cryptophthalmos	10011497	PT	Narrow	A	0	Active	10.0	14.0
Cryptorchism	10011498	PT	Narrow	A	0	Active	10.0	14.0
Currarino syndrome	10079857	PT	Narrow	A	0	Active	20.1	20.1
Cutaneous visceral angiomas with thrombocytopenia	10069098	PT	Narrow	A	0	Active	12.0	14.0
Cyclopia	10057648	PT	Narrow	A	0	Active	10.0	14.0
Cystathionine beta-synthase deficiency	10071093	PT	Narrow	A	0	Active	14.0	14.0
Cystic angiomas	10079371	PT	Narrow	A	0	Active	20.0	20.0
Cystic eyeball, congenital	10011761	PT	Narrow	A	0	Active	10.0	14.0
Cystic fibrosis	10011762	PT	Narrow	A	0	Active	10.0	14.0
Cystic fibrosis carrier	10052656	PT	Narrow	A	0	Active	10.0	14.0
Cystic fibrosis gastrointestinal disease	10079428	PT	Narrow	A	0	Active	20.0	20.0
Cystic fibrosis hepatic disease	10068289	PT	Narrow	A	0	Active	11.0	14.0
Cystic fibrosis lung	10011763	PT	Narrow	A	0	Active	10.0	14.0
Cystic fibrosis pancreatic	10011766	PT	Narrow	A	0	Active	10.0	14.0
Cystic fibrosis related diabetes	10068271	PT	Narrow	A	0	Active	11.1	14.0
Cystic lymphangioma	10058949	PT	Narrow	A	0	Active	10.0	14.0
Cystinosis	10011777	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Cystinuria	10011778	PT	Narrow	A	0	Active	10.0	14.0
Cytogenetic abnormality	10067477	PT	Narrow	A	0	Active	10.1	14.0
Dacryostenosis congenital	10011850	PT	Narrow	A	0	Active	10.0	14.0
Dandy-Walker syndrome	10048411	PT	Narrow	A	0	Active	10.0	14.0
Deaf mutism	10011875	PT	Narrow	A	0	Active	10.0	14.0
Deafness congenital	10011882	PT	Narrow	A	0	Active	10.0	14.0
Deficiency of the interleukin-1 receptor antagonist	10072224	PT	Narrow	A	0	Active	15.0	15.0
Deficiency of the interleukin-36 receptor antagonist	10079451	PT	Narrow	A	0	Active	20.0	20.0
Delayed foetal renal development	10079753	PT	Narrow	A	0	Active	20.1	20.1
Delta-beta thalassaemia	10012236	PT	Narrow	A	0	Active	10.0	14.0
Dentatorubral-pallidolusian atrophy	10075298	PT	Narrow	A	0	Active	17.1	17.1
Dentinogenesis imperfecta	10054013	PT	Narrow	A	0	Active	10.0	14.0
Dentofacial anomaly	10012331	PT	Narrow	A	0	Active	10.0	14.0
Dent's disease	10069199	PT	Narrow	A	0	Active	12.0	14.0
Denys-Drash syndrome	10070179	PT	Narrow	A	0	Active	13.0	14.0
Dermatofibrosis lenticularis disseminata	10056878	PT	Narrow	A	0	Active	10.0	14.0
Dermatoglyphic anomaly	10061455	PT	Narrow	A	0	Active	10.0	14.0
Dermoid cyst	10012522	PT	Narrow	A	0	Active	10.0	14.0
Developmental glaucoma	10012565	PT	Narrow	A	0	Active	10.0	14.0
Developmental hip dysplasia	10073767	PT	Narrow	A	0	Active	16.1	16.1
Dextrocardia	10012592	PT	Narrow	A	0	Active	10.0	14.0
Diabetic foetopathy	10059116	PT	Narrow	A	0	Active	10.0	14.0
Diaphragmatic aplasia	10012711	PT	Narrow	A	0	Active	10.0	14.0
Diastematomyelia	10012750	PT	Narrow	A	0	Active	10.0	14.0
Diencephalic syndrome of infancy	10012774	PT	Narrow	A	0	Active	10.0	14.0
Diethylstilboestrol syndrome	10012780	PT	Narrow	A	0	Active	10.0	14.0
DiGeorge's syndrome	10012979	PT	Narrow	A	0	Active	10.0	14.0
Dihydropyrimidine dehydrogenase deficiency	10052622	PT	Narrow	A	0	Active	10.0	14.0
Dilatation intrahepatic duct congenital	10013003	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Disorder of sex development	10070597	PT	Narrow	A	0	Active	13.1	14.0
Distichiasis	10066128	PT	Narrow	A	0	Active	10.0	14.0
Diverticulitis Meckel's	10013542	PT	Narrow	A	0	Active	10.0	14.0
Diverticulum of pharynx, congenital	10013568	PT	Narrow	A	0	Active	10.0	14.0
DNA mismatch repair protein gene mutation	10078672	PT	Narrow	A	0	Active	19.1	19.1
Dolichocolon	10063917	PT	Narrow	A	0	Active	10.0	14.0
Dopa-responsive dystonia	10080034	PT	Narrow	A	0	Active	20.1	20.1
Double cortex syndrome	10073490	PT	Narrow	A	0	Active	16.0	16.0
Double heterozygous sickling disorders	10013609	PT	Narrow	A	0	Active	10.0	14.0
Double outlet left ventricle	10080133	PT	Narrow	A	0	Active	20.1	20.1
Double outlet right ventricle	10013611	PT	Narrow	A	0	Active	10.0	14.0
Double ureter	10013613	PT	Narrow	A	0	Active	10.0	14.0
Dowling-Degos disease	10068651	PT	Narrow	A	0	Active	11.1	14.0
Duane's syndrome	10013799	PT	Narrow	A	0	Active	10.0	14.0
Dubin-Johnson syndrome	10013800	PT	Narrow	A	0	Active	10.0	14.0
Dubowitz syndrome	10059589	PT	Narrow	A	0	Active	10.0	14.0
Duchenne muscular dystrophy	10013801	PT	Narrow	A	0	Active	10.0	14.0
Duchenne muscular dystrophy gene carrier	10052655	PT	Narrow	A	0	Active	10.0	14.0
Ductus arteriosus premature closure	10049996	PT	Narrow	A	0	Active	10.0	14.0
Ductus arteriosus stenosis foetal	10013808	PT	Narrow	A	0	Active	10.0	14.0
Ductus venosus agenesis	10068665	PT	Narrow	A	0	Active	11.1	14.0
Duodenal atresia	10013812	PT	Narrow	A	0	Active	10.0	14.0
Duplex appendix	10078212	PT	Narrow	A	0	Active	19.1	19.1
Dyke-Davidoff-Masson syndrome	10080312	PT	Narrow	A	0	Active	20.1	20.1
Dyschondrosteosis	10071437	PT	Narrow	A	0	Active	14.1	14.1
Dysgnathia	10074336	PT	Narrow	A	0	Active	17.0	17.0
Dysmorphism	10066054	PT	Narrow	A	0	Active	10.0	14.0
Dysmyelination	10067601	PT	Narrow	A	0	Active	10.1	14.0
Dysplastic naevus syndrome	10013960	PT	Narrow	A	0	Active	12.1	14.0
Eagle Barrett syndrome	10051025	PT	Narrow	A	0	Active	10.0	14.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Ear malformation	10014016	PT	Narrow	A	0	Active	10.0	14.0
Early onset familial Alzheimer's disease	10078036	PT	Narrow	A	0	Active	19.0	19.0
Early onset primary dystonia	10076668	PT	Narrow	A	0	Active	18.1	18.1
Ebstein's anomaly	10014075	PT	Narrow	A	0	Active	10.0	14.0
Ectopia cordis	10014144	PT	Narrow	A	0	Active	10.0	14.0
Ectopic kidney	10063044	PT	Narrow	A	0	Active	10.0	14.0
Ectopic ovary	10074217	PT	Narrow	A	0	Active	16.1	16.1
Ectopic posterior pituitary gland	10077557	PT	Narrow	A	0	Active	19.0	19.0
Ectopic thyroid	10069503	PT	Narrow	A	0	Active	12.1	14.0
Ectopic ureter	10014172	PT	Narrow	A	0	Active	10.0	14.0
Ectrodactyly	10079827	PT	Narrow	A	0	Active	20.1	20.1
Ehlers-Danlos syndrome	10014316	PT	Narrow	A	0	Active	10.0	14.0
Elliptocytosis hereditary	10014490	PT	Narrow	A	0	Active	10.0	14.0
Ellis-van Creveld syndrome	10076418	PT	Narrow	A	0	Active	18.0	18.0
Emanuel syndrome	10079203	PT	Narrow	A	0	Active	20.0	20.0
Encephalocele	10014617	PT	Narrow	A	0	Active	10.0	14.0
Encephalocutaneous angiomatosis	10057653	PT	Narrow	A	0	Active	10.0	14.0
Endocardial fibroelastosis	10014663	PT	Narrow	A	0	Active	10.0	14.0
Enteric duplication	10076653	PT	Narrow	A	0	Active	18.1	18.1
Entropion congenital	10014923	PT	Narrow	A	0	Active	10.0	14.0
Epidermal naevus	10014985	PT	Narrow	A	0	Active	15.0	15.0
Epidermal naevus syndrome	10077952	PT	Narrow	A	0	Active	19.0	19.0
Epidermolysis	10053177	PT	Narrow	A	0	Active	10.0	14.0
Epidermolysis bullosa	10014989	PT	Narrow	A	0	Active	10.0	14.0
Epilepsy congenital	10015039	PT	Narrow	A	0	Active	10.0	14.0
Epispadias	10015088	PT	Narrow	A	0	Active	10.0	14.0
Erythroblastosis foetalis	10015251	PT	Narrow	A	0	Active	10.0	14.0
Erythrokeratoderma variabilis	10049048	PT	Narrow	A	0	Active	10.0	14.0
Essential fructosuria	10015487	PT	Narrow	A	0	Active	10.0	14.0
Exomphalos	10015677	PT	Narrow	A	0	Active	10.0	14.0



Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Exophthalmos congenital	10050696	PT	Narrow	A	0	Active	10.0	14.0
External auditory canal atresia	10054875	PT	Narrow	A	0	Active	10.0	14.0
Extrarenal pelvis	10072727	PT	Narrow	A	0	Active	15.1	15.1
Eye anterior chamber congenital anomaly	10061051	PT	Narrow	A	0	Active	10.0	14.0
Eyelid ptosis congenital	10015996	PT	Narrow	A	0	Active	10.0	14.0
Fabry's disease	10016016	PT	Narrow	A	0	Active	10.0	14.0
Faciodigitogenital dysplasia	10067141	PT	Narrow	A	0	Active	10.0	14.0
Facioscapulohumeral muscular dystrophy	10064087	PT	Narrow	A	0	Active	10.0	14.0
Factor I deficiency	10016075	PT	Narrow	A	0	Active	10.0	14.0
Factor II deficiency	10016076	PT	Narrow	A	0	Active	10.0	14.0
Factor II mutation	10065003	PT	Narrow	A	0	Active	10.0	14.0
Factor III deficiency	10052473	PT	Narrow	A	0	Active	10.0	14.0
Factor IX deficiency	10016077	PT	Narrow	A	0	Active	10.0	14.0
Factor V deficiency	10048930	PT	Narrow	A	0	Active	10.0	14.0
Factor V Leiden carrier	10075652	PT	Narrow	A	0	Active	18.0	18.0
Factor V Leiden mutation	10058279	PT	Narrow	A	0	Active	10.0	14.0
Factor VII deficiency	10016079	PT	Narrow	A	0	Active	10.0	14.0
Factor VIII deficiency	10016080	PT	Narrow	A	0	Active	10.0	14.0
Factor X deficiency	10052474	PT	Narrow	A	0	Active	10.0	14.0
Factor XI deficiency	10016082	PT	Narrow	A	0	Active	10.0	14.0
Factor XII deficiency	10051806	PT	Narrow	A	0	Active	10.0	14.0
Factor XIII deficiency	10016083	PT	Narrow	A	0	Active	10.0	14.0
Falot's pentalogy	10059205	PT	Narrow	A	0	Active	10.0	14.0
Falot's tetralogy	10016193	PT	Narrow	A	0	Active	10.0	14.0
Falot's trilogly	10064011	PT	Narrow	A	0	Active	10.0	14.0
Familial amyloidosis	10016202	PT	Narrow	A	0	Active	10.0	14.0
Familial amyotrophic lateral sclerosis	10077024	PT	Narrow	A	0	Active	18.1	18.1
Familial cold autoinflammatory syndrome	10064570	PT	Narrow	A	0	Active	10.0	14.0
Familial haemophagocytic lymphohistiocytosis	10070904	PT	Narrow	A	0	Active	14.0	14.0
Familial hemiplegic migraine	10067039	PT	Narrow	A	0	Active	10.0	14.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Familial high density lipoprotein deficiency	10079119	PT	Narrow	A	0	Active	20.0	20.0
Familial hypertriglyceridaemia	10059183	PT	Narrow	A	0	Active	10.0	14.0
Familial hypocalciuric hypercalcaemia	10068698	PT	Narrow	A	0	Active	11.1	14.0
Familial infantile bilateral striatal necrosis	10077450	PT	Narrow	A	0	Active	19.0	19.0
Familial mediterranean fever	10016207	PT	Narrow	A	0	Active	10.0	14.0
Familial medullary thyroid cancer	10073153	PT	Narrow	A	0	Active	16.0	16.0
Familial periodic paralysis	10016208	PT	Narrow	A	0	Active	10.0	14.0
Familial polycythaemia	10016209	PT	Narrow	A	0	Active	10.0	14.0
Familial renal glycosuria	10073689	PT	Narrow	A	0	Active	16.1	16.1
Familial scaphocephaly syndrome	10072229	PT	Narrow	A	0	Active	15.0	15.0
Familial tremor	10016212	PT	Narrow	A	0	Active	10.0	14.0
Fanconi syndrome	10016219	PT	Narrow	A	0	Active	10.0	14.0
Fatal familial insomnia	10072077	PT	Narrow	A	0	Active	15.0	15.0
Fatty acid oxidation disorder	10077951	PT	Narrow	A	0	Active	19.0	19.0
Femoral anteversion	10064516	PT	Narrow	A	0	Active	10.0	14.0
Femoral retroversion	10064514	PT	Narrow	A	0	Active	10.0	14.0
Femur-fibula-ulna complex	10068448	PT	Narrow	A	0	Active	11.1	14.0
Fibrodysplasia ossificans progressiva	10068715	PT	Narrow	A	0	Active	11.1	14.0
Fibrous dysplasia of bone	10016664	PT	Narrow	A	0	Active	10.0	14.0
Fibrous dysplasia of jaw	10070535	PT	Narrow	A	0	Active	13.1	14.0
Fibula agenesis	10054882	PT	Narrow	A	0	Active	10.0	14.0
Fissure of tongue, congenital	10016715	PT	Narrow	A	0	Active	10.0	14.0
Floating-Harbor syndrome	10079943	PT	Narrow	A	0	Active	20.1	20.1
Foetal alcohol syndrome	10016845	PT	Narrow	A	0	Active	10.0	14.0
Foetal anticonvulsant syndrome	10066485	PT	Narrow	A	0	Active	10.0	14.0
Foetal chromosome abnormality	10064041	PT	Narrow	A	0	Active	10.0	14.0
Foetal cystic hygroma	10052011	PT	Narrow	A	0	Active	10.0	14.0
Foetal malformation	10060919	PT	Narrow	A	0	Active	10.0	14.0
Foetal megacystis	10073660	PT	Narrow	A	0	Active	16.1	16.1
Foetal methotrexate syndrome	10071183	PT	Narrow	A	0	Active	14.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Foetal retinoid syndrome	10073720	PT	Narrow	A	0	Active	16.1	16.1
Foetal warfarin syndrome	10051445	PT	Narrow	A	0	Active	10.0	14.0
Foramen magnum stenosis	10064157	PT	Narrow	A	0	Active	10.0	14.0
Fragile X carrier	10052657	PT	Narrow	A	0	Active	10.0	14.0
Fragile X syndrome	10017324	PT	Narrow	A	0	Active	10.0	14.0
Fraser syndrome	10080219	PT	Narrow	A	0	Active	20.1	20.1
Frasier syndrome	10080313	PT	Narrow	A	0	Active	20.1	20.1
Freeman-Sheldon syndrome	10073655	PT	Narrow	A	0	Active	16.1	16.1
Frenulum breve	10072007	PT	Narrow	A	0	Active	15.0	15.0
Friedreich's ataxia	10017374	PT	Narrow	A	0	Active	10.0	14.0
Fryns syndrome	10075223	PT	Narrow	A	0	Active	17.1	17.1
Galactosaemia	10017604	PT	Narrow	A	0	Active	10.0	14.0
Gallbladder agenesis	10079018	PT	Narrow	A	0	Active	20.0	20.0
Gallbladder anomaly congenital	10061163	PT	Narrow	A	0	Active	10.0	14.0
Gastrointestinal arteriovenous malformation	10017932	PT	Narrow	A	0	Active	10.0	14.0
Gastrointestinal disorder congenital	10061973	PT	Narrow	A	0	Active	10.0	14.0
Gastrointestinal malformation	10061596	PT	Narrow	A	0	Active	10.0	14.0
Gastroschisis	10018046	PT	Narrow	A	0	Active	10.0	14.0
Gaucher's disease	10018048	PT	Narrow	A	0	Active	10.0	14.0
Gaucher's disease type I	10075697	PT	Narrow	A	0	Active	18.0	18.0
Gaucher's disease type II	10075698	PT	Narrow	A	0	Active	18.0	18.0
Gaucher's disease type III	10075699	PT	Narrow	A	0	Active	18.0	18.0
Gene mutation	10064571	PT	Narrow	A	0	Active	10.0	14.0
Generalised resistance to thyroid hormone	10018096	PT	Narrow	A	0	Active	10.0	14.0
Genitalia external ambiguous	10018183	PT	Narrow	A	0	Active	10.0	14.0
Gilbert's syndrome	10018267	PT	Narrow	A	0	Active	10.0	14.0
Gitelman's syndrome	10062906	PT	Narrow	A	0	Active	10.0	14.0
Glucose transporter type 1 deficiency syndrome	10078727	PT	Narrow	A	0	Active	19.1	19.1
Glucose-6-phosphate dehydrogenase deficiency	10018444	PT	Narrow	A	0	Active	10.0	14.0
Glucose-galactose malabsorption	10066388	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Glutathione synthetase deficiency	10079364	PT	Narrow	A	0	Active	20.0	20.0
Glycogen storage disease type I	10018464	PT	Narrow	A	0	Active	10.0	14.0
Glycogen storage disease type II	10053185	PT	Narrow	A	0	Active	10.0	14.0
Glycogen storage disease type III	10053250	PT	Narrow	A	0	Active	10.0	14.0
Glycogen storage disease type IV	10053249	PT	Narrow	A	0	Active	10.0	14.0
Glycogen storage disease type V	10018462	PT	Narrow	A	0	Active	10.0	14.0
Glycogen storage disease type VI	10053240	PT	Narrow	A	0	Active	10.0	14.0
Glycogen storage disease type VII	10053241	PT	Narrow	A	0	Active	10.0	14.0
Glycogen storage disease type VIII	10053242	PT	Narrow	A	0	Active	10.0	14.0
Glycogen storage disorder	10061990	PT	Narrow	A	0	Active	10.0	14.0
Gnathoschisis	10068845	PT	Narrow	A	0	Active	12.0	14.0
GNE myopathy	10077945	PT	Narrow	A	0	Active	19.0	19.0
Goitre congenital	10018499	PT	Narrow	A	0	Active	10.0	14.0
Gollop-Wolfgang complex	10079731	PT	Narrow	A	0	Active	20.1	20.1
Gonadal dysgenesis	10018504	PT	Narrow	A	0	Active	10.0	14.0
Gorham's disease	10071283	PT	Narrow	A	0	Active	14.1	14.1
Greig's syndrome	10053878	PT	Narrow	A	0	Active	10.0	14.0
Haemangioma congenital	10018818	PT	Narrow	A	0	Active	10.0	14.0
Haemangioma of retina	10018822	PT	Narrow	A	0	Active	10.0	14.0
Haemochromatosis trait	10073217	PT	Narrow	A	0	Active	16.0	16.0
Haemoglobin C disease	10018883	PT	Narrow	A	0	Active	10.0	14.0
Haemoglobin C trait	10055021	PT	Narrow	A	0	Active	10.0	14.0
Haemoglobin D disease	10055019	PT	Narrow	A	0	Active	10.0	14.0
Haemoglobin D trait	10055020	PT	Narrow	A	0	Active	10.0	14.0
Haemoglobin E disease	10053215	PT	Narrow	A	0	Active	10.0	14.0
Haemoglobin E trait	10063740	PT	Narrow	A	0	Active	10.0	14.0
Haemoglobin E-thalassaemia disease	10062917	PT	Narrow	A	0	Active	10.0	14.0
Haemoglobinopathy	10060892	PT	Narrow	A	0	Active	10.0	14.0
Haemophilia	10061992	PT	Narrow	A	0	Active	10.0	14.0
Haemophilia A with anti factor VIII	10056492	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Haemophilia A without inhibitors	10056493	PT	Narrow	A	0	Active	10.0	14.0
Haemophilia B with anti factor IX	10056494	PT	Narrow	A	0	Active	10.0	14.0
Haemophilia B without inhibitors	10056495	PT	Narrow	A	0	Active	10.0	14.0
Haemophilia carrier	10051658	PT	Narrow	A	0	Active	10.0	14.0
Haemorrhagic arteriovenous malformation	10064595	PT	Narrow	A	0	Active	10.0	14.0
Hamartoma	10061193	PT	Narrow	A	0	Active	10.0	14.0
Hamartoma vascular	10019106	PT	Narrow	A	0	Active	10.0	14.0
Hand-foot-genital syndrome	10072361	PT	Narrow	A	0	Active	15.0	15.0
Harlequin foetus	10019163	PT	Narrow	A	0	Active	10.0	14.0
Hartnup disease	10019165	PT	Narrow	A	0	Active	10.0	14.0
Heart block congenital	10019263	PT	Narrow	A	0	Active	10.0	14.0
Heart disease congenital	10019273	PT	Narrow	A	0	Active	10.0	14.0
Hemihypertrophy	10019463	PT	Narrow	A	0	Active	10.0	14.0
Hemimegalencephaly	10078100	PT	Narrow	A	0	Active	19.1	19.1
Hemivertebra	10019477	PT	Narrow	A	0	Active	10.0	14.0
Hepatic arteriovenous malformation	10019633	PT	Narrow	A	0	Active	10.0	14.0
Hepatic hamartoma	10079685	PT	Narrow	A	0	Active	20.1	20.1
Hepato-lenticular degeneration	10019819	PT	Narrow	A	0	Active	10.0	14.0
Hereditary angioedema	10019860	PT	Narrow	A	0	Active	10.0	14.0
Hereditary areflexic dystasia	10063449	PT	Narrow	A	0	Active	10.0	14.0
Hereditary cerebral degeneration	10061204	PT	Narrow	A	0	Active	10.0	14.0
Hereditary choroidal dystrophy	10019864	PT	Narrow	A	0	Active	10.0	14.0
Hereditary disorder	10061205	PT	Narrow	A	0	Active	10.0	14.0
Hereditary fructose intolerance	10019878	PT	Narrow	A	0	Active	10.0	14.0
Hereditary haemochromatosis	10057873	PT	Narrow	A	0	Active	10.0	14.0
Hereditary haemolytic anaemia	10060893	PT	Narrow	A	0	Active	10.0	14.0
Hereditary haemorrhagic telangiectasia	10019883	PT	Narrow	A	0	Active	10.0	14.0
Hereditary hypophosphataemic rickets	10077943	PT	Narrow	A	0	Active	19.0	19.0
Hereditary leiomyomatosis renal cell carcinoma	10067944	PT	Narrow	A	0	Active	11.0	14.0
Hereditary motor and sensory neuropathy	10077306	PT	Narrow	A	0	Active	19.0	19.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Hereditary motor neurone disease	10071328	PT	Narrow	A	0	Active	14.1	14.1
Hereditary multiple osteochondromas	10079019	PT	Narrow	A	0	Active	20.0	20.0
Hereditary neuropathic amyloidosis	10019889	PT	Narrow	A	0	Active	10.0	14.0
Hereditary neuropathy with liability to pressure palsies	10069382	PT	Narrow	A	0	Active	12.1	14.0
Hereditary non-polyposis colorectal cancer syndrome	10051922	PT	Narrow	A	0	Active	10.0	14.0
Hereditary optic atrophy	10019895	PT	Narrow	A	0	Active	10.0	14.0
Hereditary palmoplantar keratoderma	10072537	PT	Narrow	A	0	Active	15.1	15.1
Hereditary pancreatitis	10056976	PT	Narrow	A	0	Active	10.0	14.0
Hereditary papillary renal carcinoma	10067943	PT	Narrow	A	0	Active	11.0	14.0
Hereditary retinal dystrophy	10019899	PT	Narrow	A	0	Active	10.0	14.0
Hereditary sideroblastic anaemia	10019902	PT	Narrow	A	0	Active	10.0	14.0
Hereditary spastic paraplegia	10019903	PT	Narrow	A	0	Active	10.0	14.0
Hereditary spherocytosis	10019904	PT	Narrow	A	0	Active	10.0	14.0
Hereditary stomatocytosis	10053589	PT	Narrow	A	0	Active	10.0	14.0
Hermansky-Pudlak syndrome	10071775	PT	Narrow	A	0	Active	15.0	15.0
Hermaphroditism	10019906	PT	Narrow	A	0	Active	10.0	14.0
Hernia congenital	10019912	PT	Narrow	A	0	Active	10.0	14.0
Heterochromia iridis	10066799	PT	Narrow	A	0	Active	10.0	14.0
Heterotaxia	10067265	PT	Narrow	A	0	Active	10.0	14.0
Hexokinase deficiency anaemia	10020022	PT	Narrow	A	0	Active	10.0	14.0
High arched palate	10020046	PT	Narrow	A	0	Active	10.0	14.0
Hollow visceral myopathy	10060811	PT	Narrow	A	0	Active	10.0	14.0
Holoprosencephaly	10056304	PT	Narrow	A	0	Active	10.0	14.0
Holt-Oram syndrome	10050469	PT	Narrow	A	0	Active	10.0	14.0
Homocystinaemia	10048707	PT	Narrow	A	0	Active	10.0	14.0
Homocystinuria	10020365	PT	Narrow	A	0	Active	10.0	14.0
Hooded prepuce	10072135	PT	Narrow	A	0	Active	15.0	15.0
Huntington's disease	10070668	PT	Narrow	A	0	Active	13.1	14.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Hydranencephaly	10073472	PT	Narrow	A	0	Active	16.0	16.0
Hydrocele	10020488	PT	Narrow	A	0	Active	10.0	14.0
Hydroxyprolinaemia	10053148	PT	Narrow	A	0	Active	10.0	14.0
Hyper IgD syndrome	10072010	PT	Narrow	A	0	Active	15.0	15.0
Hyper IgE syndrome	10051040	PT	Narrow	A	0	Active	10.0	14.0
Hyper IgM syndrome	10066130	PT	Narrow	A	0	Active	10.0	14.0
Hyperexplexia	10058271	PT	Narrow	A	0	Active	10.0	14.0
Hyperinsulinism syndrome	10077858	PT	Narrow	A	0	Active	19.0	19.0
Hypermethioninaemia	10051245	PT	Narrow	A	0	Active	10.0	14.0
Hypermethioniuria	10051231	PT	Narrow	A	0	Active	10.0	14.0
Hyperprolinaemia	10058509	PT	Narrow	A	0	Active	10.0	14.0
Hypersplenism congenital	10049282	PT	Narrow	A	0	Active	10.0	14.0
Hypertelorism of orbit	10020771	PT	Narrow	A	0	Active	10.0	14.0
Hypertrophic cardiomyopathy	10020871	PT	Narrow	A	0	Active	16.0	16.0
Hypocalvaria	10073670	PT	Narrow	A	0	Active	16.1	16.1
Hypochondroplasia	10020967	PT	Narrow	A	0	Active	10.0	14.0
Hypodontia	10055001	PT	Narrow	A	0	Active	10.0	14.0
Hypomelanosis of Ito	10075301	PT	Narrow	A	0	Active	17.1	17.1
Hypophosphatasia	10049933	PT	Narrow	A	0	Active	10.0	14.0
Hypopituitarism foetal	10021068	PT	Narrow	A	0	Active	10.0	14.0
Hypoplastic left heart syndrome	10021076	PT	Narrow	A	0	Active	10.0	14.0
Hypoplastic nasal cartilage	10074970	PT	Narrow	A	0	Active	17.1	17.1
Hypoplastic right heart syndrome	10064962	PT	Narrow	A	0	Active	10.0	14.0
Hypospadias	10021093	PT	Narrow	A	0	Active	10.0	14.0
Hypotelorism of orbit	10057855	PT	Narrow	A	0	Active	10.0	14.0
Hypothalamic hamartoma	10078217	PT	Narrow	A	0	Active	19.1	19.1
Hypoxanthine-guanine phosphoribosyl transferase deficiency	10075774	PT	Narrow	A	0	Active	18.0	18.0
Ichthyosis	10021198	PT	Narrow	A	0	Active	10.0	14.0
Ileal atresia	10021298	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Immunodeficiency congenital	10021450	PT	Narrow	A	0	Active	10.0	14.0
Imperforate hymen	10021529	PT	Narrow	A	0	Active	15.0	15.0
Imperforate oesophagus	10021530	PT	Narrow	A	0	Active	10.0	14.0
Inborn error in primary bile acid synthesis	10070882	PT	Narrow	A	0	Active	14.0	14.0
Inborn error of bilirubin metabolism	10062017	PT	Narrow	A	0	Active	10.0	14.0
Inborn error of lipid metabolism	10072272	PT	Narrow	A	0	Active	15.0	15.0
Inborn error of metabolism	10062018	PT	Narrow	A	0	Active	10.0	14.0
Infantile cortical hyperostosis	10073206	PT	Narrow	A	0	Active	16.0	16.0
Infantile genetic agranulocytosis	10052210	PT	Narrow	A	0	Active	10.0	14.0
Infantile septic granulomatosis	10048708	PT	Narrow	A	0	Active	10.0	14.0
Inherited cardiac conduction disorder	10070294	PT	Narrow	A	0	Active	13.0	14.0
Iniencephaly	10022034	PT	Narrow	A	0	Active	10.0	14.0
Interferon gamma receptor deficiency	10057605	PT	Narrow	A	0	Active	10.0	14.0
Interruption of aortic arch	10022599	PT	Narrow	A	0	Active	10.0	14.0
Intestinal atresia	10062022	PT	Narrow	A	0	Active	10.0	14.0
Intestinal malrotation	10064024	PT	Narrow	A	0	Active	10.0	14.0
Intestinal neuronal dysplasia	10073659	PT	Narrow	A	0	Active	16.1	16.1
Intestinal transposition	10022712	PT	Narrow	A	0	Active	10.0	14.0
Intracranial arterial fenestration	10077285	PT	Narrow	A	0	Active	19.0	19.0
Intracranial lipoma	10072288	PT	Narrow	A	0	Active	15.0	15.0
Iris coloboma	10052642	PT	Narrow	A	0	Active	10.0	14.0
Johanson-Blizzard syndrome	10074947	PT	Narrow	A	0	Active	17.1	17.1
Joubert syndrome	10078574	PT	Narrow	A	0	Active	19.1	19.1
Juvenile Paget's disease	10078977	PT	Narrow	A	0	Active	20.0	20.0
Kabuki make-up syndrome	10063935	PT	Narrow	A	0	Active	10.0	14.0
Kaufman-McKusick syndrome	10052312	PT	Narrow	A	0	Active	10.0	14.0
Kearns-Sayre syndrome	10048804	PT	Narrow	A	0	Active	10.0	14.0
Kenny-Caffey syndrome	10073228	PT	Narrow	A	0	Active	16.0	16.0
Keratitits-ichthyosis-deafness syndrome	10048786	PT	Narrow	A	0	Active	10.0	14.0
Keratolysis exfoliativa congenital	10052290	PT	Narrow	A	0	Active	10.0	14.0



Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Keratosis follicular	10023369	PT	Narrow	A	0	Active	10.0	14.0
Kidney duplex	10023416	PT	Narrow	A	0	Active	10.0	14.0
Kidney malformation	10023430	PT	Narrow	A	0	Active	10.0	14.0
Kidney malrotation	10067877	PT	Narrow	A	0	Active	11.0	14.0
Kimmerle's anomaly	10076416	PT	Narrow	A	0	Active	18.0	18.0
Kinematic imbalances due to suboccipital strain	10062992	PT	Narrow	A	0	Active	10.0	14.0
Kleefstra syndrome	10079365	PT	Narrow	A	0	Active	20.0	20.0
Klinefelter's syndrome	10023463	PT	Narrow	A	0	Active	10.0	14.0
Klippel-Feil syndrome	10023464	PT	Narrow	A	0	Active	10.0	14.0
Klippel-Trenaunay syndrome	10051452	PT	Narrow	A	0	Active	10.0	14.0
Krabbe's disease	10023492	PT	Narrow	A	0	Active	10.0	14.0
Kyphosis congenital	10048576	PT	Narrow	A	0	Active	10.0	14.0
Labial tie	10076772	PT	Narrow	A	0	Active	18.1	18.1
Lacrimal punctum agenesis	10023636	PT	Narrow	A	0	Active	10.0	14.0
Laevocardia	10071015	PT	Narrow	A	0	Active	14.0	14.0
Lafora's myoclonic epilepsy	10054030	PT	Narrow	A	0	Active	10.0	14.0
Lamin A/C gene mutation	10075979	PT	Narrow	A	0	Active	18.0	18.0
Langer-Giedion syndrome	10050638	PT	Narrow	A	0	Active	10.0	14.0
Laron syndrome	10075492	PT	Narrow	A	0	Active	18.0	18.0
Larsen syndrome	10073856	PT	Narrow	A	0	Active	16.1	16.1
Laryngeal cleft	10069115	PT	Narrow	A	0	Active	12.0	14.0
Laryngeal web	10023871	PT	Narrow	A	0	Active	10.0	14.0
Laryngocele	10023885	PT	Narrow	A	0	Active	10.0	14.0
Laryngomalacia	10060786	PT	Narrow	A	0	Active	10.0	14.0
Laryngo-onycho-cutaneous syndrome	10062987	PT	Narrow	A	0	Active	10.0	14.0
Laurence-Moon-Bardet-Biedl syndrome	10056715	PT	Narrow	A	0	Active	10.0	14.0
LDLR mutation	10075640	PT	Narrow	A	0	Active	18.0	18.0
Leber's congenital amaurosis	10070667	PT	Narrow	A	0	Active	13.1	14.0
Lecithin-cholesterol acyltransferase deficiency	10077917	PT	Narrow	A	0	Active	19.0	19.0
Left ventricle outflow tract obstruction	10065930	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Left-to-right cardiac shunt	10077834	PT	Narrow	A	0	Active	19.0	19.0
Lens abnormality, congenital	10024202	PT	Narrow	A	0	Active	10.0	14.0
Leukodystrophy	10024381	PT	Narrow	A	0	Active	10.0	14.0
Lichen spinulosus	10024436	PT	Narrow	A	0	Active	10.0	14.0
Liddle's syndrome	10052313	PT	Narrow	A	0	Active	10.0	14.0
Li-Fraumeni syndrome	10066795	PT	Narrow	A	0	Active	10.0	14.0
Limb hypoplasia congenital	10048575	PT	Narrow	A	0	Active	10.0	14.0
Limb malformation	10024500	PT	Narrow	A	0	Active	10.0	14.0
Limb reduction defect	10024503	PT	Narrow	A	0	Active	10.0	14.0
Lipid proteinosis	10051661	PT	Narrow	A	0	Active	10.0	14.0
Lipidosis	10024585	PT	Narrow	A	0	Active	10.0	14.0
Lipodermoid tumour	10073484	PT	Narrow	A	0	Active	16.0	16.0
Lipomeningocele	10050084	PT	Narrow	A	0	Active	10.0	14.0
Lissencephaly	10048911	PT	Narrow	A	0	Active	10.0	14.0
Long QT syndrome congenital	10057926	PT	Narrow	A	0	Active	10.0	14.0
Long-chain acyl-coenzyme A dehydrogenase deficiency	10072653	PT	Narrow	A	0	Active	15.1	15.1
Low set ears	10024929	PT	Narrow	A	0	Active	10.0	14.0
Lown-Ganong-Levine syndrome	10024984	PT	Narrow	A	0	Active	10.0	14.0
Lowry-Wood syndrome	10062600	PT	Narrow	A	0	Active	10.0	14.0
Lumbarisation	10063410	PT	Narrow	A	0	Active	10.0	14.0
Lymphangiectasia intestinal congenital	10054722	PT	Narrow	A	0	Active	10.0	14.0
Lysinuric protein intolerance	10058300	PT	Narrow	A	0	Active	10.0	14.0
Lysosomal acid lipase deficiency	10077267	PT	Narrow	A	0	Active	19.0	19.0
Macrocephaly	10050183	PT	Narrow	A	0	Active	10.0	14.0
Macrocheilia	10025378	PT	Narrow	A	0	Active	10.0	14.0
Macrocornea	10059253	PT	Narrow	A	0	Active	10.0	14.0
Macroductyly	10025386	PT	Narrow	A	0	Active	10.0	14.0
Macrogenia	10025387	PT	Narrow	A	0	Active	10.0	14.0
Macroglossia	10025391	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Macrognothia	10052658	PT	Narrow	A	0	Active	10.0	14.0
Macrostomia	10025395	PT	Narrow	A	0	Active	10.0	14.0
Macrotia	10025396	PT	Narrow	A	0	Active	10.0	14.0
Macular dystrophy congenital	10025412	PT	Narrow	A	0	Active	10.0	16.1
Majeed's syndrome	10072223	PT	Narrow	A	0	Active	15.0	15.0
Malformation biliary	10025523	PT	Narrow	A	0	Active	10.0	14.0
Malformation venous	10025532	PT	Narrow	A	0	Active	10.0	14.0
Mandibulofacial dysostosis	10051456	PT	Narrow	A	0	Active	10.0	14.0
Maple syrup disease	10026817	PT	Narrow	A	0	Active	10.0	14.0
Marcus Gunn syndrome	10064583	PT	Narrow	A	0	Active	10.0	14.0
Marfan's syndrome	10026829	PT	Narrow	A	0	Active	10.0	14.0
Maxillonasal dysplasia	10075843	PT	Narrow	A	0	Active	18.0	18.0
Mayer-Rokitansky-Kuster-Hauser syndrome	10065148	PT	Narrow	A	0	Active	10.0	14.0
Medium-chain acyl-coenzyme A dehydrogenase deficiency	10072654	PT	Narrow	A	0	Active	15.1	15.1
Meier-Gorlin syndrome	10070612	PT	Narrow	A	0	Active	13.1	14.0
MELAS syndrome	10053872	PT	Narrow	A	0	Active	10.0	14.0
Melkersson-Rosenthal syndrome	10027166	PT	Narrow	A	0	Active	10.0	14.0
Membranous lipodystrophy	10065127	PT	Narrow	A	0	Active	10.0	14.0
Meningocele	10027266	PT	Narrow	A	0	Active	10.0	14.0
Meningomyelocele	10027287	PT	Narrow	A	0	Active	10.0	14.0
Menkes' syndrome	10027294	PT	Narrow	A	0	Active	10.0	14.0
Mesoblastic nephroma	10070665	PT	Narrow	A	0	Active	13.1	14.0
Mesonephric duct cyst	10027405	PT	Narrow	A	0	Active	11.1	14.0
Metabolic myopathy	10068836	PT	Narrow	A	0	Active	12.0	14.0
Metachromatic leukodystrophy	10067609	PT	Narrow	A	0	Active	10.1	14.0
Metaphyseal dysplasia	10066147	PT	Narrow	A	0	Active	10.0	14.0
Metatarsus primus varus	10027489	PT	Narrow	A	0	Active	10.0	14.0
Methylenetetrahydrofolate reductase deficiency	10070309	PT	Narrow	A	0	Active	13.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Methylenetetrahydrofolate reductase gene mutation	10074753	PT	Narrow	A	0	Active	17.0	17.0
Methylmalonic aciduria	10059521	PT	Narrow	A	0	Active	10.0	14.0
Mevalonate kinase deficiency	10072221	PT	Narrow	A	0	Active	15.0	15.0
Mevalonic aciduria	10072219	PT	Narrow	A	0	Active	15.0	15.0
Microcephaly	10027534	PT	Narrow	A	0	Active	10.0	14.0
Microcheilia	10027535	PT	Narrow	A	0	Active	10.0	14.0
Microcolon	10073456	PT	Narrow	A	0	Active	16.0	16.0
Microcornea	10057414	PT	Narrow	A	0	Active	10.0	14.0
Microencephaly	10068320	PT	Narrow	A	0	Active	11.1	14.0
Microgenia	10027541	PT	Narrow	A	0	Active	10.0	14.0
Microglossia	10027542	PT	Narrow	A	0	Active	10.0	14.0
Micrognathia	10027543	PT	Narrow	A	0	Active	10.0	14.0
Micropenis	10071706	PT	Narrow	A	0	Active	14.1	14.1
Microphthalmos	10027548	PT	Narrow	A	0	Active	10.0	14.0
Microstomia	10027553	PT	Narrow	A	0	Active	10.0	14.0
Microtia	10027555	PT	Narrow	A	0	Active	10.0	14.0
Microvillous inclusion disease	10068494	PT	Narrow	A	0	Active	11.1	14.0
Mismatch repair cancer syndrome	10077888	PT	Narrow	A	0	Active	19.0	19.0
Mitochondrial DNA deletion	10051403	PT	Narrow	A	0	Active	10.0	14.0
Mitochondrial DNA depletion	10059396	PT	Narrow	A	0	Active	10.0	14.0
Mitochondrial DNA duplication	10052640	PT	Narrow	A	0	Active	10.0	14.0
Mitochondrial DNA mutation	10052641	PT	Narrow	A	0	Active	10.0	14.0
Mitochondrial encephalomyopathy	10058799	PT	Narrow	A	0	Active	10.0	14.0
Mitochondrial enzyme deficiency	10067729	PT	Narrow	A	0	Active	10.1	14.0
Mitochondrial hepatopathy	10062938	PT	Narrow	A	0	Active	10.0	14.0
Mitochondrial myopathy	10027710	PT	Narrow	A	0	Active	10.0	14.0
Mitochondrial neurogastrointestinal encephalopathy	10065271	PT	Narrow	A	0	Active	10.0	14.0
Mitral valve atresia	10066800	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Mitral valve hypoplasia	10049211	PT	Narrow	A	0	Active	10.0	14.0
Mittendorf dot	10076031	PT	Narrow	A	0	Active	18.0	18.0
MLASA syndrome	10078801	PT	Narrow	A	0	Active	20.0	20.0
Mobile caecum syndrome	10074307	PT	Narrow	A	0	Active	17.0	17.0
Moebius II syndrome	10027802	PT	Narrow	A	0	Active	10.0	14.0
Molybdenum cofactor deficiency	10069687	PT	Narrow	A	0	Active	13.0	14.0
Monopodia	10049214	PT	Narrow	A	0	Active	10.0	14.0
Morning glory syndrome	10027974	PT	Narrow	A	0	Active	10.0	14.0
Morton's syndrome	10079320	PT	Narrow	A	0	Active	20.0	20.0
Mosaicism	10068052	PT	Narrow	A	0	Active	11.0	14.0
Mount-Reback syndrome	10065658	PT	Narrow	A	0	Active	10.0	14.0
Muckle-Wells syndrome	10064569	PT	Narrow	A	0	Active	10.0	14.0
Mucopolipidosis	10072939	PT	Narrow	A	0	Active	16.0	16.0
Mucopolipidosis type I	10072927	PT	Narrow	A	0	Active	16.0	16.0
Mucopolipidosis type II	10072928	PT	Narrow	A	0	Active	16.0	16.0
Mucopolipidosis type III	10072929	PT	Narrow	A	0	Active	16.0	16.0
Mucopolipidosis type IV	10072930	PT	Narrow	A	0	Active	16.0	16.0
Mucopolysaccharidosis	10028093	PT	Narrow	A	0	Active	10.0	14.0
Mucopolysaccharidosis I	10056886	PT	Narrow	A	0	Active	10.0	14.0
Mucopolysaccharidosis II	10056889	PT	Narrow	A	0	Active	10.0	14.0
Mucopolysaccharidosis III	10056890	PT	Narrow	A	0	Active	10.0	14.0
Mucopolysaccharidosis IV	10028095	PT	Narrow	A	0	Active	10.0	14.0
Mucopolysaccharidosis V	10056891	PT	Narrow	A	0	Active	10.0	14.0
Mucopolysaccharidosis VI	10056892	PT	Narrow	A	0	Active	10.0	14.0
Mucopolysaccharidosis VII	10056893	PT	Narrow	A	0	Active	10.0	14.0
Muir-Torre syndrome	10063042	PT	Narrow	A	0	Active	10.0	14.0
Multiple carboxylase deficiency	10028176	PT	Narrow	A	0	Active	10.0	14.0
Multiple cardiac defects	10028178	PT	Narrow	A	0	Active	10.0	14.0
Multiple congenital abnormalities	10028182	PT	Narrow	A	0	Active	10.0	14.0
Multiple cutaneous and uterine leiomyomatosis	10077859	PT	Narrow	A	0	Active	19.0	19.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Multiple endocrine neoplasia	10051747	PT	Narrow	A	0	Active	10.0	16.0
Multiple endocrine neoplasia Type 1	10073150	PT	Narrow	A	0	Active	16.0	16.0
Multiple endocrine neoplasia Type 2	10073149	PT	Narrow	A	0	Active	16.0	16.0
Multiple endocrine neoplasia Type 2A	10073148	PT	Narrow	A	0	Active	16.0	16.0
Multiple endocrine neoplasia Type 2B	10073151	PT	Narrow	A	0	Active	16.0	16.0
Multiple epiphyseal dysplasia	10028197	PT	Narrow	A	0	Active	10.0	14.0
Multiple gastrointestinal atresias	10028210	PT	Narrow	A	0	Active	10.0	14.0
Multiple lentiginos syndrome	10062901	PT	Narrow	A	0	Active	10.0	14.0
Muscular dystrophy	10028356	PT	Narrow	A	0	Active	10.0	14.0
Mutagenic effect	10028400	PT	Narrow	A	0	Active	10.0	14.0
Myeloperoxidase deficiency	10074767	PT	Narrow	A	0	Active	17.0	17.0
MYH9-related disease	10079437	PT	Narrow	A	0	Active	20.0	20.0
Myocardial bridging	10052289	PT	Narrow	A	0	Active	10.0	14.0
Myoclonic epilepsy and ragged-red fibres	10069825	PT	Narrow	A	0	Active	13.0	14.0
Myotonia congenita	10028655	PT	Narrow	A	0	Active	10.0	14.0
Myotonic dystrophy	10068871	PT	Narrow	A	0	Active	12.0	14.0
N-acetylglutamate synthase deficiency	10071092	PT	Narrow	A	0	Active	14.0	14.0
Naevus anaemicus	10069365	PT	Narrow	A	0	Active	12.1	14.0
Naevus flammeus	10067193	PT	Narrow	A	0	Active	10.0	14.0
Naevus spider congenital	10050896	PT	Narrow	A	0	Active	10.0	14.0
Nail aplasia	10079732	PT	Narrow	A	0	Active	20.1	20.1
Nail-patella syndrome	10063431	PT	Narrow	A	0	Active	10.0	14.0
Nasopharyngeal atresia	10069701	PT	Narrow	A	0	Active	13.0	14.0
Neonatal alloimmune thrombocytopenia	10075149	PT	Narrow	A	0	Active	17.1	17.1
Neonatal haemochromatosis	10078355	PT	Narrow	A	0	Active	19.1	19.1
Neonatal leukaemia	10028958	PT	Narrow	A	0	Active	11.1	14.0
Neonatal lupus erythematosus	10057887	PT	Narrow	A	0	Active	10.0	14.0
Netherton's syndrome	10062909	PT	Narrow	A	0	Active	10.0	14.0
Neural tube defect	10052046	PT	Narrow	A	0	Active	10.0	14.0
Neurofibromatosis	10029268	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Neuronal ceroid lipofuscinosis	10074607	PT	Narrow	A	0	Active	17.0	17.0
Neuronal migration disorder	10076677	PT	Narrow	A	0	Active	18.1	18.1
Neuropathy, ataxia, retinitis pigmentosa syndrome	10062940	PT	Narrow	A	0	Active	10.0	14.0
Niemann-Pick disease	10029403	PT	Narrow	A	0	Active	10.0	14.0
Nijmegen breakage syndrome	10067857	PT	Narrow	A	0	Active	11.0	14.0
Non-compaction cardiomyopathy	10079253	PT	Narrow	A	0	Active	20.0	20.0
Nonketotic hyperglycinaemia	10070639	PT	Narrow	A	0	Active	13.1	14.0
Noonan syndrome	10029748	PT	Narrow	A	0	Active	10.0	14.0
Norrie's disease	10069760	PT	Narrow	A	0	Active	13.0	14.0
Ocular albinism	10065276	PT	Narrow	A	0	Active	10.0	14.0
Oculoauriculovertebral dysplasia	10051934	PT	Narrow	A	0	Active	10.0	14.0
Oculocerebrorenal syndrome	10051707	PT	Narrow	A	0	Active	10.0	14.0
Oculodentodigital dysplasia	10063691	PT	Narrow	A	0	Active	10.0	14.0
Oculopharyngeal dystrophy	10052181	PT	Narrow	A	0	Active	10.0	14.0
Odontogenic cyst	10063413	PT	Narrow	A	0	Active	10.0	14.0
Oesophageal atresia	10030146	PT	Narrow	A	0	Active	10.0	14.0
Oesophageal cyst	10079063	PT	Narrow	A	0	Active	20.0	20.0
Olfacto genital dysplasia	10053142	PT	Narrow	A	0	Active	10.0	14.0
Olfactory nerve agenesis	10072941	PT	Narrow	A	0	Active	16.0	16.0
Olmsted syndrome	10068842	PT	Narrow	A	0	Active	12.0	14.0
Omenn syndrome	10069097	PT	Narrow	A	0	Active	12.0	14.0
Opitz-G/BBB syndrome	10079435	PT	Narrow	A	0	Active	20.0	20.0
Optic disc pit	10079967	PT	Narrow	A	0	Active	20.1	20.1
Optic nerve hypoplasia	10062942	PT	Narrow	A	0	Active	10.0	14.0
Oral-facial-digital syndrome type II	10078419	PT	Narrow	A	0	Active	19.1	19.1
Ornithine transcarbamoylase deficiency	10052450	PT	Narrow	A	0	Active	10.0	14.0
Oroticaciduria congenital	10052773	PT	Narrow	A	0	Active	10.0	14.0
Os trigonum	10069805	PT	Narrow	A	0	Active	13.0	14.0
Osteogenesis imperfecta	10031243	PT	Narrow	A	0	Active	10.0	14.0
Osteopathia striata	10073776	PT	Narrow	A	0	Active	16.1	16.1

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Osteopetrosis	10031280	PT	Narrow	A	0	Active	10.0	14.0
Osteopoikilosis	10031281	PT	Narrow	A	0	Active	10.0	14.0
Osteoporosis-pseudoglioma syndrome	10052452	PT	Narrow	A	0	Active	10.0	14.0
Ota's naevus	10051713	PT	Narrow	A	0	Active	10.0	14.0
Otocephaly	10058118	PT	Narrow	A	0	Active	10.0	14.0
Ovarian agenesis	10033120	PT	Narrow	A	0	Active	10.0	14.0
Ovarian hypoplasia	10079495	PT	Narrow	A	0	Active	20.0	20.0
Pachydermoperiostosis	10051686	PT	Narrow	A	0	Active	10.0	14.0
Pachygyria	10048910	PT	Narrow	A	0	Active	10.0	14.0
Pachyonychia congenita	10080088	PT	Narrow	A	0	Active	20.1	20.1
Pallister-Killian syndrome	10080297	PT	Narrow	A	0	Active	20.1	20.1
Pancreas divisum	10069419	PT	Narrow	A	0	Active	12.1	14.0
Parachute mitral valve	10064192	PT	Narrow	A	0	Active	10.0	14.0
Paranasal sinus aplasia	10074401	PT	Narrow	A	0	Active	17.0	17.0
Parkes-Weber syndrome	10075554	PT	Narrow	A	0	Active	18.0	18.0
Patent ductus arteriosus	10034130	PT	Narrow	A	0	Active	10.0	14.0
Pearson's syndrome	10062941	PT	Narrow	A	0	Active	10.0	14.0
Pectus carinatum	10034203	PT	Narrow	A	0	Active	10.0	14.0
Pectus excavatum	10034204	PT	Narrow	A	0	Active	10.0	14.0
Pelizaeus-Merzbacher disease	10067610	PT	Narrow	A	0	Active	10.1	14.0
Pelvic kidney	10034259	PT	Narrow	A	0	Active	10.0	14.0
Penile torsion	10070235	PT	Narrow	A	0	Active	13.0	14.0
Penoscrotal fusion	10064951	PT	Narrow	A	0	Active	10.0	14.0
Penoscrotal transposition	10067287	PT	Narrow	A	0	Active	10.0	14.0
Periodontal congenital anomaly	10057476	PT	Narrow	A	0	Active	10.0	14.0
Periventricular nodular heterotopia	10066854	PT	Narrow	A	0	Active	10.0	14.0
Perry syndrome	10079207	PT	Narrow	A	0	Active	20.0	20.0
Persistent cloaca	10069442	PT	Narrow	A	0	Active	12.1	14.0
Persistent foetal circulation	10034708	PT	Narrow	A	0	Active	10.0	14.0
Persistent left superior vena cava	10064193	PT	Narrow	A	0	Active	10.0	14.0



Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Persistent pupillary membrane	10070872	PT	Narrow	A	0	Active	14.0	14.0
Persistent urogenital sinus	10059800	PT	Narrow	A	0	Active	10.0	14.0
Peutz-Jeghers syndrome	10034764	PT	Narrow	A	0	Active	10.0	14.0
PHACES syndrome	10068032	PT	Narrow	A	0	Active	11.0	14.0
Phakomatosis	10048734	PT	Narrow	A	0	Active	10.0	14.0
Phalangeal agenesis	10054879	PT	Narrow	A	0	Active	10.0	14.0
Phalangeal hypoplasia	10049212	PT	Narrow	A	0	Active	10.0	14.0
Phenylketonuria	10034872	PT	Narrow	A	0	Active	10.0	14.0
Phimosis	10034878	PT	Narrow	A	0	Active	10.0	14.0
Phytosterolaemia	10063985	PT	Narrow	A	0	Active	10.0	14.0
Pierre Robin syndrome	10035009	PT	Narrow	A	0	Active	10.0	14.0
Pilonidal cyst congenital	10054019	PT	Narrow	A	0	Active	10.0	14.0
Plagiocephaly	10048586	PT	Narrow	A	0	Active	10.0	14.0
Platelet glycoprotein gene mutation	10071024	PT	Narrow	A	0	Active	14.0	14.0
Platonychia	10072590	PT	Narrow	A	0	Active	15.1	15.1
Platybasia	10057115	PT	Narrow	A	0	Active	10.0	14.0
Platyspondylia	10068629	PT	Narrow	A	0	Active	11.1	14.0
Poland's syndrome	10036007	PT	Narrow	A	0	Active	10.0	14.0
Polycystic liver disease	10048834	PT	Narrow	A	0	Active	10.0	14.0
Polydactyly	10036063	PT	Narrow	A	0	Active	10.0	14.0
Polymicrogyria	10073489	PT	Narrow	A	0	Active	16.0	16.0
Popliteal pterygium syndrome	10079892	PT	Narrow	A	0	Active	20.1	20.1
Porencephaly	10036172	PT	Narrow	A	0	Active	10.0	14.0
Porokeratosis	10036175	PT	Narrow	A	0	Active	10.0	14.0
Porphyria	10036181	PT	Narrow	A	0	Active	10.0	14.0
Porphyria acute	10036182	PT	Narrow	A	0	Active	10.0	14.0
Porphyria non-acute	10036186	PT	Narrow	A	0	Active	10.0	14.0
Porphyrin metabolism disorder	10061356	PT	Narrow	A	0	Active	10.0	14.0
Porphyria	10036193	PT	Narrow	A	0	Active	10.0	14.0
Portal venous system anomaly	10076609	PT	Narrow	A	0	Active	18.1	18.1

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Postauricular fistula	10036329	PT	Narrow	A	0	Active	10.0	14.0
Posterior segment of eye anomaly congenital	10053202	PT	Narrow	A	0	Active	10.0	14.0
Potter's syndrome	10036462	PT	Narrow	A	0	Active	10.0	14.0
Prader-Willi syndrome	10036476	PT	Narrow	A	0	Active	10.0	14.0
Preauricular cyst	10036509	PT	Narrow	A	0	Active	10.0	14.0
Preduodenal portal vein	10059798	PT	Narrow	A	0	Active	10.0	14.0
Preternatural anus	10064917	PT	Narrow	A	0	Active	10.0	14.0
Primary cerebellar degeneration	10036686	PT	Narrow	A	0	Active	10.0	14.0
Primary ciliary dyskinesia	10069713	PT	Narrow	A	0	Active	13.0	14.0
Primary familial brain calcification	10078822	PT	Narrow	A	0	Active	20.0	20.0
Primary familial hypomagnesaemia	10076626	PT	Narrow	A	0	Active	18.1	18.1
Primary hypercholesterolaemia	10077965	PT	Narrow	A	0	Active	19.0	19.0
Primary immunodeficiency syndrome	10064859	PT	Narrow	A	0	Active	10.0	14.0
Primary insulin like growth factor-1 deficiency	10071079	PT	Narrow	A	0	Active	14.0	14.0
Progeria	10036794	PT	Narrow	A	0	Active	10.0	14.0
Progressive cerebellar degeneration	10036801	PT	Narrow	A	0	Active	10.0	14.0
Progressive external ophthalmoplegia	10036802	PT	Narrow	A	0	Active	10.0	14.0
Progressive familial intrahepatic cholestasis	10076033	PT	Narrow	A	0	Active	18.0	18.0
Prominent epicanthal folds	10065273	PT	Narrow	A	0	Active	10.0	14.0
Protein C deficiency	10051298	PT	Narrow	A	0	Active	10.0	14.0
Protein S deficiency	10051292	PT	Narrow	A	0	Active	10.0	14.0
Proteus syndrome	10074067	PT	Narrow	A	0	Active	16.1	16.1
Protuberant ear	10071232	PT	Narrow	A	0	Active	14.1	14.1
Proximal focal femoral deficiency	10078473	PT	Narrow	A	0	Active	19.1	19.1
Pseudocholinesterase deficiency	10062674	PT	Narrow	A	0	Active	10.0	14.0
Pseudohermaphroditism	10037122	PT	Narrow	A	0	Active	10.0	14.0
Pseudohermaphroditism female	10037123	PT	Narrow	A	0	Active	10.0	14.0
Pseudohermaphroditism male	10037124	PT	Narrow	A	0	Active	10.0	14.0
Pseudohypoparathyroidism	10037126	PT	Narrow	A	0	Active	10.0	14.0
Pseudotruncus arteriosus	10050053	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Pseudoxanthoma elasticum	10037150	PT	Narrow	A	0	Active	10.0	14.0
Pterygium colli	10051972	PT	Narrow	A	0	Active	10.0	14.0
Pulmonary aplasia	10037322	PT	Narrow	A	0	Active	10.0	14.0
Pulmonary arteriovenous fistula	10037332	PT	Narrow	A	0	Active	10.0	14.0
Pulmonary artery atresia	10037337	PT	Narrow	A	0	Active	10.0	14.0
Pulmonary artery stenosis congenital	10037339	PT	Narrow	A	0	Active	10.0	14.0
Pulmonary hypoplasia	10037407	PT	Narrow	A	0	Active	10.0	14.0
Pulmonary lymphangiectasia	10073661	PT	Narrow	A	0	Active	16.1	16.1
Pulmonary malformation	10037419	PT	Narrow	A	0	Active	10.0	14.0
Pulmonary sequestration	10059160	PT	Narrow	A	0	Active	10.0	14.0
Pulmonary valve stenosis congenital	10037451	PT	Narrow	A	0	Active	10.0	14.0
Pyloric stenosis	10037621	PT	Narrow	A	0	Active	10.0	14.0
Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome	10072222	PT	Narrow	A	0	Active	15.0	15.0
Pyruvate carboxylase deficiency	10077944	PT	Narrow	A	0	Active	19.0	19.0
Pyruvate kinase deficiency anaemia	10037682	PT	Narrow	A	0	Active	10.0	14.0
Radioulnar synostosis	10037798	PT	Narrow	A	0	Active	10.0	14.0
Rathke's cleft cyst	10058969	PT	Narrow	A	0	Active	10.0	14.0
Rectal atresia	10038031	PT	Narrow	A	0	Active	10.0	14.0
Red blood cell enzymes abnormal	10049191	PT	Narrow	A	0	Active	10.0	14.0
Refsum's disease	10038275	PT	Narrow	A	0	Active	10.0	14.0
Renal aplasia	10064655	PT	Narrow	A	0	Active	10.0	14.0
Renal arteriovenous malformation	10038368	PT	Narrow	A	0	Active	10.0	14.0
Renal dysplasia	10038433	PT	Narrow	A	0	Active	10.0	14.0
Renal fusion anomaly	10068033	PT	Narrow	A	0	Active	11.0	14.0
Renal hypoplasia	10049102	PT	Narrow	A	0	Active	10.0	14.0
Renal malposition	10072019	PT	Narrow	A	0	Active	15.0	15.0
Renal vessel congenital anomaly	10038552	PT	Narrow	A	0	Active	10.0	14.0
Reproductive tract hypoplasia, male	10057858	PT	Narrow	A	0	Active	10.0	14.0
Respiratory tract malformation	10038733	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Retinal anomaly congenital	10038821	PT	Narrow	A	0	Active	10.0	14.0
Retinal arteriovenous malformation	10038824	PT	Narrow	A	0	Active	10.0	14.0
Retinal coloboma	10052643	PT	Narrow	A	0	Active	10.0	14.0
Retinitis pigmentosa	10038914	PT	Narrow	A	0	Active	10.0	14.0
Retinopathy congenital	10050706	PT	Narrow	A	0	Active	10.0	14.0
Retinoschisis congenital	10038938	PT	Narrow	A	0	Active	10.0	14.0
Rett syndrome	10077709	PT	Narrow	A	0	Active	19.0	19.0
Rhesus haemolytic disease of newborn	10039037	PT	Narrow	A	0	Active	10.0	14.0
Rib hypoplasia	10048893	PT	Narrow	A	0	Active	10.0	14.0
Rib synostosis	10076624	PT	Narrow	A	0	Active	18.1	18.1
Right aortic arch	10067407	PT	Narrow	A	0	Active	10.1	14.0
Right ventricle outflow tract obstruction	10064195	PT	Narrow	A	0	Active	10.0	14.0
Right ventricular false tendon	10080132	PT	Narrow	A	0	Active	20.1	20.1
Right-to-left cardiac shunt	10076605	PT	Narrow	A	0	Active	18.1	18.1
Riley-Day syndrome	10039179	PT	Narrow	A	0	Active	10.0	14.0
Rippling muscle disease	10069417	PT	Narrow	A	0	Active	12.1	14.0
Rotor's syndrome	10039234	PT	Narrow	A	0	Active	10.0	14.0
Rubinstein-Taybi syndrome	10039281	PT	Narrow	A	0	Active	10.0	14.0
Sacral hypoplasia	10056659	PT	Narrow	A	0	Active	10.0	14.0
Sacralisation	10064932	PT	Narrow	A	0	Active	10.0	14.0
Sarcosinaemia	10059299	PT	Narrow	A	0	Active	10.0	14.0
Scaphocephaly	10049426	PT	Narrow	A	0	Active	10.0	14.0
Schimke immunoosseous dysplasia	10048699	PT	Narrow	A	0	Active	10.0	14.0
Schinzel-Giedion syndrome	10063540	PT	Narrow	A	0	Active	10.0	14.0
Schizencephaly	10073487	PT	Narrow	A	0	Active	16.0	16.0
Scimitar syndrome	10051951	PT	Narrow	A	0	Active	10.0	14.0
Sclerolylosis	10070504	PT	Narrow	A	0	Active	13.1	14.0
Sebaceous naevus	10039785	PT	Narrow	A	0	Active	10.0	14.0
Sensory neuropathy hereditary	10040037	PT	Narrow	A	0	Active	10.0	14.0
Septate hymen	10068484	PT	Narrow	A	0	Active	15.0	15.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Septo-optic dysplasia	10067159	PT	Narrow	A	0	Active	10.0	14.0
Septum pellucidum agenesis	10062267	PT	Narrow	A	0	Active	10.0	14.0
Sertoli-cell-only syndrome	10066833	PT	Narrow	A	0	Active	10.0	14.0
Severe myoclonic epilepsy of infancy	10073677	PT	Narrow	A	0	Active	16.1	16.1
Sex chromosome abnormality	10061513	PT	Narrow	A	0	Active	10.0	14.0
Shone complex	10066802	PT	Narrow	A	0	Active	10.0	14.0
Short-chain acyl-coenzyme A dehydrogenase deficiency	10072655	PT	Narrow	A	0	Active	15.1	15.1
Shwachman-Diamond syndrome	10067940	PT	Narrow	A	0	Active	11.0	14.0
Sickle cell anaemia	10040641	PT	Narrow	A	0	Active	10.0	14.0
Sickle cell trait	10040650	PT	Narrow	A	0	Active	10.0	14.0
Silver-Russell syndrome	10062282	PT	Narrow	A	0	Active	10.0	14.0
Single umbilical artery	10049807	PT	Narrow	A	0	Active	10.0	14.0
Sirenomelia	10072457	PT	Narrow	A	0	Active	15.1	15.1
Sjogren-Larsson syndrome	10048676	PT	Narrow	A	0	Active	10.0	14.0
Skeletal dysplasia	10072610	PT	Narrow	A	0	Active	15.1	15.1
Skin hypoplasia	10040869	PT	Narrow	A	0	Active	10.0	14.0
Skin malformation	10040888	PT	Narrow	A	0	Active	10.0	14.0
Skull malformation	10062348	PT	Narrow	A	0	Active	10.0	14.0
Smith-Lemli-Opitz syndrome	10078573	PT	Narrow	A	0	Active	19.1	19.1
Sotos' syndrome	10064387	PT	Narrow	A	0	Active	10.0	14.0
Special senses congenital anomaly	10041420	PT	Narrow	A	0	Active	10.0	14.0
Spherophakia	10041513	PT	Narrow	A	0	Active	10.0	14.0
Spina bifida	10041524	PT	Narrow	A	0	Active	10.0	14.0
Spina bifida cystica	10071011	PT	Narrow	A	0	Active	14.0	14.0
Spina bifida occulta	10041525	PT	Narrow	A	0	Active	10.0	14.0
Spinal muscular atrophy	10041582	PT	Narrow	A	0	Active	11.0	14.0
Spinal vessel congenital anomaly	10041603	PT	Narrow	A	0	Active	10.0	14.0
Spine malformation	10041611	PT	Narrow	A	0	Active	10.0	14.0
Spinocerebellar ataxia	10057660	PT	Narrow	A	0	Active	10.1	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Spleen malformation	10062350	PT	Narrow	A	0	Active	10.0	14.0
Splenic hamartoma	10076586	PT	Narrow	A	0	Active	18.1	18.1
Spondyloepiphyseal dysplasia	10062920	PT	Narrow	A	0	Active	10.0	14.0
Stargardt's disease	10062766	PT	Narrow	A	0	Active	10.0	14.0
Steatocystoma multiplex	10048905	PT	Narrow	A	0	Active	10.0	14.0
Stickler's syndrome	10063402	PT	Narrow	A	0	Active	10.0	14.0
Sticky platelet syndrome	10068788	PT	Narrow	A	0	Active	12.0	14.0
Strabismus congenital	10042161	PT	Narrow	A	0	Active	10.0	14.0
Sturge-Weber syndrome	10042265	PT	Narrow	A	0	Active	10.0	14.0
Subependymal nodular heterotopia	10071150	PT	Narrow	A	0	Active	14.0	14.0
Sucrase-isomaltase deficiency	10066387	PT	Narrow	A	0	Active	10.0	14.0
Supernumerary nipple	10042571	PT	Narrow	A	0	Active	10.0	14.0
Supernumerary vertebra	10077919	PT	Narrow	A	0	Active	19.0	19.0
Syndactyly	10042778	PT	Narrow	A	0	Active	10.0	14.0
Synostosis	10042856	PT	Narrow	A	0	Active	18.1	18.1
Syringomyelia	10042928	PT	Narrow	A	0	Active	15.1	15.1
Talipes	10043101	PT	Narrow	A	0	Active	10.0	14.0
Tangier disease	10051875	PT	Narrow	A	0	Active	10.0	14.0
Tay-Sachs disease	10043147	PT	Narrow	A	0	Active	10.0	14.0
Telangiectasia congenital	10061575	PT	Narrow	A	0	Active	10.0	14.0
Teratogenicity	10043275	PT	Narrow	A	0	Active	10.0	14.0
Testicular dysplasia	10059271	PT	Narrow	A	0	Active	10.0	14.0
Testotoxicosis	10063654	PT	Narrow	A	0	Active	10.0	14.0
Tetrahydrobiopterin deficiency	10069116	PT	Narrow	A	0	Active	12.0	14.0
Thalassaemia	10043388	PT	Narrow	A	0	Active	10.0	14.0
Thalassaemia alpha	10043390	PT	Narrow	A	0	Active	10.0	14.0
Thalassaemia beta	10043391	PT	Narrow	A	0	Active	10.0	14.0
Thalassaemia sickle cell	10043395	PT	Narrow	A	0	Active	10.0	14.0
Thalidomide embryopathy	10071249	PT	Narrow	A	0	Active	14.1	14.1
Thanatophoric dwarfism	10049808	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Thrombocytopenia-absent radius syndrome	10071719	PT	Narrow	A	0	Active	14.1	14.1
Thymus hypoplasia	10052645	PT	Narrow	A	0	Active	10.0	14.0
Thyroglossal cyst	10051320	PT	Narrow	A	0	Active	10.0	14.0
Thyroglossal fistula	10062601	PT	Narrow	A	0	Active	10.0	14.0
Thyroid hemiagenesis	10077609	PT	Narrow	A	0	Active	19.0	19.0
Thyroid malformation	10062125	PT	Narrow	A	0	Active	10.0	14.0
Tibial agenesis	10079730	PT	Narrow	A	0	Active	20.1	20.1
Tibial torsion	10064515	PT	Narrow	A	0	Active	10.0	14.0
Tilted disc syndrome	10079368	PT	Narrow	A	0	Active	20.0	20.0
Timothy syndrome	10079205	PT	Narrow	A	0	Active	20.0	20.0
Tooth discolouration congenital	10044033	PT	Narrow	A	0	Active	10.0	14.0
Tooth hypoplasia	10044041	PT	Narrow	A	0	Active	10.0	14.0
Tooth malformation hereditary	10044047	PT	Narrow	A	0	Active	10.0	14.0
Tornwaldt cyst	10078492	PT	Narrow	A	0	Active	19.1	19.1
Tourette's disorder	10044126	PT	Narrow	A	0	Active	10.0	14.0
Tracheal atresia	10054955	PT	Narrow	A	0	Active	10.0	14.0
Tracheal web	10077940	PT	Narrow	A	0	Active	19.0	19.0
Tracheo-oesophageal fistula	10044310	PT	Narrow	A	0	Active	10.0	14.0
Transitional vertebrae	10074306	PT	Narrow	A	0	Active	17.0	17.0
Transposition of the great vessels	10044443	PT	Narrow	A	0	Active	10.0	14.0
Trichorhinophalangeal syndrome	10051956	PT	Narrow	A	0	Active	10.0	14.0
Trifunctional protein deficiency	10077949	PT	Narrow	A	0	Active	19.0	19.0
Trimethylaminuria	10068233	PT	Narrow	A	0	Active	11.0	14.0
Triple A syndrome	10073592	PT	Narrow	A	0	Active	16.1	16.1
Trisomy 11	10044685	PT	Narrow	A	0	Active	10.0	14.0
Trisomy 12	10063092	PT	Narrow	A	0	Active	10.0	14.0
Trisomy 13	10044686	PT	Narrow	A	0	Active	10.0	14.0
Trisomy 14	10071762	PT	Narrow	A	0	Active	15.0	15.0
Trisomy 15	10062757	PT	Narrow	A	0	Active	10.0	14.0
Trisomy 17	10053925	PT	Narrow	A	0	Active	10.0	14.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Trisomy 18	10053884	PT	Narrow	A	0	Active	10.0	14.0
Trisomy 21	10044688	PT	Narrow	A	0	Active	10.0	14.0
Trisomy 22	10044689	PT	Narrow	A	0	Active	10.0	14.0
Trisomy 4p	10080079	PT	Narrow	A	0	Active	20.1	20.1
Trisomy 8	10053871	PT	Narrow	A	0	Active	10.0	14.0
Trisomy 9	10071547	PT	Narrow	A	0	Active	14.1	14.1
Truncus arteriosus persistent	10044703	PT	Narrow	A	0	Active	10.0	14.0
Tuberous sclerosis	10045138	PT	Narrow	A	0	Active	10.0	14.0
Tumour necrosis factor receptor-associated periodic syndrome	10067774	PT	Narrow	A	0	Active	11.0	14.0
Turner's syndrome	10045181	PT	Narrow	A	0	Active	10.0	14.0
Twin reversed arterial perfusion sequence malformation	10073455	PT	Narrow	A	0	Active	16.0	16.0
Type I hyperlipidaemia	10060749	PT	Narrow	A	0	Active	10.0	14.0
Type II hyperlipidaemia	10045254	PT	Narrow	A	0	Active	10.0	14.0
Type IIa hyperlipidaemia	10045261	PT	Narrow	A	0	Active	10.0	14.0
Type IIb hyperlipidaemia	10045263	PT	Narrow	A	0	Active	10.0	14.0
Type III hyperlipidaemia	10060751	PT	Narrow	A	0	Active	10.0	14.0
Type IV hyperlipidaemia	10060753	PT	Narrow	A	0	Active	10.0	14.0
Type V hyperlipidaemia	10060755	PT	Narrow	A	0	Active	10.0	14.0
Tyrosinaemia	10063443	PT	Narrow	A	0	Active	10.0	14.0
Uhl's anomaly	10048951	PT	Narrow	A	0	Active	10.0	14.0
Umbilical artery hypoplasia	10045445	PT	Narrow	A	0	Active	10.0	14.0
Umbilical malformation	10045469	PT	Narrow	A	0	Active	10.0	14.0
Univentricular heart	10045545	PT	Narrow	A	0	Active	10.0	14.0
Urachal abnormality	10066125	PT	Narrow	A	0	Active	10.0	14.0
Urea cycle disorder	10080020	PT	Narrow	A	0	Active	20.1	20.1
Ureteric atresia	10078351	PT	Narrow	A	0	Active	19.1	19.1
Urethral atresia	10064895	PT	Narrow	A	0	Active	10.0	14.0
Urethral valves	10046479	PT	Narrow	A	0	Active	10.0	14.0



<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Urinary tract malformation	10046580	PT	Narrow	A	0	Active	10.0	14.0
Usher's syndrome	10063396	PT	Narrow	A	0	Active	10.0	14.0
Uterine aplasia	10067704	PT	Narrow	A	0	Active	10.1	14.0
Uterine cervix hypoplasia	10063120	PT	Narrow	A	0	Active	10.0	14.0
Uterine hypoplasia	10063146	PT	Narrow	A	0	Active	10.0	14.0
Uvula aplasia	10053506	PT	Narrow	A	0	Active	10.0	14.0
VACTERL syndrome	10066022	PT	Narrow	A	0	Active	10.0	14.0
Vaginal atresia	10046879	PT	Narrow	A	0	Active	10.0	14.0
Vaginal hypoplasia	10053843	PT	Narrow	A	0	Active	10.0	14.0
Vaginal septum	10064513	PT	Narrow	A	0	Active	10.0	14.0
Vascular malformation	10074979	PT	Narrow	A	0	Active	17.1	17.1
Vein of Galen aneurysmal malformation	10077889	PT	Narrow	A	0	Active	19.0	19.0
Velo-cardio-facial syndrome	10066430	PT	Narrow	A	0	Active	10.0	14.0
Venolymphatic malformation	10079880	PT	Narrow	A	0	Active	20.1	20.1
Venous angioma of brain	10053485	PT	Narrow	A	0	Active	10.0	14.0
Ventricular hypoplasia	10047296	PT	Narrow	A	0	Active	10.0	14.0
Ventricular septal defect	10047298	PT	Narrow	A	0	Active	10.0	14.0
Vertebral artery hypoplasia	10066907	PT	Narrow	A	0	Active	10.0	14.0
Vertical talus	10066242	PT	Narrow	A	0	Active	10.0	14.0
Very long-chain acyl-coenzyme A dehydrogenase deficiency	10072656	PT	Narrow	A	0	Active	15.1	15.1
Virilism foetal	10047487	PT	Narrow	A	0	Active	10.0	14.0
Vitello-intestinal duct remnant	10066969	PT	Narrow	A	0	Active	10.0	14.0
Von Hippel-Lindau disease	10047716	PT	Narrow	A	0	Active	10.0	14.0
Von Willebrand's disease	10047715	PT	Narrow	A	0	Active	10.0	14.0
Waardenburg syndrome	10069203	PT	Narrow	A	0	Active	12.0	14.0
Wagner's disease	10063383	PT	Narrow	A	0	Active	10.0	14.0
Weill-Marchesani syndrome	10064963	PT	Narrow	A	0	Active	10.0	14.0
Welander distal myopathy	10078052	PT	Narrow	A	0	Active	19.0	19.0
Werner's syndrome	10049429	PT	Narrow	A	0	Active	10.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Wildervanck syndrome	10069402	PT	Narrow	A	0	Active	12.1	14.0
Williams syndrome	10049644	PT	Narrow	A	0	Active	10.0	14.0
Winchester syndrome	10078901	PT	Narrow	A	0	Active	20.0	20.0
Wiskott-Aldrich syndrome	10047992	PT	Narrow	A	0	Active	10.0	14.0
Wolff-Parkinson-White syndrome congenital	10049291	PT	Narrow	A	0	Active	10.0	14.0
Wolf-Hirschhorn syndrome	10050361	PT	Narrow	A	0	Active	10.0	14.0
Wolfram syndrome	10078338	PT	Narrow	A	0	Active	19.1	19.1
Wyburn Mason's syndrome	10048661	PT	Narrow	A	0	Active	10.0	14.0
Xeroderma pigmentosum	10048220	PT	Narrow	A	0	Active	10.0	14.0
X-linked chromosomal disorder	10056554	PT	Narrow	A	0	Active	10.0	14.0
X-linked lymphoproliferative syndrome	10068348	PT	Narrow	A	0	Active	11.1	14.0
XXX syndrome	10076910	PT	Narrow	A	0	Active	18.1	18.1
XXXY syndrome	10048228	PT	Narrow	A	0	Active	10.0	14.0
XXYY syndrome	10048230	PT	Narrow	A	0	Active	10.0	14.0
XYY syndrome	10056894	PT	Narrow	A	0	Active	10.0	14.0
Y-linked chromosomal disorder	10056555	PT	Narrow	A	0	Active	10.0	14.0
Young's syndrome	10063689	PT	Narrow	A	0	Active	10.0	14.0

**Foetal disorders (SMQ) [20000190]**

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Alpha 1 foetoprotein amniotic fluid abnormal	10001776	PT	Narrow	A	0	Active	14.0	14.0
Alpha 1 foetoprotein amniotic fluid decreased	10060746	PT	Narrow	A	0	Active	14.0	14.0
Alpha 1 foetoprotein amniotic fluid increased	10001778	PT	Narrow	A	0	Active	14.0	14.0
Amniocentesis abnormal	10001959	PT	Narrow	A	0	Active	14.0	14.0
Amniorrhexis	10051641	PT	Narrow	A	0	Active	14.0	14.0
Amniorrhea	10066470	PT	Narrow	A	0	Active	14.0	14.0
Amnioscopy abnormal	10001965	PT	Narrow	A	0	Active	14.0	14.0
Amniotic cavity disorder	10060936	PT	Narrow	A	0	Active	14.0	14.0
Amniotic cavity infection	10060937	PT	Narrow	A	0	Active	14.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Amniotic fluid erythropoietin level increased	10064845	PT	Narrow	A	0	Active	14.0	14.0
Amniotic fluid index abnormal	10067079	PT	Narrow	A	0	Active	14.0	14.0
Amniotic fluid volume decreased	10063356	PT	Narrow	A	0	Active	14.0	14.0
Amniotic fluid volume increased	10063357	PT	Narrow	A	0	Active	14.0	14.0
Amniotic infection syndrome of Blane	10051407	PT	Narrow	A	0	Active	14.0	14.0
Anaesthetic complication foetal	10052850	PT	Narrow	A	0	Active	14.0	14.0
Angiotensin converting enzyme inhibitor foetopathy	10051098	PT	Narrow	A	0	Active	14.0	14.0
Baseline foetal heart rate variability disorder	10074638	PT	Narrow	A	0	Active	17.0	17.0
Biopsy chorionic villous abnormal	10048537	PT	Narrow	A	0	Active	14.0	14.0
Biopsy foetal abnormal	10058370	PT	Narrow	A	0	Active	14.0	14.0
Bradycardia foetal	10006094	PT	Narrow	A	0	Active	14.0	14.0
Cerebral haemorrhage foetal	10050157	PT	Narrow	A	0	Active	14.0	14.0
Cerebral infarction foetal	10008119	PT	Narrow	A	0	Active	14.0	14.0
Chronic villitis of unknown etiology	10072271	PT	Narrow	A	0	Active	15.0	15.0
Cordocentesis	10066447	PT	Narrow	A	0	Active	14.0	14.0
Diabetic foetopathy	10059116	PT	Narrow	A	0	Active	14.0	14.0
Diethylstilboestrol syndrome	10012780	PT	Narrow	A	0	Active	14.0	14.0
Discordant twin	10069150	PT	Narrow	A	0	Active	14.0	14.0
Ductus arteriosus stenosis foetal	10013808	PT	Narrow	A	0	Active	14.0	14.0
Erythroblastosis foetalis	10015251	PT	Narrow	A	0	Active	14.0	14.0
Foetal acidosis	10050347	PT	Narrow	A	0	Active	14.0	14.0
Foetal alcohol syndrome	10016845	PT	Narrow	A	0	Active	14.0	14.0
Foetal anaemia	10077577	PT	Narrow	A	0	Active	19.0	19.0
Foetal anticonvulsant syndrome	10066485	PT	Narrow	A	0	Active	14.0	14.0
Foetal arrhythmia	10016847	PT	Narrow	A	0	Active	14.0	14.0
Foetal biophysical profile score abnormal	10078124	PT	Narrow	A	0	Active	19.1	19.1
Foetal biophysical profile score equivocal	10078123	PT	Narrow	A	0	Active	19.1	19.1
Foetal cardiac disorder	10052088	PT	Narrow	A	0	Active	14.0	14.0
Foetal cerebrovascular disorder	10053601	PT	Narrow	A	0	Active	14.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Foetal chromosome abnormality	10064041	PT	Narrow	A	0	Active	14.0	14.0
Foetal compartment fluid collection	10077628	PT	Narrow	A	0	Active	19.0	19.0
Foetal cystic hygroma	10052011	PT	Narrow	A	0	Active	14.0	14.0
Foetal damage	10016852	PT	Narrow	A	0	Active	14.0	14.0
Foetal disorder	10061157	PT	Narrow	A	0	Active	14.0	14.0
Foetal distress syndrome	10016855	PT	Narrow	A	0	Active	14.0	14.0
Foetal gastrointestinal tract imaging abnormal	10077579	PT	Narrow	A	0	Active	19.0	19.0
Foetal growth abnormality	10077582	PT	Narrow	A	0	Active	19.0	19.0
Foetal growth restriction	10070531	PT	Narrow	A	0	Active	14.0	14.0
Foetal heart rate abnormal	10051139	PT	Narrow	A	0	Active	14.0	14.0
Foetal heart rate acceleration abnormality	10074642	PT	Narrow	A	0	Active	17.0	17.0
Foetal heart rate deceleration abnormality	10074636	PT	Narrow	A	0	Active	17.0	17.0
Foetal heart rate decreased	10051136	PT	Narrow	A	0	Active	14.0	14.0
Foetal heart rate disorder	10061158	PT	Narrow	A	0	Active	14.0	14.0
Foetal heart rate increased	10051138	PT	Narrow	A	0	Active	14.0	14.0
Foetal heart rate indeterminate	10079882	PT	Narrow	A	0	Active	20.1	20.1
Foetal hypokinesia	10068461	PT	Narrow	A	0	Active	14.0	14.0
Foetal macrosomia	10053700	PT	Narrow	A	0	Active	14.0	14.0
Foetal malformation	10060919	PT	Narrow	A	0	Active	14.0	14.0
Foetal malnutrition	10016862	PT	Narrow	A	0	Active	14.0	14.0
Foetal megacystis	10073660	PT	Narrow	A	0	Active	16.1	16.1
Foetal methotrexate syndrome	10071183	PT	Narrow	A	0	Active	14.0	14.0
Foetal monitoring abnormal	10071507	PT	Narrow	A	0	Active	14.1	14.1
Foetal movement disorder	10077576	PT	Narrow	A	0	Active	19.0	19.0
Foetal musculoskeletal imaging abnormal	10077580	PT	Narrow	A	0	Active	19.0	19.0
Foetal non-stress test abnormal	10071516	PT	Narrow	A	0	Active	15.1	15.1
Foetal placental thrombosis	10072240	PT	Narrow	A	0	Active	15.0	15.0
Foetal renal imaging abnormal	10077581	PT	Narrow	A	0	Active	19.0	19.0
Foetal renal impairment	10078987	PT	Narrow	A	0	Active	20.0	20.0
Foetal retinoid syndrome	10073720	PT	Narrow	A	0	Active	16.1	16.1

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Foetal tachyarrhythmia	10077575	PT	Narrow	A	0	Active	19.0	19.0
Foetal therapeutic procedure	10057294	PT	Narrow	A	0	Active	14.0	14.0
Foetal warfarin syndrome	10051445	PT	Narrow	A	0	Active	14.0	14.0
Foetal-maternal haemorrhage	10016871	PT	Narrow	A	0	Active	14.0	14.0
Gestational age test abnormal	10072479	PT	Narrow	A	0	Active	15.1	15.1
Haemorrhage foetal	10061191	PT	Narrow	A	0	Active	14.0	14.0
Hydrops foetalis	10020529	PT	Narrow	A	0	Active	14.0	14.0
Hypocalvaria	10073670	PT	Narrow	A	0	Active	16.1	16.1
Hypopituitarism foetal	10021068	PT	Narrow	A	0	Active	14.0	14.0
Intrauterine infection	10056254	PT	Narrow	A	0	Active	14.0	14.0
Maternal condition affecting foetus	10057673	PT	Narrow	A	0	Active	14.0	14.0
Maternal death affecting foetus	10026912	PT	Narrow	A	0	Active	14.0	14.0
Maternal drugs affecting foetus	10026923	PT	Narrow	A	0	Active	14.0	14.0
Maternal hypertension affecting foetus	10026924	PT	Narrow	A	0	Active	14.0	14.0
Meconium in amniotic fluid	10051133	PT	Narrow	A	0	Active	14.0	14.0
Meconium increased	10027059	PT	Narrow	A	0	Active	14.0	14.0
Meconium peritonitis	10058113	PT	Narrow	A	0	Active	14.0	14.0
Meconium stain	10057028	PT	Narrow	A	0	Active	14.0	14.0
Mirror syndrome	10068875	PT	Narrow	A	0	Active	14.0	14.0
Nonreassuring foetal heart rate pattern	10074641	PT	Narrow	A	0	Active	17.0	17.0
Oligohydramnios	10030289	PT	Narrow	A	0	Active	14.0	14.0
Omphalorrhexis	10064270	PT	Narrow	A	0	Active	14.0	14.0
Paternal drugs affecting foetus	10050425	PT	Narrow	A	0	Active	14.0	14.0
Polyhydramnios	10036079	PT	Narrow	A	0	Active	14.0	14.0
Prenatal screening test abnormal	10069151	PT	Narrow	A	0	Active	14.0	14.0
Radiation injury affecting foetus	10053602	PT	Narrow	A	0	Active	14.0	14.0
Sinusoidal foetal heart rate pattern	10074643	PT	Narrow	A	0	Active	17.0	17.0
Tachycardia foetal	10043074	PT	Narrow	A	0	Active	14.0	14.0
Thalidomide embryopathy	10071249	PT	Narrow	A	0	Active	14.1	14.1

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Twin reversed arterial perfusion sequence malformation	10073455	PT	Narrow	A	0	Active	16.0	16.0
Ultrasound antenatal screen abnormal	10045400	PT	Narrow	A	0	Active	14.0	14.0
Ultrasound foetal abnormal	10077578	PT	Narrow	A	0	Active	19.0	19.0
Umbilical cord abnormality	10048596	PT	Narrow	A	0	Active	14.0	14.0
Umbilical cord around neck	10045447	PT	Narrow	A	0	Active	14.0	14.0
Umbilical cord compression	10045451	PT	Narrow	A	0	Active	14.0	14.0
Umbilical cord cyst	10079122	PT	Narrow	A	0	Active	20.0	20.0
Umbilical cord haemorrhage	10064534	PT	Narrow	A	0	Active	14.0	14.0
Umbilical cord occlusion	10076714	PT	Narrow	A	0	Active	18.1	18.1
Umbilical cord prolapse	10045452	PT	Narrow	A	0	Active	14.0	14.0
Umbilical cord short	10045453	PT	Narrow	A	0	Active	14.0	14.0
Umbilical cord thrombosis	10071652	PT	Narrow	A	0	Active	14.1	14.1
Umbilical cord vascular disorder	10045454	PT	Narrow	A	0	Active	14.0	14.0
Vesicoamniotic shunt	10068236	PT	Narrow	A	0	Active	14.0	14.0
Virilism foetal	10047487	PT	Narrow	A	0	Active	14.0	14.0
Alpha 1 foetoprotein abnormal	10001773	PT	Broad	A	0	Active	14.0	14.0
Alpha 1 foetoprotein decreased	10001780	PT	Broad	A	0	Active	14.0	14.0
Alpha 1 foetoprotein increased	10001781	PT	Broad	A	0	Active	14.0	14.0

**Lactation related topics (incl neonatal exposure through breast milk) (SMQ) [20000187]**

**Functional lactation disorders (SMQ) [20000188]**

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Breast milk discolouration	10058665	PT	Narrow	A	0	Active	14.0	
Galactocele	10017590	PT	Narrow	A	0	Active	14.0	
Galactostasis	10060710	PT	Narrow	A	0	Active	14.0	
Lactation disorder	10061261	PT	Narrow	A	0	Active	14.0	
Lactation inhibition therapy	10069058	PT	Narrow	A	0	Active	14.0	
Lactation puerperal increased	10023671	PT	Narrow	A	0	Active	14.0	

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Lactation stimulation therapy	10079806	PT	Narrow	A	0	Active	20.1	
Mastitis	10026883	PT	Narrow	A	0	Active	17.0	
Mastitis bacterial	10065212	PT	Narrow	A	0	Active	17.0	
Mastitis fungal	10065211	PT	Narrow	A	0	Active	17.0	
Mastitis postpartum	10026889	PT	Narrow	A	0	Active	14.0	
Neonatal insufficient breast milk syndrome	10072188	PT	Narrow	A	0	Active	15.0	
Nipple infection	10029419	PT	Narrow	A	0	Active	14.0	
Nipple inflammation	10064043	PT	Narrow	A	0	Active	14.0	
Retracted nipple	10038944	PT	Narrow	A	0	Active	14.0	
Suppressed lactation	10042576	PT	Narrow	A	0	Active	14.0	
Viral mastitis	10074560	PT	Narrow	A	0	Active	17.0	

**Neonatal exposures via breast milk (SMQ) [20000189]**

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Exposure during breast feeding	10071402	PT	Narrow	A	0	Active	14.1	
Intoxication by breast feeding	10049999	PT	Narrow	A	0	Active	14.0	

**Neonatal disorders (SMQ) [20000191]**

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Acne infantile	10000507	PT	Narrow	A	0	Active	14.0	14.0
Adrenocortical insufficiency neonatal	10001391	PT	Narrow	A	0	Active	14.0	14.0
Agitation neonatal	10001500	PT	Narrow	A	0	Active	14.0	14.0
Alveolar capillary dysplasia	10077023	PT	Narrow	A	0	Active	18.1	18.1
Anaemia neonatal	10002068	PT	Narrow	A	0	Active	14.0	14.0
Anaesthetic complication neonatal	10052851	PT	Narrow	A	0	Active	14.0	14.0
Aorticopulmonary window repair	10066834	PT	Narrow	A	0	Active	14.0	14.0
Apgar score abnormal	10056850	PT	Narrow	A	0	Active	14.0	14.0
Apgar score low	10002944	PT	Narrow	A	0	Active	14.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Arrhythmia neonatal	10003124	PT	Narrow	A	0	Active	14.0	14.0
Arterial switch operation	10066129	PT	Narrow	A	0	Active	14.0	14.0
Atelectasis neonatal	10003599	PT	Narrow	A	0	Active	14.0	14.0
Atrial septal defect repair	10003667	PT	Narrow	A	0	Active	14.0	14.0
Atrial switch operation	10068964	PT	Narrow	A	0	Active	14.0	14.0
Balloon atrial septostomy	10064200	PT	Narrow	A	0	Active	14.0	14.0
Birth trauma	10004954	PT	Narrow	A	0	Active	14.0	14.0
Blood loss anaemia neonatal	10005644	PT	Narrow	A	0	Active	14.0	14.0
Bradycardia neonatal	10056471	PT	Narrow	A	0	Active	14.0	14.0
Breast engorgement in newborn	10006241	PT	Narrow	A	0	Active	14.0	14.0
Bronchopulmonary dysplasia	10006475	PT	Narrow	A	0	Active	14.0	14.0
Caput succedaneum	10056311	PT	Narrow	A	0	Active	14.0	14.0
Cardiac arrest neonatal	10007516	PT	Narrow	A	0	Active	14.0	14.0
Cardiomyopathy neonatal	10050111	PT	Narrow	A	0	Active	14.0	14.0
Cardio-respiratory arrest neonatal	10007618	PT	Narrow	A	0	Active	14.0	14.0
Cephalhaematoma	10008014	PT	Narrow	A	0	Active	14.0	14.0
Cerebral haemorrhage neonatal	10008112	PT	Narrow	A	0	Active	14.0	14.0
Circulatory failure neonatal	10009196	PT	Narrow	A	0	Active	14.0	14.0
Cleft lip repair	10056999	PT	Narrow	A	0	Active	14.0	14.0
Cleft palate repair	10009272	PT	Narrow	A	0	Active	14.0	14.0
Coagulation disorder neonatal	10009732	PT	Narrow	A	0	Active	14.0	14.0
Collodion baby	10009926	PT	Narrow	A	0	Active	16.1	16.1
Coma neonatal	10059497	PT	Narrow	A	0	Active	14.0	14.0
Convulsion neonatal	10010911	PT	Narrow	A	0	Active	14.0	14.0
Coxsackie viral disease of the newborn	10011260	PT	Narrow	A	0	Active	14.0	14.0
Cranial nerve injury secondary to birth trauma	10011308	PT	Narrow	A	0	Active	14.0	14.0
Cranial sutures widening	10058604	PT	Narrow	A	0	Active	14.0	14.0
Cyanosis neonatal	10011705	PT	Narrow	A	0	Active	14.0	14.0
Death neonatal	10011912	PT	Narrow	A	0	Active	14.0	14.0
Delayed closure of cranial sutures	10054008	PT	Narrow	A	0	Active	14.0	14.0



Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Delayed fontanelle closure	10054034	PT	Narrow	A	0	Active	14.0	14.0
Developmental hip dysplasia	10073767	PT	Narrow	A	0	Active	16.1	16.1
Diarrhoea infectious neonatal	10012744	PT	Narrow	A	0	Active	14.0	14.0
Diarrhoea neonatal	10012743	PT	Narrow	A	0	Active	14.0	14.0
Discordant twin	10069150	PT	Narrow	A	0	Active	14.0	14.0
Disseminated intravascular coagulation in newborn	10013443	PT	Narrow	A	0	Active	14.0	14.0
Disturbance of thermoregulation of newborn	10074158	PT	Narrow	A	0	Active	16.1	16.1
Drug withdrawal syndrome neonatal	10013756	PT	Narrow	A	0	Active	14.0	14.0
Dry lung syndrome	10074163	PT	Narrow	A	0	Active	16.1	16.1
Dyskinesia neonatal	10013922	PT	Narrow	A	0	Active	14.0	14.0
Early infantile epileptic encephalopathy with burst-suppression	10071545	PT	Narrow	A	0	Active	14.1	14.1
Eczema infantile	10014198	PT	Narrow	A	0	Active	14.0	14.0
Encephalopathy neonatal	10014633	PT	Narrow	A	0	Active	14.0	14.0
Endocardial cushion defect repair	10014657	PT	Narrow	A	0	Active	14.0	14.0
Epileptic encephalopathy	10077380	PT	Narrow	A	0	Active	19.0	19.0
Erythema toxicum neonatorum	10056274	PT	Narrow	A	0	Active	14.0	14.0
Facial nerve injury due to birth trauma	10016056	PT	Narrow	A	0	Active	16.1	16.1
Familial infantile bilateral striatal necrosis	10077450	PT	Narrow	A	0	Active	19.0	19.0
Feeding intolerance	10076042	PT	Narrow	A	0	Active	18.0	18.1
Fever neonatal	10016562	PT	Narrow	A	0	Active	14.0	14.0
Fixed bowel loop	10074216	PT	Narrow	A	0	Active	16.1	16.1
Floppy infant	10051004	PT	Narrow	A	0	Active	14.0	14.0
Fontanelle bulging	10016945	PT	Narrow	A	0	Active	14.0	14.0
Fontanelle depressed	10053214	PT	Narrow	A	0	Active	14.0	14.0
Fracture of clavicle due to birth trauma	10017107	PT	Narrow	A	0	Active	16.1	16.1
Fryns syndrome	10075223	PT	Narrow	A	0	Active	17.1	17.1
Funisitis	10064502	PT	Narrow	A	0	Active	14.0	14.0
Gangrene neonatal	10017717	PT	Narrow	A	0	Active	14.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Gasping syndrome	10069162	PT	Narrow	A	0	Active	14.0	14.0
Granulocytopenia neonatal	10018688	PT	Narrow	A	0	Active	14.0	14.0
Grey syndrome neonatal	10018723	PT	Narrow	A	0	Active	14.0	14.0
Group B streptococcus neonatal sepsis	10053588	PT	Narrow	A	0	Active	14.0	14.0
Haemolysis neonatal	10050190	PT	Narrow	A	0	Active	14.0	14.0
Haemorrhage neonatal	10061993	PT	Narrow	A	0	Active	14.0	14.0
Haemorrhagic disease of newborn	10019008	PT	Narrow	A	0	Active	14.0	14.0
Head circumference abnormal	10060043	PT	Narrow	A	0	Active	14.0	14.0
Hepatitis neonatal	10019785	PT	Narrow	A	0	Active	14.0	14.0
Hepatocellular damage neonatal	10019834	PT	Narrow	A	0	Active	14.0	14.0
Hepatosplenomegaly neonatal	10019848	PT	Narrow	A	0	Active	14.0	14.0
Herpes simplex virus conjunctivitis neonatal	10049458	PT	Narrow	A	0	Active	14.0	14.0
Hygroma colli	10050249	PT	Narrow	A	0	Active	14.0	14.0
Hyperbilirubinaemia neonatal	10020580	PT	Narrow	A	0	Active	14.0	14.0
Hyperkinesia neonatal	10020652	PT	Narrow	A	0	Active	14.0	14.0
Hypertension neonatal	10049781	PT	Narrow	A	0	Active	14.0	14.0
Hypertonia neonatal	10048615	PT	Narrow	A	0	Active	14.0	14.0
Hypoglycaemia neonatal	10020994	PT	Narrow	A	0	Active	14.0	14.0
Hypokinesia neonatal	10021022	PT	Narrow	A	0	Active	14.0	14.0
Hypoplastic nasal cartilage	10074970	PT	Narrow	A	0	Active	17.1	17.1
Hypothermia neonatal	10050080	PT	Narrow	A	0	Active	14.0	14.0
Hypotonia neonatal	10021119	PT	Narrow	A	0	Active	14.0	14.0
Hypoventilation neonatal	10021134	PT	Narrow	A	0	Active	14.0	14.0
Immature larynx	10048855	PT	Narrow	A	0	Active	14.0	14.0
Immature respiratory system	10021412	PT	Narrow	A	0	Active	14.0	14.0
Inclusion conjunctivitis neonatal	10053991	PT	Narrow	A	0	Active	14.0	14.0
Incubator therapy	10056613	PT	Narrow	A	0	Active	14.0	14.0
Infantile apnoea	10077321	PT	Narrow	A	0	Active	19.0	19.0
Infantile asthma	10049585	PT	Narrow	A	0	Active	14.0	14.0
Infantile back arching	10077276	PT	Narrow	A	0	Active	19.0	19.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Infantile colic	10021746	PT	Narrow	A	0	Active	14.0	14.0
Infantile haemangioma	10075378	PT	Narrow	A	0	Active	17.1	17.1
Infantile scurvy	10021749	PT	Narrow	A	0	Active	14.0	14.0
Infantile spasms	10021750	PT	Narrow	A	0	Active	14.0	14.0
Infantile spitting up	10063338	PT	Narrow	A	0	Active	14.0	14.0
Infantile vomiting	10075315	PT	Narrow	A	0	Active	17.1	17.1
Injury to brachial plexus due to birth trauma	10022158	PT	Narrow	A	0	Active	16.1	16.1
Injury to spinal cord secondary to birth trauma	10022343	PT	Narrow	A	0	Active	14.0	14.0
Intoxication by breast feeding	10049999	PT	Narrow	A	0	Active	14.0	14.0
Intraventricular haemorrhage neonatal	10022841	PT	Narrow	A	0	Active	14.0	14.0
Isoimmune haemolytic disease	10023052	PT	Narrow	A	0	Active	14.0	14.0
Jaundice neonatal	10023138	PT	Narrow	A	0	Active	14.0	14.0
Johanson-Blizzard syndrome	10074947	PT	Narrow	A	0	Active	17.1	17.1
Junctional ectopic tachycardia	10074640	PT	Narrow	A	0	Active	17.0	17.0
Kernicterus	10023376	PT	Narrow	A	0	Active	14.0	14.0
Large for dates baby	10023789	PT	Narrow	A	0	Active	14.0	14.0
Late metabolic acidosis of newborn	10024004	PT	Narrow	A	0	Active	14.0	14.0
Lenticulostratial vasculopathy	10073774	PT	Narrow	A	0	Active	16.1	16.1
Leukopenia neonatal	10050504	PT	Narrow	A	0	Active	14.0	14.0
Low birth weight baby	10067508	PT	Narrow	A	0	Active	14.0	14.1
Lymphocytopenia neonatal	10025279	PT	Narrow	A	0	Active	14.0	14.0
Meconium abnormal	10051132	PT	Narrow	A	0	Active	14.0	14.0
Meconium aspiration syndrome	10076496	PT	Narrow	A	0	Active	18.1	18.1
Meconium cyst	10074182	PT	Narrow	A	0	Active	16.1	16.1
Meconium ileus	10027058	PT	Narrow	A	0	Active	14.0	14.0
Meconium increased	10027059	PT	Narrow	A	0	Active	14.0	14.0
Meconium peritonitis	10058113	PT	Narrow	A	0	Active	14.0	14.0
Meconium plug syndrome	10057075	PT	Narrow	A	0	Active	14.0	14.0
Meconium stain	10057028	PT	Narrow	A	0	Active	14.0	14.0
Melaena neonatal	10049777	PT	Narrow	A	0	Active	14.0	14.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Meningitis neonatal	10058780	PT	Narrow	A	0	Active	14.0	14.0
Meningoencephalitis herpes simplex neonatal	10053586	PT	Narrow	A	0	Active	14.0	14.0
Myasthenia gravis neonatal	10028419	PT	Narrow	A	0	Active	14.0	14.0
Necrotising enterocolitis neonatal	10055667	PT	Narrow	A	0	Active	14.0	14.0
Neonatal alloimmune thrombocytopenia	10075149	PT	Narrow	A	0	Active	17.1	17.1
Neonatal alveolar aeration excessive	10028918	PT	Narrow	A	0	Active	14.0	14.0
Neonatal anoxia	10028921	PT	Narrow	A	0	Active	14.0	14.0
Neonatal anuria	10049778	PT	Narrow	A	0	Active	14.0	14.0
Neonatal asphyxia	10028923	PT	Narrow	A	0	Active	14.0	14.0
Neonatal aspiration	10059033	PT	Narrow	A	0	Active	14.0	14.0
Neonatal behavioural syndrome	10072605	PT	Narrow	A	0	Active	15.1	15.1
Neonatal candida infection	10028924	PT	Narrow	A	0	Active	14.0	14.0
Neonatal cardiac failure	10049780	PT	Narrow	A	0	Active	14.0	14.0
Neonatal cholestasis	10056528	PT	Narrow	A	0	Active	14.0	14.0
Neonatal complications of substance abuse	10061862	PT	Narrow	A	0	Active	14.0	14.0
Neonatal diabetes mellitus	10028933	PT	Narrow	A	0	Active	14.0	14.0
Neonatal disorder	10028934	PT	Narrow	A	0	Active	14.0	14.0
Neonatal exchange blood transfusion	10028937	PT	Narrow	A	0	Active	14.0	14.0
Neonatal gastrointestinal disorder	10076388	PT	Narrow	A	0	Active	18.0	18.0
Neonatal gastrointestinal haemorrhage	10074159	PT	Narrow	A	0	Active	16.1	16.1
Neonatal haemochromatosis	10078355	PT	Narrow	A	0	Active	19.1	19.1
Neonatal hepatomegaly	10049995	PT	Narrow	A	0	Active	14.0	14.0
Neonatal hypocalcaemia	10079306	PT	Narrow	A	0	Active	20.0	20.0
Neonatal hyponatraemia	10049222	PT	Narrow	A	0	Active	14.0	14.0
Neonatal hypoparathyroidism	10056974	PT	Narrow	A	0	Active	14.0	14.0
Neonatal hypotension	10049223	PT	Narrow	A	0	Active	14.0	14.0
Neonatal hypoxia	10050081	PT	Narrow	A	0	Active	14.0	14.0
Neonatal infection	10061308	PT	Narrow	A	0	Active	14.0	14.0
Neonatal infective mastitis	10028950	PT	Narrow	A	0	Active	14.0	14.0
Neonatal intestinal dilatation	10058934	PT	Narrow	A	0	Active	14.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Neonatal intestinal obstruction	10028951	PT	Narrow	A	0	Active	14.0	14.0
Neonatal intestinal perforation	10074160	PT	Narrow	A	0	Active	16.1	16.1
Neonatal mucocutaneous herpes simplex	10053587	PT	Narrow	A	0	Active	14.0	14.0
Neonatal multi-organ failure	10050401	PT	Narrow	A	0	Active	14.0	14.0
Neonatal neuroblastoma	10049793	PT	Narrow	A	0	Active	14.0	14.0
Neonatal oversedation	10050395	PT	Narrow	A	0	Active	14.0	14.0
Neonatal pneumonia	10053584	PT	Narrow	A	0	Active	14.0	14.0
Neonatal respiratory acidosis	10028966	PT	Narrow	A	0	Active	14.0	14.0
Neonatal respiratory alkalosis	10028967	PT	Narrow	A	0	Active	14.0	14.0
Neonatal respiratory arrest	10028968	PT	Narrow	A	0	Active	14.0	14.0
Neonatal respiratory depression	10028970	PT	Narrow	A	0	Active	14.0	14.0
Neonatal respiratory distress syndrome	10028974	PT	Narrow	A	0	Active	14.0	14.0
Neonatal respiratory distress syndrome prophylaxis	10054933	PT	Narrow	A	0	Active	14.0	14.0
Neonatal respiratory failure	10028975	PT	Narrow	A	0	Active	14.0	14.0
Neonatal tachycardia	10049775	PT	Narrow	A	0	Active	14.0	14.0
Neonatal tachypnoea	10057183	PT	Narrow	A	0	Active	14.0	14.0
Neonatal testicular torsion	10075380	PT	Narrow	A	0	Active	17.1	17.1
Neonatal tetany	10057037	PT	Narrow	A	0	Active	14.0	14.0
Neonatal thyrotoxicosis	10028976	PT	Narrow	A	0	Active	14.0	14.0
Neonatal toxicity	10078986	PT	Narrow	A	0	Active	20.0	20.0
Neonatal warming therapy	10056585	PT	Narrow	A	0	Active	14.0	14.0
Neuroendocrine cell hyperplasia of infancy	10072968	PT	Narrow	A	0	Active	16.0	16.0
Neutropenia neonatal	10029358	PT	Narrow	A	0	Active	14.0	14.0
Norwood procedure	10068098	PT	Narrow	A	0	Active	14.0	14.0
Oedema neonatal	10061317	PT	Narrow	A	0	Active	14.0	14.0
Omphalitis	10030306	PT	Narrow	A	0	Active	14.0	14.0
Ophthalmia neonatorum	10030861	PT	Narrow	A	0	Active	14.0	14.0
Overfeeding of infant	10059260	PT	Narrow	A	0	Active	14.0	14.0
Parenteral nutrition associated liver disease	10074151	PT	Narrow	A	0	Active	16.1	16.1

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Patent ductus arteriosus repair	10034131	PT	Narrow	A	0	Active	14.0	14.0
Perinatal brain damage	10056392	PT	Narrow	A	0	Active	14.0	14.0
Perinatal HBV infection	10075233	PT	Narrow	A	0	Active	17.1	17.1
Perinatal HIV infection	10071049	PT	Narrow	A	0	Active	14.0	14.0
Perinatal stroke	10073945	PT	Narrow	A	0	Active	16.1	16.1
Peripheral oedema neonatal	10049779	PT	Narrow	A	0	Active	14.0	14.0
Periventricular haemorrhage neonatal	10076706	PT	Narrow	A	0	Active	18.1	18.1
Periventricular leukomalacia	10052594	PT	Narrow	A	0	Active	14.0	14.0
Polycythaemia neonatorum	10060476	PT	Narrow	A	0	Active	16.1	16.1
Poor feeding infant	10075316	PT	Narrow	A	0	Active	17.1	17.1
Poor sucking reflex	10058605	PT	Narrow	A	0	Active	14.0	14.0
Poor weight gain neonatal	10050086	PT	Narrow	A	0	Active	14.0	14.0
Posthaemorrhagic hydrocephalus	10079859	PT	Narrow	A	0	Active	20.1	20.1
Postmature baby	10036392	PT	Narrow	A	0	Active	14.0	14.0
Premature baby	10036590	PT	Narrow	A	0	Active	14.0	14.0
Premature closure of cranial sutures	10048907	PT	Narrow	A	0	Active	14.0	14.0
Primary familial hypomagnesaemia	10076626	PT	Narrow	A	0	Active	18.1	18.1
Pulmonary air leakage	10067826	PT	Narrow	A	0	Active	14.0	14.0
Pulmonary dysmaturity syndrome	10053766	PT	Narrow	A	0	Active	14.0	14.0
Pulmonary lymphangiectasia	10073661	PT	Narrow	A	0	Active	16.1	16.1
Pulmonary oedema neonatal	10050459	PT	Narrow	A	0	Active	14.0	14.0
Purpura neonatal	10037557	PT	Narrow	A	0	Active	14.0	14.0
Pyloromyotomy	10037626	PT	Narrow	A	0	Active	14.0	14.0
Rash neonatal	10037871	PT	Narrow	A	0	Active	14.0	14.0
Renal failure neonatal	10038447	PT	Narrow	A	0	Active	14.0	14.0
Renal impairment neonatal	10049776	PT	Narrow	A	0	Active	14.0	14.0
Repair of imperforate rectum	10038570	PT	Narrow	A	0	Active	14.0	14.0
Respiratory disorder neonatal	10061484	PT	Narrow	A	0	Active	14.0	14.0
Respiratory tract haemorrhage neonatal	10038728	PT	Narrow	A	0	Active	14.0	14.0
Retinopathy of prematurity	10038933	PT	Narrow	A	0	Active	14.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Rhesus incompatibility	10063676	PT	Narrow	A	0	Active	14.0	14.0
Sepsis neonatal	10040049	PT	Narrow	A	0	Active	14.0	14.0
Small for dates baby	10041092	PT	Narrow	A	0	Active	14.0	14.0
Somnolence neonatal	10041350	PT	Narrow	A	0	Active	14.0	14.0
Sporadic infantile bilateral striatal necrosis	10077451	PT	Narrow	A	0	Active	19.0	19.0
Subarachnoid haemorrhage neonatal	10042317	PT	Narrow	A	0	Active	14.0	14.0
Subdural haemorrhage neonatal	10042365	PT	Narrow	A	0	Active	14.0	14.0
Subgaleal haematoma	10069510	PT	Narrow	A	0	Active	14.0	14.0
Sudden infant death syndrome	10042440	PT	Narrow	A	0	Active	14.0	14.0
Systemic-pulmonary artery shunt	10052717	PT	Narrow	A	0	Active	14.0	14.0
Tetanus neonatorum	10043378	PT	Narrow	A	0	Active	14.0	14.0
Tetralogy of Fallot repair	10067017	PT	Narrow	A	0	Active	14.0	14.0
Thrombocytopenia neonatal	10043557	PT	Narrow	A	0	Active	14.0	14.0
Thrombophlebitis neonatal	10043586	PT	Narrow	A	0	Active	14.0	14.0
Transient hypogammaglobulinaemia of infancy	10044388	PT	Narrow	A	0	Active	14.0	14.0
Transient hypothyroxinaemia of prematurity	10075901	PT	Narrow	A	0	Active	18.0	18.0
Transient neonatal pustular melanosis	10072688	PT	Narrow	A	0	Active	15.1	15.1
Transient tachypnoea of the newborn	10044403	PT	Narrow	A	0	Active	14.0	14.0
Tremor neonatal	10044575	PT	Narrow	A	0	Active	14.0	14.0
Umbilical discharge	10072595	PT	Narrow	A	0	Active	15.1	15.1
Umbilical granuloma	10067731	PT	Narrow	A	0	Active	14.0	14.0
Umbilical sepsis	10045470	PT	Narrow	A	0	Active	14.0	14.0
Urinary tract infection neonatal	10046573	PT	Narrow	A	0	Active	14.0	14.0
Venous thrombosis neonatal	10064602	PT	Narrow	A	0	Active	14.0	14.0
Ventricular septal defect repair	10047301	PT	Narrow	A	0	Active	14.0	14.0
Vision abnormal neonatal	10047511	PT	Narrow	A	0	Active	14.0	14.0
Weight decrease neonatal	10047894	PT	Narrow	A	0	Active	14.0	14.0
ABO incompatibility	10000206	PT	Broad	A	0	Active	14.0	14.0
Alloimmunisation	10060935	PT	Broad	A	0	Active	14.0	14.0
Apparent life threatening event	10065044	PT	Broad	A	0	Active	14.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Breast milk substitute intolerance	10072187	PT	Broad	A	0	Active	15.0	15.0
Extraocular retinoblastoma	10015831	PT	Broad	A	0	Active	14.0	14.0
Failure to thrive	10016165	PT	Broad	A	0	Active	14.0	14.0
Growth failure	10071095	PT	Broad	A	0	Active	14.0	20.0
Maternal exposure during delivery	10071407	PT	Broad	A	0	Active	15.0	15.0
Neuroblastoma	10029260	PT	Broad	A	0	Active	14.0	14.0
Thymus enlargement	10065588	PT	Broad	A	0	Active	14.0	14.0

**Normal pregnancy conditions and outcomes (SMQ) [20000193]**

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Alpha 1 foetoprotein amniotic fluid normal	10001779	PT	Narrow	A	0	Active	14.0	14.0
Amniocentesis normal	10001963	PT	Narrow	A	0	Active	14.0	14.0
Amnioscopy normal	10001966	PT	Narrow	A	0	Active	14.0	14.0
Biopsy foetal normal	10058398	PT	Narrow	A	0	Active	14.0	14.0
Birth weight normal	10078661	PT	Narrow	A	0	Active	19.1	19.1
Caesarean delivery on maternal request	10076983	PT	Narrow	A	0	Active	18.1	18.1
Cervical dilatation	10079273	PT	Narrow	A	0	Active	20.0	20.0
Chloasma	10008570	PT	Narrow	A	0	Active	14.0	14.0
Delivery	10067647	PT	Narrow	A	0	Active	14.0	14.0
False negative pregnancy test	10063476	PT	Narrow	A	0	Active	14.0	14.0
First trimester pregnancy	10052395	PT	Narrow	A	0	Active	14.0	14.0
Foetal heart rate normal	10051140	PT	Narrow	A	0	Active	14.0	14.0
Human chorionic gonadotropin increased	10071332	PT	Narrow	A	0	Active	14.1	14.1
Human chorionic gonadotropin positive	10071335	PT	Narrow	A	0	Active	14.1	14.1
Labour pain	10059204	PT	Narrow	A	0	Active	14.0	14.0
Live birth	10049550	PT	Narrow	A	0	Active	14.0	14.0
Multigravida	10028160	PT	Narrow	A	0	Active	14.0	14.0
Multiparous	10028163	PT	Narrow	A	0	Active	14.0	14.0
Newborn head moulding	10077984	PT	Narrow	A	0	Active	19.0	19.0



Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Normal foetus	10049081	PT	Narrow	A	0	Active	14.0	14.0
Normal labour	10029767	PT	Narrow	A	0	Active	14.0	14.0
Normal newborn	10029769	PT	Narrow	A	0	Active	14.0	14.0
Nulliparous	10029827	PT	Narrow	A	0	Active	14.0	14.0
Parity	10033997	PT	Narrow	A	0	Active	14.0	14.0
Planning to become pregnant	10076056	PT	Narrow	A	0	Active	18.0	18.0
Postpartum state	10048738	PT	Narrow	A	0	Active	14.0	14.0
Pregnancy	10036556	PT	Narrow	A	0	Active	14.0	14.0
Pregnancy after post coital contraception	10063671	PT	Narrow	A	0	Active	14.0	14.0
Pregnancy of partner	10050192	PT	Narrow	A	0	Active	14.0	14.0
Pregnancy on contraceptive	10067667	PT	Narrow	A	0	Active	14.0	14.0
Pregnancy on oral contraceptive	10036567	PT	Narrow	A	0	Active	14.0	14.0
Pregnancy test positive	10036575	PT	Narrow	A	0	Active	14.0	14.0
Pregnancy test urine positive	10036578	PT	Narrow	A	0	Active	14.0	14.0
Pregnancy with contraceptive device	10063130	PT	Narrow	A	0	Active	14.0	14.0
Pregnancy with contraceptive patch	10067082	PT	Narrow	A	0	Active	14.0	14.0
Pregnancy with implant contraceptive	10063122	PT	Narrow	A	0	Active	14.0	14.0
Pregnancy with injectable contraceptive	10053394	PT	Narrow	A	0	Active	14.0	14.0
Prenatal care	10052859	PT	Narrow	A	0	Active	14.0	14.0
Primigravida	10036757	PT	Narrow	A	0	Active	14.0	14.0
Primiparous	10036758	PT	Narrow	A	0	Active	14.0	14.0
Second trimester pregnancy	10052396	PT	Narrow	A	0	Active	14.0	14.0
Term birth	10072953	PT	Narrow	A	0	Active	16.0	16.0
Third trimester pregnancy	10052397	PT	Narrow	A	0	Active	14.0	14.0
Ultrasound antenatal screen normal	10045401	PT	Narrow	A	0	Active	14.0	14.0
Unintended pregnancy	10045542	PT	Narrow	A	0	Active	14.0	14.0
Unwanted pregnancy	10046267	PT	Narrow	A	0	Active	14.0	14.0
Uterine contractions during pregnancy	10049975	PT	Narrow	A	0	Active	14.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Alpha 1 foetoprotein normal	10001782	PT	Broad	A	0	Active	14.0	14.0
Breast engorgement	10006240	PT	Broad	A	0	Active	14.0	14.0
<b>Pregnancy, labour and delivery complications and risk factors (excl abortions and stillbirth) (SMQ) [20000186]</b>								
Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Abnormal labour	10000153	PT	Narrow	A	0	Active	14.0	14.0
Abnormal labour affecting foetus	10000154	PT	Narrow	A	0	Active	14.0	14.0
Acute fatty liver of pregnancy	10000746	PT	Narrow	A	0	Active	14.0	14.0
Afterbirth pain	10049589	PT	Narrow	A	0	Active	14.0	14.0
Amniocentesis abnormal	10001959	PT	Narrow	A	0	Active	14.0	14.0
Amniorrhaxis	10051641	PT	Narrow	A	0	Active	14.0	14.0
Amniorrhoea	10066470	PT	Narrow	A	0	Active	14.0	14.0
Amnioscopy abnormal	10001965	PT	Narrow	A	0	Active	14.0	14.0
Amniotic cavity disorder	10060936	PT	Narrow	A	0	Active	14.0	14.0
Amniotic cavity infection	10060937	PT	Narrow	A	0	Active	14.0	14.0
Amniotic fluid erythropoietin level increased	10064845	PT	Narrow	A	0	Active	14.0	14.0
Amniotic fluid index abnormal	10067079	PT	Narrow	A	0	Active	14.0	14.0
Amniotic fluid index decreased	10075866	PT	Narrow	A	0	Active	18.0	18.0
Amniotic fluid index increased	10075867	PT	Narrow	A	0	Active	18.0	18.0
Amniotic fluid volume decreased	10063356	PT	Narrow	A	0	Active	14.0	14.0
Amniotic fluid volume increased	10063357	PT	Narrow	A	0	Active	14.0	14.0
Amniotic infection syndrome of Blane	10051407	PT	Narrow	A	0	Active	14.0	14.0
Amniotic membrane rupture test positive	10078834	PT	Narrow	A	0	Active	20.0	20.0
Anaemia of pregnancy	10066468	PT	Narrow	A	0	Active	14.0	14.0
Anaphylactoid syndrome of pregnancy	10067010	PT	Narrow	A	0	Active	14.0	14.0
Angiotensin II receptor type 1 antibody positive	10079737	PT	Narrow	A	0	Active	20.1	20.1
Arrested labour	10003118	PT	Narrow	A	0	Active	14.0	14.0
Artificial rupture of membranes	10003440	PT	Narrow	A	0	Active	14.0	14.0
Assisted delivery	10061661	PT	Narrow	A	0	Active	14.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Bacteriuria in pregnancy	10004058	PT	Narrow	A	0	Active	14.0	14.0
Benign hydatidiform mole	10004272	PT	Narrow	A	0	Active	14.0	14.0
Biopsy chorionic villous abnormal	10048537	PT	Narrow	A	0	Active	14.0	14.0
Blood type incompatibility	10078985	PT	Narrow	A	0	Active	20.0	20.0
Breech delivery	10006346	PT	Narrow	A	0	Active	14.0	14.0
Breech presentation	10006356	PT	Narrow	A	0	Active	14.0	14.0
Brief psychotic disorder, with postpartum onset	10006362	PT	Narrow	A	0	Active	14.0	14.0
Brow presentation	10052848	PT	Narrow	A	0	Active	14.0	14.0
Caesarean section	10006924	PT	Narrow	A	0	Active	14.0	14.0
Cephalo-pelvic disproportion	10008020	PT	Narrow	A	0	Active	14.0	14.0
Cervical incompetence	10008267	PT	Narrow	A	0	Active	14.0	14.0
Cervix cerclage procedure	10054992	PT	Narrow	A	0	Active	14.0	14.0
Cervix dystocia	10054939	PT	Narrow	A	0	Active	14.0	14.0
Chloasma	10008570	PT	Narrow	A	0	Active	14.0	14.0
Cholestasis of pregnancy	10049055	PT	Narrow	A	0	Active	14.0	14.0
Chronic villitis of unknown etiology	10072271	PT	Narrow	A	0	Active	15.0	15.0
Complication of delivery	10061781	PT	Narrow	A	0	Active	14.0	14.0
Complication of pregnancy	10061452	PT	Narrow	A	0	Active	14.0	14.0
Decidual cast	10068735	PT	Narrow	A	0	Active	14.0	14.0
Delayed delivery	10012186	PT	Narrow	A	0	Active	14.0	14.0
Delivery outside health facility	10072446	PT	Narrow	A	0	Active	15.1	15.1
Diabetes complicating pregnancy	10012596	PT	Narrow	A	0	Active	14.0	14.0
Discordant twin	10069150	PT	Narrow	A	0	Active	14.0	14.0
Drug dependence, antepartum	10013675	PT	Narrow	A	0	Active	14.0	20.1
Drug dependence, postpartum	10013676	PT	Narrow	A	0	Active	14.0	20.1
Drug use disorder, antepartum	10079382	PT	Narrow	A	0	Active	20.0	20.0
Drug use disorder, postpartum	10079383	PT	Narrow	A	0	Active	20.0	20.0
Eclampsia	10014129	PT	Narrow	A	0	Active	14.0	14.0
Ectopic pregnancy	10014166	PT	Narrow	A	0	Active	14.0	14.0
Ectopic pregnancy termination	10014168	PT	Narrow	A	0	Active	14.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Ectopic pregnancy with contraceptive device	10074497	PT	Narrow	A	0	Active	17.0	17.0
Elderly primigravida	10014349	PT	Narrow	A	0	Active	14.0	14.0
Endometritis bacterial	10074861	PT	Narrow	A	0	Active	17.0	17.0
Endometritis decidual	10014792	PT	Narrow	A	0	Active	14.0	14.0
Exposure during pregnancy	10073513	PT	Narrow	A	0	Active	16.0	16.0
Exposure via father	10071403	PT	Narrow	A	0	Active	15.0	15.0
External cephalic version	10070636	PT	Narrow	A	0	Active	14.0	14.0
Face presentation	10016035	PT	Narrow	A	0	Active	14.0	14.0
Failed induction of labour	10016123	PT	Narrow	A	0	Active	14.0	14.0
Failed trial of labour	10016142	PT	Narrow	A	0	Active	14.0	14.0
False labour	10016194	PT	Narrow	A	0	Active	14.0	14.0
Foetal arm prolapse	10016846	PT	Narrow	A	0	Active	14.0	14.0
Foetal exposure during delivery	10071409	PT	Narrow	A	0	Active	15.0	15.0
Foetal exposure during pregnancy	10071404	PT	Narrow	A	0	Active	15.0	15.0
Foetal exposure timing unspecified	10071405	PT	Narrow	A	0	Active	15.0	15.0
Foetal malposition	10016863	PT	Narrow	A	0	Active	14.0	14.0
Foetal malpresentation	10058013	PT	Narrow	A	0	Active	14.0	14.0
Foetal monitoring abnormal	10071507	PT	Narrow	A	0	Active	14.1	14.1
Foetal placental thrombosis	10072240	PT	Narrow	A	0	Active	15.0	15.0
Gestational diabetes	10018209	PT	Narrow	A	0	Active	14.0	14.0
Gestational hypertension	10070538	PT	Narrow	A	0	Active	14.0	14.0
Gestational oedema	10063412	PT	Narrow	A	0	Active	14.0	14.0
Gestational trophoblastic detachment	10049469	PT	Narrow	A	0	Active	14.0	14.0
Glucose tolerance impaired in pregnancy	10018430	PT	Narrow	A	0	Active	14.0	14.0
Glycosuria during pregnancy	10018475	PT	Narrow	A	0	Active	14.0	14.0
Haemorrhage in pregnancy	10018981	PT	Narrow	A	0	Active	14.0	15.0
HELLP syndrome	10049058	PT	Narrow	A	0	Active	14.0	14.0
Herpes gestationis	10019939	PT	Narrow	A	0	Active	14.0	14.0
Heterotopic pregnancy	10064228	PT	Narrow	A	0	Active	14.0	14.0
High foetal head	10020065	PT	Narrow	A	0	Active	14.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
High risk pregnancy	10052744	PT	Narrow	A	0	Active	14.0	14.0
Hyperemesis gravidarum	10020614	PT	Narrow	A	0	Active	14.0	14.0
Hyperreactio luteinalis	10074866	PT	Narrow	A	0	Active	17.0	17.0
Impetigo herpetiformis	10021534	PT	Narrow	A	0	Active	14.0	14.0
Incoordinate uterine action	10021648	PT	Narrow	A	0	Active	14.0	14.0
Induced labour	10021718	PT	Narrow	A	0	Active	14.0	14.0
Inferior vena cava syndrome	10070911	PT	Narrow	A	0	Active	14.1	14.1
Intrapartum haemorrhage	10067703	PT	Narrow	A	0	Active	14.0	14.0
Intrauterine infection	10056254	PT	Narrow	A	0	Active	14.0	14.0
Kleihauer-Betke test positive	10072577	PT	Narrow	A	0	Active	15.1	15.1
Labour augmentation	10079807	PT	Narrow	A	0	Active	20.1	20.1
Labour complication	10061050	PT	Narrow	A	0	Active	14.0	14.0
Labour induction	10052856	PT	Narrow	A	0	Active	14.0	14.0
Labour stimulation	10052855	PT	Narrow	A	0	Active	14.0	14.0
Large for dates baby	10023789	PT	Narrow	A	0	Active	14.0	14.0
Lochial infection	10066103	PT	Narrow	A	0	Active	14.0	14.0
Locked twins	10024787	PT	Narrow	A	0	Active	14.0	14.0
Lymphocytic hypophysitis	10063685	PT	Narrow	A	0	Active	14.0	14.0
Malignant hydatidiform mole	10025598	PT	Narrow	A	0	Active	14.0	14.0
Malignant neoplasm of placenta	10026350	PT	Narrow	A	0	Active	14.0	14.0
Mastitis postpartum	10026889	PT	Narrow	A	0	Active	14.0	14.0
Maternal alcohol use	10065158	PT	Narrow	A	0	Active	14.0	14.0
Maternal cancer in pregnancy	10079877	PT	Narrow	A	0	Active	20.1	20.1
Maternal death during childbirth	10066376	PT	Narrow	A	0	Active	14.0	14.0
Maternal distress during labour	10056391	PT	Narrow	A	0	Active	14.0	14.0
Maternal exposure before pregnancy	10071406	PT	Narrow	A	0	Active	15.0	15.0
Maternal exposure during pregnancy	10071408	PT	Narrow	A	0	Active	14.1	14.1
Maternal exposure timing unspecified	10071415	PT	Narrow	A	0	Active	15.0	15.0
Maternal therapy to enhance foetal lung maturity	10058340	PT	Narrow	A	0	Active	14.0	14.0
Metastases to placenta	10049725	PT	Narrow	A	0	Active	14.0	14.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Mirror syndrome	10068875	PT	Narrow	A	0	Active	14.0	14.0
Missed labour	10059107	PT	Narrow	A	0	Active	14.0	14.0
Multiple pregnancy	10028243	PT	Narrow	A	0	Active	14.0	14.0
Oblique presentation	10052849	PT	Narrow	A	0	Active	14.0	14.0
Obstetric infection	10053636	PT	Narrow	A	0	Active	14.0	14.0
Obstetric procedure complication	10061315	PT	Narrow	A	0	Active	14.0	14.0
Obstetrical pulmonary embolism	10029925	PT	Narrow	A	0	Active	14.0	14.0
Obstructed labour	10029934	PT	Narrow	A	0	Active	14.0	14.0
Oligohydramnios	10030289	PT	Narrow	A	0	Active	14.0	14.0
Omphalorrhexis	10064270	PT	Narrow	A	0	Active	14.0	14.0
Paternal exposure before pregnancy	10080093	PT	Narrow	A	0	Active	20.1	20.1
Paternal exposure during pregnancy	10080091	PT	Narrow	A	0	Active	20.1	20.1
Paternal exposure timing unspecified	10080092	PT	Narrow	A	0	Active	20.1	20.1
Pelvic haematoma obstetric	10034248	PT	Narrow	A	0	Active	14.0	14.0
Perineal repair breakdown	10034528	PT	Narrow	A	0	Active	14.0	14.0
Peripartum cardiomyopathy	10049430	PT	Narrow	A	0	Active	14.0	14.0
Peripartum haemorrhage	10072693	PT	Narrow	A	0	Active	15.1	15.1
Placenta accreta	10062936	PT	Narrow	A	0	Active	14.0	14.0
Placenta praevia	10035119	PT	Narrow	A	0	Active	14.0	14.0
Placenta praevia haemorrhage	10035121	PT	Narrow	A	0	Active	14.0	14.0
Placental chorioangioma	10056718	PT	Narrow	A	0	Active	14.0	14.0
Placental disorder	10035132	PT	Narrow	A	0	Active	14.0	14.0
Placental dysplasia	10054810	PT	Narrow	A	0	Active	14.0	14.0
Placental hypertrophy	10068326	PT	Narrow	A	0	Active	14.0	14.0
Placental infarction	10064620	PT	Narrow	A	0	Active	14.0	14.0
Placental insufficiency	10035138	PT	Narrow	A	0	Active	14.0	14.0
Placental necrosis	10035139	PT	Narrow	A	0	Active	14.0	14.0
Placental neoplasm	10061349	PT	Narrow	A	0	Active	14.0	14.0
Placental polyp	10035142	PT	Narrow	A	0	Active	14.0	14.0
Placental transfusion syndrome	10035146	PT	Narrow	A	0	Active	14.0	14.0

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Polyhydramnios	10036079	PT	Narrow	A	0	Active	14.0	14.0
Polymorphic eruption of pregnancy	10066100	PT	Narrow	A	0	Active	14.0	14.0
Postpartum disorder	10061469	PT	Narrow	A	0	Active	14.0	14.0
Postpartum haemorrhage	10036417	PT	Narrow	A	0	Active	14.0	14.0
Postpartum hypopituitarism	10036297	PT	Narrow	A	0	Active	14.0	14.0
Postpartum neurosis	10036419	PT	Narrow	A	0	Active	14.0	14.0
Postpartum sepsis	10036422	PT	Narrow	A	0	Active	14.0	14.0
Postpartum stress disorder	10056394	PT	Narrow	A	0	Active	14.0	14.0
Postpartum thrombosis	10077022	PT	Narrow	A	0	Active	18.1	18.1
Postpartum uterine subinvolution	10036423	PT	Narrow	A	0	Active	14.0	14.0
Postpartum venous thrombosis	10036300	PT	Narrow	A	0	Active	14.0	14.0
Precipitate labour	10036519	PT	Narrow	A	0	Active	14.0	14.0
Pre-eclampsia	10036485	PT	Narrow	A	0	Active	14.0	14.0
Pregnancy in habitual aborter	10036562	PT	Narrow	A	0	Active	14.0	14.0
Pregnancy of unknown location	10072811	PT	Narrow	A	0	Active	15.1	15.1
Pregnancy with advanced maternal age	10036582	PT	Narrow	A	0	Active	14.0	14.0
Pregnancy with young maternal age	10069615	PT	Narrow	A	0	Active	14.0	14.0
Premature delivery	10036595	PT	Narrow	A	0	Active	14.0	14.0
Premature labour	10036600	PT	Narrow	A	0	Active	14.0	14.0
Premature rupture of membranes	10036603	PT	Narrow	A	0	Active	14.0	14.0
Premature separation of placenta	10036608	PT	Narrow	A	0	Active	14.0	14.0
Prenatal screening test abnormal	10069151	PT	Narrow	A	0	Active	14.0	14.0
Preterm premature rupture of membranes	10073024	PT	Narrow	A	0	Active	16.0	16.0
Previous caesarean section	10036656	PT	Narrow	A	0	Active	14.0	14.0
Prolonged labour	10036872	PT	Narrow	A	0	Active	14.0	14.0
Prolonged pregnancy	10036877	PT	Narrow	A	0	Active	14.0	14.0
Prolonged rupture of membranes	10073027	PT	Narrow	A	0	Active	16.0	16.0
Prophylaxis against Rh isoimmunisation	10066359	PT	Narrow	A	0	Active	14.0	14.0
Prophylaxis of abortion	10065000	PT	Narrow	A	0	Active	14.0	14.0
Puerperal infection	10072652	PT	Narrow	A	0	Active	15.1	15.1

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Puerperal pyrexia	10037294	PT	Narrow	A	0	Active	14.0	14.0
Renal disorder in pregnancy	10056505	PT	Narrow	A	0	Active	14.0	14.0
Retained placenta operation	10078243	PT	Narrow	A	0	Active	19.1	19.1
Retained placenta or membranes	10038758	PT	Narrow	A	0	Active	14.0	14.0
Retained products of conception	10038773	PT	Narrow	A	0	Active	14.0	14.0
Retroplacental haematoma	10054798	PT	Narrow	A	0	Active	14.0	14.0
Rhesus incompatibility	10063676	PT	Narrow	A	0	Active	14.0	14.0
Risk of future pregnancy miscarriage	10078342	PT	Narrow	A	0	Active	19.1	19.1
Rubella in pregnancy	10039264	PT	Narrow	A	0	Active	14.0	14.0
Ruptured ectopic pregnancy	10048407	PT	Narrow	A	0	Active	14.0	14.0
Short interpregnancy interval	10079272	PT	Narrow	A	0	Active	20.0	20.0
Shortened cervix	10067726	PT	Narrow	A	0	Active	14.0	14.0
Shoulder dystocia	10040613	PT	Narrow	A	0	Active	14.0	14.0
Silent thyroiditis	10079012	PT	Narrow	A	0	Active	20.0	20.0
Small size placenta	10072038	PT	Narrow	A	0	Active	15.0	15.0
Subchorionic haematoma	10072596	PT	Narrow	A	0	Active	15.1	15.1
Third stage postpartum haemorrhage	10043449	PT	Narrow	A	0	Active	14.0	14.0
Threatened labour	10043508	PT	Narrow	A	0	Active	14.0	14.0
Thyroid dysfunction in pregnancy	10056525	PT	Narrow	A	0	Active	14.0	14.0
Transverse presentation	10044456	PT	Narrow	A	0	Active	14.0	14.0
Traumatic delivery	10044520	PT	Narrow	A	0	Active	14.0	14.0
Tubal rupture	10067553	PT	Narrow	A	0	Active	14.0	14.0
Twin pregnancy	10045188	PT	Narrow	A	0	Active	14.0	14.0
Ultrasound antenatal screen abnormal	10045400	PT	Narrow	A	0	Active	14.0	14.0
Umbilical cord abnormality	10048596	PT	Narrow	A	0	Active	14.0	14.0
Umbilical cord around neck	10045447	PT	Narrow	A	0	Active	14.0	14.0
Umbilical cord compression	10045451	PT	Narrow	A	0	Active	14.0	14.0
Umbilical cord cyst	10079122	PT	Narrow	A	0	Active	20.0	20.0
Umbilical cord haemorrhage	10064534	PT	Narrow	A	0	Active	14.0	14.0
Umbilical cord prolapse	10045452	PT	Narrow	A	0	Active	14.0	14.0



Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Umbilical cord short	10045453	PT	Narrow	A	0	Active	14.0	14.0
Umbilical cord thrombosis	10071652	PT	Narrow	A	0	Active	14.1	14.1
Umbilical cord vascular disorder	10045454	PT	Narrow	A	0	Active	14.0	14.0
Unstable foetal lie	10046255	PT	Narrow	A	0	Active	14.0	14.0
Uterine adhesions	10074333	PT	Narrow	A	0	Active	17.0	17.0
Uterine cervix stenosis	10067732	PT	Narrow	A	0	Active	14.0	14.0
Uterine compression sutures	10078738	PT	Narrow	A	0	Active	19.1	19.1
Uterine contractions abnormal	10061400	PT	Narrow	A	0	Active	14.0	14.0
Uterine contractions during pregnancy	10049975	PT	Narrow	A	0	Active	14.0	14.0
Uterine dehiscence	10070301	PT	Narrow	A	0	Active	14.0	14.0
Uterine hyperstimulation	10066288	PT	Narrow	A	0	Active	14.0	17.1
Uterine hypertonus	10046790	PT	Narrow	A	0	Active	14.0	14.0
Uterine hypotonus	10046792	PT	Narrow	A	0	Active	14.0	14.0
Uterine inversion	10046796	PT	Narrow	A	0	Active	14.0	14.0
Uterine irritability	10079224	PT	Narrow	A	0	Active	20.0	20.0
Uterine malposition	10046800	PT	Narrow	A	0	Active	14.0	14.0
Uterine rupture	10046820	PT	Narrow	A	0	Active	14.0	14.0
Uterine tachysystole	10080022	PT	Narrow	A	0	Active	20.1	20.1
Vasa praevia	10047036	PT	Narrow	A	0	Active	14.0	14.0
Venous thrombosis in pregnancy	10067030	PT	Narrow	A	0	Active	14.0	14.0
Vomiting in pregnancy	10047704	PT	Narrow	A	0	Active	14.0	14.0
Antiphospholipid syndrome	10002817	PT	Broad	A	0	Active	14.0	14.0
Induction of cervix ripening	10073175	PT	Broad	A	0	Active	16.0	16.0
Perineal haematoma	10034520	PT	Broad	A	0	Active	14.0	14.0
Perineal injury	10073329	PT	Broad	A	0	Active	16.0	16.0
Pituitary infarction	10035092	PT	Broad	A	0	Active	14.0	14.0
Postponement of preterm delivery	10073177	PT	Broad	A	0	Active	16.0	16.0
Reversible cerebral vasoconstriction syndrome	10073240	PT	Broad	A	0	Active	18.0	18.0
Uterine scar	10074527	PT	Broad	A	0	Active	17.0	17.0
Uterine scar diverticulum	10076608	PT	Broad	A	0	Active	18.1	18.1

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Varicose veins vaginal	10066002	PT	Broad	A	0	Active	14.0	14.0
Vulvovaginal injury	10071212	PT	Broad	A	0	Active	14.0	14.0

**Termination of pregnancy and risk of abortion (SMQ) [20000192]**

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Abnormal product of conception	10060927	PT	Narrow	A	0	Active	14.0	14.0
Aborted pregnancy	10000209	PT	Narrow	A	0	Active	14.0	14.0
Abortion	10000210	PT	Narrow	A	0	Active	14.0	14.0
Abortion complete	10061614	PT	Narrow	A	0	Active	14.0	14.0
Abortion complete complicated	10000212	PT	Narrow	A	0	Active	14.0	14.0
Abortion complicated	10061615	PT	Narrow	A	0	Active	14.0	14.0
Abortion early	10052846	PT	Narrow	A	0	Active	14.0	14.0
Abortion incomplete	10000217	PT	Narrow	A	0	Active	14.0	14.0
Abortion incomplete complicated	10000218	PT	Narrow	A	0	Active	14.0	14.0
Abortion induced	10000220	PT	Narrow	A	0	Active	14.0	14.0
Abortion induced complete	10060928	PT	Narrow	A	0	Active	14.0	14.0
Abortion induced complete complicated	10000221	PT	Narrow	A	0	Active	14.0	14.0
Abortion induced complicated	10000223	PT	Narrow	A	0	Active	14.0	14.0
Abortion induced incomplete	10053984	PT	Narrow	A	0	Active	14.0	14.0
Abortion induced incomplete complicated	10000225	PT	Narrow	A	0	Active	14.0	14.0
Abortion infected	10000228	PT	Narrow	A	0	Active	14.0	14.0
Abortion late	10052847	PT	Narrow	A	0	Active	14.0	14.0
Abortion missed	10000230	PT	Narrow	A	0	Active	14.0	14.0
Abortion of ectopic pregnancy	10066266	PT	Narrow	A	0	Active	14.0	14.0
Abortion spontaneous	10000234	PT	Narrow	A	0	Active	14.0	14.0
Abortion spontaneous complete	10061616	PT	Narrow	A	0	Active	14.0	14.0
Abortion spontaneous complete complicated	10000236	PT	Narrow	A	0	Active	14.0	14.0
Abortion spontaneous complicated	10000238	PT	Narrow	A	0	Active	14.0	14.0
Abortion spontaneous incomplete	10061617	PT	Narrow	A	0	Active	14.0	14.0

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Abortion spontaneous incomplete complicated	10000239	PT	Narrow	A	0	Active	14.0	14.0
Abortion threatened	10000242	PT	Narrow	A	0	Active	14.0	14.0
Anembryonic gestation	10079814	PT	Narrow	A	0	Active	20.1	20.1
Biochemical pregnancy	10063639	PT	Narrow	A	0	Active	14.0	17.1
Ectopic pregnancy termination	10014168	PT	Narrow	A	0	Active	14.0	14.0
Evacuation of retained products of conception	10015550	PT	Narrow	A	0	Active	14.0	14.0
Foetal death	10055690	PT	Narrow	A	0	Active	14.0	15.0
Foeticide	10075033	PT	Narrow	A	0	Active	17.1	17.1
Habitual abortion	10062935	PT	Narrow	A	0	Active	14.0	14.0
Imminent abortion	10051459	PT	Narrow	A	0	Active	14.0	14.0
Induced abortion failed	10053191	PT	Narrow	A	0	Active	14.0	14.0
Induced abortion haemorrhage	10052844	PT	Narrow	A	0	Active	14.0	14.0
Induced abortion infection	10052845	PT	Narrow	A	0	Active	14.0	14.0
Molar abortion	10065942	PT	Narrow	A	0	Active	14.0	14.0
Mycoplasmal postabortal fever	10028479	PT	Narrow	A	0	Active	14.0	14.0
Post abortion complication	10036244	PT	Narrow	A	0	Active	14.0	14.0
Post abortion haemorrhage	10036246	PT	Narrow	A	0	Active	14.0	14.0
Post abortion infection	10061467	PT	Narrow	A	0	Active	14.0	14.0
Premature baby death	10076700	PT	Narrow	A	0	Active	18.1	18.1
Prophylaxis of abortion	10065000	PT	Narrow	A	0	Active	14.0	14.0
Retained products of conception	10038773	PT	Narrow	A	0	Active	14.0	14.0
Risk of future pregnancy miscarriage	10078342	PT	Narrow	A	0	Active	19.1	19.1
Selective abortion	10067499	PT	Narrow	A	0	Active	14.0	14.0
Stillbirth	10042062	PT	Narrow	A	0	Active	14.0	14.0
Twin reversed arterial perfusion sequence malformation	10073455	PT	Narrow	A	0	Active	16.0	16.0
Vanishing twin syndrome	10071398	PT	Narrow	A	0	Active	14.1	14.1

## 7.4. SMQ Terms for Hypertension

SMQ Export: 20.1 - English

1/8/2018 2:15:07 PM

Include Inactive PT: No

Term Attributes: Name, Code, Level, Scope, Category, Weight, Status, Addition Version, Last Modified Version

### Hypertension (SMQ) [20000147]

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Accelerated hypertension	10000358	PT	Narrow	A	0	Active	11.1	11.1
Blood pressure ambulatory increased	10005732	PT	Narrow	A	0	Active	11.1	11.1
Blood pressure diastolic increased	10005739	PT	Narrow	A	0	Active	11.1	11.1
Blood pressure inadequately controlled	10051128	PT	Narrow	A	0	Active	11.1	11.1
Blood pressure increased	10005750	PT	Narrow	A	0	Active	11.1	11.1
Blood pressure management	10063926	PT	Narrow	A	0	Active	11.1	11.1
Blood pressure orthostatic increased	10053355	PT	Narrow	A	0	Active	11.1	11.1
Blood pressure systolic increased	10005760	PT	Narrow	A	0	Active	11.1	11.1
Diastolic hypertension	10012758	PT	Narrow	A	0	Active	11.1	11.1
Eclampsia	10014129	PT	Narrow	A	0	Active	11.1	11.1
Endocrine hypertension	10057615	PT	Narrow	A	0	Active	11.1	11.1
Essential hypertension	10015488	PT	Narrow	A	0	Active	11.1	11.1
Gestational hypertension	10070538	PT	Narrow	A	0	Active	13.1	13.1
HELLP syndrome	10049058	PT	Narrow	A	0	Active	11.1	11.1
Hyperaldosteronism	10020571	PT	Narrow	A	0	Active	11.1	11.1
Hypertension	10020772	PT	Narrow	A	0	Active	11.1	11.1
Hypertension neonatal	10049781	PT	Narrow	A	0	Active	11.1	11.1
Hypertensive angiopathy	10059238	PT	Narrow	A	0	Active	11.1	11.1
Hypertensive cardiomegaly	10020801	PT	Narrow	A	0	Active	11.1	11.1
Hypertensive cardiomyopathy	10058222	PT	Narrow	A	0	Active	11.1	11.1
Hypertensive cerebrovascular disease	10077000	PT	Narrow	A	0	Active	18.1	18.1
Hypertensive crisis	10020802	PT	Narrow	A	0	Active	11.1	11.1
Hypertensive emergency	10058179	PT	Narrow	A	0	Active	11.1	11.1
Hypertensive encephalopathy	10020803	PT	Narrow	A	0	Active	11.1	11.1

Name	Code	Level	Scope	Category	Weight	Status	Addition Version	Last Modified Version
Hypertensive end-organ damage	10079496	PT	Narrow	A	0	Active	20.0	20.0
Hypertensive heart disease	10020823	PT	Narrow	A	0	Active	11.1	11.1
Hypertensive nephropathy	10055171	PT	Narrow	A	0	Active	11.1	11.1
Labile hypertension	10049079	PT	Narrow	A	0	Active	11.1	11.1
Malignant hypertension	10025600	PT	Narrow	A	0	Active	11.1	11.1
Malignant hypertensive heart disease	10025603	PT	Narrow	A	0	Active	11.1	11.1
Malignant renal hypertension	10026674	PT	Narrow	A	0	Active	11.1	11.1
Maternal hypertension affecting foetus	10026924	PT	Narrow	A	0	Active	11.1	11.1
Mean arterial pressure increased	10026985	PT	Narrow	A	0	Active	12.1	12.1
Metabolic syndrome	10052066	PT	Narrow	A	0	Active	11.1	11.1
Neurogenic hypertension	10067598	PT	Narrow	A	0	Active	11.1	11.1
Orthostatic hypertension	10065508	PT	Narrow	A	0	Active	11.1	11.1
Page kidney	10076704	PT	Narrow	A	0	Active	18.1	18.1
Pre-eclampsia	10036485	PT	Narrow	A	0	Active	11.1	11.1
Prehypertension	10065918	PT	Narrow	A	0	Active	11.1	11.1
Procedural hypertension	10062886	PT	Narrow	A	0	Active	11.1	11.1
Renal hypertension	10038464	PT	Narrow	A	0	Active	11.1	11.1
Renal sympathetic nerve ablation	10074864	PT	Narrow	A	0	Active	17.0	17.0
Renovascular hypertension	10038562	PT	Narrow	A	0	Active	11.1	11.1
Retinopathy hypertensive	10038926	PT	Narrow	A	0	Active	11.1	11.1
Secondary aldosteronism	10039808	PT	Narrow	A	0	Active	11.1	11.1
Secondary hypertension	10039834	PT	Narrow	A	0	Active	11.1	11.1
Supine hypertension	10078932	PT	Narrow	A	0	Active	20.0	20.0
Systolic hypertension	10042957	PT	Narrow	A	0	Active	11.1	11.1
Withdrawal hypertension	10048007	PT	Narrow	A	0	Active	11.1	12.0
Aldosterone urine abnormal	10061625	PT	Broad	A	0	Active	11.1	14.0
Aldosterone urine increased	10001653	PT	Broad	A	0	Active	11.1	14.0
Angiotensin converting enzyme increased	10049530	PT	Broad	A	0	Active	11.1	14.0
Angiotensin I increased	10002488	PT	Broad	A	0	Active	11.1	14.0
Angiotensin II increased	10002495	PT	Broad	A	0	Active	11.1	14.0
Angiotensin II receptor type 1 antibody positive	10079737	PT	Broad	A	0	Active	20.1	20.1

<b>Name</b>	<b>Code</b>	<b>Level</b>	<b>Scope</b>	<b>Category</b>	<b>Weight</b>	<b>Status</b>	<b>Addition Version</b>	<b>Last Modified Version</b>
Blood aldosterone abnormal	10005294	PT	Broad	A	0	Active	11.1	14.0
Blood aldosterone increased	10005296	PT	Broad	A	0	Active	11.1	14.0
Blood catecholamines abnormal	10005412	PT	Broad	A	0	Active	11.1	14.0
Blood catecholamines increased	10005414	PT	Broad	A	0	Active	11.1	14.0
Blood pressure abnormal	10005728	PT	Broad	A	0	Active	11.1	14.0
Blood pressure ambulatory abnormal	10005730	PT	Broad	A	0	Active	11.1	14.0
Blood pressure diastolic abnormal	10005736	PT	Broad	A	0	Active	11.1	14.0
Blood pressure fluctuation	10005746	PT	Broad	A	0	Active	11.1	14.0
Blood pressure orthostatic abnormal	10053354	PT	Broad	A	0	Active	11.1	14.0
Blood pressure systolic abnormal	10005757	PT	Broad	A	0	Active	11.1	14.0
Catecholamines urine abnormal	10061747	PT	Broad	A	0	Active	11.1	14.0
Catecholamines urine increased	10061034	PT	Broad	A	0	Active	11.1	14.0
Diuretic therapy	10053073	PT	Broad	A	0	Active	11.1	14.0
Ectopic aldosterone secretion	10014148	PT	Broad	A	0	Active	11.1	14.0
Ectopic renin secretion	10014171	PT	Broad	A	0	Active	11.1	14.0
Epinephrine abnormal	10061845	PT	Broad	A	0	Active	14.0	14.0
Epinephrine increased	10015064	PT	Broad	A	0	Active	14.0	14.0
Labile blood pressure	10023533	PT	Broad	A	0	Active	11.1	14.0
Metanephrine urine abnormal	10062193	PT	Broad	A	0	Active	11.1	14.0
Metanephrine urine increased	10027445	PT	Broad	A	0	Active	11.1	14.0
Non-dipping	10065226	PT	Broad	A	0	Active	11.1	14.0
Norepinephrine abnormal	10061874	PT	Broad	A	0	Active	11.1	14.0
Norepinephrine increased	10029752	PT	Broad	A	0	Active	11.1	14.0
Normetanephrine urine increased	10049097	PT	Broad	A	0	Active	14.0	14.0
Pseudoaldosteronism	10037113	PT	Broad	A	0	Active	11.1	14.0
Renin abnormal	10038556	PT	Broad	A	0	Active	11.1	14.0
Renin increased	10038559	PT	Broad	A	0	Active	11.1	14.0
Renin-angiotensin system inhibition	10049415	PT	Broad	A	0	Active	11.1	14.0
Tyramine reaction	10067895	PT	Broad	A	0	Active	11.1	14.0

## 7.5. List of Per-Protocol Chemotherapy Regimens in Preferred Term

Agent Name in Preferred Term
ALTRETAMINE
ANETUMAB RAVTANSINE
ANTINEOPLASTIC AGENTS
BEVACIZUMAB
BEVACIZUMAB W/CARBOPLATIN*
CAPECITABINE
CARBOPLATIN*
CARBOPLATIN W/GEMCITABINE*
CARBOPLATIN W/GEMCITABINE HYDROCHLORIDE*
CISPLATIN*
CISPLATIN W/DOCETAXEL*
CISPLATIN W/GEMCITABINE HYDROCHLORIDE*
CISPLATIN W/PACLITAXEL*
CYCLOPHOSPHAMIDE
DECITABINE
DOCETAXEL
DOXORUBICIN
DOXORUBICIN HYDROCHLORIDE
ETOPOSIDE
GEMCITABINE
GEMCITABINE HYDROCHLORIDE
IFOSFAMIDE
INVESTIGATIONAL DRUG
IRINOTECAN
IXABEPILONE
LIPOSOMAL DOXORUBICIN HYDROCHLORIDE
LURBINECTEDIN
MELPHALAN
METHOTREXATE
NINTEDANIB
NIRAPARIB
OLAPARIB
OMEPRAZOLE
OTHER ANTINEOPLASTIC AGENTS
OXALIPLATIN*
PACLITAXEL

<b>Agent Name in Preferred Term</b>
PACLITAXEL ALBUMIN
PACLITAXEL POLIGLUMEX
PACLITAXEL W/CARBOPLATIN*
PAZOPANIB
PEGYLATED LIPOSOMAL DOXORUBICIN
PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE
PEMETREXED
PEMETREXED DISODIUM
PLATINUM COMPOUNDS*
PRALATREXATE
RUCAPARIB
TAXANES
TOPOTECAN
TRABECTEDIN
TRASTUZUMAB EMTANSINE
VELIPARIB
VINORELBINE
VINORELBINE TARTRATE

\* Denotes platinum-based therapies.



## **8. STATISTICAL OUTPUT SHELLS**

The list of statistical output and corresponding table/figure/listing shells are provided in a separate document.

## **9. REVISION HISTORY**

- The efficacy analyses were revised between versions 2.0 and 3.0 of the SAP in order to ensure consistency with the revised Protocol v3.2. Table, figure, and listing shells were modified to account for the revised analyses.

**STATISTICAL ANALYSIS PLAN  
ADDENDUM**

**A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and  
Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade  
Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer  
Who Have Received Three or Four Previous Chemotherapy Regimens  
Protocol PR-30-5020-C**

Protocol Number: PR-30-5020-C

Protocol Version and Date: Version 8.0: 21 December 2017 (Amendment 5)  
Version 7.0: 07 April 2017 (Amendment 4)  
Version 6.0: 14 September 2016 (Amendment 3.2)  
Version 5.0: 07 September 2016 (Amendment 3.1)  
Version 4.0: 29 July 2016 (Amendment 3)  
Version 3.0: 24 May 2016 (Amendment 2)  
Version 2.0: 30 October 2015 (Amendment 1)  
Version 1.0: 17 December 2014 (Original)

Name of Test Drug: Niraparib ([3S]-3-[4-{7-(aminocarbonyl)-2H-indazol-2-yl}  
phenyl] piperidine [tosylate monohydrate salt])

Phase: Phase 2

Methodology: Open-Label, Single-Arm

Sponsor: TESARO, Inc.  
1000 Winter Street  
Waltham MA 02451  
Tel: PPD

Sponsor Representative: PPD MD  
Senior Medical Director

Statistical Analysis Plan Date/Version: 19 January 2018, Version 3.0

SAP Addendum Date/Version: 11 December 2018, Version 1.0

**Confidentiality Statement**

The information contained herein is confidential and the proprietary property of  
TESARO, Inc., and any unauthorized use or disclosure of such information  
without the prior written authorization of TESARO, Inc., is expressly prohibited.

## APPROVAL SIGNATURE PAGE

Protocol Title: A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Protocol Number: PR-30-5020-C

Sponsor: TESARO, Inc.  
1000 Winter Street  
Waltham MA 02451

---

Author Signatory:  
PPD PhD  
Director, Biostatistics

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

PPD

### Sponsor Approval:

By signing this document, I acknowledge that I have read the document and approve of the planned statistical analyses described herein. I agree that the planned statistical analyses are appropriate for this study, are in accordance with the study objectives, and are consistent with the statistical methodology described in the protocol, clinical development plan, and all applicable regulatory guidances and guidelines.

I have discussed any questions I have regarding the contents of this document with the biostatistical author.

I also understand that any subsequent changes to the planned statistical analyses, as described herein, may have a regulatory impact and/or result in timeline adjustments. All changes to the planned analyses will be described in the clinical study report.

Sponsor Signatory:  
Katarina Luptakova, MD  
Senior Medical Director

Signature \_\_\_\_\_

Date: \_\_\_\_\_

PPD

## TABLE OF CONTENTS

1.	INTRODUCTION .....	5
2.	PATIENT POPULATION .....	6
2.1.	Patient Populations.....	6
2.2.	Prior Chemotherapy .....	7
3.	ADDITIONAL ANALYSES .....	8
3.1.	Patient Disposition and Baseline Status.....	8
3.2.	Efficacy Evaluation.....	9
3.2.1.	Objective Response Rate (ORR) and Duration of Response (DOR) .....	9
3.2.2.	Overall Survival (OS) and Clinical Benefit Rate (CBR) ..	9
3.3.	Safety Evaluation .....	11
3.3.1.	Study Treatment Exposure.....	11
3.3.2.	Adverse Events .....	11
3.4.	List of statistical output.....	13

## LIST OF ABBREVIATIONS AND DEFINITION OF TERMS

Abbreviation	Definition
AE	Adverse event
AESI	Adverse event(s) of special interest
AML	Acute myeloid leukemia
BMI	Body mass index
BRCA	Breast cancer gene
CBR	Clinical benefit rate
CI	Confidence interval
CR	Complete response
CSR	Clinical study report
CTCAE	Common Terminology Criteria for Adverse Events
DCR	Disease control rate
DOR	Duration of response
ECOG	Eastern Cooperative Oncology Group
eCRF	Electronic case report form
HRD	Homologous recombination deficiency
ITT	Intent-to-treat
KM	Kaplan-Meier
MDS	Myelodysplastic syndrome
MedDRA	Medical Dictionary for Regulatory Activities
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease (in the context of disease evaluation) or protocol deviation
PFI	Platinum-free interval
PFS	Progression-free survival
PP	Per-protocol
PR	Partial response
PT	Preferred Term (MedDRA)
RECIST	Response Evaluation Criteria in Solid Tumors
SAE	Serious adverse event
SAF	Safety
SAP	Statistical analysis plan
SD	Stable disease (in the context of disease evaluation) or standard deviation (in the context of statistics)
SOC	System Organ Class (MedDRA)
TEAE	Treatment-emergent adverse event

## **1. INTRODUCTION**

This addendum to the main statistical analysis plan (SAP) of the QUADRA trial is designed to outline the additional analyses of study data in order to further investigate the study objectives.

Study designs, patient populations, efficacy and safety endpoints, data handling rules, statistical methods, and formats for data presentation are identified and provided in the main SAP. The statistical analyses and summary tabulations described in this SAP addendum will be added to the results sections of the clinical study report (CSR).

## **2. PATIENT POPULATION**

### **2.1. Patient Populations**

The following patient populations are defined in the main SAP and used for data presentation and analysis:

- Safety (SAF) population is defined as all patients who receive at least 1 dose of study drug.
- Intent-to-Treat (ITT) population is defined as all dosed patients with measurable disease at baseline.
  - Measurable disease at baseline is determined by the existence of at least 1 target lesion at baseline tumor scan based on investigator's assessment.

In this document, a modified ITT population for a biomarker subpopulation (BM) is defined as all ITT patients who meet all of the following criteria:

- at least 3 prior lines of chemotherapy
- BRCAmut (regardless of platinum-sensitivity) or HRDpos/platinum-sensitive
- no PARP inhibitor listed in prior therapy

Platinum sensitivity status is defined in the main SAP based on platinum-free interval (PFI) to the last platinum-based therapy, which is the duration between the end date of last platinum-based therapy and the date of disease progression following the last platinum-based therapy.

- Platinum-sensitive: PFI  $\geq$ 6 months (180 days)
- Platinum-resistant: PFI  $>$ 4 weeks (28 days) and  $<$ 6 months (180 days)
- Platinum-refractory: PFI  $\leq$ 4 weeks (28 days)
- Platinum status unknown: PFI is missing



## 2.2. Prior Chemotherapy

A list of the per-protocol chemotherapy regimens is provided in the main SAP.

In this document, the following prior chemotherapy will be grouped and summarized based on the reported regimens.

<b>Chemotherapy</b>	<b>Reported regimen in preferred term</b>
Bevacizumab	BEVACIZUMAB BEVACIZUMAB W/CARBOPLATIN
Doxorubicin	DOXORUBICIN DOXORUBICIN HYDROCHLORIDE LIPOSOMAL DOXORUBICIN HYDROCHLORIDE PEGYLATED LIPOSOMAL DOXORUBICIN PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE
Liposomal Doxorubicin	LIPOSOMAL DOXORUBICIN HYDROCHLORIDE PEGYLATED LIPOSOMAL DOXORUBICIN PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE
Gemcitabine	CARBOPLATIN W/GEMCITABINE CARBOPLATIN W/GEMCITABINE HYDROCHLORIDE CISPLATIN W/GEMCITABINE HYDROCHLORIDE GEMCITABINE GEMCITABINE HYDROCHLORIDE
Taxane	CARBOPLATIN W/PACLITAXEL CISPLATIN W/DOCETAXEL CISPLATIN W/PACLITAXEL DOCETAXEL PACLITAXEL PACLITAXEL ALBUMIN PACLITAXEL POLIGLUMEX PACLITAXEL W/CARBOPLATIN TAXANES

### **3. ADDITIONAL ANALYSES**

#### **3.1. Patient Disposition and Baseline Status**

During the conduct of the study, patients were enrolled under the original protocol and subsequent protocol amendments. Patient disposition and baseline status will be tabulated for all patients in the SAF population according to their enrolling protocol versions, including:

- Demographics
- Baseline disease characteristics
- Prior anti-cancer chemotherapy
- BRCA/HRD biomarker status

Patient disposition and baseline status will also be summarized for the BM subpopulation defined in section 2.1.

The last platinum-based therapy will be further summarized by the following categories:

- Last platinum therapy is given as the last chemotherapy regimen
- Last platinum therapy is given as the penultimate chemotherapy regimen (second to the last regimen)
- Last platinum therapy is given as the antepenultimate chemotherapy regimen or earlier (third to the last regimen or earlier)

For platinum-sensitive patients, treatment-free interval (TFI) will be defined and summarized by the duration from the end of last chemotherapy regimen to the date of subsequent disease progression prior to the study treatment. If there is no date reported for the subsequent disease progression, it will be imputed by the date of first study treatment.

A listing of prior ovarian cancer treatment will be generated for patients reported any prior PARP treatment in the SAF population.

## 3.2. Efficacy Evaluation

### 3.2.1. Objective Response Rate (ORR) and Duration of Response (DOR)

The investigator-assessed confirmed ORR per RECIST v1.1 will be analyzed for the BM subpopulation defined in section 2.1 overall and in the following biomarker subsets:

- BRCAmut (regardless of platinum-sensitivity)
  - BRCAmut/Platinum-sensitive
  - BRCAmut/Platinum-resistant or refractory or status-unknown, and by
    - BRCAmut/Platinum-resistant
    - BRCAmut/Platinum-refractory
    - BRCAmut/Platinum status unknown
- Non-BRCAmut/HRDpos/Platinum-sensitive
  - BRCAwt/HRDpos/Platinum-sensitive
  - BRCAunk/HRDpos/Platinum-sensitive

Furthermore the investigator-assessed confirmed ORR per RECIST v1.1 will be analyzed for the BM subpopulation defined in section 2.1 by prior lines of chemotherapy overall and in the above biomarker subsets:

- 3 prior lines
- 4 prior lines
- $\geq 5$  prior lines

In addition, the following subgroup analyses on ORR will be performed for the BM subpopulation:

- Age categories [ $<65$ ,  $\geq 65$ ]
- Primary tumor site [ovarian, primary peritoneal, fallopian tube]

DOR will be analyzed using Kaplan-Meier (KM) methods to provide quartile estimates and 2-sided 95% CIs for the BM subpopulation and by biomarker subsets. The DOR for the BM subpopulation overall and by biomarker subsets will be plotted by KM curves, respectively.

### 3.2.2. Overall Survival (OS) and Clinical Benefit Rate (CBR)

Clinical benefit rate (CBR) at 16 and 24 weeks (CBR16 and CBR24) are defined as proportion of patients with CR/PR or patients with SD with a duration of at least 16 and 24 weeks, respectively.

Kaplan-Meier estimates for OS for patients by the following subgroups will be provided:

- Patients who met CBR16 response (CBR16 responder: CR or PR or SD at least 16 weeks), vs. patients who did not meet CBR16 response
- Patients who had an objective response (CR/PR), vs. patients who had SD for at least 16 weeks, vs. Rest of patients who did not meet CBR16 response.

- To account for a lead-time bias, a landmark analysis that will only include patients at risk at 16 weeks (i.e. excluding patients who had died or were censored before 16 weeks) will be performed.
- Kaplan-Meier estimates for OS for patients who had SD for at least 16 weeks will be provided further by BRCA/HRD status.
  - BRCAmut
  - Non-BRCAmut/HRDpos
  - HRDneg/HRDunk
    - HRDneg
    - HRDunk

The same subgroup analyses will be performed for OS according to CBR24.

### 3.3. Safety Evaluation

#### 3.3.1. Study Treatment Exposure

Study treatment exposure will be summarized for the BM subpopulation defined in section 2.1. The definitions in the main SAP will be used.

- Number and percent of patients beginning 1, 2, 3, ..., 12, and >12 cycles
- Number of cycles started
- Overall treatment exposure (months), defined as the  $[\text{last dose date} - \text{first dose date} + 1]/30.4375$ .
- Time on study (months), defined as the  $[\text{last visit date or date of death} - \text{first dose date} + 1]/30.4375$ .
- Dose intensity (mg/day), defined as sum of the daily doses actually consumed divided by overall treatment exposure (days)
- Relative dose intensity (%), defined as dose intensity divided by intended dose intensity (i.e. 300 mg/day).

Dose reductions and dose interruptions by cycle:

- Number and percentage of patients with a dose reduction for any reason and due to an AE
- Number and percentage of patients with a dose interruption for any reason and due to an AE

Dose intensity (mg/day) during the first two cycles (DIC2) will also be calculated for all dosed patients, defined as sum of the daily doses actually consumed during the first two cycles divided by treatment exposure of the first two cycles (i.e. first dose date up to Cycle 3 Day 1 or last dose date, whichever is earlier). For exploratory purpose, patients will be classified according to the DIC2 into >200 mg/day vs. ≤200 mg/day.

In addition, patients will be classified according to their baseline body weight and platelet count:

- Baseline body weight ≥77 kg and baseline platelet count ≥150,000/μL
- Baseline body weight <77 kg or baseline platelet count <150,000/μL

#### 3.3.2. Adverse Events

The following AE tables will be summarized for the BM subpopulation:

- Overview of AEs
- TEAE by SOC and PT
- TEAE by PT (sorted by frequency)
- Related TEAE by SOC and PT
- Treatment-emergent SAEs by SOC and PT
- Related treatment-emergent SAEs by SOC and PT
- TEAE by SOC, PT, and maximum grade
- Related TEAE by SOC, PT, and maximum grade

- Grade  $\geq 3$  TEAEs by SOC and PT
- Grade  $\geq 3$  TEAEs by PT (sorted by frequency)
- Related Grade  $\geq 3$  TEAEs by SOC and PT
- TEAEs resulting in death by SOC and PT
- TEAEs resulting in study drug dose interruption by SOC and PT
- TEAEs resulting in study drug dose reduction by SOC and PT
- TEAEs resulting in study drug withdrawal by SOC and PT
- TEAEs of special interest (MDS/AML, secondary cancers other than MDS/AML, pneumonitis, embryo-fetal toxicity) and other grouped events (hematological toxicities: thrombocytopenia, anemia, neutropenia, etc.)
  - All TEAEs
  - Grade  $\geq 3$  TEAE
  - TEAE resulting in dose interruption
  - TEAE resulting in dose reduction
  - TEAE resulting in study drug withdrawal

### 3.4. List of statistical output

Output Number	Output Name
Table 14.1.17	Patient Disposition, by Protocol Version (SAF population)
Table 14.1.18	Demographics, by Protocol Version (SAF population)
Table 14.1.19	Cancer stage, by Protocol Version (SAF population)
Table 14.1.20	Baseline disease characteristics, by Protocol Version (SAF population)
Table 14.1.21	Prior anti-cancer therapy, by Protocol Version (SAF population)
Table 14.1.22	Histology, by Protocol Version (SAF population)
Table 14.1.23	BRCA/HRD biomarker, by Protocol Version (SAF population)
Table 14.1.24	Biomarker/Platinum-sensitivity, by Protocol Version (SAF population)
Table 14.1.25	Prior chemotherapy group, by Protocol Version (SAF population)
Listing 16.2.4.11	Ovarian cancer treatment for patients listed with prior PARP treatment (SAF population)
Table 14.1.26	Patient Disposition (BM subpopulation)
Table 14.1.27	Demographics (BM subpopulation)
Table 14.1.28	Cancer stage (BM subpopulation)
Table 14.1.29	Baseline disease characteristics (BM subpopulation)
Table 14.1.30	Prior anti-cancer therapy (BM subpopulation)
Table 14.1.31	Histology (BM subpopulation)
Table 14.1.32	BRCA/HRD biomarker (BM subpopulation)
Table 14.1.33	Biomarker/Platinum-sensitivity (BM subpopulation)
Table 14.1.34	Prior chemotherapy group (BM subpopulation)
Table 14.1.35	Last platinum-based therapy and Treatment-free interval (ITT population)
Table 14.1.36	Last platinum-based therapy and Treatment-free interval (BM subpopulation)

Listing 16.2.1.3	Discontinuation from Treatment (BM subpopulation)
Listing 16.2.1.4	Discontinuation from Study (BM subpopulation)
Listing 16.2.4.12	Demographics (BM subpopulation)
Listing 16.2.4.13	Ovarian Cancer Treatment (BM subpopulation)
Listing 16.2.4.14	BRCA and HRD status (BM subpopulation)
Table 14.2.15a	Overall Survival by CBR16 in two groups (ITT Population $\geq 3$ prior lines)
Table 14.2.15b	Overall Survival by CBR16 in three groups (ITT Population $\geq 3$ prior lines)
Table 14.2.15c	Overall Survival by CBR16 in three groups (ITT Population $\geq 3$ prior lines patients at risk at 16 weeks)
Table 14.2.15d	Overall Survival for patients who had SD $\geq 16$ weeks, by biomarker group (ITT Population $\geq 3$ prior lines)
Table 14.2.15e	Overall Survival for patients who had SD $\geq 16$ weeks, by biomarker group (ITT Population $\geq 3$ prior lines)
Table 14.2.16a	Overall Survival by CBR24 in two groups (ITT Population $\geq 3$ prior lines)
Table 14.2.16b	Overall Survival by CBR24 in three groups (ITT Population $\geq 3$ prior lines)
Table 14.2.16c	Overall Survival by CBR24 in three groups (ITT Population $\geq 3$ prior lines patients at risk at 24 weeks)
Table 14.2.16d	Overall Survival for patients who had SD $\geq 24$ weeks, by biomarker group (ITT Population $\geq 3$ prior lines)
Table 14.2.16e	Overall Survival for patients who had SD $\geq 24$ weeks, by biomarker group (ITT Population $\geq 3$ prior lines)
Table 14.2.16f	Overall Survival by CBR16/CBR24 in four groups (ITT Population $\geq 3$ prior lines)
Figure 14.2.11a	Overall Survival by CBR16 in two groups (ITT Population $\geq 3$ prior lines)
Figure 14.2.11b	Overall Survival by CBR16 in three groups (ITT Population $\geq 3$ prior lines)



Figure 14.2.11c	Overall Survival by CBR16 in three groups (ITT Population $\geq 3$ prior lines patients at risk at 16 weeks)
Figure 14.2.11d	Overall Survival for patients who had SD $\geq 16$ weeks, by biomarker group (ITT Population $\geq 3$ prior lines)
Figure 14.2.11e	Overall Survival for patients who had SD $\geq 16$ weeks, by biomarker group (ITT Population $\geq 3$ prior lines)
Figure 14.2.12a	Overall Survival by CBR24 in two groups (ITT Population $\geq 3$ prior lines)
Figure 14.2.12b	Overall Survival by CBR24 in three groups (ITT Population $\geq 3$ prior lines)
Figure 14.2.12c	Overall Survival by CBR24 in three groups (ITT Population $\geq 3$ prior lines patients at risk at 24 weeks)
Figure 14.2.12d	Overall Survival for patients who had SD $\geq 24$ weeks, by biomarker group (ITT Population $\geq 3$ prior lines)
Figure 14.2.12e	Overall Survival for patients who had SD $\geq 24$ weeks, by biomarker group (ITT Population $\geq 3$ prior lines)
Figure 14.2.12f	Overall Survival by CBR16/CBR24 in four groups (ITT Population $\geq 3$ prior lines)
Table 14.2.17	ORR by prior lines of chemotherapy (BM subpopulation)
Table 14.2.18	ORR by biomarker and prior lines of chemotherapy (BM subpopulation BRCAmut)
Table 14.2.19	ORR by biomarker and prior lines of chemotherapy (BM subpopulation, non-BRCAmut/HRDpos/Platinum-sensitive)
Table 14.2.20	ORR by baseline subgroup (BM subpopulation)
Table 14.2.21	DOR overall and by biomarker subset (BM subpopulation)
Figure 14.2.21A	KM curves of DOR overall (BM subpopulation)
Figure 14.2.21B	KM curves of DOR by biomarker subset (BM subpopulation)
Table 14.3.1.31	Overview of AEs (BM subpopulation)
Table 14.3.1.32	TEAEs by SOC and PT (BM subpopulation)
Table 14.3.1.33	TEAEs, sorted by PT (BM subpopulation)

Table 14.3.1.34	Related TEAEs by SOC and PT (BM subpopulation)
Table 14.3.1.35	Serious TEAEs, by SOC and PT (BM subpopulation)
Table 14.3.1.36	Related Serious TEAEs, by SOC and PT (BM subpopulation)
Table 14.3.1.37	TEAEs by SOC, PT and maximum toxicity grade
Table 14.3.1.38	Related TEAEs by SOC, PT and maximum toxicity grade
Table 14.3.1.39	Grade $\geq 3$ TEAEs, by SOC and PT (BM subpopulation)
Table 14.3.1.40	Grade $\geq 3$ TEAEs, sorted by PT (BM subpopulation)
Table 14.3.1.41	Related Grade $\geq 3$ TEAEs, by SOC and PT (BM subpopulation)
Table 14.3.1.42	TEAEs resulting in death, by SOC and PT (BM subpopulation)
Table 14.3.1.43	TEAEs resulting in dose interruption, by SOC and PT (BM subpopulation)
Table 14.3.1.44	TEAEs resulting in dose reduction, by SOC and PT (BM subpopulation)
Table 14.3.1.45	TEAEs resulting in drug withdrawal, by SOC and PT (BM subpopulation)
Table 14.3.1.46	TEAEs of special interest (AESI) and other grouped events (BM subpopulation)
Table 14.3.1.47	Grade $\geq 3$ AESI and other grouped events (BM subpopulation)
Table 14.3.1.48	Serious AESI and other grouped events (BM subpopulation)
Table 14.3.1.49	AESI and other grouped events resulting in dose interruption (BM subpopulation)
Table 14.3.1.50	AESI and other grouped events resulting in dose reduction (BM subpopulation)
Table 14.3.1.51	AESI and other grouped events resulting in drug withdrawal (BM subpopulation)
Table 14.3.1.52	Summary tabulation for patients who experienced thrombocytopenia and who did and did not received platelet transfusion during study (SAF Population)

Table 14.3.1.53	Summary tabulation for patients who experienced anemia and who did and did not received red blood cell transfusion or erythropoietin during study (SAF Population)
Table 14.3.1.54	Summary tabulation for patients who experienced neutropenia and who did and did not receive colony stimulating factors during study (SAF Population)
Table 14.3.5.24	Dose interruption and dose reductions, by Cycle (BM subpopulation)
Table 14.3.5.25	Study drug exposure (BM subpopulation)
Table 14.3.2.8	Listing of TEAEs leading to death (BM subpopulation)
Table 14.3.2.9	Listing of Serious TEAEs (BM subpopulation)
Table 14.3.2.10	Listing of TEAEs resulting in dose interruption (BM subpopulation)
Table 14.3.2.11	Listing of TEAEs resulting in dose reduction (BM subpopulation)
Table 14.3.2.12	Listing of TEAEs resulting in study drug withdrawal (BM subpopulation)
Table 14.3.2.13	Listing of AESIs and other grouped events (BM subpopulation)